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ABSTRACT 
 Concise syntheses of the natural products brosimones A and B have been 
achieved using sequential dehydrogenative Diels-Alder (DHDA) cycloadditions. The 
syntheses employ either Pt/C-cyclopentene or DDQ to effect dehydrogenation of 
prenylchalcone substrates in combination with silver nanoparticles (AgNP’s) to promote 
subsequent Diels-Alder cycloadditions.  
              A concise, biomimetic approach to sorbiterrin A has been developed employing 
consecutive Michael additions of a 4-hydroxypyrone to a sorbicillinol derivative and 
silver nanoparticle-mediated bridged aldol/dehydration to construct the [3.3.1] ring 
system. The relative stereochemistry of sorbiterrin A was unambiguously confirmed by 
X-ray crystallographic analysis. 
            Metal-catalyzed, double Claisen rearrangement of a bis-allyloxyflavone has been 
utilized to enable a concise synthesis of the hydrobenzofuro[3,2-b]chromenone core 
structure of the natural products sanggenon A and sanggenol F. In addition, catalytic, 
enantioselective [4+2] cycloadditions of 2’-hydroxychalcones have been accomplished 
using B(OPh)3/BINOL complexes. Asymmetric syntheses of the flavonoid Diels-Alder 
natural products sanggenons C and O have been achieved employing a stereodivergent 
		 x 
reaction of a racemic mixture (stereodivergent RRM) involving [4+2] cycloaddition. 
Diaporine is a natural product containing a novel epoxyquinol dimer framework. 
An efficient annulation involving pyrone addition to a quinone has been developed for 
rapid assembly of the γ-naphthopyrone core structure. Dimerization was achieved 
through a Pd(II)-mediated dehydrogenative coupling. A natural product and precursor to 
diaporine, aurofusarin, was synthesized in excellent yield through an oxidation and 
demethylation sequence. In addition, diastereoselective epoxidation of aurofusarin was 
achieved using a phase transfer catalytic system.  
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Chapter 1 
Prenylflavonoid and Polyketide-derived Natural 
Products 
1.1  Introduction to Prenylflavonoid and Related Natural Products 
1.1.1 Isolation and Structure 
Polyphenolic metabolites dominate natural products isolated from the roots of the 
mulberry tree (Morus alba) and ginger-family Zingiberaceae plants. Amongst them, 
prenylflavanoids and other closely related natural products possess unique structural 
features, the most common being a cyclohexenyl chalcone core derived from enzyme-
controlled [4+2] cycloadditions between 2’-hydroxychalcone dienophiles and a variety of 
dienes.1 Over fifty prenylflavonoid cycloadducts and related natural products have been 
isolated to date, representative examples of which are shown in Figure 1.1. Based on the 
dienes involved in the [4+2] cycloadditions, Nomura and coworkers2 classified these 
natural products as follows: Diels-Alder-type cycloadducts involving 1) a flavonoid 
diene, as found in kuwanons G (1)3 and H (2),4 which are among the earliest isolated 
biologically active exo cycloadducts; 2) an acyclic monoterpene as dienophile as in 
panduratin A (3)5 and the isomeric Diels-Alder cycloadduct nicolaioidesin B (4);6 3) a 2-
arylbenzofuran diene, as in mulberrofuran C (5);7 4) a stilbene diene, as found in 
kuwanons X (6)8 and Y (7);9 and 5) a chalcone diene, as found in  the congeners 
brosimones A (8)10 and B (9).11 Structures bearing polycyclic ketals, oxidized bicyclic 
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cores, and hydroxy-benzofuro[3,2-b]chromenones were also found in the natural products 
australisine A (10), 12  sorocenol B (11), 13  and sanggenons C (12) 14  and O (13), 15 
respectively.  
 
Figure 1.1 Representative prenylflavonoid and related natural products. 
           Extensive structural examination of these natural products by 1H NMR analysis 
indicates that endo and exo Diels-Alder cycloadducts have distinguishable proton-proton 
coupling patterns. 16  The three substituents on carbons 3’’, 4’’, and 5’’of the 
methylcyclohexene ring display “cis-trans” and “all-trans” relationships in exo and endo 
cycloadducts, respectively (Figure 1.2). These “cis-trans” protons of exo adducts exhibit 
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J3’’H-4’’H values of approximately 5 Hz,  and J4’’H-5’’H values in the range of 4 to 11 Hz.  In 
the “all-trans” exo adducts, the values for both J3’’H-4’’H and J4’’H-5’’H are both found to be 
approximately 11 Hz. The representative examples shown in Figure 1.3 demonstrate the 
generality of these trends, which in turn allows for facile relative stereochemical 
assignment of prenylflavonoid natural products.  
 
Figure 1.2 Relative stereochemistry assignments based on 1H NMR coupling constants. 
 
Figure 1.3 Representative coupling constants for exo and endo cycloadducts. 
The absolute stereochemical configurations of prenylflavanoid and related natural 
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products are typically determined via X-ray crystallographic and circular dichroism (CD) 
analysis. Pioneering work in this area was done by Nomura and coworkers to determine 
the absolute configuration of mulberrofuran C (5).12 In order to obtain a high quality 
single crystal for X-ray crystallographic analysis, a four-step derivatization sequence was 
conducted (Scheme 1.1). Photo-mediated ketalization of mulberrofuran C (5) under 
acidic conditions afforded mulberrofuran G (14). Permethylation of 14 with dimethyl 
sulfate and potassium carbonate led to mulberrofuran G methyl ether (15) in 83% yield. 
Compound 15 was then brominated and aromatized to form the crystalline compound 16. 
X-Ray crystallographic analysis of 16 revealed an R configuration at the carbon 
stereocenter. In addition to a relative stereochemistry assignment, the absolute 
configuration of mulberrofuran C (5) was determined as 3’’S, 4’’R, and 5’’S. This study 
also facilitated the absolute configuration determination of  related  natural  products.  By  
Scheme 1.1 Stereochemical Assignment of Mulberrofuran C 
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comparing CD spectra of both 5 and 14, the absolute stereochemical configurations of 
related natural products were also determined (e.g. sanggenons C (12) and O (13)17).    
1.1.2 Biogenesis and Biological Activity 
          In 1990, Nomura and coworkers craftily designed experiments to investigate the 
biosynthesis of prenylflavonoid and related natural products.18 Instead of doing 14C 
labeling feeding experiment, Nomura and coworkers fed the unnatural O-methylated 
chalcone (17) to Morus alba cell cultures in which case several metabolites 18-22 were 
isolated (Figure 1.4). These O-methylated compounds all correlated to natural products 
detected in the root bark of the mulberry tree. More interestingly, O-methylated Diels-
Alder cycloadducts 21 and 22 shared the same optical rotations with their natural product 
analogs kuwanon J (23) and chalcomoracin (24). These facts strongly suggested that 
these secondary metabolites are enzymatic Diels-Alder cycloadducts.19 In addition, the 
first well-characterized Diels–Alderase was reported in 2011 by Liu and coworkers.20 
They isolated a cyclase, SpnF, that catalyses a transannular [4+2] cycloaddition to form 
the cyclohexene ring in tetracyclic natural product spinosyn A. 
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Figure 1.4 Metabolism of an O-methylated chalcone in Morus alba cell culture. 
           Since all diene precursors seem to be derived from the prenyl moiety, this led to 
the assumption that an enzymatic dehydrogenation is also involved in the biosynthetic 
pathway of prenylflavonoids and related natural products. Parallel studies by Nomura and 
coworkers showed that by feeding artocarpesin (25) and morachalcone A (26) to Morus 
alba cell cultures, optically active artonin I (27) was isolated. This result indicated that 
the prenyl group in 25 is converted to a diene, which subsequently reacts with dienophile 
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26 to form cycloadduct 27 (Scheme 1.2). 
Scheme 1.2 Enzymatic Synthesis of Artonin I Using Morus alba Cell Culture 
 
           In terms of their biological activities, prenylflavonoids and related natural products 
have demonstrated a very broad range of action. For instance, kuwanons G (1) (Ki = 470 
nm) and H (2) (Ki = 290 nm) were shown as inhibitors of gastrin-releasing peptide 
receptor (GRP-R), and they are the only reported small molecules which have such 
biological activity. The peptide contains 27 amino acid residues, and greatly effects on 
cell proliferation and differentiation.21 Since a number of human cancer cells feature 
overexpression of GRP-R, kuwanons G and H could be considered potential anti-cancer 
agents.   
         Notably, another prenylflavonoid, panduratin A, (3) also shows interesting 
biological activities. By blocking the activation of NF-κB and phosphorylation of IκBα,22 
the racemic natural product can reduce expression of metalloproteinase-1 (interstitial 
collagenase and fibroblast collagenase) in UV-irradiated human skin fibroblasts,23 as well 
as inhibit both NO (IC50 = 0.18 µM) and prostaglandin E2 (IC50 = 0.02 µM) production. 
In addition, panduratin A (3) is also cytotoxic agent against several cancer cell lines 
including DU-145 prostate cancer cells (IC50 = 13.5‒14 µM),24 HT-29 colorectal cancer 
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cells (IC50 = 28 µM),25 and Panc-1 pancreatic cancer cells (PC100 = 2.5 µM).26 Recently, 
panduratin A (3) has also shown inhibitory effects on HIV-1 protease27 and was found to 
have antibacterial properties against Staphylococcus aureus strains.28  
1.1.3 Previous Syntheses of Prenylflavonoid and Related Natural Products 
         A successful chemical synthesis of these prenylflavonoid and related natural 
products requires a reliable and efficient Diels-Alder cycloaddition protocol to construct 
the common methylcyclohexene core using 2’-hydroxychalcones. However, the utility of 
these relatively electron-rich dienophiles was considered very challenging. Traditional 
Lewis acid-mediated “LUMO-lowering” conditions or thermal conditions often resulted 
in side reactions such as flavanone formation.29 
        Initially, thermal cycloadditions were employed in syntheses of several 
prenylflavonoid and related natural products. Lee and coworkers (Scheme 1.3) reported 
the syntheses of nicolaioidesin C (28) and crinatusins C1 (29) and C2 (30).30 Thermal 
Diels-Alder cycloaddition between MOM-chalcone 31 and myrcene (33) at 220 ºC, 
followed by global deprotection, yielded nicolaioidesin C (28)  in 65% combined yield, 
but in a 7:3 ratio with the inseparable, isomeric cycloadduct 34. Using the fully protected 
chalcone dienophile 32 delivered a higher overall yield and regioselectivity (28 : 34 = 4 : 
1) after deprotection. In parallel, crinatusin C1 (29) and crinatusin C2 (30) were 
synthesized using the corresponding chalcones 35 or 36. Similar regioselectivities were 
observed.  
 
 
		
9 
Scheme 1.3 Syntheses of Nicolaioidesin C and Crinatusins C1 and C2 
 
          Rahman and coworkers (Scheme 1.4) also developed syntheses of panduratin A (3) 
and the regioisomeric Diels-Alder cycloadduct nicolaioidesin B (4). The reported 
synthesis required high temperature (150 ºC) using neat chalcone 37 and trans-β-ocimene 
(38). Final MEM deprotection of the resulting cycloadducts using aqueous HCl provided 
panduratin A (3) and nicolaiodesin B (4) as an inseparable mixture. 
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Scheme 1.4 Syntheses of Panduratin A (3) and Nicolaioidesin B (4) 
 
           An early investigation of more complex prenylflavonoid synthesis was conducted 
by Rahman and coworkers. In 2011, the investigators reported the syntheses of methyl 
ethers of kuwanon V (39) and dorstenone (40) (Scheme 1.5). The requisite flavonoid 
diene was synthesized through a five-step sequence utilizing a key Heck cross coupling 
reaction. The resulting allylic alcohol was then treated with acetyl chloride and pyridine, 
and under thermal conditions, the acetyoxyl group was eliminated to afford the chalcone 
diene 44. Separately, the prenylchalcone dienophile 47 was prepared using a Claisen 
rearrangement as the key step. Thermolysis of 44 and 47 provided the endo and exo 
Diels-Alder cycloadducts 48 and 49 in 55% combined yield and 2 : 3 diastereoselectivity. 
Notably, the in situ-generated silver nanoparticle catalyst (prepared from AgOTf and 
Bu4NBH4) which was developed in our laboratory31 (cf. Scheme 1.8) dramatically 
lowered the reaction temperature and provided increased yield for the Diels-Alder 
cycloaddition.  Attempted deprotections of 48 and 49 to access natural products 39 and 
40 were not successful and led to decomposition.  
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Scheme 1.5 Syntheses of Kuwanon V (39) and Dorsterone (40) 
 
              Rizzacasa and coworkers also disclosed their efforts toward the racemic 
synthesis of methyl ether mulberrofuran C (5) (Scheme 1.6). The key 2-arylbenzofuran 
diene intermediate (55) was synthesized through a Sonogashira coupling, deacetylation, 
cyclization, and Suzuki-Miyaura coupling sequence from alkyne 50. Diels-Alder 
cycloaddition between diene 55 and dienophile 56 under thermal conditions afforded 
hexamethyl ethers of natural products 5 and 59 in 40% combined yield and approximate 
1 : 1 diastereoselectivity. O-Methyl deprotection attempts all failed to provide the desired 
natural products.  
 
 
 
		
12 
Scheme 1.6 Syntheses of Mulberrofurans C (5) and J (57) 
 
            Recently, our laboratory developed a catalytic system for [4+2] cycloadditions of 
highly electron-rich 2’-hydroxychalcone dienophiles (Scheme 1.7). 32  In this catalytic 
system, a combination of CoI2/1,10-phenanthroline/ZnI2/Bu4NBH4 was used to achieve a 
radical anion-meditated, stepwise cycloaddition process. The Lewis acid ZnI2 is believed 
to coordinate to the 2’-hydroxychalcone (60) to afford a complex, which is further 
reduced by Co(I)33 and borohydride 34 through a metal ion-promoted single electron 
transfer to form a radical anion 61. Regioselective addition of 61 to isoprene 6235 would 
afford a stabilized, allylic radical 63a, which has a resonance structure 63b. Further 
cyclization may generate ketyl 64. Subsequent single electron transfer may afford 
cycloadduct 65. In addition, nicolaioidesin C (28) was prepared using this method 
efficiently.32 
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Scheme 1.7 Electron-transfer initiated Diels-Alder cycloaddition of 2′-
hydroxychalcones. 
 
             Further exploration led to the discovery of silver nanoparticles (AgNPs) as a 
heterogeneous catalyst for Diels-Alder cycloadditions of 2’-hydroxychalcones. The 
AgNPs were prepared through reduction of AgBF4 employing Bu4NBH4. Excellent yields 
(up to 99%) and high turnover numbers (TON > 340) were obtained when silica-
supported AgNP’s were used in the model reaction (Scheme 1.8). Mechanistically, the 
AgNP catalyst may coordinate with 2’-hydroxychalcone 60, followed by single electron 
transfer (SET)36 to afford phenoxyl radical37 intermediate 67 with resonance structure 68. 
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The activated dienophile 67/68 may undergo concerted [4+2] cycloaddition with diene 62 
to form intermediate 69, which generates cycloadduct 65 via back electron transfer (BET) 
and protonation. The success of AgNP catalyst was further demonstrated in the synthesis 
of panduratin A (3), where extremely high endo/exo selectivity and yield were observed.  
Scheme 1.8 Silver Nanoparticle-catalyzed Diels-Alder Cycloaddition 
 
             The first asymmetric total synthesis of (‒)-nicolaioidesin C (28) was disclosed by 
Palomo and coworkers.38 Their synthesis involves a Brønsted acid-catalyzed Diels-Alder 
cycloaddition between cinnamoyl dienophile (71) and myrcene (33). Compared to 
electron-rich 2’-hydroxychalcone (Scheme 1.3), (+)-camphor-derived dienophile (71) 
easily undergoes [4+2] cycloaddition with myrcene using trifluoromethanesulfonic acid 
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(TfOH) as catalyst. Carbonyl reduction followed by cleavage of the resulting diol 
afforded aldehyde 73. Compound 73 was then further reacted with aryl organolithium 
reagent, followed by a Dess-Martin periodinane oxidation and MOM deprotection to 
provide (‒)-nicolaioidesin C (28).  
Scheme 1.9 Asymmetric Synthesis of (‒)-Nicolaioidesin C 
 
1.1.4  Conclusion 
         Prenylflavonoid cycloadducts and related natural products are an intriguing class 
of natural products owing to their complex chemical structures, potent biological 
activities, and interesting biosynthetic origins. The key transformation to construct 
cyclohexenyl chalcone cores remained challenging before our laboratory discovered two 
catalytic systems based on electron transfer involving CoI2/1,10-
phenanthroline/ZnI2/Bu4NBH4 and silver nanoparticles (AgNP’s). However, biomimetic 
(cf. Scheme 1.2) and catalytic, asymmetric approaches remain as demanding tasks in the 
synthesis of this natural product family, which will be the subject of later thesis chapters.   
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1.2  Introduction to Polyketide-derived Natural Products 
1.2.1 Isolation and Structure Elucidation 
          Secondary metabolites featuring polyketide synthases (PKSs) in their biosynthesis 
are typically referred to as polyketide natural products (Scheme 1.10). These compounds 
are typically isolated from almost any source including bacteria, fungi, plants, and a few 
animal lineages. Polyketides produced by bacteria and fungi often provide microbes 
survival advantage by suppressing other microorganism’s proliferation.  To date, nearly 
7000 polyketide nature products have been isolated or identified,39 most of which can be 
classified into two major categories: reduced polyketides and aromatic polyketides. 
Reduced polyketides contain numerous ether or hydroxyl functional groups, and are 
normally present as polyene macrolides or polyethers. The macrolide erythromycin A 
(78)40, isolated from the fungal strain Streptomyces erythreus in 1952, is one of most 
well-known example of reduced polyketide natural products. It possesses a 14-membered 
lactone ring with 10 stereocenters, which in addition to the attached L-cladinose and D-
desosamine moieties, makes this molecule a challenging synthetic target. Similarly, 
rapamycin (75)41 was isolated from Streptomyces hygroscopicus from an Easter Island 
soil sampleRapamycin contains a 31-membered ring, a plethora of stereocenters and 
sensitive functional groups including a diketo hemiketal moiety. Other representative 
reduced polyketides are shown in Scheme 1.10.  
In comparison to reduced polyketides, the aromatic type of polyketides normally 
present fewer asymmetric and geometrical centers.  The aromatic moieties may be 
derived from stepwise condensations  of  chain   carboxylic   acid-derived   units  without  
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Scheme 1.10 Representative Polyketide Natural Products 
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significant carbonyl reduction. Further modification of the core structures affords 
additional complexity. Structurally, aromatic polyketides can either be as simple as 
salicylic acid or complex as the polycyclic compounds doxorubicin (82) 42  and 
tetracycline (83). 43  A number of dimeric molecules including diaporine (84) 44  and 
viriditoxin (86)45 are also identified as aromatic polyketides. In addition, oxidation of 
aromatic substrates has been proposed to afford dearomatized intermediates such as 
ortho-quinols, which allows for the formation of numerous structural architectures (e.g. 
sorbiterrin A (85)46 and bisorbicillinol (87)47).  
1.2.2 Biological Activity 
Polyketide natural products have had a profound impact on human medicines.  
Approximately 20% of the current drugs on the market are comprised of polyketide-type 
compounds.  Among 7000 known polyketide natural products, more than 20 (>0.3%) 
have been developed into marketed drugs. This “hit rate” is about 300 fold greater when 
compared to the common pharmaceutical screen hit rate (<0.001%).48 These compounds 
have been used in a broad range of therapeutic areas including antibiotics, anticancer, 
immunosuppressants, and cholesterol-lowering medications.  Notably, tetracycline has 
served as a widely used human and veterinary antibiotic for decades.49 Tetracycline was 
extremely efficient to treat acne and rosacea,50 and helped reduce the death rate of 
cholera before significant resistance was observed.51 Doxorubicin (82) features a similar 
structure to tetracycline, and has been commercialized as an anti-cancer medication. It 
can be used to treat a large variety of cancers, including leukemia, carcinoma, and soft 
tissue sarcomas.52 Many of the reduced polyketides are excellent drugs: rapamycin (75) is 
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an immunosuppressant;53 rifamycin S (76),54 erythromycin A (78)55 and monensin A (80) 
56 are outstanding antibiotics; amphotericin B (79)57 is potent to various fungi; spinosyn 
A (81) can be used as an insecticide.58    
1.2.3 Biogenesis 
          Polyketides are class of secondary metabolites whose biosynthesis is catalyzed by 
polyketide synthases (PKSs). In the early 1900s, it was not certain how these natural 
products were produced. In 1893 Collie,59 Robinson60 and coworkers disclosed their 
work to demonstrate that polyketone compounds/intermediates 89 and 92 can condense 
to form polyketide-like molecules (Scheme 1.11). Their publications expedited the 
investigation of polyketide biosynthesis. Shortly afterwards Birth, who was trained by 
Robinson, published a ground-breaking result. He fed Penicillium patulum with 14C 
labeled acetic acid, and observed production of the corresponding 14C labeled 6-
methylsalicylic acid. This result unambiguously demonstrated that aromatic compounds 
such as 6-methylsalicylic acid are derived from four simple acetic acid units.61  Further 
application of this isotope technique resulted in the elucidation of more and more 
complex polyketides, and the biosynthetic study of this natural product family advanced. 
In 1980s, the explosion of genetic techniques quickly equipped scientists with the ability 
to discover the enzymes responsible for polyketide biosynthesis. 6-Methylslicylic acid 
synthase (6-MSAS) was the first isolated PKS.62 Shortly afterwards, numerous PKSs 
were isolated and sequenced, resulting in the classification of PKSs into 3 types. The first 
type of PKSs are modulated, containing multifunctional enzymes. These enzymes only 
perform one cycle of polyketide chain extension. 6-Deoxyerythronolide B PKS (DEBS)63  
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Scheme 1.11 Pioneering Biosynthesis Study 
 
is the most well studied and representative type I PKS.64 It contains three modules 
(DEBS 1, DEBS 2, and DEBS 3) which are covalently linked to form a multifunctional 
enzyme. As Figure 1.5 (adapted from Weissman, et al. Nat. Prod. Rep. 2001, 18, 380) 
shows, a number of acyl carrier proteins (ACP) which promote chain extension, whereas 
keto synthases (KS) catalyze the condensation. Subsequently, keto reductase (KR), 
dehydratase (DH), and enoyl reductase (ER) further modify the chain to produce reduced 
polyketides. Conversely, enzymes in type II PKS can repeatedly catalyze polyketide 
chain elongation, and are in charge of the biosynthesis of aromatic polyketide. A catalytic 
sequence is shown in Figure 1.6. In the activated model, dissociable enzymes such as 
KSα, KSβ and ACP associate to form a highly structured multifunctional sequence as 
tetracenomycin PKS (TcmKLM) (Figure 1.6).  Numerous acyl CoA substrates are 
carried by ACP and condensed by KS to form polycyclic aromatic structures. 
Subsequently, post-polyketide modification produces complex polyketide compounds 
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such as tetracenomycin C (96).65 The first type III PKS was isolated and characterized by 
Horinouchi and co-worker in 1999.66 This type of PKS catalyzes the homodimerization 
of acyl CoA substrates and further transformations. A representative natural scaffold 
derived from type III PKS-catalyzed biosynthesis is flavolin. Besides the 
abovementioned three polyketide biosynthesis pathways, post polyketide transformations 
also contributes to the colorful spectrum of polyketide natural product structural 
complexity, which will be discussed in detail in Chapters 3 and 4.   
 
Figure 1.5 Reduced Polyketide Synthesis Catalyzed by a Type I Polyketide Synthase. 
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Figure 1.6 Type II Polyketide Synthase-catalyzed Synthesis of Aromatic Polyketides 
1.2.4 Selected Total Syntheses of Aromatic Polyketide Natural Products 
          Due to the striking biological activities and insufficient material source from 
isolation, the synthesis of polyketide natural products has attracted enormous attention. 
Many polyketides total syntheses are remarkable, and the synthetic community regards 
them as classics or milestones in total synthesis. Discodermolide, 67  azaspiracid, 
rubicordifolin, tetracycline, bisanthraquinones, lejimalide B, and kedarcidin exemplify 
representative achievements in polyketide total synthesis.68 In the following discussion, 
the major focus will be on the aromatic polyketide total synthesis, as it is closely related 
to our research interests.  
          Tetracyclines are extraordinary antibiotics with broad spectrum of applications. In 
1962, Woodward and coworkers demonstrated their semisynthesis towards the 
tetracycline type natural product 6-demethyl-6-deoxytetracycline.69 Shortly afterwards 
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Muxfeldt, Rogalski, Stork, and Hagedorn published a series of syntheses on similar 
scaffolds.70 A remarkable total synthesis of tetracycline type of natural product was 
achieved in 2005 by the Myers group (Scheme 1.12).71 They demonstrated a very concise 
route towards this complex muticyclic molecule (‒)-doxycycline (109). They envisioned 
the pentacylic core could be constructed through a Michael addition and Dieckmann 
condensation cascade. Inspired by Stork’s previous work,72 they targeted the use of the 3-
benzyloxyisoxazole  moiety 100  to mask  the unstable β-enolamide functionality.  In the  
Scheme 1.12 Total Synthesis of (‒)-Doxycycline 
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depicted synthesis, a two-step anionic transformation merged epoxy ester 97 and 
organolithium 98 to afford ketone 99 in 73% yield. Epoxide opening, catalyzed by 
lithium triflate, followed by silyl ether deprotection, provided the ring closure product 
100 in a reasonable yield. NBSH was used to effect the regioselective/transpositive 
allylic reduction of 100 to 101 in 74% yield. After a deprotection, oxidation and 
protection sequence, the desired enone 102 was obtained in   66% yield over 3 steps. A 
slightly different sequence was also developed to prepare enone 106. The additional 
hydroxyl group was installed in 87% yield by sulfoxidation of 103 combined with a 
Mislow-Evans type rearrangement. The resulting enones 102 and 106 were finally 
exposed to a conjugate addition and Dieckmann condensation cascade reaction with the 
benzylic anion precursor 107 to form the tetracyclic structures. Finally, global 
deprotection afforded tetracycline type natural product (‒)-doxycycline (109) and its 
analog in excellent yield. 
         Another remarkable group of polyketides are the bisanthraquinone natural products. 
A growing number of research groups have been attracted to their various architectures 
and diverse array of biological activities. In 2005 and 2009, Nicolaou and coworkers 
disclosed their epic syntheses of 2, 2'-epi-cytoskyrin A (123) and rugulosin (124) 
(Scheme 1.13), 73  which serve as “model” for biomimetic synthesis. Starting from 
aldehyde (110), Brown allylation74 installed the allyl group in 86% ee after MOM group 
protection. Desilylation and Swern oxidation75 gave aldehyde 111 in 74% yield (3 steps). 
Finally, the desired enone 112 was obtained in 91% yield for 3 steps through a 
subsequent Grignard  addition, IBX oxidation, and olefin  metathesis.76   TBS-benzamide  
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Scheme 1.13  Total Synthesis of rugulosin (124) 
 
114 was then prepared from the benzoyl chloride 113 through a two-step sequence, with 
the resultant amide then treated with t-BuLi and DMF to afford aldehyde 114 in 93% 
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yield over 3 steps. Compound 114 was subjected to TMSCN to form TMS cyanohydrin 
115 in situ. Acidic work-up allowed for further cyclization of 115 to generate a phthalate 
intermediate. The TBS protecting group was then switched to MOM group using a 
desilylation / re-protection sequence. This three step sequence afforded MOM ether 116 
in 33% overall yield. Phthalate 116 was set to perform the Hauser annulation with 112 
upon treatment with LiHMDS. Building blocks 117a and 117b were successfully 
prepared using the aforementioned synthetic route in 80% and 91% yields, respectively. 
With advanced monomeric building blocks in hand, Nicolaou and coworkers performed 
an extraordinary biomimetic hetero Diels-Alder cycloaddition. By treating 117 with 
MnO2, naphthoquinone intermediate 118 was generated in situ. Enone tautomerization 
afforded an enol intermediate, which dimerized through an endo-anti geometry to afford 
119. Subsequently oxidative cleavage of the C-O bond afforded a bisnaphthoquinone 
dimer, which further underwent double Michael additions to form the caged compound 
122. Finally, global deprotection accessed 2, 2'-epi-cytoskyrin A (123) and rugulosin 
(124) in good yields.  
         The sporolides feature striking architectures, and as a result have drawn significant 
attention from the synthetic chemistry community. In 2009, Nicolaou and coworkers 
disclosed their synthesis of sporolide B (143) (Scheme 1.14). 77  Starting from the 
enantiomerically pure iodoenone 125, they performed a Luche reduction followed by 
benzylation to prepare vinyl iodide 126 in quantitative yield. Carboxymethylation of 126, 
followed by DIBAL-H reduction, DHP protection, and desilylation furnished allylic 
alcohol 127 in 81% yield over four steps. Subsequently, 127 was converted to an enone 
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by Dess–Martin periodinane oxidation, which was then iodinated, reduced, and protected 
as TBS vinyl iodide 128 in 62% yield for 4 steps. Sonogashira coupling of 128 with 
TMS-acetylene followed by deprotection of the THP and oxidation of the resulting 
primary alcohol afforded aldehyde 129 in 81% yield for 3 steps. Finally, the 
chloroacetylene moiety was successfully installed using lithiochloroacetylene prepared in 
situ with cis-1,2-dichloroethylene and MeLi. The resulting product was submitted to 
several protecting group manipulations to afford the desired acetoxy chloroacetylene 130 
in 44% yield for four steps. The remaining propargyl alcohol fragment was prepared 
starting from Wittig olefination of aldehyde 131; the resulting olefin was converted into a 
diol using an asymmetric Sharpless asymmetric dihydroxylation reaction. The diol was 
then differentially protected to afford compound 132 in 65% yield for four steps. The 
TBS group was then removed which was followed by Dess–Martin periodinane oxidation 
and further oxidation with NaClO2 to afford acid 133 in 84% yield for 3 steps. Coupling 
133 and 134 by EDCl led to propargyl alcohol 135 in 73% yield, which was further 
oxidized by Pb(OAc)4 to afford the hydroxy acetylenic fragment 136 in 89% yield. Next, 
ruthenium-catalyzed [2+2+2] cycloaddition was investigated. Using [Cp*RuCl(cod)] as 
catalyst, 130 and 148 underwent [2+2+2] cycloaddition to afford the desired benzenoid 
system 144 with complete regioselectivity. The steric bulkiness of the chlorine residue on 
130 and the coordinating ability of the free hydroxy group in 137 were found to be 
responsible for high regioselectivity. Subsequent acetylation, desilylation, and Ag2O-
mediated oxidation led to ortho-quinone 139 in 61% yield over 3 steps. Heating 139 to 
110 ºC facilitated intramolecular Diels-Alder (IMDA) cycloaddition to afford the desired  
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Scheme 1.14 Total Synthesis of (‒)-Sporolide B 
 
product 140 in 40% yield. Silylation and debenzylation were carried out prior to PIFA 
oxidation to give quinone monoketal 141 in 34% yield for five steps. Global deprotection 
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led to 142, which was epoxidized with tBuOOH and DBU to generate sporolide B (143) 
in 63% yield. 
           In addition to the above inspiring polyketide syntheses, we are very interested in 
syntheses of bisnaphthopyrone natural products including viriditoxin (86) and 
bisorbicillinol (87) (cf. Chapter 4, Scheme 4.3) which are more related to our target 
molecules. In 2011, Shaw and coworkers disclosed an asymmetric synthesis of 
viriditoxin (Scheme 1.15).78 They first prepared the pyranone 146 and orsellinic acid 
derivative 147 from known compounds.79 A Michael addition–Dieckmann condensation 
sequence was initiated by treating 147 and 146 with LDA, which afforded tricyclic 
compound 148. Subsequent oxidation, methylation and deprotection of EMO group on 
148 accessed the crucial naphthopyranone 149. They next evaluated a number of chiral 
vanadium catalysts, and eventually found  that  catalyst  150  gave  an  optimal  yield  and   
Scheme 1.15 Total Synthesis of (‒)-Viriditoxin 
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diastereoselectivity in the dimerization of compound 149. The TIPS group was then 
removed and the resulting hydroxyl group was subsequently oxidized to form aldehyde 
152, which was finally converted to viriditoxin (86) after further oxidation and 
methylation.  
1.2.5 Conclusion 
      Polyketide natural products feature a range of molecular architectures and interesting 
biological activities that have attracted many researchers in both chemistry and biology. 
Deeper understanding the biosynthesis of these compounds have allow scientists to 
engineer the corresponding genes and access more diverse structural complexity. In most 
cases, preliminary biological activity research lacks useful amounts of natural material. 
Therefore, synthetic chemists are needed to develop synthetic methods to access 
additional polyketide architectures as well as preparative amounts of polyketide 
molecules. In particular, in the following chapters we will describe our syntheses of novel 
sorbicillinoloide and naphthopyrone type of polyketides that are inspired by 
aforementioned polyketides syntheses.  
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Chapter 2 
 Biomimetic Dehydrogenative Diels-Alder 
Cycloadditions: Total Syntheses of Brosimones A and B  
2.1 Introduction  
2.1.1 Nature-Inspired Synthetic Design 
Brosimones A (8)10 and B (9)11 are prenylchalcone natural products isolated from 
the Brazilian plant Brosimopsis oblongifolia. Like most prenylflavanoid and related 
prenylchalcone natural products, these compounds are believed to be derived from 
enzyme-catalyzed Diels-Alder cycloadditions between 2’-hydroxychalcone dienophiles 
and dienes. The pioneering studies by Nomura and coworkers also determined that the 
requisite diene subunits may arise from prenyl groups in nature (cf. Chapter 1.1.2) as 
part of a formal dehydrogenation Diels-Alder sequence (DHDA). Specifically, the natural 
product brosimone B (9) presents an intriguing heterodimeric architecture derived from 
Diels-Alder cycloaddition between diene chalcone reaction partner 153 and 2’-
hydroxychalcone 154 (Scheme 2.1). In addition, compound 153 is assumed to be derived 
from naturally occurring 154, and 154 is co-isolated with the brosimone natural products. 
More interestingly, a second enzymatic dehydrogenative Diels-Alder cycloaddition of 9 
could afford brosimone A (8). The intriguing biosynthetic relationship and structures of 
the brosimones, in particular the [3.3]metacyclophane core80 of 8, underscores the 
compounds as attractive targets for development of dehydrogenative Diels-Alder 
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cycloadditions. 
Scheme 2.1 Proposed Biosyntheses of Brosimones A (8) and B (9) 
 
As part of our continuing interest in prenylflavanoid and related prenylchalcone 
natural products,32 our laboratory has reported silica-supported silver nanoparticles 
(AgNP’s)31, 81  as a highly efficient catalyst for [4+2] cycloadditions of 2’-
hydroxychalcones (cf. Chapter 1.1.3).  Inspired by the aforementioned biosynthesis 
studies of brosimones A and B, we thought to further investigate the development of this 
catalyst system to enable biomimetic, dehydrogenative Diels-Alder (DHDA) 
cycloadditions employing prenyl groups as diene precursors.  In this regard, we 
envisioned a multicatalytic reaction 82  scheme wherein an initial catalytic 
dehydrogenation of the prenyl moiety to a substituted 1,3-butadiene followed by an 
AgNP-catalyzed Diels-Alder cycloaddition with a 2’-hydroxychalcone would allow for 
facile access to the brosimones (Figure 2.1). This proposed investigation was not only 
designed to expand our understanding of the substrate scope of silica-supported AgNP-
catalyzed [4+2] cycloadditions, but also to develop new methods for accessing diene 
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functionalities from prenyl moieties.  
 
Figure 2.1 Design of biomimetic, dehydrogenative Diels-Alder cycloadditions. 
2.1.2 Previous Oxidative Synthons for 1,3-Dienes 
To the best of our knowledge, the direct chemical conversion of prenyl groups to 
1,3-dienes has rarely been reported. Two early precedents are depicted in Scheme 2.2. In 
1983, Semmelhack and coworkers disclosed their synthesis towards clavicipitic acid 
(155) (Schem 2.2a). In their synthesis, the investigators proposed that the allylic 
methylene proton could be deprotonated with LDA, and the resulting carbanion may add 
to the indole chromium complex. Further oxidation with iodine would then form the 
desired tricyclic core structure of 155. However, under the depicted conditions, diene 157 
was isolated as the sole product in 70% yield. Presumably, the carbanion formed above 
was trapped by iodine to generate an allylic iodide, which undergoes elimination to form 
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diene 157 under basic conditions.83 A similar phenomenon was observed by Simpkins 
and coworkers (Scheme 2.2b),84 who planned to iodinate the bridgehead carbon via a 
lithium enolate intermediate. However, upon treatment of compound 158 with LDA 
followed by I2, diene 159 was isolated instead of the desired compound 160. 
Scheme 2.2 Dehydrogenation of Prenyl Groups Using LDA/I2 
 
            At the same time as our investigations, Lei and co-workers disclosed their 
excellent syntheses of prenylflavonoids kuwanon I (165) and J (166).85  In their synthesis, 
the investigators first prepared an allylic peroxide from 161 via a visible-light-mediated 
regioselective Schenck ene reaction86 which was followed by reduction with PPh3 to 
afford an 8 : 1 mixture of tertiary allylic alcohol 162 and secondary allylic alcohol 163 in 
62% combined yield. Subsequently, 162 was dehydrated with DBU/SOCl2 which resulted 
in the production of the desired diene 164 in 75% yield. Subsequent Diels-Alder 
chemistry completed the synthesis of 165 and 166. (cf. Scheme 3.4)  
 
		
41 
Scheme 2.3 Lei’s Stepwise Preparation of a 1,3-Diene from a Prenyl Group 
	
Scheme 2.4  Dehydrogenative Cycloadditions of Terminal Olefins 
 
Recently, C-H activation has emerged as an extremely attractive research area. In 
this regard, White and coworkers successfully developed methodology for allylic C-H 
activation (Scheme 2.4).87A Pd(II)/bis(sulfoxide)88 catalyst in conjunction with 2,6-
dimethyl-1,4-benzoquinone as terminal oxidant was found to be extremely efficient for 
allylic C-H activation.20 Mechanistically, terminal olefin 167 was proposed to undergo 
reaction with Pd(II) to form a π-allyl palladium species 170, which may undergo β-
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hydride elimination to afford diene 171.  Compound 171 was subsequently trapped by 
dienophile 168 via a highly endo selective Diels-Alder cycloaddition to afford 172 in 
74% yield and over 20 : 1 d.r.. 
2.2 Results 
         To simplify our study of dehydrogenative Diels-Alder cycloadditions, Dr. Huan 
Huan Cong from our lab previously prepared the model prenylchalcone compound 177 
(Scheme 2.5). Treatment of acetophenone 173 with prenyl bromide 174 and potassium 
carbonate in refluxing acetone afforded the O-prenylated compound 175.89 Upon of 
microwave irradiation, 175 was converted to the C-prenylated compound 176 in 76% 
yield. Finally, benzaldehyde was condensed with acetophenone 176 via a NaH-catalyzed 
Claisen-Schmidt condensation to form the desired prenylchalcone 177 in 39% yield.  
Scheme 2.5 Synthesis of Model Prenylchalcone 177 
 
         We next sought to examine catalysts to achieve the in situ dehydrogenation of 
prenyl groups to 1,3-dienes and subsequent silica-supported AgNP-catalyzed Diels-Alder 
cycloaddition with 2’-hydroxychalcones. In light of White’s report (cf. Scheme 2.4), Dr. 
Cong commenced our study with prenylchalcone 177 as substrate and palladium catalyst, 
AgNP catalyst (0.20 mol% Ag loading), and 1 atm of oxygen (Table 2.1).90 However, 
palladium was found to be unreactive (entries 1 and 2), leading examination of other 
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transition metals including Rh (0), Ru (0), and Pt (0). These metals have shown striking 
catalytic activities in dehydrogenative oxidations of amines, 91  alcohols, 92  and 
heterocycles.93 With Rh/C, we observed low yields of dimeric products with less than 
10% conversion, Ru/C showed slightly higher conversion. However, the major product 
was identified as the prenylflavone 180 and only trace amounts of the desired Diels-Alder 
cycloadducts were obtained. To our delight, using platinum on activated carbon (5 wt % 
Pt/C, 10% Pt loading)94 and silica-supported AgNPs under 1 atm O2 afforded the desired  
Table 2.1 Model Study for Dehydrogenative Diels-Alder Cycloaddition 
 
entry catalyst conv.a (yield)c endo/exoa 
1 10 mol% Pd2(dba)2 <2%  
2 10 mol% Pd/C (5% wt)   
3 10 mol% Rh/C (5% wt) ~10%  
4 10 mol% Ru/C (5% wt) ~20%b  
5 10 mol% Pt/C (5% wt) 86% (59%) 57:43 
aBased on 1H NMR integration. bApprox. 20% conversion to the prenylflavone was observed. 
cIsolated yield in parentheses. 
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cycloadducts 178/179 in 59% isolated yield (86% conversion) in approximately 1 : 1 
diastereoselectivity. 
 Encouraged by these promising results, we turned our attention towards further 
optimization of reaction conditions. Focusing on the combined catalyst system of 
supported Pt and silica-supported AgNP’s, we first evaluated the effect of solvent on 
reactivity. Chlorobenzene, CCl4, CHCl3, and 1,2-dichloroethane were evaluated as 
solvents using 10 mol% Pt/C, 0.2 mol% AgNP, and 1 atm of O2. DCE showed optimal 
conversion and afforded a 60% isolated yield and a 57:43 endo/exo ratio (entries 1-5). 
Lowering the catalyst loading or temperature resulted in decreased conversion and yield 
(entries 6-7). The reaction could also be conducted under air instead of oxygen with only 
a slight decrease in reactivity and similar diastereoselectivity. We proposed that the low 
mass balance (entry 8) may be due to the harsh conditions employed. Therefore, we 
examined the strained alkenes as hydrogen scavengers (entries 9 and 10) including 
norbornene95(entry 9) and cyclopentene96 (entry 10).  Use of cyclopentene afforded the 
best mass balance and was chosen as the optimal hydrogen scavenger. Surprisingly, use 
of other platinum sources (Pt(acac)2 and Pt/silica) resulted in nearly complete loss of 
reactivity (entries 11-12). Control experiments showed that reactions with cyclopentene 
did not proceed without Pt/C (entry 13) and were significantly less efficient in the 
absence of AgNP’s (entry 14). In addition, reaction without the hydrogen scavenger only 
produced the desired products in 25% yield (entry 15). The different endo/exo ratios for 
entries 10 and 14 may be explained by conversion of endo-178 to exo-179 under AgNP-
catalyzed conditions (cf. Scheme 2.12). 
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Table 2.2 Optimization of the Model Reaction 
 
entry hydrogen scavenger Pt catalyst solvent conv.a endo/exoa 
1 O2 (1 atm.) 10 mol% Pt/C PhMe 86% (59%)d 52:48 
2 O2 (1 atm.) 10 mol% Pt/C PhCl 82% (55%) d 55:45 
3 O2 (1 atm.) 10 mol% Pt/C CCl4 46% (22%) d 58:42 
4 O2 (1 atm.) 10 mol% Pt/C CHCl3 33% (19%) d 52:48 
5 O2 (1 atm.) 10 mol% Pt/C DCE 79% (60%)d 57:43 
6 O2 (1 atm.) 5 mol% Pt/C DCE 55% (49%)d 54:46 
7b O2 (1 atm.) 10 mol% Pt/C DCE 29% 55:45 
8 air (1 atm) 10 mol% Pt/C DCE 71%(52%) d 51:49 
9 norbornenee 10 mol% Pt/C DCE 76%(44%) d 51:49 
10 cyclopentenef  10 mol% Pt/C DCE 66%(61%) d 42:58 
11 cyclopentene f 10 mol% Pt(acac)2 DCE <2%  
12 cyclopentene f 10 mol% Pt/silica DCE <2%  
13 cyclopentene f none DCE <2%  
14g cyclopentene f 10 mol% Pt/C DCE 38%  72:28 
15 none 10 mol% Pt/C DCE 40% (25%) d 55:45 
aBased on 1H NMR integration. bReaction conducted at 50 oC. dIsolated yield in parentheses. e10 
equivalents. f9 equivalents.  gIn the absence of AgNP’s 
            Based on our synthetic design, we propose that chalcone 27 undergoes Pt/C-
catalyzed prenyl dehydrogenation94c and AgNP-catalyzed [4+2] cycloaddition with the in 
situ-generated diene 181.  In order to confirm the intermediacy of 181, N-
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phenylmaleimide 182 was used in a trapping experiment using prenylchalcone 177 as 
diene precursor, which afforded cycloadduct 183 in unoptimized 40 % yield and >10:1 
endo/exo diasteroselectivity (Scheme 2.6). The structure and stereochemistry of 
cycloadduct 183 were unambiguously confirmed by NMR and X-ray crystallography. 
Scheme 2.6  In situ Trapping of A Diene Intermediate with A Reactive Dienophile 
 
         With a model dehydrogenative Diels-Alder reaction established, we then focused 
our efforts towards the total syntheses of brosimones A and B. In previous syntheses of 
prenylflavonoids, the cyclohexenyl chalcone core was shown to be labile (cf. Chapter 
1.1.3) as several syntheses failed in the final deprotection steps. Accordingly, our efforts 
were directed to choosing an appropriate protecting group. The methoxymethyl ether 
(MOM) protecting group is known to be removed under mild acidic conditions, hence 
MOM-protected prenylchalcone 187 was synthesized. Starting from the commercially 
available prenylacetophenone 184, MOM ether prenylacetophenone 185 was prepared in 
92% yield (Scheme 2.7). Subsequently, benzaldehyde 186 was condensed with 185 under 
previously described conditions (cf. Scheme 2.5) to afford the desired monomer 187 in 
quantitative yield.  Treatment of 187 under our optimized dehydrogenative Diels-Alder 
cycloaddition conditions led to 79% conversion based on 1H NMR intergration; however 
only a 39% yield of the desired cycloadducts 188 and 189 were obtained in 1:1 
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diastereoselectivity. The low yield may be due to dehydrogenation of the cyclohexenyl 
chalcone moiety. The acid-labile MOM groups in the presence of silica gel at high 
temperature may also result in undesired decomposition. Even so, the obtain brosimone B 
precursor exo-189 was treated with a broad spectrum of acidic MOM deprotection 
conditions. Representative conditions, 3M HCl in methanol, CBr4 in iPrOH, and Dowex 
resin are shown in Scheme 2.8. Unfortunately, brosimone B was not detected under these 
conditions.  
Scheme 2.7 Synthesis of MOM Ether Prenylchalcone 187 
 
Scheme 2.8  Attempted Synthesis of Brosimone B 
 
          In a parallel route, benzyl protected prenylchalcone 192 was synthesized in 80% 
yield via Claisen-Schmidt condensation between prenylacetophenone 190 and 
benzaldehyde 191 (Scheme 2.9). Treatment of 192 with our standard dehydrogenative 
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Diels-Alder cycloaddition conditions at 90 ºC afforded a 1 : 0.9 mixture of endo-193 and 
exo-194 in 45% combined yield. The relative stereochemistry of endo-193 and exo-194 
was easily assigned based on the coupling constants between 3’’, 4’’ and 4’’, 5’’ (see 
experimental section for detail).   Increasing the temperature to 110 ºC improved the 
conversion and yield of this reaction to 64%, and more interestingly, a higher exo/endo 
ratio was observed which may be due to interconversion between 193 and 194 (cf. 
Scheme 2.12). 
Scheme 2.9 Synthesis of a Brosimone B Precursor 
 
           After the desired exo cycloadduct was isolated, several hydrogenolysis conditions 
were performed to remove all six benzyl protecting groups and keep the enone moiety 
intact. We initiated condition screening with Pd/C and hydrogen. Use of 10 mol% of 
Pd/C and 1 atm H2 in acetone at room temperature afforded only a 12% yield of the over-
reduced product 195, with the remaining mass being a mixture of inseparable benzyl 
ether-protected brosimones (entry 1). Increasing the catalyst loading only produced more 
over-reduced product 195 without any of the desired brosimone B (9) (entry 2). 
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Switching to EtOAc as solvent reduced the reaction conversion (entry 3). Finally, 
replacing H2 with 1,4-cyclohexadiene97 allowed for selective reduction of the benzyl 
protecting groups, resulting in a 32% yield of brosimone B as well as a 40% recovery of 
starting material. Further investigation revealed that, using two equivalents of ammonium 
formate98 as additive increased the yield dramatically to 85%. Notably, only trace 
amounts of the over reduced product 195 were observed. However, NMR spectra of 
synthetic brosimone B did not fully match with those reported by Messana and coworkers 
for the natural product.11 The measured coupling constants for H-1’’’ have diffirent 
values than those orginally reported (geminal coupling constants:  synthetic 15.5 Hz vs. 
reported 18 Hz). We hypothesized that the double bond on the cyclohexene ring may 
have isomerized to form a conjugated system with the aromatic ring.  
Table 2.3 Synthesis of Brosimone B 
 
entry condition hydrogen donor  yield (195/9) 
1 10 mol% Pd/C, acetone, rt 1 atm H2 12%/0% 
2 40 mol% Pd/C, acetone, rt 1 atm H2 34%/0% 
3 40 mol% Pd/C, EtOAc, rt 1 atm H2 12%/0% 
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4 40 mol% Pd/C, acetone, rt 1,4-cyclohexadiene (50 equiv) 0%/32% 
5 40 mol% Pd/C, acetone, 40 ºC 1,4-cyclohexadiene (50 equiv), HCO2NH4 (2 equiv) 
3%/85% 
 
To further confirm the structure of our synthetic compound, we derivatized 
synthetic brosimone B as the hexamethyl ether compound 196. X-Ray crystallographic 
analysis of 196 showed a structure identical to that proposed by Messana and coworkers.  
Fortunately, Professor Messana provided us the original spectra of brosimone B (9), 
which were in agreement with those we obtained (see experimental section).  
Scheme 2.10 Derivatization of Brosimone B 
 
We next studied the dehydrogenative cycloaddition of exo-194 to access 
brosimone A precursor exo-197 (Table 2.4). Treatment of exo-194 with 10 mol% Pt/C 
and 0.2 mol% AgNP’s in combination with cyclopentene as H2 scavenger did not lead to 
substantial formation of desired cycloadducts at 90 ˚C. Increasing the temperature to 130 
˚C afforded only trace (5%) amounts of the desired exo-exo-197 (entry 1). Higher catalyst 
loading only increased the conversion of this reaction (entry 2). Switching to O2 or (t-
BuO)2 as hydrogen scavengers led to catastrophic degradation of starting material (entries 
3-4). The hindered oxidant 2,6-dimethylbenzoquinone and Pd/C were then employed to 
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effect the dehydrogenation, however no reaction was observed (entry 5). To our delight, 
we found that in the presence of excess 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ)99 and AgNP’s and Pd/C as catalysts, exo-194 was converted to the cycloadduct 
exo-endo-198 in 28% yield using chlorobenzene as solvent (entry 6). Surprisingly, 
conditions with different dehydrogenative catalysts such as Pd/C, PdCl2, and Pd/bis-
sulfoxide (entries 6-8) led to similar results, which encouraged us to further explore these 
reaction conditions.  
Table 2.4 Second Dehydrogenative Diels-Alder Cycloaddition 
 
entry [H] scavenger co-catalyst temp. conv.a(yield)b endo:exoa 
1 1,4-cyclopentenec 10 mol% Pt/C 130 ºC 18% (<5%) exo only 
2 1,4-cyclopentenec 30 mol% Pt/C 130 ºC 25% (<5%)  exo only 
3 O2 (1 atm.) 10 mol% Pt/C 130 ºC 65% (none)  - 
4 (t-BuO)2 (1.2 equiv) 10 mol% Pt/C 90 ºC  100% (0%)  - 
5 benzoquinoned 10 mol% Pd/C 130 ºC no reaction - 
6 DDQ (1.3 equiv) 10 mol% Pd/C 90 ºC 100% (28%)e endo only 
7 DDQ (1.3 equiv) 10 mol% PdCl2 90 ºC 100% (23%) e endo only 
8 DDQ (1.3 equiv) 10 mol% PdL 90 ºC 100% (32%) e endo only 
aBased on 1H NMR integration. bIsolated yield of exo and endo cycloadduct mixture. c50 
equivalents.d1.5 equivalents of 2, 6-dimethylbenzoquinone. eSee text and experiments below. 
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After screening a series of reaction parameters, we the found this reaction could 
also be conducted without any dehydrogenative catalyst. In the presence of DDQ and 
AgNP’s as catalyst, a 17% yield of cycloadduct exo-endo-198 and 34% yield of DDQ 
adduct 200 were isolated. (Scheme 2.11). Formation of the DDQ adduct 200 further 
supported the intermediacy of diene 199.  In a similar fashion, treatment of 
prenylchalcone 192 with DDQ in the absence of AgNP’s afforded the DHDA adduct 201 
in 55% yield and 5:1 d.r. with no exo-193 or endo-192 observed (Scheme 2.12), major 
endo diastereomer shown). The structure and stereochemistry of 201 were confirmed by 
X-ray crystallography.  
Scheme 2.11  Second Dehydrogenative Cycloaddition 
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Scheme 2.12  DDQ-derived Cycloadduct Formation 
	
Since we observed trace amounts of exo-exo-197 using 1,4-cyclopentene, Pt/C, 
and AgNP under 130 ºC (cf. Table 2.4, entry 1), we speculated that the reaction 
temperature might play significant role. Further experiments revealed that increasing the 
reaction temperature to 130 °C for the dehydrogenative Diels-Alder reaction of exo-194 
in the presence of DDQ and AgNP’s predominantly afforded exo-exo-cycloadduct 197 in 
62% yield (Scheme 2.11).  Replacement of AgNP’s with Lewis acids led to inferior 
results. Substantial decomposition occurred with BF3•Et2O, Cu(OTf)2,100 or In(OTf)3101 
as Lewis acids;  a 7% yield of 197 was obtained using AgOTf (20 mol%) as catalyst. 
Cycloadduct 197 was also not observed in a control experiment with silica gel at 130 °C, 
demonstrating the importance of AgNP’s to access brosimone A derivative 197.  
Further studies showed that adduct 200 could also be converted to 197 in 84% 
yield under AgNP-catalyzed conditions, which suggested a tandem retro-Diels-
Alder/Diels-Alder process102 consistent with the temperature-dependent stereoselectivity 
affording 198 (the kinetically favored product) and 197 (the thermodynamically favored 
product). Moreover, 198 was converted exclusively to 197 under AgNP-promoted 
conditions at 130 °C.  A control experiment without AgNP’s also showed trace 
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conversion of 198 to 197, reinforcing the fact that AgNP’s may facilitate tandem retro-
Diels-Alder/Diels-Alder processes.   
             Using our previously developed transfer hydrogenolysis condition (cf. Table 2.3), 
brosimone A (8) was obtained in good yield (90%). Since there is no reactive enone 
functionality in brosimone A, the mild reductant ammonium formate was substituted 
with formic acid to increase the reaction rate and maintain similar yield (91%) (Scheme 
2.13). Spectral data for synthetic brosimone A were in good agreement with those 
reported by Messana and coworkers for the natural product.10 The intriguing 
metacyclophane architecture drove us to obtain an X-ray structure.  However, several 
crystallization attempts failed due to the non-crystalline nature of 8.  Therefore 8 was 
Scheme 2.13 Synthesis of Brosimone A 
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methylated to afford 202, which allowed unambiguous structural and stereochemical 
assignments for synthetic brosimone A (8). The X-ray structure of 202 revealed a C2-
symmetric syn-[3,3]metacyclophane103 with slightly distorted aromatic rings80 (ϕCa-Cb-
Cc-Cd=6.4˚).       
Our previous studies provided strong evidence for an electron transfer mechanism 
for AgNP-catalyzed Diels-Alder cycloadditions.31 A simplified computational model of 
the AgNP-catalyzed cycloadditions was constructed using the corresponding diene of 
substrate 196, which experimentally was found to have similar reactivity to 194. To 
illustrate this, treatment of 196 with excess DDQ and 0.3 mol% AgNP at 90 ºC led to 
exo-endo cycloadduct 203, whose structure was confirmed by X-ray crystallography 
(Scheme 2.14). At higher temperatures (130 ºC), the exo-exo cycloadduct 202 was found 
to be the sole product. Interestingly, the relative stereochemistry between the two 
carbonyl groups are both syn in cycloadducts 202 and 203. No products with an anti 
geometry were observed. To provide more information about this temperature depended 
reaction, we collaborated with Prof. Richard Johnson and coworkers from University of 
New Hampshire to employ density functional theory (B3LYP/LANL2DZ) to predict the 
energetics for the cycloaddition by the previously proposed mechanism (cf. Scheme 1.8). 
Results are depicted in Figure 2.2. The lowest barriers were observed for a process that 
involved one electron oxidation of the substrate, deprotonation of the phenol, and 
complexation of the resultant radical with Ag(I) on the surface of the AgNP’s. Figure 2.2 
shows the energetics of stepwise intramolecular cycloadditions104 to yield the observed 
cycloadducts. Our predicted reaction energetics and calculated transition states support 
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the observation that the exo-endo-syn stereoisomer (cf. 198, Scheme 2.11) is the kinetic 
product which may be converted to the more thermodynamically stable exo-exo-syn 
diastereomer (cf. 197, Scheme 2.11) through cycloreversion. Pathways to exo-exo-anti 
and exo-endo-anti products (Scheme 2.14), which were not observed experimentally, lie 
at higher energy.105 
Scheme 2.14 Model Reactions for Calculations 
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Figure 2.2 B3LYP/LANL2DZ energetics of AgNP-catalyzed cycloadditions. 
 
2.3 Conclusion and Outlook  
In summary, we have developed biomimetic, dehydrogenative Diels-Alder 
cycloadditions which have enabled concise syntheses of the natural product brosimone B 
and the [3.3]metacyclophane natural product brosimone A. The syntheses employ Pt/C-
cyclopentene or DDQ to effect the dehydrogenation of prenylchalcones, which could be 
converted to the thermodynamic [4+2] exo-exo cycloadduct using AgNP’s at higher 
temperature. Density functional theory (DFT) was also employed to predict the energetics 
of AgNP-catalyzed cycloadditions. These computations revealed that the lowest barriers 
were observed for a process involving one electron oxidation, phenolic deprotonation, 
and complexation of the resultant radical with Ag(I) on the surface of the AgNP. Further 
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applications of dehydrogenative Diels-Alder cycloadditions may allow for rapid access to 
a wide range of prenylflavonoid natural products. Future investigations are also 
warranted to develop an asymmetric AgNP catalyst, which can be used to prepare 
enantioenriched prenylflavonoid natural products. In addition, honogeneous Pt catalysts 
could be used to shorten the reaction time by increasing the efficiency of the 
dehydrogenative reaction (cf. Table 2.2). Several homogeneous Pt (0) catalysts could be 
considered as shown in Figure 2.3. 
 
 
Figure 2.3   Possible Homogeneous Pt catalysts for DHDA Cycloadditions. 
 
2.4 Experimental Section 
General Information 
         1H NMR spectra were recorded at 400 or 500 MHz at ambient temperature with 
CDCl3 (Cambridge Isotope Laboratories, Inc.) as the solvent unless otherwise stated. 13C 
NMR spectra were recorded at 100 or 125 MHz at ambient temperature with CDCl3 as 
the solvent unless otherwise stated. Chemical shifts are reported in parts per million 
relative to CDCl3 (1H, δ 7.26; 13C, δ 77.16). Data for 1H NMR are reported as follows: 
chemical shift, integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet) and coupling constants. All 13C NMR 
spectra were recorded with complete proton decoupling. Infrared spectra were recorded 
on a Nicolet Nexus 670 FT-IR spectrophotometer. High-resolution mass spectrometry 
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was obtained at the Boston University Chemical Instrumentation Center using a Waters 
Q-TOF mass spectrometer. Melting points were recorded on a Mel-temp apparatus 
(Laboratory Devices). Analytical liquid chromatography was performed using a Waters 
ACQUITY UPLC® system equipped with PDA, ELS, and SQ detectors. Analytical thin 
layer chromatography (TLC) was performed using 0.25 mm silica gel 60-F plates 
(Silicycle, Inc.). Flash chromatography was performed using 200-400 mesh silica gel 
(Sorbent Technologies, Inc.). Preparative TLC was conducted with glass backed 250 µm 
or 1000 µm silica gel 60-F plates (Silicycle, Inc.). Preparative HPLC was conducted 
using a PLC 2020 Personal Purification System (Gilson, Inc.). Yields refer to 
chromatographically and spectroscopically pure compounds, unless otherwise stated. 
Diels-Alder reactions were conducted in Teflon® capped, heavy wall sealed vials 
(Chemglass CG-1880, 15 mL or CG-4920-01 Complete Package) to minimize 
solvent/reagent evaporation. All other reactions were carried out in oven-dried glassware 
under an argon/nitrogen atmosphere unless otherwise noted. The ArthurTM Suite Reaction 
Planner (Symyx Technologies, Inc.) was used for experimental procedure planning. 
 
Chemical Reagents and Solvents 
HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, toluene, acetonitrile, and 
benzene were purchased from Fisher and VWR and were purified and dried by passing 
through a PURE SOLV® solvent purification system (Innovative Technology, Inc.). 
Anhydrous 1,2-dichloroethane (DCE), chlorobenzene, and acetone from Aldrich were 
degassed using freeze-pump-thaw. The silica-supported AgNP catalyst was prepared by 
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reduction of AgBF4 with Bu4NBH4. Reagents were purchased from Strem, Aldrich, 
Acros, TCI America, Indofine, and Alfa Aesar and were used as received.  
 
Additional Experiments 
NMR study for DDQ-mediated dehydrogenation: 
To an NMR tube were sequentially added compound 53 (15.0 mg, 0.039 mmol, 1.0 
equiv), DDQ (8.9 mg, 0.039 mmol, 1.0 equiv), and degassed CDCl3 (0.8 mL) under Ar. 
A 1H NMR spectrum taken 10 minutes later at 25 oC clearly shows that the corresponding 
DDQ adduct forms in situ. Key protons are highlighted. 
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Compound Preparation and Characterization 
 
 
Prenylacetophenone 176: To a 10 mL microwave vial equipped with stirbar were added 
O-prenylated acetophenone 175 (1.20 g, 5.12 mmol, 1.0 equiv) and N,N-diethylaniline 
(4.0 mL) at 25 oC under air. The reaction vial was capped and heated in a microwave 
instrument (CEM Discover® SP, 300 W) at 200 oC for 80 min. The reaction mixture was 
cooled to ambient temperature, diluted with water, washed with 2 M HCl, extracted with 
EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification on 
silica gel (5% EtOAc in hexanes) afforded compound 176 (912 mg, 3.89 mmol, 76% 
yield) as a colorless oil. 
Characterization data were identical with those reported in the literature.106  
 
 
Prenylchalcone 177: To a stirred solution of acetophenone 176 (975.0 mg, 4.16 mmol, 
1.0 equiv) and benzaldehyde (0.430 mL, 4.23 mmol, 1.02 equiv) in THF (10.0 mL) was 
added NaH (60% dispersion in mineral oil, 361.0 mg, 8.78 mmol, 2.1 equiv) at 0 oC. The 
reaction mixture was slowly warmed to r.t. and stirred for 18 h before being quenched by 
water. The resulting yellow suspension was neutralized to pH 5 by 2M HCl, extracted 
with EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. 
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Purification on silica gel (4% EtOAc in hexanes) afforded compound 177 (522.0 mg, 
1.62 mmol, 39% yield) as a yellow solid.  
m.p. 94-96 oC (CH2Cl2); Rf: 0.65 (20% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.48 (1H, s), 7.85 (1H, d, J = 15.5 Hz), 7.63 (2H, m) , 7.60 
(1H, s), 7.55 (1H, d, J = 15.5 Hz), 7.44-7.40 (3H, m), 6.43 (1H, s), 5.32 (1H, t, J = 7.2 Hz), 
3.83 (3H, s), 3.28 (2H, d, J = 7.5 Hz), 1.81 (3H, s), 1.76 (3H, s); 13C NMR (100.0 MHz, 
CDCl3) δ 191.6, 165.5, 164.2, 143.8, 134.9, 132.8, 130.5, 129.7, 129.0 (2C), 128.4 (2C), 
122.3, 121.6, 120.5, 113.3, 99.3, 55.6, 28.0, 25.8, 17.8; IR νmax (film): 2916, 1636, 1576, 
1362, 1215, 1131 cm-1; HRMS (ESI+) m/z calculated for C21H23O3 (M + H+) 323.1647, 
found 323.1654. 
 
 
Cycloadducts exo-179 and endo-178 (Representative procedure for Table 2.2, entry 10): 
To a reaction vial equipped with stirbar were added silica-supported AgNP catalyst (50.0 
mg, containing 13.4 µg Ag, 0.2 mol% Ag loading), 5 wt% Pt/C (24.0 mg, 10 mol% Pt 
loading), prenylchalcone 177 (19.7 mg, 0.061 mmol, 1.0 equiv), cyclopentene (0.050 mL, 
0.55 mmol, 9.0 equiv) and anhydrous degassed DCE (1.0 mL) at r.t. under Ar. The vial 
was sealed with a Teflon® cap and heated at 90 oC for 36 h. The resulting reaction 
mixture was cooled to r.t., filtered through a short Celite® pad with the aid of ethyl 
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acetate, and concentrated in vacuo. Purification using silica gel (3-10% EtOAc in 
hexanes) afforded compounds exo-179 and endo-178 (58/42 ratio, 12.0 mg, 0.037 mmol, 
61% yield) as yellow oils. 
Further separation of exo-179 and endo-178 was achieved by preparative TLC (5% 
EtOAc in hexanes).  
 
exo-179: yellow oil. Rf: 0.40 (20% EtOAc in hexanes); 
1H NMR (500 MHz, acetone-d6) δ 13.38 (1H, s), 13.03 (1H, s), 8.11 (1H, br), 7.89 (2H, 
m), 7.81-7.79 (2H, m), 7.52-7.49 (3H, m), 7.25-7.22 (3H, m), 7.13-7.10 (2H, m), 7.03-
7.00 (1H, m), 6.18 (1H, s, br), 6.13 (1H, s), 5.47 (1H, s), 4.94 (1H, t, J=7.5 Hz), 4.19 (2H, 
br), 3.74 (3H, s), 3.65 (3H, s, br), 3.48 (1H, m), 2.92 (2H, m), 2.45 (1H, m) 2.28 (1H, dd, 
J = 17.9, 5.3 Hz), 1.86 (3H, s), 1.65 (3H, s), 1.57 (3H, s); 13C NMR (125 MHz, CDCl3) δ 
207.0, 191.8, 165.7, 164.0, 163.9, 163.8, 144.5, 143.9, 135.0, 134.9, 132.5, 130.8, 130.1, 
129.5, 129.2 (2C), 128.7 (2C), 128.5 (2C), 127.5 (2C), 126.5, 124.6, 124.2, 122.3, 121.0, 
120.7, 114,4, 113.7, 99.3, 98.5, 55.6, 55.4, 52.6, 52.5, 44.1, 39.2, 28.1, 25.8, 23.5, 17.8; 
IR νmax (film): 2914, 1635, 1573, 1376, 1207, 1130 cm-1; HRMS (ESI+) m/z calculated 
for C42H43O6 (M+ H+) 643.3060, found 643.3075. 
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Key NOE correlations for exo-179: 
 
 
 
 
 
 
 
 
 
 
endo-178: yellow solid. m.p. >150 oC (decompose); Rf: 0.40 (20% EtOAc in hexanes); 
1H NMR (500 MHz, acetone-d6) δ 13.40 (1H, s), 12.48 (1H, s), 8.05 (1H, s, br), 7.93 (1H, 
s), 7.90 (1H, d, J = 15.5 Hz), 7.784 (1H, d, J = 8.0 Hz), 7.780 (1H, d, J = 7.0 Hz), 7.74 
(1H, d, J = 15.5 Hz), 7.52-7.47 (3H, m), 7.178 (1H, d, J = 8.0 Hz), 7.175 (1H, d, J = 7.0 
Hz), 7.12-7.00 (3H, m), 6.333 (1H, s), 6.329 (1H, s), 5.58 (1H, dq, J = 5.0, 1.0 Hz), 5.37 
(1H, tq, J = 7.2, 1.3 Hz), 4.54 (1H, dd, J = 12.0, 5.5 Hz), 4.35 (1H, dd, J = 5.5, 5.0 Hz), 
3.87 (3H, s), 3.39 (1H, ddd, J = 12.0, 12.0, 5.5 Hz), 3.33 (2H, d, J = 7.2 Hz), 3.29 (3H, s), 
2.53 (1H, dd, J = 18.2, 5.5 Hz), 2.28 (1H, dd, J = 18.2, 12.0 Hz), 1.96 (3H, s), 1.77 (3H, d, 
J =1.3 Hz), 1.75 (3H, d, J =1.0 Hz); 13C NMR (125 MHz, CDCl3) δ 204.6, 192.1, 166.1, 
164.2, 163.7, 163.5, 144.7, 144.0, 135.8, 135.2, 133.0, 132.2, 130.7, 129.7, 129.2 (2C), 
128.48 (2C), 128.46 (2C), 127.4 (2C), 126.3, 122.7, 122.5, 121.5, 120.9, 120.5, 114.6, 
113.3, 99.12, 99.08, 55.8, 54.7, 49.3, 40.3, 38.0, 37.2, 28.5, 26.0, 23.4, 18.1; IR νmax 
(film): 2966, 2911, 1635, 1576, 1375, 1216 cm-1; HRMS (ESI+) m/z calculated for 
C42H43O6 (M + H+) 643.3060, found 643.3076. 
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Relative stereochemistry assignment for endo-178 was based on comparison key 1H 
NMR coupling constants with those reported for related natural products.16 The  
configuration of endo-178 was further confirmed by NOE experiments. Key NOE 
correlations for endo-178 are shown below:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cycloadduct 183: To a reaction vial equipped with stirbar were added 5 wt% Pt/C (25.0 
mg, 10 mol% Pt loading), prenylchalcone 177 (19.7 mg, 0.061 mmol, 1.0 equiv), N-
phenylmaleimide 182 (108.0 mg, 0.62 mmol, 10.0 equiv), cyclopentene (0.100 mL, 1.0 
mmol, 20.0 equiv), and anhydrous DCE (1.0 mL) at r.t. under Ar. The vial was then 
sealed with a Teflon® cap, and heated at 90 oC for 24 h. The resulting reaction mixture 
was cooled to r.t., filtered through a short Celite® pad with the aid of ethyl acetate, and 
concentrated in vacuo. Purification using silica gel (5-25% EtOAc in hexanes) afforded 
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compound 183 (12.0 mg, 0.024 mmol, 40% yield) as a yellow solid. The X-ray crystal 
structure for compound 183 may be found in Section II.C. 
m.p. >180 oC (decompose); Rf: 0.10 (20% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.28 (1H, s), 7.82 (1H, d, J = 15.5 Hz), 7.62 (1H, s), 7.58 
(2H, m), 7.44 (1H, d, J = 15.5 Hz), 7.40 (3H, m), 7.36-7.28 (3H, m), 7.06 (2H, m), 6.49 
(1H, s), 5.82 (1H, s), 4.11 (1H, s, br), 3.87 (3H, s), 3.53 (1H, dd, J = 8.7, 7.2 Hz), 3.41 
(1H, ddd, J = 9.0, 8.7, 2.2 Hz), 2.85 (1H, dd, J = 16.2, 2.2 Hz), 2.47 (1H, dd, J = 16.2, 9.0 
Hz), 1.92 (3H, s); 13C NMR (100.0 MHz, CDCl3) δ 192.5, 178.9, 176.5, 165.7, 163.8, 
144.6, 136.9, 135.0, 132.1, 131.3, 130.6, 129.13 (2C), 129.09 (2C), 128.7 (2C), 128.5, 
126.2 (2C), 123.0, 121.1, 119.8, 113.7, 99.7, 56.0, 43.6, 40.3, 34.8, 28.8, 23.8; IR νmax 
(film): 2928, 2852, 1710, 1636, 1576, 1382, 1214 cm-1; HRMS (ESI+) m/z calculated for 
C31H28NO5 (M + H+) 494.1967, found 494.1957. 
 
 
Prenylacetophenone 185. To a stirred solution of acetophenone 184 (178 mg, 0.81 
mmol, 1.0 equiv.) in CH2Cl2 (2.0 mL) was added sequentially N,N-diisopropylethylamine 
(0.310 mL, 1.78 mmol, 2.2 equiv.) and chloromethyl methyl ether (67.5 µL, 0.89 mmol, 
1.1 equiv.) at 0 °C. The reaction mixture was slowly warmed to r.t. and stirred for 1 h. 
The resulting light brown solution was neutralized to pH 5 by 2M HCl, extracted with 
EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification on 
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silica gel (5% EtOAc in hexanes) afforded the title compound 185 (196 mg, 92% yield) 
as colorless oil. Characterization data were identical with those reported in literature.107  
 
Prenylchalcone 187. To a stirred solution of acetophenone 185 (196 mg, 0.74 mmol, 1.0 
equiv.) and benzaldehyde 186 (168.4 mg, 0.74 mmol, 1.0 equiv.) in THF (5.0 mL) was 
added NaH (60% dispersion in mineral oil, 68 mg, 1.7 mmol, 2.3 equiv.) at 0 oC. The 
reaction mixture was slowly warmed to r.t. and stirred for 48 h before quenched by water. 
The resulting yellow suspension was neutralized to pH 5 by 2 M HCl, extracted with 
EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification on 
silica gel (20% EtOAc in hexanes) afforded the title compound 187 (341 mg, 96% yield) 
as orange oil.  
Rf: 0.50 (33% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.38 (1H, s), 8.15 (1H, d, J = 16.0 Hz), 7.61 (1H, s), 7.58 
(1H, d, J = 8.5 Hz), 7.56 (1H, d, J = 16.0 Hz), 6.84 (1H, d, J = 2.0 Hz), 6.74 (1H, dd, J = 
8.5, 2.0 Hz), 6.62 (1H, s), 5.28 (1H, t, J = 7.5 Hz), 5.26 (2H, s), 5.22 (2H, s), 5.18 (2H, s), 
3.50 (3H, s), 3.47 (3H, s), 3.46 (3H, s), 3.27 (2H, d, J = 7.0 Hz), 1.74 (3H, s), 1.73 (3H, 
s); 13C NMR (125 MHz, CDCl3) δ 192.3, 164.7, 161.1, 160.4, 157.8, 139.3, 132.6, 130.0, 
129.9, 122.4, 121.7, 118.9, 118.5, 114.3, 109.3, 103.3, 102.0, 94.6, 94.2, 93.9, 56.3, 
56.22, 56.19, 28.3, 25.7, 17.8; IR νmax (film): 2915, 1636, 1560, 1154, 1074 cm-1; HRMS 
(ESI+) m/z calculated for C26H33O8 (M + H+) 473.2175, found 473.2155. 
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Prenylacetophenone 190: To a stirred solution of acetophenone 184 (250.8 mg, 1.14 
mmol, 1.0 equiv) in acetone (3.0 mL) was added K2CO3 (203.0 mg, 1.47 mmol, 1.29 
equiv), and the reaction was stirred for 15 min at 40 °C in air. Benzyl bromide (0.140 mL, 
1.18 mmol, 1.03 equiv) was then added and the reaction was further stirred for 5 h at 
40 °C in air. The resulting light yellow solution was quenched by washing with 2 M HCl, 
extracted by EtOAc, dried over Na2SO4, and concentrated in vacuo. Purification on silica 
gel (2% EtOAc in hexanes) afforded compound 190 (310.0 mg, 1.00 mmol, 88% yield) 
as a white solid. 
m.p. 90-92 oC (CH2Cl2), Rf: 0.45 (25% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 12.68 (1H, s), 7.44-7.32 (6H, m), 6.46 (1H, s), 5.28 (1H, t, 
J = 7.0 Hz), 5.11 (2H, s), 3.28 (2H, d, J = 7.0 Hz), 2.55 (3H, s), 1.75 (3H, s), 1.65 (3H, s); 
13C NMR (125 MHz, CDCl3) δ 202.6, 163.8, 163.0, 136.1, 133.0, 131.0, 128.6 (2C), 
128.1, 127.3 (2C), 122.2, 121.9, 113.4, 100.2, 70.1, 28.2, 26.2, 25.8, 17.8; IR νmax (film): 
2968, 1636, 1500, 1389, 1275, 1245, 830 cm-1; HRMS (ESI+) m/z calculated for 
C20H23O3 (M + H+) 311.1647, found 311.1638. 
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Prenylchalcone 192: To a stirred solution of acetophenone 190 (261.1 mg, 0.84 mmol, 
1.027 equiv) and benzaldehyde 191108 (260.7 mg, 0.82 mmol, 1.0 equiv) in THF (5.0 mL) 
was added NaH (60% dispersion in mineral oil, 74.2 mg, 1.86 mmol, 2.3 equiv) at 0 oC 
under Ar. The reaction mixture was slowly warmed to r.t. and stirred for 48 h before 
being quenched by water. The resulting yellow suspension was neutralized to pH 5 by 2 
M HCl, extracted with EtOAc, washed with brine, dried over Na2SO4, and concentrated 
in vacuo. Recrystalization in EtOAc and hexanes (1:4) afforded compound 192 (367.2 
mg). The mother liquid was further purified by preparative TLC (10% EtOAc in hexanes) 
affording another 33.2 mg of compound 192 (400.4 mg isolated in total, 0.656 mmol, 80% 
yield) 
Yellow solid, m.p. 148-149 oC (CH2Cl2), Rf: 0.45 (25% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.65 (1H, s), 8.12 (1H, d, J = 15.5 Hz), 7.69 (1H, d, J = 
15.5 Hz), 7.56 (1H, m), 7.48-7.32 (16H, m), 6.65 (2H, m), 6.49 (1H, s), 5.20 (1H, tq, J 
=7.0, 1.0 Hz), 5.17 (2H, s), 5.11 (2H, s), 5.09 (2H, s), 3.21 (2H, d, J =7.0 Hz), 1.71 (3H, 
d, J =1.0 Hz), 1.61 (3H, s); 13C NMR (125 MHz, CDCl3) δ 192.6, 165.3, 163.0, 162.1, 
159.7, 140.3, 136.40, 136.35, 136.33, 132.39, 132.35, 130.1, 128.9 (2C), 128.8 (2C), 
128.7 (2C), 128.42, 128.39, 128.2, 127.7 (2C), 127.6 (2C), 127.4 (2C), 122,9, 121,8, 
119.4, 117.8, 113.9, 106.8, 100.8, 100.5, 70.7, 70.4, 70.2, 28.8, 25.9, 18.0; IR νmax (film): 
3034, 2916, 1629, 1555, 1377, 1257, 1133, 1002, 735 cm-1; HRMS (ESI+) m/z calculated 
for C41H39O5 (M + H+) 611.2797, found 611.2813. 
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Cycloadducts exo-194 and endo-193: To a reaction vial equipped with stirbar were 
added silica-supported AgNP catalyst (25.0 mg, containing 6.8 µg Ag, 0.2 mol% Ag 
loading), 5 wt% Pt/C (33.0 mg, 10 mol% Pt loading), prenylchalcone 192 (50.0 mg, 0.08 
mmol, 1.0 equiv), cyclopentene (0.100 mL, 1.0 mmol, 12.5 equiv), and anhydrous 
degassed DCE (1.5 mL) at r.t. under Ar. The vial was sealed with a Teflon® cap and 
heated at 110 oC for 48 h. The resulting reaction mixture was cooled to rt, filtered through 
a short Celite® pad with the aid of ethyl acetate, and concentrated in vacuo. Purification 
using silica gel (5-15% EtOAc in hexanes) afforded a mixture of compounds exo-194 and 
endo-193 (55/45 ratio, 32.1 mg, 0.051 mmol, 64% yield) as yellow oils. 
Further separation of exo-194 and endo-193 was achieved by preparative TLC (4:1:1 
hexanes : CH2Cl2 : Et2O). 
exo-194: yellow oil. Rf: 0.25 (25% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3, 50 oC) δ 13.42 (1H, s), 12.90 (1H, s), 8.16 (1H, d, J = 15.5 
Hz), 7.59 (1H, d, J = 7.5 Hz ), 7.56(1H, s, br), 7.50 (1H, s, br), 7.46-7.22 (30H, m), 6.98 
(1H, s, br), 6.90 (1H, d, J = 8.0Hz), 6.67-6.64 (2H, m), 6.38 (1H, bs), 6.32 (1H, dd, J = 
8.5, 2.0 Hz), 6.26 (1H, s, br), 6.17 (1H, s), 5.45 (1H, s), 5.19 (2H, s), 5.10 (2H, s), 4.97-
4.86 (9H, m), 4.31 (1H, s, br), 4.02 (1H, s, br), 3.92 (1H, s, br), 2.98 (2H, m), 2.25 (2H, 
m), 1.75 (3H, s), 1.65 (3H, s), 1.50 (3H, s); 13C NMR (125 MHz, CDCl3, 50 oC) δ 207.8, 
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192.5, 165.5, 163.7, 162.9, 162.7, 162.3, 159.7, 158.4, 157.3, 140.1, 137.6, 137.3, 136.6, 
136.4 (2C), 136.3, 133.8, 133.7, 131.7, 131.5, 131.0, 130.9, 128.92 (2C), 128.90 (2C), 
128.77 (2C), 128.73 (2C), 128.63 (2C), 128.60 (2C), 128.33, 128.31, 128.08, 128.07, 
127.92, 127.77, 127.57 (2C), 127.52 (2C), 127.41 (2C), 127.37 (2C), 127.06 (2C), 126.95 
(2C), 125.2, 124.7, 123.7, 123.2, 121.3, 119.3, 118.1, 114.9, 114.2, 107.3, 106.4, 101.5, 
101.2, 100.7, 99.9, 70.9, 70.8, 70.6, 70.5, 70.3, 70.1, 50.0, 44.4, 37.5 (2C broad weak 
peak), 29.0, 25.7, 23.2, 17.9; IR νmax (film): 3033, 2907, 1629, 1557, 1375, 1167, 1027, 
736 cm-1; HRMS (ESI+) m/z calculated for C82H75O10 (M + H+) 1219.5360, found 
1219.5894. 
Due to the broadness of the corresponding 1H NMR peaks of exo-194, the relative 
stereochemistry assignment for exo-194 was based on the comparision to compound 196, 
the structure of which was determined by X-ray crystal structure analysis. The following 
scheme shows that 196 can also be accessed from 194 which also indicates 194 has same 
exo relative stereochemistry as 196. 
 
 
endo-193: yellow oil. Rf: 0.25 (25% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.54 (1H, s), 12.68 (1H, s), 8.17 (1H, d, J = 15.8 Hz), 
7.75 (1H, s, br), 7.53-7.50 (3H, m), 7.42-7.27 (21H, m), 7.27-7.15 (7H, m), 6.96 (2H, s, 
		
72 
br), 6.94 (1H, d, J = 8.5 Hz), 6.58-6.55 (2H, m), 6.41 (1H, d, J = 2.4 Hz), 6.39 (1H, s), 
6.34 (1H, dd, J =8.5, 2.4 Hz), 6.10 (1H, s), 5.56 (1H, dq, J = 5.0, 1.4 Hz), 5.20 (1H, d, J = 
12.7 Hz), 5.16 (1H, d, J = 12.7 Hz), 5.12 (1H, t, J = 7.1 Hz), 5.02 (2H, s), 4.95-4.83 (8H, 
m), 4.57 (1H, d, J = 12.0 Hz), 4.52 (1H, m), 4.33 (1H, s, br), 3.74 (1H, s, br), 3.06 (2H, 
m), 2.44 (1H, m), 1.82 (3H, s), 1.69 (3H, d, J =1.4 Hz), 1.57 (3H, s); 13C NMR (125 
MHz, CDCl3, 50 oC) δ 205.4, 192.8, 165.5, 163.8, 163.0, 162.4, 162.2, 159.4, 158.3, 
157.4, 139.3, 137.3, 137.2 (2C), 136.7, 136.63, 136.59, 136.2, 135.8, 132.3, 132.1, 130.2, 
130.1, 128.82 (2C), 128.75 (2C), 128.6 (2C), 128.3 (2C), 128.2 (2C), 128.1 (2C), 128.0, 
127.82, 127.76, 127.68 (2C), 127.6 (2C), 127.4 (2C), 127.1 (2C), 127.0 (2C), 126.9 (2C), 
126.7, 126.6, 126.0, 123.28, 123.17, 122.9, 121.5, 120.7, 119.4, 118.4, 114.8, 113.9, 
107.5, 106.4, 101.7, 101.4, 100.4, 100.2, 70.7, 70.6, 70.4, 70.3, 70.0, 69.8, 47.9, 37.6, 
37.1, 32.7, 28.8, 25.7, 23.3, 17.9; IR νmax (film): 3032, 2911, 1626, 1558, 1375, 1246, 
1117, 1027, 735 cm-1; HRMS (ESI+) m/z calculated for C82H75O10 (M + H+) 1219.5360, 
found 1219.5385. 
Relative stereochemistry assignment for endo-193 was based on comparison of key 1H 
NMR coupling constants with those reported for related natural products. 
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Brosimone B (9): To a reaction vial equipped with stirbar were added exo-194 (30.0 mg, 
0.025 mmol), 10% wt Pd/C (10.5 mg, 0.0098 mmol, 0.4 equiv), ammonium formate (3.1 
mg, 0.05 mmol, 2.0 equiv), 1,4-cyclohexadiene (116 µL, 1.23 mmol, 50.0 equiv), and 
degassed acetone (3.0 mL) under Ar. The vial was sealed and heated at 40 oC for 24 h. 
The resulting reaction mixture was filtered through a short Celite® pad with the aid of 
ethyl acetate, and concentrated in vacuo. Purification using preparative HPLC (SunfireTM 
19 x 50 mm C18 column, gradient from 90% H2O/10% CH3CN to 10% H2O/90% 
CH3CN over 20 min, held to 25 min. Retention time: 11.3 min.) afforded compound 9 
(14.1 mg, 0.021 mmol, 85% yield) as yellow, amorphous powder.  
Rf: 0.25 (5% MeOH in CH2Cl2);  
IR νmax (film): 3305, 2919, 2850, 1629, 1377, 1239, 847 cm-1; HRMS (ESI+) m/z 
calculated for C40H39O10 (M + H+) 679.2543, found 679.2631 
 
		
74 
1H NMR: 
Positions Natural11 9 (400 MHz, 
acetone-d6, 60 oC) 
Synthetic 9 (500 MHz, acetone-
d6, 60 oC) 
OH 13.53 1H, s 13.34 1H, s 
OH 12.95 1H, s 12.79 1H, s 
α 8.04 1H, d, J=15.0 8.05 1H, d, J=15.4 
6’ 7.79 1H, bs 7.79 1H, bs   
β 7.68 1H, d, J=15.0 7.68 1H, d, J=15.4 
6 7.44 1H, d, J=8.3 7.45 1H, d, J =8.5 
14’’ 7.24 1H, bs 7.26 1H, bs 
20’’ 6.80 1H, d, J=8.3 6.80 1H, d, J=8.5 
3 6.45 1H, d, J=2.3 6.45 1H, d, J=2.3 
5 6.40 1H, dd, J=8.3,2.3 6.40 1H, d, J=8.5, 2.3 
17’’ 6.18 1H, d, J=2.3 6.17 1H, d, J=2.3 
3’ 6.10 1H, bs 6.10 1H, bs 
19’’ 6.02 1H, dd, J=8.3, 2.3 6.02 1H, dd, J=8.5, 2.3 
11’’ 6.01 1H, s 5.98 1H, bs 
2’’ 5.32 1H, bs 5.34 1H, bs 
2’’’ 4.98 1H, bt, J=7.0 4.99 1H, bt, J=6.7 
4’’ 4.21 1H, bt, J=10.5 4.26 1H, bt, J=10.5  
3’’ 4.07 1H, bd, J=10.5 4.07 1H, bd, J=10.5 
5’’ overlap 3.66 1H, bs 
1’’’ 2.92 1H, dd, J=15.0, 6.8 2.93 1H, dd, J=15.5, 6.7  
1’’’ 2.85 1H, dd, J=15.0, 7.5 2.88 1H, dd, J=15.5, 7.5  
6’’ 2.43 1H, m 2.46 1H, bs 
6’’ 2.15 1H, dd, J=18.0, 4.5 2.14 1H, dd, J=17.5, J=4.2 
7’’ 1.75 3H, s 1.74 3H, s 
5’’ 1.60 3H, s 1.58 3H, s 
4’’ 1.50 3H, s 1.51 3H, s 
 
13C NMR: 
Positions 
 
Natural11 9 (100 MHz, 
acetone-d6, 27 oC) 
Synthetic 9 (100 MHz, 
acetone-d6, 27 oC) 
8’’ 208.7 208.7 
C=O 193 193.0 
10’’ 165.4 165.5 
2’ 164.1 164.2 
4’ 162.7 162.7 
12’’ 162.6 162.6 
4 162 162.0 
2 159.8 159.8 
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16’’ 157 157.0 
18’’ 156.2 156.3 
α 141 141.0 
1’’ 134.8 134.8 
20’’ 133.1 133.1 
6’ 132 132.0 
6 132 132.0 
3’’’ 131.7 131.7 
14’’ 129.7 129.7 
2’’ 125.2 125.3 
2’’’ 123.8 123.8 
13’’ 123.4 123.4 
15’’ 121.8 121.8 
5’ 120.1 120.1 
β 117.7 117.8 
1 115.3 115.4 
1’ 115.1 115.2 
9’’ 114.6 114.6 
19’’ 108.9 108.9 
5 107.3 107.3 
3 103.5 103.62 
3’ 103.5 103.56 
11’’ 103.3 103.3 
17’’ 102.4 102.4 
4’’ 50.7 50.7 
3’’ 42.8 42.8 
6’’ 38.7 38.7 (weak peak) 
5’’ 37.8 37.8 
1’’’ 28.6 28.6 
4’’’ 25.6 25.7 
7’’ 23.3 23.3 
5’’’ 17.7 17.7 
 
 
		
76 
Cycloadduct 196 (prepared from brosimone B): To a reaction vial equipped with stirbar 
were added brosimone B (9.2 mg, 0.014 mmol, 1.0 equiv), potassium carbonate (15.0 
mg, 0.11 mmol, 8.0 equiv), and acetone (2.0 mL) under air. Dimethyl sulfate (10 uL, 0.11 
mmol, 8.0 equiv) was slowly added. The vial was sealed and heated at 40 oC for 4 h 
before quenched by 1M HCl. The resulting light yellow suspension was extracted with 
EtOAc, washed with brine, dried over Na2SO4, and concentrated in vacuo. Purification on 
silica gel (15-20% EtOAc in hexanes) affored brosimone B hexamethylether 196 (1.5 mg, 
0.0021 mmol, 15% yield), which was found to be identical with the exo-cycloadduct 
obtained from DHDA reaction of 204. The X-ray crystal structure of compound 196 can 
be found below.  
 
 
Cycloadduct 196 (prepared from 204): To a reaction vial equipped with stirbar were 
added silica-supported AgNP catalyst (25.0 mg, containing 6.8 µg Ag, 0.2 mol% Ag 
loading), 5 wt% Pt/C (33.0 mg, 10 mol% Pt loading), prenylchalcone 204 (31.3 mg, 0.08 
mmol, 1.0 equiv), cyclopentene (0.100 mL, 1.0 mmol, 12.5 equiv), and anhydrous 
degassed DCE (1.5 mL) at r.t. under Ar. The vial was sealed with a Teflon® cap and 
heated at 110 oC for 48 h. The resulting reaction mixture was cooled to r.t., filtered 
through a short Celite® pad with the aid of ethyl acetate, and concentrated in vacuo. 
Purification using silica gel (15-20% EtOAc in hexanes) affored a mixture of endo/exo-
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cycloadducts (20.3 mg, 43:57 ratio, 0.052 mmol, 65% yield) as yellow oils. Further 
separation by preparative TLC (100% CH2Cl2) afforded exo-cycloadduct 196 as a yellow 
solid. 
m.p. 185-187 oC (CH2Cl2), Rf: 0.15 (25% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 13.54 (1H, s), 13.13 (1H, s), 8.07 (1H, d, J = 15.5 Hz), 
7.75(1H, s, br), 7.74 (1H, d, J = 15.5 Hz ), 7.56 (1H, d, J = 8.5 Hz ), 6.95 (1H, d, J = 8.2 
Hz ), 6.78 (1H, s, br), 6.59 (1H, dd, J = 2.2, 8.5 Hz ), 6.52 (1H, d, J = 2.2 Hz ), 6.26 (2H, 
m), 6.13 (1H, s), 5.99 (1H, s, br), 5.47 (1H, s, br), 4.87 (1H, t, J = 6.7 Hz ), 4.12 (1H, d, J 
= 8.6 Hz), 4.00 (1H, s, br), 3.96 (3H, s), 3.88 (3H, s), 3,77 (1H, s, br), 3.73 (3H, s), 3.70 
(3H, s, br), 3.68 (3H, s), 3.46 (3H, s, br), 2.95 (1H, dd, J = 15.6, 6.7 Hz), 2.80 (1H, dd, J 
=15.6, 6.7 Hz), 2.50 (1H, s, br), 2.25 (1H, d, J = 18.0 Hz ), 1.88 (3H, s), 1.63 (3H, s), 
1.54 (3H, s); 13C NMR (100 MHz, CDCl3, 44 oC) δ 207.7, 192.6, 165.5, 163.8, 163.7, 
163.6, 163.3, 160.9, 159.3, 158.4, 140.5, 135.2, 132.3, 132.1, 130.5, 129.6 (2C), 124.7, 
124.4 (2C), 122.7, 120.9, 119.4, 117.6, 114.5, 114.2, 105.8, 104.6, 99.2, 99.1, 98.9, 98.5, 
55.7 (2C), 55.6, 55.5, 55.3, 55.2, 51.8, 41.4, 39.6, 37.2, 28.1, 25.8, 23.6, 17.8; IR νmax 
(film): 2940, 2839, 1631, 1558, 1377, 1209, 1128, 758 cm-1; HRMS (ESI+) m/z 
calculated for C46H51O10 (M+H+) 763.3482, found 763.3494. 
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Cycloadducts exo-endo-198 and 200: To a reaction vial equipped with stirbar were 
added exo-194 (30.0 mg, 0.025 mmol, 1.0 equiv), DDQ (9.0 mg, 0.040 mmol, 1.6 equiv), 
silica-supported AgNP catalyst (30.0 mg, containing 8.1 µg Ag, 0.3 mol% Ag loading), 
and degassed PhCl (2.5 mL) under Ar. The vial was sealed and heated at 90 oC for 48 h. 
The resulting reaction mixture was filtered through a short Celite® pad with the aid of 
ethyl acetate, and concentrated in vacuo. Purification using silica gel (7% EtOAc in 
hexanes) afforded compound exo-endo-198 (5.0 mg, 0.0043 mmol, 17% yield) as a pale 
yellow oil, compound 200 (12.0 mg, 0.0085 mmol, 34% yield) as an orange oil, and 
starting material (8.0 mg, 0.0068 mmol, 27% yield).   
 
DDQ adduct 200 was alternatively prepared from exo-194 in the absence of AgNP 
catalyst: To a reaction vial equipped with stirbar were added exo-194 (40.0 mg, 0.033 
mmol, 1.0 equiv), DDQ (15.0 mg, 0.066 mmol, 2.1 equiv), and degassed DCE (2.0 mL) 
under Ar. The vial was sealed and heated at 90 oC for 24 h. The resulting reaction 
mixture was filtered through a short Celite® pad with the aid of ethyl acetate, and 
concentrated in vacuo. Purification using silica gel (20% CH2Cl2 in hexanes) afforded 
compound 200 (22.0 mg, 0.015 mmol, 44% yield) as an orange oil.  
 
exo-endo-198: Rf: 0.4 (20% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 12.55 (1H, s), 11.56 (1H, s), 7.55 (1H, s), 7.48-7.12 (30H, 
m), 7.12-7.04 (3H, m), 6.72 (1H, s), 6.63 (1H, d, J =8.5 Hz), 6.56 (1H, s), 6.48 (1H, dd, J 
=8.4, 2.0 Hz), 6.09 (1H, s), 5.97 (1H, s), 5.70 (1H, s), 5.17-4.92 (11H, m), 4.79 (1H, d, J 
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=11.2 Hz), 4.72 (1H, d, J =11.2 Hz), 4.24-4.23 (2H, m), 4.20-4.05 (2H, m), 3.89 (1H, d, J 
=6.5 Hz), 3.76 (1H, s, br), 3.24 (1H, d, J =17.1 Hz), 2.50 (1H, d, J =17.1 Hz), 2.31 (1H, s, 
br), 2.10 (1H, d, J =17.4 Hz), 1.67 (3H, s), 1.58 (3H, s); 13C NMR (100 MHz, CDCl3, 44 
oC) δ 207.0, 206.2, 164.1, 163.0, 162.1 (2C), 158.8, 158.5, 157.3, 156.9, 137.6, 137.3, 
137.2, 136.7, 136.6, 136.4, 136.2, 135.1, 134.6, 132.6 (2C, broad weak peak), 129.8, 
128.80 (2C), 128.78 (2C), 128.72 (2C), 128.67 (2C), 128.5 (4C), 128.2, 128.1, 128.0, 
127.91 (2C), 127.90, 127.86, 127.7, 127.7 (4C), 127.5 (2C), 127.3 (2C), 126.9 (2C), 
126.5 (2C, broad weak peak), 125.7, 123.1, 121.0, 120.6, 116.9, 114.8, 106.8, 105.7, 
101.9, 100.6, 100.2, 100.0, 70.9, 70.84, 70.77, 70.42, 70.38, 70.1, 52.8, 46.6, 41.5, 40.9, 
39.1 (broad weak peak), 36.7 ( broad weak peak), 32.6, 31.6, 23.8, 22.8; IR νmax (film): 
3064, 3032, 2908, 1631, 1502, 1165, 737 cm-1; HRMS (ESI+) m/z calculated for 
C82H73O10 (M + H+) 1217.5204, found 1217.5221 
  
200: Rf: 0.25 (40% EtOAc in hexanes)  
1H NMR (500 MHz, CDCl3, 56 oC) δ 13.42 (1H, s), 12.84 (1H, s), 8.18 (1H, d, J = 15.8 
Hz), 7.65-7.61 (3H, m), 7.54-7.15 (32H, m), 6.69 (1H, dd, J = 8.5, 2.0 Hz), 6.66-6.63 
(2H, m), 6.49 (1H, d, J = 2.0 Hz), 6.25 (1H, s, br), 6.19 (1H, s, br), 5.36 (1H, s), 5.20 (2H, 
s), 5.10 (2H, s), 5.09 (2H, s), 5.00 (1H, d, J = 11.6 Hz), 4.97 (1H, d, J = 11.6 Hz), 4.91 
(1H, d, J = 11.6 Hz), 4.83 (1H, d, J = 11.6 Hz), 4.79 (1H, m), 4.19-3.99 (4H, m), 3.12 
(1H, d, J = 16.4 Hz), 2.73 (1H, d, J = 16.4 Hz), 2.17 (2H, m), 1.78 (3H, s), 1.65 (3H, s); 
13C NMR (100 MHz, CDCl3, 44 oC) δ 209.1, 192.7, 177.9, 176.4, 165.3, 165.0, 162.8, 
162.7, 160.8, 159.8, 158.4, 156.7, 144.6, 142.3, 140.9, 137.9, 137.6, 136.6, 136.5, 135.9, 
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135.0, 133.0 (2C), 131.6, 130.9, 130.4 (2C), 129.1 (2C), 129.0 (2C), 128.9 (2C), 128.8, 
128.7 (2C), 128.64 (2C), 128.58 (2C), 128.5, 128.4, 128.2, 127.88, 127.86 (2C), 127.8, 
127.7 (2C), 127.43 (4C), 127.40 (4C), 124.8 (2C), 123.9, 120.5, 119.1 117.9, 116.8, 
115.0, 114.98, 114.93, 114.4, 112.9, 107.4, 106.7, 101.7, 101.2, 101.0, 100.6, 71.6, 70.8, 
70.7, 70.6, 70.4, 70.3, 59.7, 52.5, 51.7, 38.5, 38.2, 36.3, 31.9, 23.3, 23.1; IR νmax (film): 
3066, 3033, 2901, 1720, 1630, 1555, 1502, 1166, 836 cm-1; HRMS (ESI+) m/z calculated 
for C90H73Cl2N2O12 (M + H+) 1443.4541, found 1443.5409 
 
DDQ adduct 201: To a reaction vial equipped with stirbar were added 192 (40.0 mg, 
0.06 mmol, 1.0 equiv), DDQ (30.0 mg, 0.12 mmol, 2.1 equiv) and degassed DCE (2.0 
mL) under Ar. The vial was sealed and heated at 90 oC for 24 h. The resulting reaction 
mixture was filtered through a short Celite® pad with the aid of ethyl acetate, and 
concentrated in vacuo. Purification using silica gel (5-10% EtOAc in hexanes) afforded a 
mixture of DDQ adducts (30.0 mg, 0.033 mmol 55% yield) containing 5:1 ratio of 201 
and its exo diastereomer. Further purification using silica gel (100% CH2Cl2) afforded 
compound 201 as an orange solid. The X-ray crystal structure for compound 201 can be 
found below.  
m.p. 170-171 oC (CH2Cl2), Rf: 0.25 (20% EtOAc in hexanes)  
1H NMR (400 MHz, CDCl3) δ 13.68 (1H, s), 8.26 (1H, d, J = 15.2 Hz), 7.73 (1H, d, J = 
8.5 Hz), 7.50-7.32 (16H, m), 7.09 (1H, s), 6.70 (1H, dd, J = 8.5, 2.5 Hz), 6.60 (1H, d, J = 
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2.5 Hz), 6.46 (1H, s), 5.43 (1H, d, J =2.8 Hz), 5.28 (1H, d, J = 12.8 Hz), 5.24 (1H, d, J = 
12.8 Hz), 5.09 (2H, s), 5.04 (1H, d, J =11.6 Hz), 4.96 (1H, d, J =11.6 Hz), 4.80 (1H, s, 
br), 3.39 (1H, d, J =18.0 Hz), 2.82 (1H, d, J =18.0 Hz), 1.91 (3H, s); 13C NMR (100 
MHz, CDCl3) δ 192.2, 179.0, 177.2, 167.0, 162.8, 160.8, 159.8, 145.0, 143.8, 141.4, 
136.5, 136.3, 134.6, 132.9, 132.7, 131.0, 129.0 (2C), 128.93 (2C), 128.88, 128.86 (2C), 
128.4, 128.2, 128.0 (2C), 127.6 (2C), 127.0 (2C), 119,2, 117,72, 117.66, 114.9, 114.8, 
114.6, 114.5, 107.4, 101.8, 101.1, 71.4, 70.6, 70.4, 57.6, 49.4, 40.9, 31.5, 23.1; IR νmax 
(film): 2917, 2850, 1718, 1557, 1206, 1018 cm-1; HRMS (ESI+) m/z calculated for 
C49H37Cl2N2O7 (M + H+) 834.1939, found 834.1933. 
 
 
Cycloadduct exo-exo-197 (prepared from exo-194): To a reaction vial equipped with 
stirbar were added a mixture of exo-194 (26.0 mg, 0.021 mmol, 1.0 equiv.), DDQ (7.2 
mg, 0.032 mmol, 1.5 equiv.), silica-supported AgNP catalyst (26.0 mg, containing 7.0 µg 
Ag, 0.3 mol% Ag loading), and degassed PhCl (2.5 mL) under Ar. The vial was sealed 
and heated at 130 oC for 72 h. The resulting reaction mixture was filtered through a short 
Celite® pad with the aid of ethyl acetate, and concentrated in vacuo. Purification using 
silica gel (10% EtOAc in hexanes), followed by preparative TLC (100% toluene) 
afforded compound exo-exo-197 (16.0 mg, 0.013 mmol, 62% yield) as a light yellow oil. 
		
82 
 
Cycloadduct exo-exo-197 (prepared from exo-endo-198): To a reaction vial equipped 
with stirbar were sequentially added exo-endo-198 (9.5 mg, 0.0078 mmol, 1.0 equiv), 
silica-supported AgNP catalyst (9.5 mg, containing 2.5 µg Ag, 0.3 mol% Ag loading), 
and degassed PhCl (2.0 mL) under Ar. The vial was sealed and heated at 130 oC for 48 h. 
The resulting reaction mixture was filtered through a short Celite® pad with the aid of 
ethyl acetate, and concentrated in vacuo. Purification using silica gel (10% EtOAc in 
hexanes) afforded exo-exo-197 (9.0 mg, 0.0074 mmol, 95% yield). 
 
 
Cycloadduct exo-exo-197 (prepared from 200): To a reaction vial equipped with stirbar 
were sequentially added DDQ adduct 200 (5.0 mg, 0.003 mmol, 1.0 equiv), silica-
supported AgNP catalyst (5.0 mg, containing 1.3 µg Ag, 0.4 mol% Ag loading), and 
degassed PhCl (2.0 mL) under Ar. The vial was sealed and heated at 130 oC for 48 h. The 
resulting reaction mixture was filtered through a short Celite® pad with the aid of ethyl 
acetate, and concentrated in vacuo. Purification using silica gel (10% EtOAc in hexanes) 
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afforded exo-exo-197 (4.2 mg, 0.0025 mmol, 84% yield). 
exo-exo-197: Rf: 0.25 (20% EtOAc in hexanes); 
1H NMR (500 MHz, C6D6=7.16, 60 oC) δ 12.86 (2H, s), 8.31 (2H, s), 7.45 (4H, d, J =7.5 
Hz), 7.24 (2H, d, J =8.5 Hz), 7.25-7.01 (26H, m), 6.56 (2H, d, J =2.0 Hz), 6.40 (2H, dd, J 
= 8.5, 2.0 Hz), 6.10 (2H, s), 5.51 (2H, s, br), 5.10 (2H, d, J =10.0 Hz), 4.95 (2H, s), 4.93 
(2H, s), 4.66 (2H, d, J =10.0 Hz), 4.62 (2H, d, J =11.8 Hz), 4.58 (2H, d, J =11.8 Hz), 4.47 
(4H, s), 4.17 (2H, s, br), 2.44-2.31 (4H, m), 1.57 (6H, s); 13C NMR (100 MHz, CDCl3, 44 
oC) δ 206.7 (2C), 162.8 (2C), 162.3 (2C), 158.6 (2C), 157.3 (2C), 137.6 (2C), 137.2 (4C), 
136.2 (2C), 134.4 (2C), 130.9 (2C, broad weak peak), 128.8 (4C), 128.7 (4C), 128.6 (4C), 
128.1 (2C), 128.0 (2C), 127.8 (2C), 127.7 (8C), 127.2 (4C), 126.6 (2C, broad weak peak), 
125.4 (2C), 121.8 (2C), 115.6 (2C), 106.3 (2C), 101.8 (2C), 99.9 (2C), 70.6 (2C), 70.3 
(2C), 70.2 (2C), 50.7 (2C), 40.8 (2C), 39.0 (2C, weak peak), 37.4 (2C), 23.0 (2C); IR 
νmax (film): 3064, 3032, 2911, 1630, 1502, 1126, 736 cm-1; HRMS (ESI+) m/z calculated 
for C82H73O10 (M + H+) 1217.5204, found 1217.5199. 
 
 
Brosimone A (8): To a reaction vial equipped with stirbar were added exo-exo-197 (20.8 
mg, 0.017 mmol), 10% wt Pd/C (7.3 mg, 0.0068 mmol, 0.6 equiv), ammonium formate 
(2.2 mg, 0.034 mmol, 2.0 equiv), 1,4-cyclohexadiene (80.8 µL, 0.85 mmol, 50 equiv), 
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formic acid (6.4 µL, 0.170 mmol, 10.0 equiv), and degassed acetone (2.0 mL) under Ar. 
The vial was sealed and heated at 40 oC for 24 h. The resulting reaction mixture was 
filtered through a short Celite® pad with the aid of ethyl acetate, and concentrated in 
vacuo. Purification on silica gel (5%-7% MeOH in CH2Cl2) afforded brosimone A (8) 
(10.5 mg, 0.015 mmol, 91% yield) as a pale white, amorphous powder.  
Rf: 0.30 (5% MeOH in CH2Cl2) 
IR νmax (film): 3164, 1622, 1508, 1380, 1250, 1183 cm-1; HRMS (ESI+) m/z calculated for 
C40H37O10 (M + H+) 677.2387, found 677.2377. 
 
 
 
1H NMR 
Positions 
 
Natural 8 (400 MHz, acetone-d6, 
25 oC) 
Synthetic 8 (500 MHz, acetone-d6, 
25 oC)  
OH not observed   12.42 2H, s 
14,14’ 8.51 2H, bs 8.51 2H, bs 
20,20’ 7.10 2H, d, J=8.0 Hz 7.09 2H, d, J=8.0 Hz 
17,17’ 6.33 2H, d, J=2.0 Hz 6.33 2H, d, J=2.0 Hz 
19,19’ 6.20 2H, dd, J=2.0, 8.0 Hz 6.18 2H, dd, J=2.0,8.0 Hz  
11,11’ 5.97 2H, s 5.97 2H, s 
2,2’ 5.34 2H, s 5.34 2H, s 
4,4’ 4.86 2H, bt, J=10.0 Hz 4.85 2H, bt, J=10.8 Hz 
3,3’ 4.13 2H, bd, J=10.0 Hz 4.13 2H, d, J=10.8 Hz 
5,5’ 3.86 2H, bs 3.87 2H, bs 
6,6’ 2.33 4H, m 2.33 4H, m 
7,7’ 1.73 6H, s 1.74 6H, s 
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13C NMR: 
Positions Natural10 8 (100 MHz, DMSO-d6, 90 
oC) 
Synthetic 8 (100 MHz, DMSO-d6, 44 
oC) 
8,8’ 208.2 208.4 
12,12’ 162.7 162.7 
10,10’ 162.7 162.6 
16,16’ 156.8 156.7 
18,18’ 156.4 156.24 
20,20’ 136.4 136.4 
1,1’ 133.8 133.5 
14,14’ 128.7 128.1 
2,2’ 125.9 125.8 
13,13’ 122.9 122.9 
15,15’ 121.1 121.0 
9,9’ 115.2 115.0 
19,19’ 107.3 106.8 
17,17’ 104 103.5 
11,11’ 102 101.6 
4,4’ 49.4 48.7 
3,3’ 41.9 41.8 
6,6’ 39.2 39.2 
5,5’ 37.4 37.0 
7,7’ 23.5 23.5 
 
 
Cycloadduct 202 (prepared from brosimone A): To a reaction vial equipped with stirbar 
were added synthetic 8 (11.6 mg, 0.017 mmol), potassium carbonate (15.3 mg, 0.11 
mmol, 6.5 equiv), and acetone (2.0 mL) under air. MeI (21.3 uL, 0.34 mmol, 20 equiv) 
was slowly added. The vial was heated at 40 oC for 12 h before quenched by 1M HCl. 
The resulting light yellow suspension was extracted with EtOAc, washed with brine, 
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dried over Na2SO4 and concentrated in vacuo. Purification on silica gel (15-20% EtOAc 
in hexanes) affored brosimone A hexamethylether 202 (1.7 mg, 0.002 mmol, 13% yield) 
which was found to be identical with the exo-cycloadduct obtained from DHDA reaction 
of 196. The X-ray crystal structure of compound 202 can be found below. 
 
 
Cycloadduct 202 (prepared from 196): To a reaction vial equipped with stirbar were 
sequentially added compound 196 (18.0 mg, 0.024 mmol, 1.0 equiv), DDQ (8.0 mg, 
0.035 mmol, 1.5 equiv), silica-supported AgNP catalyst (18.0 mg, containing 4.8 µg Ag, 
0.2 mol% Ag loading), and degassed PhCl (2.0 mL) under Ar. The vial was sealed and 
heated at 130 oC for 72 h. The resulting reaction mixture was filtered through a short 
Celite® pad with the aid of ethyl acetate, and concentrated in vacuo. Purification using 
silica gel (15% EtOAc in hexanes) afforded exo-exo-202 (13.0 mg, 0.017 mmol, 72% 
yield).  
202: white solid, m.p. >260 oC (decompose), Rf: 0.25 (25% EtOAc in hexanes); 
IR νmax (film): 3004, 2910, 2837, 1630, 1505, 1374, 1206, 1125, 1032, 751 cm-1; HRMS 
(ESI+) m/z calculated for C46H49O10 (M + H+) 761.3326, found 761.3347. 
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1H NMR 
Positions 202 derived from natural 810 (400 
MHz, CDCl3, 30 oC) 
Synthetic 202 (500 MHz, 
CDCl3, 30 oC) 
OH 11.90 2H, OH 11.90 2H, OH 
14,14’ 7.80 2H, s 7.80 2H, s 
20,20’ 7.12 2H, d, J=8.0 Hz 7.13 2H, d, J=8.0 Hz 
19,19’,17,17’ 6.3-6.4 4H, m 6.3-6.4 4H, m  
11,11’ 5.90, 2H, s  5.90, 2H, s 
2,2’ 5.30, 2H, bs 5.32, 2H, bs 
4,4’ 4.7-4.8 2H, b 4.7-4.8 2H, b 
3,3’ 4.02 2H, bd 4.03 2H bd, J=8.3 Hz 
OCH3 3.82 6H, s 3.83 6H, s 
OCH3 3.72 6H, s 3.73 6H, s 
OCH3 3.62 6H, s  3.63 6H, s  
6,6’ 2.6-2.8 2H, m 2.6-2.8 2H, m 
6,6’ 2.30 2H, bd 2.30 2H, bd, J=18.7 Hz 
7,7’ 1.70 6H, s 1.72 6H, s 
13C NMR 
Positions 202 derived from natural 810 (100 
MHz, CDCl3, 30 oC) 
Synthetic 202 (125 MHz, CDCl3, 
30 oC) 
8,8’ not observed 206.9 
12,12’ 162.3 163.0 
10,10’ 162.3 162.3 
16,16’ 159.5 159.5 
18,18’ 158.2 158.2 
20,20’ 134.5 134.5 
1,1’ 133.8 133.8 
14,14’ 
2,2’ 
131.3 
125.4 
131.3 
125.4 
13,13’ 123.8 123.7 
15,15’ 121.3 121.2 
9,9’ 115.2 115.2 
19,19’ 104.2 104.2 
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17,17’ 99.2 99.2 
11,11’ 98.1 98.1 
OMe 55.8 55.8 
OMe 55.3 55.2 
OMe 54.9 54.9 
4,4’ 50.5 50.5 
3,3’ 40.2 40.2 
6,6’ 40.2 40.2 
5,5’ 36.7 36.7 
7,7’ 22.9 22.9 
 
 
Cycloadduct 203: To a reaction vial equipped with stirbar were sequentially added 
compound 196 (13.0 mg, 0.017 mmol, 1.0 equiv), DDQ (5.8 mg, 0.026 mmol, 1.5 equiv), 
silica-supported AgNP catalyst (13.0 mg, containing 3.5 µg Ag, 0.2 mol% Ag loading), 
and degassed PhCl (2.0 mL) under Ar. The vial was sealed and heated at 90 oC for 48 h. 
The resulting reaction mixture was filtered through a short Celite® pad with the aid of 
ethyl acetate and concentrated in vacuo. Purification using silica gel (8% EtOAc in 
hexanes) afforded exo-endo-203 (2.0 mg, 0.0026 mmol, 15% yield), exo-exo-202 (1.0 mg, 
0.001 mmol, 7% yield). 
White solid, m.p. >260 oC (decompose), Rf: 0.25 (25% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3, 50 oC) δ 12.20 (1H, s), 11.15 (1H, s), 7.45 (1H, s), 7.34 (1H, 
s), 7.15 (1H, d, J =8.4 Hz), 7.11 (1H, d, J =8.4 Hz), 6.62 (1H, d, J =2.4 Hz), 6.52 (1H, dd, 
J = 8.4, 2.4 Hz), 6.37-6.34 (2H, m), 6.01 (1H, s), 5.81(1H, s), 5.33 (1H, s), 4.33-4.26 (2H, 
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m), 4.06-4.04 (1H, m), 3.89 (3H, s), 3.85 (3H, s) 3.74-3.72 (1H, m), 3.716 (3H, s), 3.70 
(3H, s), 3.57 (3H, s), 3.56 (1H, br, s), 3.24 (1H, bd, J =18.0 Hz), 2.54 (1H, bt, J =13.0 
Hz), 2.36 (1H, dd, J =18.0, 3.25 Hz), 2.18 (1H, d, J =18.0 Hz), 1.96 (3H, s), 1.71 (3H, s); 
13C NMR (100 MHz, CDCl3, 44 oC) δ 206.8, 206.7, 165.0, 163.1, 162.7, 161.5, 159.8, 
159.6, 158.3, 157.8, 136.5, 134.7, 134.5, 130.2, 129.8, 127.9, 126.7, 125.7, 124.5, 122.2, 
120.9, 120.6, 116.9, 115.3, 104.7, 104.2, 99.4, 99.3, 99.0, 98.6, 56.1, 55.8, 55.6, 55.4, 
55.2, 55.0, 53.0, 47.4, 41.1, 41.0, 39.9, 37.6, 32.7, 30.9, 23.9, 22.9; IR νmax (film): 2997, 
2943, 2836, 1633, 1505, 1375, 1207, 1125, 1032, 835 cm-1; HRMS (ESI+) m/z calculated 
for C46H49O10 (M + H+) 761.3336, found 761.3331. 
 
X-Ray Crystallography Data for Cycloadduct 183: 
 
Crystals of cycloadduct 183 suitable for X-ray analysis were obtained by slow 
evaporation from ethyl acetate and hexanes. 
Crystal data 
C31H27NO5 Z = 2 
Mr = 493.54 F(000) = 520 
Triclinic, P¯1 Dx = 1.346 Mg m-3 
Hall symbol:  -P 1 Mo Kα radiation, λ = 0.71073 Å 
a = 9.2901 (8) Å Cell parameters from 9871 reflections 
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b = 10.0843 (9) Å θ = 2.6–30.7° 
c = 14.6921 (13) Å µ = 0.09 mm-1 
α = 83.647 (2)° T = 100 K 
β = 75.338 (2)° Prism, pale yellow 
γ = 66.100 (2)° 0.32 × 0.27 × 0.18 mm 
V = 1217.37 (19)  Å3  
 
Data collection 
Bruker Apex Duo diffractometer 7520 independent reflections 
Radiation source: iµS microfocus tube 6139 reflections with I > 2σ(I) 
multilayer optic Rint = 0.029 
ω & φ scans θmax = 30.7°, θmin = 1.4° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -13∅13 
Tmin = 0.971, Tmax = 0.984 k = -14∅14 
52545 measured reflections l = -20∅21 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq 
O1 0.33854 
(11) 
0.91316 (9) 0.12469 (7) 0.02742 
(19) 
O2 -0.04750 
(13) 
1.38236 
(10) 
0.41146 (7) 0.0344 (2) 
O3 -0.12571 
(10) 
0.96095 (9) 0.15659 (6) 0.02552 
(19) 
O4 -0.20550 
(12) 
1.39764 (9) 0.29323 (7) 0.0302 (2) 
H4 -0.1699 1.4268 0.3290 0.045* 
O5 0.58552 
(10) 
0.42290 (9) 0.08919 (6) 0.02389 
(18) 
N1 0.49440 
(11) 
0.67124 
(10) 
0.09699 (7) 0.01896 
(18) 
C1 0.94257 0.70340 -0.00999 0.0301 (3) 
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(15) (14) (10) 
H1 1.0428 0.7089 -0.0339 0.036* 
C2 0.82325 
(16) 
0.76170 
(14) 
-0.06101 
(10) 
0.0281 (3) 
H2 0.8434 0.8063 -0.1190 0.034* 
C3 0.67362 
(15) 
0.75319 
(13) 
-0.02517 (9) 0.0243 (2) 
H3 0.5925 0.7934 -0.0584 0.029* 
C4 0.64664 
(13) 
0.68401 
(12) 
0.06066 (8) 0.0198 (2) 
C5 0.34819 
(13) 
0.79053 
(12) 
0.12470 (8) 0.0195 (2) 
C6 0.21173 
(13) 
0.73692 
(12) 
0.15185 (8) 0.0192 (2) 
H6 0.1438 0.7748 0.1060 0.023* 
C7 0.10351 
(13) 
0.78554 
(12) 
0.25207 (8) 0.0199 (2) 
H7 0.0140 0.7544 0.2594 0.024* 
C8 0.02639 
(13) 
0.94868 
(12) 
0.26460 (8) 0.0193 (2) 
C9 0.06075 
(13) 
1.01983 
(12) 
0.32544 (8) 0.0203 (2) 
H9 0.1379 0.9653 0.3594 0.024* 
C10 -0.01485 
(14) 
1.17156 
(12) 
0.33928 (8) 0.0218 (2) 
C11 0.02007 
(15) 
1.24669 
(13) 
0.40507 (9) 0.0248 (2) 
C12 0.13402 
(15) 
1.16526 
(13) 
0.46417 (9) 0.0244 (2) 
H12 0.1813 1.0645 0.4616 0.029* 
C13 0.17041 
(15) 
1.23471 
(14) 
0.52179 (9) 0.0253 (2) 
H13 0.1169 1.3351 0.5244 0.030* 
C14 0.28651 
(14) 
1.16724 
(13) 
0.58092 (8) 0.0242 (2) 
C15 0.34064 1.25575 0.61834 0.0314 (3) 
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(17) (15) (10) 
H15 0.3009 1.3549 0.6058 0.038* 
C16 0.45269 
(18) 
1.19733 
(17) 
0.67385 
(10) 
0.0353 (3) 
H16 0.4889 1.2570 0.6975 0.042* 
C17 0.51055 
(16) 
1.05045 
(17) 
0.69398 
(10) 
0.0329 (3) 
H17 0.5835 1.0115 0.7326 0.040* 
C18 0.47559 
(13) 
0.54061 
(12) 
0.10703 (8) 0.0192 (2) 
C19 0.29712 
(13) 
0.57060 
(12) 
0.14195 (8) 0.0202 (2) 
H19 0.2606 0.5396 0.0942 0.024* 
C20 0.26995 
(15) 
0.48562 
(13) 
0.23352 (9) 0.0249 (2) 
H20A 0.1648 0.4806 0.2451 0.030* 
H20B 0.3515 0.3874 0.2272 0.030* 
C21 0.27874 
(14) 
0.55710 
(13) 
0.31541 (8) 0.0231 (2) 
C22 0.37625 
(17) 
0.46576 
(14) 
0.38309 
(10) 
0.0319 (3) 
H22A 0.3656 0.5253 0.4330 0.048* 
H22B 0.4879 0.4221 0.3509 0.048* 
H22C 0.3378 0.3912 0.4088 0.048* 
C23 0.19711 
(14) 
0.70053 
(13) 
0.32389 (8) 0.0219 (2) 
H23 0.1982 0.7480 0.3744 0.026* 
C24 0.45941 
(16) 
0.96099 
(15) 
0.65636 (9) 0.0292 (3) 
H24 0.4997 0.8619 0.6691 0.035* 
C25 0.34919 
(15) 
1.01848 
(14) 
0.60028 (9) 0.0253 (2) 
H25 0.3163 0.9577 0.5751 0.030* 
C26 -0.12904 
(14) 
1.25248 
(12) 
0.28574 (8) 0.0223 (2) 
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C27 -0.16722 
(14) 
1.18440 
(12) 
0.22344 (8) 0.0218 (2) 
H27 -0.2429 1.2387 0.1886 0.026* 
C28 -0.09188 
(13) 
1.03520 
(12) 
0.21372 (8) 0.0200 (2) 
C29 -0.24508 
(16) 
1.04203 
(15) 
0.10400 
(10) 
0.0312 (3) 
H29A -0.3438 1.0993 0.1462 0.047* 
H29B -0.2645 0.9764 0.0708 0.047* 
H29C -0.2068 1.1047 0.0598 0.047* 
C30 0.76467 
(14) 
0.62584 
(13) 
0.11197 (9) 0.0245 (2) 
H30 0.7453 0.5799 0.1695 0.029* 
C31 0.91261 
(15) 
0.63731 
(15) 
0.07606 
(10) 
0.0294 (3) 
H31 0.9923 0.6001 0.1103 0.035* 
 
 
X-Ray Crystallography Data for Cycloadduct 196: 
 
Crystals of cycloadduct 196 suitable for X-ray analysis were obtained by slow 
evaporation from chloroform and hexanes. 
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Crystal data 
		C46H50O10	 γ 	=	69.319	(1)°	
Mr	=	762.86	 V	=	2045.96	(9)		Å3	
Triclinic,	P¯1	 Z	=	2	
a	=	12.1017	(3)	Å	 Cu	Kα	radiation,	λ	=	1.54178	Å	
b	=	12.6126	(3)	Å	 µ	=	0.71	mm-1	
c	=	15.6750	(4)	Å	 T	=	100	K	
α 	=	74.636	(1)°	 0.20	×	0.15	×	0.11	mm	
β 	=	67.610	(1)°	 	
Data collection 
		Bruker	Proteum-R		
diffractometer	
6851	independent	reflections	
Absorption	correction:	multi-scan		
SADABS	(Sheldrick,	1996)	
6511	reflections	with	I	>	2σ(I)	
Tmin	=	0.711,	Tmax	=	0.753	 Rint	=	0.034	
64093	measured	reflections	 	
Refinement 
		R[F2	>	2σ(F2)]	=	0.042	 0	restraints	
wR(F2)	=	0.100	 H	atoms	treated	by	a	mixture	of	independent	and	constrained	refinement	
S	=	1.10	 Δ〉max	=	0.36	e	Å-3	
6851	reflections	 Δ〉min	=	-0.31	e	Å-3	
520	parameters	 	
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
	 x	 y	 z	 Uiso*/Ueq	
O1	 0.05002	(13)	 1.37135	(11)	 0.17656	(9)	 0.0373	(3)	
O2	 0.32030	(13)	 0.99368	(11)	 0.20420	(8)	 0.0336	(3)	
O3	 0.31454	 0.73922	 0.48747	(8)	 0.0295	(3)	
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(12)	 (10)	
O4	 0.33016	(12)	 0.60085	(10)	 0.63622	(9)	 0.0281	(3)	
H4	 0.337	(2)	 0.6304	(19)	 0.5741	(17)	 0.042*	
O5	 0.13812	(11)	 0.75393	(9)	 0.92207	(8)	 0.0252	(3)	
O6	 0.40364	(12)	 1.40737	(11)	 0.87179	(10)	 0.0342	(3)	
O7	 0.31761	(11)	 1.19007	(11)	 0.70286	(8)	 0.0300	(3)	
O8	 0.17349	(11)	 0.97569	(10)	 0.98539	(8)	 0.0264	(3)	
O9	 0.32394	(12)	 0.79036	(11)	 1.03579	(8)	 0.0299	(3)	
H9	 0.256	(2)	 0.854	(2)	 1.0383	(16)	 0.045*	
O10	 0.67745	(11)	 0.61848	(10)	 0.79613	(9)	 0.0270	(3)	
C1	 0.6785	(2)	 0.5268	(2)	 0.53010	(18)	 0.0555	(6)	
H1A	 0.5887	 0.5410	 0.5442	 0.083*	
H1B	 0.7134	 0.4492	 0.5590	 0.083*	
H1C	 0.7190	 0.5341	 0.4623	 0.083*	
C2	 0.70036	(19)	 0.61262	(17)	 0.56801	(15)	 0.0381	(5)	
C3	 0.60805	(17)	 0.69235	(16)	 0.61282	(12)	 0.0298	(4)	
H3	 0.5265	 0.6921	 0.6202	 0.036*	
C4	 0.61569	(16)	 0.78393	(15)	 0.65379	(12)	 0.0261	(4)	
H4A	 0.5897	 0.8594	 0.6165	 0.031*	
H4B	 0.7034	 0.7702	 0.6492	 0.031*	
C5	 0.53505	(15)	 0.78774	(14)	 0.75488	(12)	 0.0219	(3)	
C6	 0.42529	(15)	 0.87271	(13)	 0.78114	(11)	 0.0207	(3)	
H6	 0.3997	 0.9303	 0.7339	 0.025*	
C7	 0.34902	(15)	 0.87837	(13)	 0.87463	(11)	 0.0200	(3)	
C8	 0.22893	 0.96515	 0.90187	 0.0204	(3)	
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(15)	 (13)	 (11)	
C9	 0.16399	(14)	 1.03807	(13)	 0.83115	(11)	 0.0187	(3)	
H9A	 0.2270	 1.0393	 0.7674	 0.022*	
C10	 0.06737	(15)	 0.98028	(13)	 0.83478	(11)	 0.0201	(3)	
H10	 0.0257	 0.9523	 0.9015	 0.024*	
C11	 0.13446	(15)	 0.87798	(13)	 0.78226	(11)	 0.0197	(3)	
C12	 0.16493	(15)	 0.89392	(13)	 0.68692	(11)	 0.0202	(3)	
H12	 0.1403	 0.9695	 0.6555	 0.024*	
C13	 0.23076	(15)	 0.80404	(13)	 0.63324	(11)	 0.0207	(3)	
C14	 0.25355	(16)	 0.82139	(14)	 0.53262	(12)	 0.0234	(4)	
C15	 0.20214	(17)	 0.93497	(15)	 0.48497	(12)	 0.0264	(4)	
H15	 0.1528	 0.9954	 0.5207	 0.032*	
C16	 0.22249	(16)	 0.95604	(15)	 0.39304	(12)	 0.0243	(4)	
H16	 0.2732	 0.8941	 0.3591	 0.029*	
C17	 0.17439	(16)	 1.06480	(15)	 0.33991	(12)	 0.0240	(4)	
C18	 0.07818	(16)	 1.15467	(15)	 0.38149	(12)	 0.0264	(4)	
H18	 0.0417	 1.1441	 0.4475	 0.032*	
C19	 0.03366	(17)	 1.25829	(15)	 0.33102	(13)	 0.0281	(4)	
H19	 -0.0315	 1.3180	 0.3616	 0.034*	
C20	 0.08626	(18)	 1.27346	(15)	 0.23449	(13)	 0.0295	(4)	
C21	 -0.0382	(2)	 1.46813	(16)	 0.21941	(16)	 0.0405	(5)	
H21A	 -0.1162	 1.4491	 0.2577	 0.061*	
H21B	 -0.0543	 1.5334	 0.1709	 0.061*	
H21C	 -0.0046	 1.4882	 0.2589	 0.061*	
C22	 0.22620	(16)	 1.08327	(15)	 0.24160	(12)	 0.0261	(4)	
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C23	 0.3826	(2)	 1.00967	(19)	 0.10578	(14)	 0.0462	(5)	
H23A	 0.3226	 1.0273	 0.0725	 0.069*	
H23B	 0.4486	 0.9394	 0.0883	 0.069*	
H23C	 0.4193	 1.0732	 0.0891	 0.069*	
C24	 0.18209	(18)	 1.18589	(16)	 0.18987	(12)	 0.0306	(4)	
H24	 0.2171	 1.1968	 0.1238	 0.037*	
C25	 0.26809	(15)	 0.69319	(14)	 0.68138	(12)	 0.0216	(3)	
C26	 0.23927	(15)	 0.67420	(13)	 0.77792	(12)	 0.0221	(3)	
H26	 0.2654	 0.5991	 0.8097	 0.026*	
C27	 0.17218	(15)	 0.76542	(14)	 0.82761	(11)	 0.0207	(3)	
C28	 0.17755	(19)	 0.64225	(15)	 0.97145	(13)	 0.0334	(4)	
H28A	 0.1404	 0.5904	 0.9620	 0.050*	
H28B	 0.1507	 0.6464	 1.0382	 0.050*	
H28C	 0.2686	 0.6133	 0.9481	 0.050*	
C29	 0.10081	(14)	 1.16177	(13)	 0.85254	(11)	 0.0191	(3)	
H29	 0.0361	 1.1585	 0.9154	 0.023*	
C30	 0.03331	(15)	 1.23328	(13)	 0.78143	(12)	 0.0224	(3)	
H30A	 -0.0199	 1.3075	 0.8029	 0.027*	
H30B	 0.0961	 1.2496	 0.7208	 0.027*	
C31	 -0.04606	(15)	 1.17495	(14)	 0.76750	(11)	 0.0225	(3)	
C32	 -0.03097	(15)	 1.06326	(14)	 0.79372	(11)	 0.0222	(3)	
H32	 -0.0873	 1.0327	 0.7859	 0.027*	
C33	 -0.14309	(18)	 1.25044	(16)	 0.72281	(15)	 0.0342	(4)	
H33A	 -0.1890	 1.2039	 0.7169	 0.051*	
H33B	 -0.1025	 1.2873	 0.6608	 0.051*	
H33C	 -0.2010	 1.3093	 0.7616	 0.051*	
C34	 0.18946	 1.21934	 0.85642	 0.0200	(3)	
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(15)	 (13)	 (11)	
C35	 0.16526	(16)	 1.26449	(13)	 0.93574	(12)	 0.0227	(3)	
H35	 0.0965	 1.2528	 0.9890	 0.027*	
C36	 0.23751	(17)	 1.32591	(14)	 0.94014	(12)	 0.0263	(4)	
H36	 0.2175	 1.3565	 0.9951	 0.032*	
C37	 0.33922	(16)	 1.34224	(14)	 0.86349	(13)	 0.0262	(4)	
C38	 0.50828	(19)	 1.42609	(19)	 0.79263	(17)	 0.0456	(5)	
H38A	 0.5725	 1.3528	 0.7821	 0.068*	
H38B	 0.5424	 1.4787	 0.8044	 0.068*	
H38C	 0.4814	 1.4596	 0.7373	 0.068*	
C39	 0.36922	(16)	 1.29584	(14)	 0.78390	(13)	 0.0268	(4)	
H39	 0.4402	 1.3051	 0.7320	 0.032*	
C40	 0.29441	(16)	 1.23535	(14)	 0.78060	(12)	 0.0231	(3)	
C41	 0.4311	(2)	 1.1918	(2)	 0.62854	(15)	 0.0477	(6)	
H41A	 0.4324	 1.2714	 0.6032	 0.072*	
H41B	 0.4372	 1.1537	 0.5793	 0.072*	
H41C	 0.5018	 1.1514	 0.6521	 0.072*	
C42	 0.38965	(15)	 0.79311	(14)	 0.94394	(11)	 0.0226	(3)	
C43	 0.49967	(16)	 0.70520	(14)	 0.91932	(12)	 0.0244	(4)	
H43	 0.5262	 0.6476	 0.9662	 0.029*	
C44	 0.57015	(15)	 0.70223	(14)	 0.82621	(12)	 0.0225	(3)	
C45	 0.71631	(17)	 0.52862	(15)	 0.86486	(13)	 0.0307	(4)	
H45A	 0.7308	 0.5608	 0.9088	 0.046*	
H45B	 0.7936	 0.4736	 0.8344	 0.046*	
H45C	 0.6513	 0.4896	 0.8987	 0.046*	
C46	 0.8348	(2)	 0.5956	(3)	 0.5522	(2)	 0.0756	(10)	
H46A	 0.8421	 0.6430	 0.5891	 0.113*	
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H46B	 0.8763	 0.6179	 0.4858	 0.113*	
H46C	 0.8741	 0.5147	 0.5713	 0.113*	
 
 
 
X-Ray Crystallography Data for Cycloadduct 203: 
 
Crystals of cycloadduct exo-endo-203 suitable for X-ray analysis were obtained by slow 
evaporation from chloroform and hexanes. 
Crystal data 
		C46H48O10	 γ 	=	106.66	(3)°	
Mr	=	760.84	 V	=	1982.1	(7)		Å3	
Triclinic,	P¯1	 Z	=	2	
a	=	11.251	(2)	Å	 Cu	Kα	radiation,	λ	=	1.54178	Å	
b	=	12.075	(2)	Å	 µ	=	0.73	mm-1	
c	=	16.130	(3)	Å	 T	=	296	K	
α 	=	108.38	(3)°	 0.36	×	0.06	×	0.04	mm	
β 	=	90.09	(3)°	 	
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Data collection 
		Bruker	Proteum-R		
diffractometer	
6877	independent	reflections	
Absorption	correction:	multi-scan		
TWINABS	(Sheldrick,	1997)	
5425	reflections	with	I	>	2σ(I)	
Tmin	=	0.609,	Tmax	=	0.864	 Rint	=	0.073	
6877	measured	reflections	 	
 
Refinement 
		R[F2	>	2σ(F2)]	=	0.066	 0	restraints	
wR(F2)	=	0.210	 H-atom	parameters	constrained	
S	=	1.08	 Δ〉max	=	0.21	e	Å-3	
6877	reflections	 Δ〉min	=	-0.25	e	Å-3	
516	parameters	 	
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
	 x	 y	 z	 Uiso*/Ueq	 	
O1	 0.6990	(2)	 0.7354	(2)	 0.55186	(17)	 0.0884	(7)	 	
O2	 0.4524	(2)	 0.1670	(3)	 0.1197	(2)	 0.1041	(9)	 	
O3	 0.1463	(2)	 0.3178	(2)	 0.03046	(16)	 0.0818	(7)	 	
C0AA	 -0.2577	(4)	 -0.0426	(3)	 0.1990	(3)	 0.0822	(10)	 	
H0AA	 -0.3334	 -0.0675	 0.1591	 0.123*	 	
H0AB	 -0.2797	 -0.0291	 0.2594	 0.123*	 	
H0AC	 -0.2172	 -0.1072	 0.1828	 0.123*	 	
O5	 -0.2562	(2)	 0.2825	(2)	 0.14303	(16)	 0.0749	(6)	 	
O6	 0.2101	(2)	 0.8339	(2)	 0.43862	(15)	 0.0779	(7)	 	
O7	 -0.22146	(19)	 0.3364	(2)	 0.37406	(15)	 0.0724	(6)	 	
O8	 0.0099	(2)	 0.75527	(19)	 0.50737	(14)	 0.0726	(6)	 	
		
101 
H8	 0.0756	 0.8065	 0.5023	 0.109*	 	
O9	 0.3879	(2)	 0.55675	(18)	 0.30948	(15)	 0.0705	(6)	 	
O10	 -0.0287	(3)	 0.8591	(2)	 0.30773	(19)	 0.0930	(8)	 	
C1	 0.7797	(4)	 0.8396	(4)	 0.6167	(3)	 0.1011	(13)	 	
H1A	 0.8346	 0.8923	 0.5881	 0.152*	 	
H1B	 0.8302	 0.8131	 0.6517	 0.152*	 	
H1C	 0.7301	 0.8852	 0.6551	 0.152*	 	
C2	 0.6252	(3)	 0.7556	(3)	 0.4939	(2)	 0.0666	(8)	 	
C3	 0.6245	(3)	 0.8684	(3)	 0.4924	(2)	 0.0694	(8)	 	
H3	 0.6781	 0.9412	 0.5334	 0.083*	 	
C4	 0.5438	(3)	 0.8741	(3)	 0.4297	(2)	 0.0662	(8)	 	
H4	 0.5438	 0.9525	 0.4290	 0.079*	 	
C5	 0.4635	(3)	 0.7719	(3)	 0.36829	(19)	 0.0595	(7)	 	
C6	 0.3799	(3)	 0.7870	(3)	 0.3012	(2)	 0.0624	(7)	 	
H6	 0.3880	 0.8761	 0.3181	 0.075*	 	
C7	 0.2407	(3)	 0.7178	(3)	 0.29454	(19)	 0.0580	(7)	 	
H7	 0.2290	 0.6289	 0.2639	 0.070*	 	
C8	 0.1657	(3)	 0.7624	(3)	 0.2376	(2)	 0.0654	(8)	 	
H8A	 0.1723	 0.8499	 0.2699	 0.078*	 	
C9	 0.0287	(3)	 0.6873	(3)	 0.2234	(2)	 0.0614	(7)	 	
C10	 -0.0037	(3)	 0.5628	(3)	 0.18195	(19)	 0.0590	(7)	 	
H10	 0.0583	 0.5290	 0.1540	 0.071*	 	
C11	 -0.1233	(3)	 0.4828	(3)	 0.17879	(18)	 0.0582	(7)	 	
C12	 -0.1485	(3)	 0.3510	(3)	 0.15859	(18)	 0.0585	(7)	 	
C13	 -0.0410	(3)	 0.3013	(2)	 0.16697	(17)	 0.0527	(6)	 	
H13	 0.0369	 0.3645	 0.1632	 0.063*	 	
C14	 -0.0456	(3)	 0.1802	(3)	 0.09277	(18)	 0.0584	(7)	 	
H14	 -0.0632	 0.1905	 0.0353	 0.070*	 	
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C15	 0.0830	(3)	 0.1650	(3)	 0.09519	(18)	 0.0589	(7)	 	
C16	 0.1813	(3)	 0.2414	(3)	 0.06624	(19)	 0.0639	(8)	 	
C17	 0.3011	(3)	 0.2384	(3)	 0.0743	(2)	 0.0724	(9)	 	
H17	 0.3656	 0.2914	 0.0544	 0.087*	 	
C18	 0.3294	(3)	 0.1584	(3)	 0.1115	(2)	 0.0737	(9)	 	
C19	 0.4878	(5)	 0.0948	(6)	 0.1633	(6)	 0.161	(3)	 	
H19A	 0.4562	 0.1099	 0.2211	 0.242*	 	
H19B	 0.5789	 0.1165	 0.1705	 0.242*	 	
H19C	 0.4527	 0.0080	 0.1285	 0.242*	 	
C20	 0.2378	(5)	 0.3972	(4)	 -0.0013	(3)	 0.1107	(15)	 	
H20A	 0.3018	 0.4522	 0.0467	 0.166*	 	
H20B	 0.1989	 0.4455	 -0.0248	 0.166*	 	
H20C	 0.2761	 0.3489	 -0.0480	 0.166*	 	
C21	 0.1139	(3)	 0.0848	(3)	 0.1297	(2)	 0.0640	(8)	 	
H21	 0.0494	 0.0307	 0.1487	 0.077*	 	
C22	 0.2350	(3)	 0.0792	(3)	 0.1380	(2)	 0.0693	(8)	 	
H22	 0.2523	 0.0219	 0.1615	 0.083*	 	
C23	 -0.1500	(3)	 0.0722	(3)	 0.1004	(2)	 0.0652	(8)	 	
H23A	 -0.2286	 0.0707	 0.0718	 0.078*	 	
H23B	 -0.1315	 -0.0043	 0.0677	 0.078*	 	
C24	 -0.1701	(3)	 0.0735	(3)	 0.1926	(2)	 0.0610	(7)	 	
C25	 -0.1181	(3)	 0.1698	(3)	 0.26292	(19)	 0.0582	(7)	 	
H25	 -0.1387	 0.1645	 0.3189	 0.070*	 	
C26	 -0.0284	(3)	 0.2868	(2)	 0.25920	(17)	 0.0523	(6)	 	
H26	 0.0560	 0.2766	 0.2648	 0.063*	 	
C27	 0.1870	(3)	 0.7312	(3)	 0.38201	(19)	 0.0591	(7)	 	
C28	 0.0950	(3)	 0.6250	(3)	 0.39351	(17)	 0.0554	(7)	 	
C29	 0.0807	(3)	 0.5044	(2)	 0.33923	(16)	 0.0521	(6)	 	
H29	 0.1470	 0.4896	 0.3054	 0.063*	 	
C30	 -0.0220	(2)	 0.4071	(2)	 0.33187	 0.0498	(6)	 	
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(16)	
C31	 -0.1175	(3)	 0.4316	(3)	 0.38501	(17)	 0.0547	(7)	 	
C32	 -0.3212	(3)	 0.3531	(4)	 0.4256	(3)	 0.0868	(11)	 	
H32A	 -0.2894	 0.3893	 0.4879	 0.130*	 	
H32B	 -0.3842	 0.2737	 0.4157	 0.130*	 	
H32C	 -0.3589	 0.4077	 0.4089	 0.130*	 	
C33	 -0.1036	(3)	 0.5477	(3)	 0.44484	(18)	 0.0589	(7)	 	
H33	 -0.1668	 0.5611	 0.4823	 0.071*	 	
C34	 0.0017	(3)	 0.6430	(3)	 0.44979	(17)	 0.0565	(7)	 	
C35	 0.5477	(3)	 0.6496	(3)	 0.4325	(2)	 0.0663	(8)	 	
H35	 0.5496	 0.5717	 0.4330	 0.080*	 	
C36	 0.4679	(3)	 0.6577	(3)	 0.3708	(2)	 0.0607	(7)	 	
C37	 0.3890	(3)	 0.4391	(3)	 0.3088	(3)	 0.0780	(9)	 	
H37A	 0.4718	 0.4302	 0.2973	 0.117*	 	
H37B	 0.3267	 0.3760	 0.2626	 0.117*	 	
H37C	 0.3693	 0.4301	 0.3659	 0.117*	 	
C38	 0.4229	(3)	 0.7482	(4)	 0.2088	(2)	 0.0772	(10)	 	
H38A	 0.5063	 0.8048	 0.2087	 0.093*	 	
H38B	 0.4314	 0.6651	 0.1952	 0.093*	 	
C39	 0.3360	(3)	 0.7476	(3)	 0.1377	(2)	 0.0762	(10)	 	
C40	 0.2224	(3)	 0.7557	(3)	 0.1521	(2)	 0.0748	(9)	 	
H40	 0.1729	 0.7573	 0.1050	 0.090*	 	
C41	 0.3869	(4)	 0.7345	(5)	 0.0494	(3)	 0.1034	(14)	 	
H41A	 0.3228	 0.7313	 0.0067	 0.155*	 	
H41B	 0.4104	 0.6589	 0.0292	 0.155*	 	
H41C	 0.4604	 0.8047	 0.0550	 0.155*	 	
C42	 -0.0653	(3)	 0.7363	(3)	 0.2620	(2)	 0.0698	(8)	 	
C43	 -0.1026	(5)	 0.9037	(4)	 0.3752	(3)	 0.1032	(13)	 	
H43A	 -0.1824	 0.9001	 0.3482	 0.155*	 	
H43B	 -0.0581	 0.9886	 0.4102	 0.155*	 	
H43C	 -0.1180	 0.8529	 0.4133	 0.155*	 	
C44	 -0.1866	(3)	 0.6629	(3)	 0.2544	(2)	 0.0754	(9)	 	
H44	 -0.2496	 0.6982	 0.2783	 0.090*	 	
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C45	 -0.2168	(3)	 0.5375	(3)	 0.2121	(2)	 0.0668	(8)	 	
O46	 -0.3359	(2)	 0.4700	(2)	 0.2084	(2)	 0.0892	(7)	 	
H46	 -0.3432	 0.3958	 0.1821	 0.134*	 	
 
 
 
X-Ray Crystallography Data for Cycloadduct 202: 
 
Crystals of cycloadduct exo-exo-202 suitable for X-ray analysis were obtained by slow 
evaporation from dichloromethane and hexanes. 
 
Crystal data 
C46H48O10•0.22(CH2Cl2) Z = 4 
Mr = 779.78 F(000) = 1653.8 
Triclinic, P¯1 Dx = 1.256 Mg m-3 
Hall symbol:  -P 1 Cu Kα radiation, λ = 1.54178 Å 
a = 14.5625 (8) Å Cell parameters from 9871 reflections 
b = 15.5540 (9) Å θ = 2.6–30.7° 
c = 20.3677 (12) Å µ = 0.09 mm-1 
α = 112.316 (3)° T = 100 K 
β = 93.533 (3)° Prism, pale yellow 
γ = 102.068 (3)° 0.06 × 0.05 × 0.05 mm 
V = 4122.5 (4) Å3  
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Data collection 
Bruker Proteum-R diffractometer 14354 independent reflections 
Radiation source: rotating anode 12450 reflections with I > 2σ(I) 
multilayer optic Rint = 0.040 
ω & φ scans θmax = 66.6°, θmin = 3.1° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -17∅17 
Tmin = 0.703, Tmax = 0.753 k = -18∅16 
14354 measured reflections l = 0∅24 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 	 x	 y	 z	 Uiso*/Ueq	 Occ.	(<1)	O1	 -0.18049	(7)	 0.22128	(8)	 -0.04663	(5)	 0.0314	(2)	 	O10	 0.68214	(9)	 0.52463	(9)	 0.37709	(7)	 0.0449	(3)	 	O9	 0.40106	(7)	 0.44179	(7)	 0.21050	(6)	 0.0267	(2)	 	O3	 -0.07070	(6)	 0.41231	(7)	 0.28918	(5)	 0.0214	(2)	 	O2	 0.11042	(7)	 0.31986	(7)	 0.11198	(5)	 0.0258	(2)	 	O7	 0.32959	(7)	 0.77253	(7)	 0.48407	(5)	 0.0284	(2)	 	H7	 0.3605	 0.7915	 0.4565	 0.043*	 	O8	 0.11350	(7)	 0.49502	(7)	 0.48131	(5)	 0.0221	(2)	 	O6	 0.39333	(7)	 0.75859	(7)	 0.36660	(5)	 0.0261	(2)	 	O5	 0.16060	(7)	 0.80841	(6)	 0.29190	(5)	 0.0217	(2)	 	O11	 0.63852	(7)	 0.78912	(8)	 0.55742	(6)	 0.0335	(3)	 	O20	 0.65270	(9)	 1.37940	(8)	 0.11359	(6)	 0.0371	(3)	 	O12	 0.67271	(7)	 0.98487	(7)	 0.41850	(5)	 0.0250	(2)	 	O13	 0.87676	(7)	 0.82516	(7)	 0.31894	(5)	 0.0252	(2)	 	O15	 0.55460	(7)	 0.71148	(7)	 0.05403	(5)	 0.0242	(2)	 	O14	 0.81087	(8)	 0.68507	(7)	 0.19572	(6)	 0.0330	(3)	 	H14A	 0.8449	 0.7139	 0.2363	 0.049*	 	C80	 0.46661	(9)	 0.89480	(10)	 0.21218	(8)	 0.0220	(3)	 	H80	 0.4453	 0.8438	 0.2268	 0.026*	 	O16	 0.63775	(7)	 0.95287	(8)	 0.05422	(5)	 0.0295	(2)	 	
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O18	 1.02627	(7)	 0.94853	(8)	 0.21064	(5)	 0.0303	(2)	 	O17	 0.79331	(8)	 0.90983	(9)	 0.02060	(5)	 0.0374	(3)	 	H17	 0.7393	 0.9187	 0.0134	 0.056*	 	O19	 0.66481	(7)	 1.18946	(7)	 0.25422	(5)	 0.0263	(2)	 	C1	 -0.27963	(11)	 0.17622	(14)	 -0.06564	(9)	 0.0392	(4)	 	H1A	 -0.2906	 0.1103	 -0.0689	 0.059*	 	H1B	 -0.3029	 0.1753	 -0.1122	 0.059*	 	H1C	 -0.3136	 0.2121	 -0.0289	 0.059*	 	C2	 -0.13626	(10)	 0.22661	(10)	 0.01684	(7)	 0.0240	(3)	 	C3	 -0.18122	(10)	 0.19562	(10)	 0.06458	(8)	 0.0239	(3)	 	H3	 -0.2475	 0.1662	 0.0544	 0.029*	 	C4	 -0.12701	(10)	 0.20863	(10)	 0.12796	(7)	 0.0215	(3)	 	H4	 -0.1580	 0.1879	 0.1610	 0.026*	 	C5	 -0.02991	(9)	 0.25040	(9)	 0.14518	(7)	 0.0189	(3)	 	C9	 0.02400	(9)	 0.26443	(9)	 0.21599	(7)	 0.0194	(3)	 	H9	 -0.0235	 0.2435	 0.2438	 0.023*	 	C15	 0.07468	(9)	 0.37064	(9)	 0.26149	(7)	 0.0172	(3)	 	H15	 0.1269	 0.3909	 0.2367	 0.021*	 	C16	 0.00701	(9)	 0.43552	(9)	 0.27026	(7)	 0.0176	(3)	 	C17	 0.03679	(9)	 0.52805	(9)	 0.26470	(7)	 0.0175	(3)	 	C23	 0.12006	(9)	 0.55401	(10)	 0.23765	(7)	 0.0185	(3)	 	H23	 0.1485	 0.5046	 0.2110	 0.022*	 	C22	 0.16255	(9)	 0.64647	(10)	 0.24748	(7)	 0.0183	(3)	 	C33	 0.26019	(9)	 0.67203	(10)	 0.22680	(8)	 0.0206	(3)	 	H33	 0.2853	 0.7434	 0.2509	 0.025*	 	C32	 0.33003	(9)	 0.62609	(9)	 0.25467	(7)	 0.0187	(3)	 	H32	 0.2991	 0.5563	 0.2395	 0.022*	 	C38	 0.42327	(9)	 0.63529	(10)	 0.22335	(7)	 0.0203	(3)	 	
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H38	 0.4502	 0.7051	 0.2354	 0.024*	 	C39	 0.49546	(10)	 0.60211	(10)	 0.25852	(7)	 0.0214	(3)	 	C40	 0.48216	(10)	 0.50735	(10)	 0.25375	(8)	 0.0230	(3)	 	C42	 0.54672	(11)	 0.48373	(11)	 0.29258	(8)	 0.0293	(3)	 	H42	 0.5374	 0.4194	 0.2882	 0.035*	 	C43	 0.62535	(11)	 0.55428	(11)	 0.33805	(9)	 0.0312	(3)	 	C44	 0.74430	(14)	 0.60021	(14)	 0.43826	(10)	 0.0480	(5)	 	H44A	 0.7949	 0.6360	 0.4220	 0.072*	 	H44B	 0.7725	 0.5726	 0.4680	 0.072*	 	H44C	 0.7080	 0.6437	 0.4666	 0.072*	 	C41	 0.38397	(12)	 0.34587	(11)	 0.20628	(10)	 0.0350	(4)	 	H41A	 0.4366	 0.3185	 0.1879	 0.053*	 	H41B	 0.3245	 0.3069	 0.1739	 0.053*	 	H41C	 0.3791	 0.3465	 0.2542	 0.053*	 	C7	 -0.03843	(10)	 0.26763	(11)	 0.03126	(8)	 0.0252	(3)	 	H7A	 -0.0078	 0.2877	 -0.0023	 0.030*	 	C6	 0.01406	(9)	 0.27910	(10)	 0.09446	(7)	 0.0211	(3)	 	C8	 0.15910	(12)	 0.34242	(15)	 0.05989	(9)	 0.0425	(4)	 	H8A	 0.1517	 0.2837	 0.0165	 0.064*	 	H8B	 0.2268	 0.3707	 0.0794	 0.064*	 	H8C	 0.1324	 0.3884	 0.0478	 0.064*	 	C10	 0.09591	(10)	 0.20243	(10)	 0.20587	(8)	 0.0235	(3)	 	H10A	 0.0606	 0.1343	 0.1892	 0.028*	 	H10B	 0.1323	 0.2086	 0.1677	 0.028*	 	C11	 0.16484	(10)	 0.22855	(10)	 0.27271	(8)	 0.0231	(3)	 	C12	 0.22321	(12)	 0.15855	(11)	 0.26940	(9)	 0.0344	(4)	 	
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H12A	 0.2694	 0.1845	 0.3136	 0.052*	 	H12B	 0.2570	 0.1479	 0.2280	 0.052*	 	H12C	 0.1814	 0.0975	 0.2645	 0.052*	 	C13	 0.17366	(10)	 0.30904	(10)	 0.33097	(7)	 0.0216	(3)	 	H13	 0.2175	 0.3202	 0.3716	 0.026*	 	C14	 0.11919	(9)	 0.38376	(9)	 0.33723	(7)	 0.0186	(3)	 	H14	 0.0662	 0.3742	 0.3647	 0.022*	 	C24	 0.18246	(9)	 0.48497	(9)	 0.37851	(7)	 0.0175	(3)	 	C30	 0.24624	(9)	 0.52752	(9)	 0.34629	(7)	 0.0176	(3)	 	H30	 0.2570	 0.4891	 0.2999	 0.021*	 	C29	 0.29686	(9)	 0.62487	(10)	 0.37783	(7)	 0.0185	(3)	 	C28	 0.28595	(9)	 0.67810	(10)	 0.44918	(7)	 0.0209	(3)	 	C27	 0.22701	(10)	 0.63528	(10)	 0.48529	(7)	 0.0221	(3)	 	H27	 0.2225	 0.6710	 0.5340	 0.027*	 	C25	 0.17490	(9)	 0.54068	(10)	 0.45040	(7)	 0.0184	(3)	 	C26	 0.10835	(10)	 0.54380	(11)	 0.55590	(7)	 0.0241	(3)	 	H26A	 0.1712	 0.5607	 0.5843	 0.036*	 	H26B	 0.0628	 0.5017	 0.5710	 0.036*	 	H26C	 0.0875	 0.6024	 0.5634	 0.036*	 	C31	 0.34592	(9)	 0.67390	(10)	 0.33635	(7)	 0.0199	(3)	 	C18	 -0.00904	(9)	 0.60152	(10)	 0.29801	(7)	 0.0185	(3)	 	C19	 0.03076	(9)	 0.69581	(10)	 0.30742	(7)	 0.0195	(3)	 	H19	 -0.0005	 0.7446	 0.3302	 0.023*	 	C20	 0.11589	(9)	 0.71836	(9)	 0.28355	(7)	 0.0182	(3)	 	C21	 0.12431	(12)	 0.88619	(11)	 0.33539	(9)	 0.0317	(4)	 	H21A	 0.0585	 0.8769	 0.3148	 0.048*	 	H21B	 0.1633	 0.9467	 0.3370	 0.048*	 	H21C	 0.1262	 0.8884	 0.3842	 0.048*	 	
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O4	 -0.09089	(7)	 0.58423	(7)	 0.32394	(5)	 0.0240	(2)	 	H4A	 -0.1086	 0.5255	 0.3153	 0.036*	 	C34	 0.25506	(10)	 0.64361	(10)	 0.14713	(8)	 0.0235	(3)	 	H34	 0.2040	 0.6549	 0.1229	 0.028*	 	C35	 0.31680	(10)	 0.60372	(11)	 0.10803	(8)	 0.0245	(3)	 	C36	 0.30465	(12)	 0.57450	(14)	 0.02813	(9)	 0.0364	(4)	 	H36A	 0.2495	 0.5932	 0.0129	 0.055*	 	H36B	 0.2947	 0.5047	 0.0040	 0.055*	 	H36C	 0.3618	 0.6065	 0.0154	 0.055*	 	C37	 0.40162	(10)	 0.58408	(11)	 0.14117	(8)	 0.0242	(3)	 	H37A	 0.4582	 0.6045	 0.1210	 0.029*	 	H37B	 0.3900	 0.5140	 0.1275	 0.029*	 	C46	 0.57624	(10)	 0.66898	(11)	 0.30277	(8)	 0.0252	(3)	 	H46	 0.5874	 0.7330	 0.3060	 0.030*	 	C45	 0.64156	(11)	 0.64718	(11)	 0.34259	(9)	 0.0304	(3)	 	H45	 0.6961	 0.6950	 0.3723	 0.036*	 	C47	 0.53713	(12)	 0.76809	(14)	 0.54191	(11)	 0.0434	(4)	 	H47A	 0.5168	 0.8280	 0.5607	 0.065*	 	H47B	 0.5084	 0.7258	 0.5646	 0.065*	 	H47C	 0.5168	 0.7361	 0.4898	 0.065*	 	C48	 0.69020	(10)	 0.84354	(10)	 0.52643	(8)	 0.0245	(3)	 	C49	 0.64992	(10)	 0.88739	(10)	 0.48778	(8)	 0.0233	(3)	 	H49	 0.5834	 0.8817	 0.4826	 0.028*	 	C50	 0.70788	(9)	 0.93950	(10)	 0.45684	(7)	 0.0203	(3)	 	C52	 0.80623	(9)	 0.94788	(9)	 0.46230	(7)	 0.0193	(3)	 	C55	 0.87220	(9)	 1.00371	(9)	 0.42940	(7)	 0.0188	(3)	 	H55	 0.9351	 0.9886	 0.4338	 0.023*	 	
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C61	 0.84063	(9)	 0.97630	(9)	 0.34902	(7)	 0.0176	(3)	 	H61	 0.7823	 0.9985	 0.3429	 0.021*	 	C60	 0.92114	(9)	 1.02466	(10)	 0.31794	(7)	 0.0195	(3)	 	H60	 0.9746	 0.9936	 0.3188	 0.023*	 	C70	 0.89018	(9)	 1.00443	(9)	 0.23956	(7)	 0.0187	(3)	 	C76	 0.80485	(9)	 1.01688	(9)	 0.21626	(7)	 0.0185	(3)	 	H76	 0.7703	 1.0497	 0.2515	 0.022*	 	C75	 0.76597	(9)	 0.98365	(9)	 0.14321	(7)	 0.0201	(3)	 	C77	 0.66654	(10)	 0.97609	(9)	 0.11875	(7)	 0.0207	(3)	 	C78	 0.59389	(9)	 0.98538	(9)	 0.16964	(7)	 0.0184	(3)	 	H78	 0.6279	 1.0219	 0.2201	 0.022*	 	C84	 0.51989	(9)	 1.03694	(9)	 0.15598	(7)	 0.0196	(3)	 	H84	 0.4767	 0.9914	 0.1105	 0.023*	 	C85	 0.55954	(9)	 1.12859	(9)	 0.14614	(7)	 0.0193	(3)	 	C86	 0.62971	(10)	 1.20513	(10)	 0.19658	(7)	 0.0202	(3)	 	C88	 0.66235	(10)	 1.29033	(10)	 0.18820	(7)	 0.0235	(3)	 	H88	 0.7097	 1.3417	 0.2234	 0.028*	 	C89	 0.62445	(11)	 1.29911	(10)	 0.12735	(8)	 0.0257	(3)	 	C90	 0.73172	(15)	 1.45330	(12)	 0.16077	(10)	 0.0470	(5)	 	H90A	 0.7151	 1.4800	 0.2091	 0.071*	 	H90B	 0.7477	 1.5043	 0.1431	 0.071*	 	H90C	 0.7865	 1.4264	 0.1624	 0.071*	 	C54	 0.78759	(10)	 0.85259	(10)	 0.53438	(8)	 0.0242	(3)	 	H54	 0.8157	 0.8245	 0.5619	 0.029*	 	C53	 0.84298	(10)	 0.90305	(10)	 0.50168	(7)	 0.0218	(3)	 	H53	 0.9093	 0.9074	 0.5062	 0.026*	 	C51	 0.57411	(10)	 0.98298	(13)	 0.41406	(9)	 0.0320	(4)	 	H51A	 0.5362	 0.9163	 0.3908	 0.048*	 	
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H51B	 0.5595	 1.0187	 0.3858	 0.048*	 	H51C	 0.5589	 1.0127	 0.4625	 0.048*	 	C56	 0.88893	(10)	 1.11245	(10)	 0.47035	(7)	 0.0219	(3)	 	H56A	 0.8267	 1.1285	 0.4743	 0.026*	 	H56B	 0.9218	 1.1315	 0.5196	 0.026*	 	C57	 0.94721	(9)	 1.16969	(10)	 0.43494	(7)	 0.0206	(3)	 	C59	 0.95936	(9)	 1.13007	(10)	 0.36620	(7)	 0.0206	(3)	 	H59	 0.9942	 1.1707	 0.3465	 0.025*	 	C62	 0.81969	(9)	 0.86835	(10)	 0.30639	(7)	 0.0194	(3)	 	C63	 0.74105	(9)	 0.81902	(9)	 0.24635	(7)	 0.0191	(3)	 	C69	 0.66768	(9)	 0.86077	(9)	 0.23578	(7)	 0.0185	(3)	 	H69	 0.6605	 0.9159	 0.2745	 0.022*	 	C68	 0.60582	(9)	 0.82618	(9)	 0.17252	(7)	 0.0191	(3)	 	C66	 0.61541	(9)	 0.74197	(10)	 0.11657	(8)	 0.0207	(3)	 	C67	 0.56706	(11)	 0.63188	(11)	 -0.00642	(8)	 0.0281	(3)	 	H67A	 0.6307	 0.6479	 -0.0185	 0.042*	 	H67B	 0.5192	 0.6176	 -0.0476	 0.042*	 	H67C	 0.5598	 0.5756	 0.0054	 0.042*	 	C65	 0.68251	(10)	 0.69492	(10)	 0.12621	(8)	 0.0240	(3)	 	H65	 0.6860	 0.6368	 0.0887	 0.029*	 	C64	 0.74498	(10)	 0.73245	(10)	 0.19066	(8)	 0.0226	(3)	 	C79	 0.53867	(9)	 0.88365	(9)	 0.16130	(8)	 0.0202	(3)	 	H79	 0.5033	 0.8488	 0.1112	 0.024*	 	C81	 0.43091	(9)	 0.97102	(10)	 0.23794	(8)	 0.0214	(3)	 	C83	 0.45884	(10)	 1.05445	(10)	 0.21648	(8)	 0.0230	(3)	 	H83A	 0.4945	 1.1116	 0.2592	 0.028*	 	H83B	 0.4004	 1.0690	 0.2008	 0.028*	 	C71	 0.94290	(9)	 0.96069	 0.18580	(8)	 0.0235	(3)	 	
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(10)	C72	 1.07662	(12)	 0.89328	(14)	 0.15864	(9)	 0.0411	(4)	 	H72A	 1.0346	 0.8298	 0.1293	 0.062*	 	H72B	 1.1323	 0.8859	 0.1835	 0.062*	 	H72C	 1.0972	 0.9265	 0.1277	 0.062*	 	C73	 0.91054	(10)	 0.93281	(11)	 0.11370	(8)	 0.0290	(3)	 	H73	 0.9487	 0.9065	 0.0789	 0.035*	 	C74	 0.82259	(10)	 0.94295	(11)	 0.09187	(8)	 0.0258	(3)	 	C87	 0.73310	(12)	 1.26639	(11)	 0.30937	(8)	 0.0336	(4)	 	H87A	 0.7885	 1.2864	 0.2888	 0.050*	 	H87B	 0.7529	 1.2451	 0.3463	 0.050*	 	H87C	 0.7049	 1.3206	 0.3311	 0.050*	 	C91	 0.55507	(11)	 1.22420	(11)	 0.07612	(8)	 0.0258	(3)	 	H91	 0.5292	 1.2304	 0.0346	 0.031*	 	C92	 0.52395	(10)	 1.14040	(10)	 0.08610	(7)	 0.0224	(3)	 	H92	 0.4766	 1.0892	 0.0507	 0.027*	 	C82	 0.35930	(11)	 0.97838	(11)	 0.28843	(9)	 0.0303	(3)	 	H82A	 0.2983	 0.9770	 0.2643	 0.045*	 	H82B	 0.3816	 1.0388	 0.3311	 0.045*	 	H82C	 0.3512	 0.9242	 0.3028	 0.045*	 	C58	 0.99478	(11)	 1.27191	(10)	 0.48357	(8)	 0.0268	(3)	 	H58A	 1.0280	 1.3044	 0.4557	 0.040*	 	H58B	 1.0406	 1.2734	 0.5215	 0.040*	 	H58C	 0.9468	 1.3048	 0.5053	 0.040*	 	Cl1S	 0.94737	(7)	 0.59677	(7)	 0.09858	(5)	 0.0408	(3)	 0.4464	(17)	Cl2S	 1.01012	(9)	 0.47364	(9)	 -0.02966	(7)	 0.0505	(4)	 0.4464	(17)	C1S	 0.9980	(4)	 0.5018	(4)	 0.0608	(3)	 0.0507	(12)	 0.4464	(17)	H1SA	 0.9586	 0.4443	 0.0647	 0.061*	 0.4464	(17)	
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H1SB	 1.0617	 0.5172	 0.0888	 0.061*	 0.4464	(17)	
 
 
X-Ray Crystallography Data for Cycloadduct 201: 
 
Crystals of cycloadduct 201 suitable for X-ray analysis were obtained by slow 
evaporation from chloroform and hexanes. 
 
Crystal data 
C49H36Cl2N2O7·CHCl3 Z = 2 
Mr = 955.07 F(000) = 984 
Triclinic, P¯1 Dx = 1.403 Mg m-3 
Hall symbol:  -P 1 Cu Kα radiation, λ = 1.54178 Å 
a = 12.0120 (8) Å Cell parameters from 9945 reflections 
b = 13.0042 (8) Å θ = 3.0–66.5° 
c = 16.4711 (10) Å µ = 3.38 mm-1 
α = 72.110 (3)° T = 100 K 
β = 68.742 (3)° Prism, orange 
γ = 76.633 (3)° 0.06 × 0.05 × 0.05 mm 
V = 2261.0 (2) Å3  
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Data collection 
Bruker Proteum-R  
diffractometer 
7864 independent reflections 
Radiation source: rotating anode 6165 reflections with I > 2σ(I) 
multilayer Rint = 0.080 
φ & ω scans θmax = 67.2°, θmin = 3.0° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1996) 
h = -11∅14 
Tmin = 0.647, Tmax = 0.753 k = -15∅15 
35662 measured reflections l = -19∅19 
 
Refinement 		Refinement	on	F2	 Primary	atom	site	location:	structure-invariant	direct	methods	Least-squares	matrix:	full	 Secondary	atom	site	location:	difference	Fourier	map	
R[F2	>	2σ(F2)]	=	0.060	 Hydrogen	site	location:	inferred	from	neighbouring	sites	
wR(F2)	=	0.168	 H	atoms	treated	by	a	mixture	of	independent	and	constrained	refinement	
S	=	1.05	 w	=	1/[σ2(Fo2)	+	(0.0863P)2	+	2.0108P]			where	P	=	(Fo2	+	2Fc2)/3	7864	reflections	 (Δ/σ)max	<	0.001	581	parameters	 Δ〉max	=	0.88	e	Å-3	30	restraints	 Δ〉min	=	-0.68	e	Å-3	
 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 	 x	 y	 z	 Uiso*/Ueq	 	Cl1	 0.08660	(9)	 0.11256	(7)	 0.66556	(5)	 0.0484	(3)	 	Cl2	 0.36533	(9)	 0.12145	(7)	 0.61584	(5)	 0.0425	(2)	 	Cl1S	 -0.42089	(11)	 0.07194	(8)	 0.88005	(8)	 0.0629	(3)	 	Cl2S	 -0.32218	(12)	 0.13383	(14)	 0.99182	(8)	 0.0811	(4)	 	
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Cl3S	 -0.16520	(11)	 0.02860	(10)	 0.85373	(8)	 0.0664	(3)	 	O1	 0.50478	(17)	 0.32722	(16)	 0.32383	(13)	 0.0244	(4)	 	O2	 -0.5946	(2)	 0.3209	(2)	 0.79074	(15)	 0.0383	(6)	 	O3	 0.0849	(2)	 0.50956	(17)	 0.63149	(15)	 0.0340	(5)	 	O4	 -0.3052	(2)	 0.48956	(17)	 0.81600	(14)	 0.0314	(5)	 	O5	 0.3103	(2)	 0.50599	(18)	 0.56130	(15)	 0.0332	(5)	 	H5	 0.238	(4)	 0.521	(3)	 0.592	(3)	 0.050*	 	O6	 0.0276	(2)	 0.1047	(2)	 0.51143	(17)	 0.0454	(6)	 	O7	 0.4986	(2)	 0.10324	(16)	 0.43386	(14)	 0.0283	(5)	 	N1	 0.4954	(3)	 0.0531	(2)	 0.24029	(18)	 0.0360	(6)	 	C1	 0.8887	(4)	 0.2035	(3)	 0.1142	(2)	 0.0487	(10)	 	H1	 0.9486	 0.1716	 0.0693	 0.058*	 	C2	 0.8748	(3)	 0.3123	(4)	 0.1053	(2)	 0.0523	(10)	 	H2	 0.9253	 0.3563	 0.0538	 0.063*	 	C3	 0.7864	(3)	 0.3615	(3)	 0.1711	(2)	 0.0429	(8)	 	H3	 0.7770	 0.4381	 0.1636	 0.051*	 	C4	 0.7138	(3)	 0.2982	(3)	 0.2464	(2)	 0.0325	(7)	 	C5	 0.6214	(3)	 0.3468	(3)	 0.3192	(2)	 0.0292	(7)	 	H5A	 0.6367	 0.3120	 0.3774	 0.035*	 	H5B	 0.6242	 0.4261	 0.3049	 0.035*	 	C6	 0.4072	(3)	 0.3565	(2)	 0.38992	(18)	 0.0223	(6)	 	C7	 0.4097	(3)	 0.4166	(2)	 0.44563	(19)	 0.0250	(6)	 	H7	 0.4834	 0.4375	 0.4399	 0.030*	 	C8	 0.3043	(3)	 0.4458	(2)	 0.50949	(19)	 0.0253	(6)	 	C9	 0.1935	(3)	 0.4134	(2)	 0.52044	(19)	 0.0223	(6)	 	
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C10	 0.0835	(3)	 0.4451	(2)	 0.58898	(19)	 0.0266	(6)	 	C11	 -0.0281	(3)	 0.4015	(2)	 0.60863	(19)	 0.0258	(6)	 	H11	 -0.0321	 0.3590	 0.5723	 0.031*	 	C12	 -0.1250	(3)	 0.4217	(2)	 0.67825	(19)	 0.0258	(6)	 	H12	 -0.1141	 0.4616	 0.7138	 0.031*	 	C13	 -0.2432	(3)	 0.3902	(2)	 0.70544	(19)	 0.0265	(6)	 	C14	 -0.2742	(3)	 0.3290	(2)	 0.6625	(2)	 0.0300	(7)	 	H14	 -0.2133	 0.3035	 0.6143	 0.036*	 	C15	 -0.3894	(3)	 0.3037	(3)	 0.6869	(2)	 0.0324	(7)	 	H15	 -0.4078	 0.2626	 0.6558	 0.039*	 	C16	 -0.4780	(3)	 0.3403	(3)	 0.7585	(2)	 0.0319	(7)	 	C17	 -0.6289	(3)	 0.2574	(3)	 0.7486	(2)	 0.0356	(7)	 	H17A	 -0.5789	 0.1851	 0.7521	 0.043*	 	H17B	 -0.6176	 0.2948	 0.6845	 0.043*	 	C18	 -0.7590	(3)	 0.2450	(3)	 0.7977	(2)	 0.0411	(8)	 	C19	 -0.7932	(4)	 0.1441	(4)	 0.8441	(3)	 0.0598	(12)	 	H19	 -0.7348	 0.0809	 0.8473	 0.072*	 	C20	 -0.9189	(6)	 0.1363	(6)	 0.8876	(3)	 0.085	(2)	 	H20	 -0.9461	 0.0676	 0.9192	 0.102*	 	C21	 -0.9996	(5)	 0.2305	(7)	 0.8829	(3)	 0.0813	(19)	 	H21	 -1.0832	 0.2251	 0.9113	 0.098*	 	C22	 0.2986	(3)	 0.3231	(2)	 0.39815	(18)	 0.0215	(6)	 	C23	 0.1957	(3)	 0.3528	(2)	 0.46229	(18)	 0.0218	(6)	 	H23	 0.1223	 0.3315	 0.4677	 0.026*	 	C24	 -0.8455	(4)	 0.3374	(4)	 0.7970	(3)	 0.0605	(12)	 	H24	 -0.8205	 0.4071	 0.7661	 0.073*	 	C25	 -0.9657	(5)	 0.3297	(6)	 0.8400	(3)	 0.0781	(16)	 	H25	 -1.0238	 0.3932	 0.8394	 0.094*	 	C26	 -0.4520	(3)	 0.4013	(3)	 0.8037	(2)	 0.0318	(7)	 	H26	 -0.5130	 0.4252	 0.8526	 0.038*	 	
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C27	 -0.3366	(3)	 0.4269	(2)	 0.77706	(19)	 0.0275	(6)	 	C28	 -0.3964	(3)	 0.5253	(3)	 0.8909	(2)	 0.0332	(7)	 	H28A	 -0.4248	 0.4615	 0.9402	 0.040*	 	H28B	 -0.4662	 0.5693	 0.8722	 0.040*	 	C29	 -0.3420	(3)	 0.5924	(3)	 0.9219	(2)	 0.0316	(7)	 	C30	 -0.2497	(4)	 0.5462	(3)	 0.9581	(3)	 0.0445	(9)	 	H30	 -0.2208	 0.4708	 0.9634	 0.053*	 	C31	 -0.1982	(4)	 0.6074	(3)	 0.9870	(3)	 0.0528	(10)	 	H31	 -0.1343	 0.5744	 1.0116	 0.063*	 	C32	 -0.2408	(4)	 0.7172	(4)	 0.9796	(3)	 0.0547	(11)	 	H32	 -0.2059	 0.7602	 0.9988	 0.066*	 	C33	 -0.3331	(5)	 0.7638	(3)	 0.9444	(3)	 0.0584	(12)	 	H33	 -0.3622	 0.8391	 0.9395	 0.070*	 	C34	 -0.3848	(4)	 0.7017	(3)	 0.9158	(2)	 0.0428	(9)	 	H34	 -0.4496	 0.7344	 0.8922	 0.051*	 	C35	 0.2999	(3)	 0.2543	(2)	 0.33762	(18)	 0.0218	(6)	 	H35	 0.3653	 0.2769	 0.2799	 0.026*	 	C36	 0.3359	(3)	 0.1269	(2)	 0.37473	(18)	 0.0239	(6)	 	C37	 0.2260	(3)	 0.0621	(2)	 0.4109	(2)	 0.0301	(7)	 	C38	 0.1354	(3)	 0.0924	(2)	 0.4976	(2)	 0.0323	(7)	 	C39	 0.1875	(3)	 0.1016	(2)	 0.5636	(2)	 0.0322	(7)	 	C40	 0.3053	(3)	 0.1077	(2)	 0.54150	(19)	 0.0293	(7)	 	C41	 0.3922	(3)	 0.1097	(2)	 0.44922	(19)	 0.0250	(6)	 	C42	 0.1630	(3)	 0.0850	(3)	 0.3401	(2)	 0.0353	(7)	 	H42A	 0.2186	 0.0580	 0.2874	 0.042*	 	H42B	 0.0914	 0.0462	 0.3654	 0.042*	 	C43	 0.1250	(3)	 0.2058	(3)	 0.3112	(2)	 0.0313	(7)	 	C44	 0.0147	(4)	 0.2398	(3)	 0.2813	(3)	 0.0497	(10)	 	H44A	 -0.0007	 0.3195	 0.2633	 0.074*	 	H44B	 -0.0548	 0.2119	 0.3310	 0.074*	 	H44C	 0.0277	 0.2100	 0.2302	 0.074*	 	
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C45	 0.1850	(3)	 0.2781	(2)	 0.31324	(19)	 0.0263	(6)	 	H45	 0.1526	 0.3526	 0.2978	 0.032*	 	C46	 0.2680	(3)	 -0.0562	(3)	 0.4387	(2)	 0.0345	(7)	 	N2	 0.2972	(3)	 -0.1457	(3)	 0.4619	(2)	 0.0528	(9)	 	C48	 0.4266	(3)	 0.0840	(2)	 0.3002	(2)	 0.0277	(6)	 	C49	 0.7304	(3)	 0.1862	(3)	 0.2539	(2)	 0.0404	(8)	 	H49	 0.6815	 0.1410	 0.3054	 0.048*	 	C50	 0.8164	(4)	 0.1396	(3)	 0.1881	(2)	 0.0460	(9)	 	H50	 0.8253	 0.0633	 0.1942	 0.055*	 	C1S	 -0.2987	(4)	 0.1204	(3)	 0.8840	(3)	 0.0491	(10)	 	H1S	 -0.2883	 0.1932	 0.8403	 0.059*	 	
 
 
Energy Calculations 
All structures were fully optimized by using Density Functional Theory (DFT) 
with the B3LYP Functional. 109  All calculations were carried out with the 
Dunning/Huzinaga valence double-zeta basis set for C, H and O atoms and a Hay-Wadt 
core potential110 together with the associated basis set (LANL2DZ) for Ag.111 Structures 
were characterized by frequency analysis at the same level of theory. 
 
Scheme 2.15 Ag+-Catalyzed Stepwise Radical [4+2] Cycloaddition to Exo-endo-syn 
and Exo-exo-syn Cycloadducts 
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The initial bond-forming transition state leading to anti cycloadducts was optimized for 
both endo and exo [4+2] cycloadditions. In both cases the barrier was significantly higher 
than the syn structures (at least 10 kcal/mol). This calculation result is consistent with our 
experimental observation that no anti products were isolated.  
 
Scheme 2.16 Calculations of Ag+-catalyzed, Stepwise Radical [4+2] Cycloadditions 
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2.4 Selected Spectra: 
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1H NMR spectrum for brosimone B provided by Prof. Irene Messana. 
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1H NMR spectrum for brosimone A (acetone-d6, 400 MHz) provided by Prof. Irene 
Messana. 
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Chapter 3 
Asymmetric Syntheses of the Flavonoid Diels-Alder Natural 
Products Sanggenons C and O 
3.1  Introduction  
          The sanggenons belong to the prenylflavonoid class of natural products (cf. 
Chapter 1, 1.1). These natural products were first isolated by Nomura and coworkers 
from the root bark of Morus sp., used as a traditional medicine in China for thousands of 
years. Sanggenon natural products typically feature a densely functionalized hydroxy-
benzofuro[3,2-b]chromenone ring system (Figure 3.1, highlighted in red); all of these 
compounds possess a cis stereochemical configuration at carbon centers 2 and 3. Many of 
the congengers bear a prenylated or dehydroprenylated phenol moiety, e.g. sanggenol F 
(206),112 sanggenons A (207), and M (208). 113 More advanced architectures contain a 
tetra-substituted cyclohexene ring, which may be derived from enzymatic Diels-Alder 
cycloaddition. Sanggenons C (12)14, 17 and O (13)15, 114 are both endo cycloadducts, 
whereas sanggenon D (7)115 is an exo cycloadduct with unknown relative stereochemistry 
between the hemiketal and cyclohexene moieties. Cathayanons A (213) and B (214)116 
have similar cyclohexene ring structures, with slight regiochemical differences in 
comparison to sanggenons C and O. Cathayanins B (209) and C (212)117 are likely 
derived from ketalization of sanggenons C and O, respectively. An alternative cyclization 
of sanggenon C may form an additional [3.3.1] ring system as found in cathayanin E 
(211).118  
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Figure 3.1 Sanggenon-type of natural products. 
           Among these sanggenon-type natural products, sanggenons C (12) and O (13) have 
striking biological activities, including antitumor, antiviral, and anti-inflammatory 
properties (cf. Chapter 1)119 which underscores these compounds as attractive synthetic 
targets. The structures of sanggenons C (12) and O (13) were elucidated by Nomura and 
		
148 
coworkers. Based on 1H NMR studies, they assigned the relative configurations of these 
two molecules as endo Diels-Alder cycloadducts based on key proton coupling constants 
(cf. Chapter 1).  Further ketalization of synthetic sanggenons C (12) and O (13) afforded 
cathayanins B (209) and C (212) (Scheme 3.1). Since 209 and 212 are apparent 
diastereomeric compounds differing at positions 2 and 3, Nomura measured the CD 
spectrum of a 1 : 1 mixture of 209 and 212. Comparing the CD spectrum with 
mulberrofuran G (215) (cf. Chapter 1, 1.1.1) led to the assumption that sanggenons C 
and O have absolute configurations 3’’S, 4’’R, and 5’’S.  
Scheme 3.1 Stereochemical Assignments of Sanggenons C and O 
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Although chemical syntheses of related Diels-Alder type natural products 
including sorocenol B81b and brosimones A and B120 have been achieved, at the outset of 
our studies there were no reported catalytic, enantioselective [4+2] cycloadditions of 2′-
hydroxychalcones, nor were there published reports of Diels-Alder cycloadditions of 
complex flavonoid dienes. In this chapter, a catalytic enantioselective synthesis of 
sanggenons C and O will be described which reports on progress along these lines.  
3.2  Retrosynthetic Analysis of Sanggenons C and O 
Inspired by the biosynthesis of prenylflavonoid natural products (cf. Chapter 1, 
1.1.2), we proposed that sanggenons C (12), D (210), and O (13) are Diels-Alder 
cycloadducts between a flavonoid diene (216) and a 2′-hydroxychalcone (217) (Scheme 
3.2). Among these compounds, sanggenons C and O were shown to be endo cycloadducts 
epimeric at positions 2 and 3. We considered a stereodivergent reaction of a racemic 
mixture (stereodivergent RRM) utilizing racemic diene 216 as a promising strategy to 
synthesize these two targets, assuming that issues of endo/exo, facial-, and enantio-
selectivity could be addressed. The requisite flavonoid diene (216) may be derived from 
dehydrogenation of the prenyl group of sanggenol F (1) or the protected derivative (219) 
(cf. Chapter 2, 2.1.2). 87 Alternatively, the flavonoid diene may be derived from 
isomerization of the chromene ring in sanggenon A (207) or the corresponding protected 
substrate (220).121 The core structure of sanggenol F (206) may be prepared from olefin 
cross metathesis of precursor 218. We envisioned that 218 may in turn be derived from 
hemiketalization of diketone 221, which may arise from metal-catalyzed double Claisen 
rearrangement122 of bis-allyloxyflavone ether 222.  Compound 222 can  be  derived  from 
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Scheme 3.2 Retrosynthetic Analyses of Sanggenons C and O 
  
the commercially available compound morin (223). 
3.3  Related Asymmetric Diels-Alder Reaction and Stereodivergent 
RRM 
3.3.1 Related Asymmetric Diels-Alder Reactions 
        Numerous catalysts have been developed for asymmetric Diels-Alder reactions.123 
Kelly and coworkers developed a BH3/1,1’-bi-2-naphthol (BINOL) system which was 
successfully applied to the asymmetric Diels-Alder cycloaddition of juglone (224) 
(Scheme 3.3a).124 In this reaction, the investigators proposed that asymmetric boron 
complex 224 was an active intermediate in the process. Up to 98% ee was achieved 
despite  the  requirement  for  a  stoichiometric  amount   of   both   borane   and   BINOL. 
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Scheme 3.3 Related Asymmetric Diels-Alder Reactions 
 
Catalytic enantioselective Diels-Alder cycloadditions have also been well-studied for 
model dienophiles such as bromoenal 225 (Scheme 3.3b). A series of boron-based chiral 
Lewis acids such as 226 were developed by Corey and coworkers. In the proposed 
assembly 228, the electrophilic boron coordinates with the oxygen atom of the aldehyde, 
while the oxygen atom of 226 hydrogen bonds with the aldehyde hydrogen. These 
interactions form a chiral complex with aldehyde 225, promoting the diene to approach 
from the less hindered face to afford enantioenriched cycloadduct 227 in quantitative 
yield and excellent enantioselectivity.125 Evans’ auxiliary may also be employed in 
asymmetric Diels-Alder reactions. Bidentate compound 229 allows for chelation of chiral 
magnesium complexes such as 224 (Scheme 3.3c). Subsequent [4+2] cycloaddition 
afforded cycloadduct 230 in 85% yield and 80% ee.126  
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Scheme 3.4 Asymmetric Synthesis of Prenylflavonoid and Related Natural Products 
 
More recently, Lei and coworkers120b applied the BH3/BINOL system (cf. Scheme 3.3a) 
in the asymmetric Diels-Alder reaction of 2’-hydroxylchalcones (Scheme 3.4). By using 
stoichiometric amounts of borane and BINOL, dienophile 232 and diene 233 underwent 
an asymmetric Diels-Alder reaction to form endo-234 and exo-235 cycloadducts with 99% 
combined yield, 4.6 : 1 d.r. and 97% and 11% ee, respectively. In addition, this method 
was further applied in the asymmetric syntheses of kuwanon X (cf. Figure 1.1),127 
kuwanon I (165),128 kuwanon J (166), and brosimones A (8) and B (9).  
3.3.2 Stereodivergent Reaction of a Racemic Mixture 
          Kinetic resolution129 is regarded as an important method to prepare enantioenriched 
materials. Simple kinetic resolution takes advantage of a difference in reaction rate 
between two enantiomers with a homochiral reagent as catalyst (Figure 3.2). The 
efficiency of simple kinetic resolutions is measured in terms of a selectivity factor s, 
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defined as s = kfast/kslow. In the absence of selectivity, s = 1. Larger s values (s ≥ 200) will 
lead to a product with greater than 95% ee. However, the yield of a simple kinetic 
resolution for a single enantiomer can never surpass 50%.  For a divergent reaction on 
racemic mixture (divergent RRM), high selectivity factors are not necessary to achieve 
highly enantioenriched materials. In this strategy, a chiral catalyst (cat. X*) facilitates the 
reaction of both enantiomers to form two products, A (derived from enantiomer R) and B 
(derived from enantiomer S). As for parallel kinetic resolution, two chiral catalysts (cat. 
X* and cat. Y*) are used for two parallel reactions of two enantiomers of a substrate, 
respectively. Therefore, two parallel kinetic resolutions take place simultaneously to 
afford enantioenriched products A and B.   
 
Figure 3.2 Three type of kinetic resolution methods. 
            Stereodivergent reactions on racemic mixtures (stereodivergent RRM) is a 
divergent resolution method used to resolve two enantiomers and form two 
enantioenriched products. Recently, Rovis and coworkers130 utilized this strategy in an 
asymmetric Stetter reaction (Scheme 3.5a). Using an NHC catalyst, in this reaction the 
racemic aldehyde 236 was converted into cyclopentenones 237 and 238 in high 
enantioselectivity. 
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Scheme 3.5 Stereodivergent Reactions on Racemic Mixtures 
 
This strategy has also been exploited in the total synthesis of cyanthiwigin and 
cyathane natural products by Sarpong and coworkers,131 wherein racemic diene 239 was 
cyclopropanated via a chiral rhodium-catalyzed process to yield enantioenriched 240 and 
241. (‒)-cyanthiwigin G (242) and (+)-cyathin A3 (243) after further modifications.  
3.4  Results 
             Our synthesis of sangennons C and O commenced with tetra-MOM group 
protection of the commercially available compound morin (223). Using an excess amount 
of MOMCl and Hünig's base yielded tetra-MOM ether morin 244 in 55% yield. The 
strong hydrogen bond between 5-H and 4-O inhibits the deprotonation of the phenol, 
which leads to the selective MOM protection. Subsequent 5-allylation using allyl 
bromide and cesium carbonate in DMF provided 245 in quantitative yield.  
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Scheme 3.6 Synthesis of Compound 245 
 
               Next we investigated the selective deprotection of the 3-MOM group. We 
envisioned that 3-O and 4-O may act as a potential chelation pocket for proton and metal 
ion, and therefore planned to take advantage of this chelation pocket and activate the 3-
MOM group. Selective 3-MOM deprotection was accomplished using NaI and a catalytic 
amount of aqueous HCl (Scheme 3.7).  In this transformation, protonation of the 4-
carbonyl and O-3 of substrate 245 appears to activate the 3-MOM group for 
chemoselective deprotection (cf. 247).   
Scheme 3.7 Synthesis of Bis-allyloxyflavone Ether 222 
 
 Finally, 3-allylation and global MOM deprotection afforded the desired bis-
allyloxyflavone ether substrate 222 in 91% yield (2 steps).            
A number of rare earth metal triflates were evaluated for the double rearrangement 
of bis-allyloxyflavone substrate 222 (Table 3.1).132 Among the metal triflates, Yb(OTf)3 
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was found to produce the double rearrangement product 221 in 72% yield. In this 
reaction, hexafluoro-2-propanol (HFIP) was used as a polar, non-coordinating 133 
cosolvent to solubilize the polar rearrangement substrate. Other rare earth triflates were 
found to produce the double rearrangement product 221 along with the single 
rearrangement product 248 in varying ratios. Based on examination of a DFT molecular 
model (Figure 3.3) for substrate 222, there are two possible chelation sites between O-3 
and O-4 (2.85 Å) and O-5 and O-4 (2.72 Å) through either five or six-membered 
arrangements.  Selective binding to either or both chelation pockets may occur depending 
on the ionic radius134 of the Lewis acid to enable 3-allyl rearrangement and/or 5-allyl 
rearrangement.135 Different modes of chelation by rare earth metal triflates may explain 
the product distributions observed in Table 3.1 For example, La(OTf)3 with a larger ionic 
radius (103.2 Å) may preferentially chelate between O-3 and O-4 due to the larger 
binding pocket to afford the 3-allyl rearrangement product 248 as the major product. The 
product of mono-aromatic Claisen rearrangement (not shown) was not observed during 
the screening. 
Table 3.1 Evaluation of Lewis Acids for Double Rearrangement of 222 
 
entrya M(OTf)x ionic radii (pm) yield% (55, 56 )b 
1 Yb(OTf)3 86.8 72%, 0% 
2 Y(OTf)3 90.0 60%, 36% 
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3 Gd(OTf)3 93.8 48%, 40% 
4 Nd(OTf)3 98.3 38%, 62% 
5 La(OTf)3 103.2 0%, 70% 
aAll reactions were carried out with substrate 222 (0.13 mmol) and M(OTf)3 (15 mol% ) at 0.1 M 
in CH2Cl2/HFIP (4:1) at 50 °C.  bIsolated yield determined using purified 221 and 248. 
 
 
Figure 3.3 DFT model (B3LYP/6-31G*) of compound 222. 
         Based on the above screening, Yb(OTf)3 was chosen as the optimal catalyst for the 
double rearrangement , which led to formation of 221 in 72% yield (Scheme 3.8).   After 
obtaining the desired hydrobenzofuro[3,2-b]chromenone core structure (±)-221, we 
investigated syntheses of the natural products sangenol F(206) and sanggenon A (207). 
Hemiacetal (±)-221 was then submitted to cross-metathesis136 conditions to install the 
prenyl group in which case (±)-sanggenol F (206) was directly accessed in 65% yield 
with full conversion of the starting material. However, sanggenol F (206) was extremely 
difficult to purify from residual ruthenium byproducts.  
Scheme 3.8 Synthesis of Sanggenol F 
 
Therefore, we first conducted silylation of hemiacetal (±)-221 which afforded (±)-
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249 in 90% yield (Scheme 3.9). Interestingly, we also isolated a 9% yield of a diketone 
product 250. This result suggests that the hemiacetal (±)-221 undergoes equilibration 
with a diketone compound under basic condition, which may also explain the moderate 
yield of sanggenol F (206) in the aforementioned olefin metathesis reaction. Treatment of 
(±)-249 with second generation of Grubbs’ catalyst along with 2-methyl-2-butene only 
afforded a 44% yield of the cross-metathesis product (±)-sanggenol F (206). Compared to 
unprotected hemiacetal (±)-221, the bulky TBS protecting group increases the steric 
hindrance of the allyl group at position C-2. Next, we considered using the more reactive 
reaction partner isobutene in the cross-metathesis. As depicted in Scheme 3.9, (±)-249 
was smoothly converted to the prenylated compound 251 in almost quantitative yield 
using isobutene and Grubbs’ catalyst. Subsequently, global desilylation yielded (±)-
sanggenol F (206) in excellent yield. In addition, this sequence enabled purification of the 
final product from residual ruthenium byproducts, which is in contrast to the direct cross-
metathesis method (cf. Scheme 3.8).  
Scheme 3.9 Alternative Route for the Synthesis of Sanggenol F 
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Table 3.2 Synthesis of Sanggenon A 
 
entrya catalyst  oxidant  solvent  Temp. yield%b 
1 10 mol% Pt/C cyclopentene DCE 80 ºC 10% 
2 10 mol% Pt/C 1 atm O2 DCE 80 ºC 22% 
3 none DDQ CH2Cl2 rt. decomposed 
4 none DDQ THF rt. 38% 
5 none DDQ THF 60 ºC 78% 
aSee experimental section for reaction details.  bIsolated yield determined using purified 
207. 
We next investigated the synthesis of sanggenon A (207) directly from sanggenol 
F (206) via a biomimetic pathway. Successful dehydrogenative conditions developed in 
previous syntheses of the brosimones (cf. Chapter 2) were screened in this 
transformation (Table. 3.2). The Pt/C-based conditions proved inefficient for the 
conversion of sanggenol F (206) to sanggenon A (207), which only allowed up to a 22% 
yield of 2 (entries, 1 and 2). Treatment of 1 with DDQ in dichloromethane caused severe 
decomposition (entry 3). To our delight, using THF instead of CH2Cl2 as solvent, 
sanggenol F (206) was oxidized by DDQ to afford sanggenon A (207) cleanly at room 
temperature (entry 4). Increasing the temperature to 60 ºC, sanggenon A (207) was 
obtained with optimal yield (78%) (entry 5). As DDQ is a strong electron-acceptor,137 a 
charge-transfer complex may be produced when an electron-donating solvent such as 
THF is employed.138 The formation of such a complex may modulate the reactivity of reactivity 
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Table 3.3 [4+2] Cycloaddition Attempts with sanggenon A 
	
entrya condition solvent  temp. result 
1 2 equiv AcOH DCE 80 ºC trace products 
2 10 mol% Sc(OTf)3 DCE 80 ºC decomposed 
3 hν (400 nm >λ> 325 nm) CH2Cl2 rt. decomposed 
 
DDQ139, which appears to largely suppress the decomposition observed using oxidative 
conditions with halogenated solvents. 
We next evaluated (±)-sanggenon A (207) as a diene precursor for [4+2] 
cycloaddition. Treatment of 207 under Brønsted acidic, thermal, or photochemical 
conditions (Table 3.3) in the presence of silica-supported silver nanoparticles 
(AgNP’s)140 and 2′-hydroxychalcone 60 as dienophile did not lead to the desired [4+2] 
cycloaddition; only severe decomposition of (±)-sanggenon A was observed.  
Treatment of (±)-251 with DDQ in THF (cf. Table 3.2) cleanly afforded the 
chromene (±)-252 in 73% yield (Scheme 3.10). We anticipated that the TBS-protected 
chromene 252 could generate the desired diene 254 in situ through retro 6π-
electrocyclization followed by deprotonation/protonation (formal 1,7 hydrogen shift).141 
Accordingly,  (±)-chromene  252  was  employed  in  cycloadditions  with  acetylated 
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Scheme 3.10  Syntheses of Sanggenons C (12) and O (13) 
 
2′-hydroxychalcone 232 in the presence of AgNP’s to yield a mixture of two endo 
cycloadducts 255/256 with minimal production of exo diastereomers. The mixture of 
endo cycloadducts was sequentially treated with aqueous NaHCO3 and NEt3•3HF to yield 
a mixture of (±)-sanggenons C (12) and O (13) in 36% yield over 3 steps and in a 4 : 1 
diastereomeric ratio.   
           We next investigated the asymmetric synthesis of sanggenon natural products.  
Previously, our group developed an asymmetric scandium(III)-catalyzed rearrangement 
of 3-allyloxyflavones.122 We examined this catalytic system in the synthesis of hydroxy-
benzofuro[3,2-b]chromenone structures. As depicted in Scheme 3.11, treatment of 222 
with 30 mol% Sc(OTf)3 and 4-phenyl substituted Pybox ligand 257 produced the 
rearrangement product 248 in 67% yield and up to 74% ee. Screening of several ligands 
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failed to provide further improvement of enantioselectivity. Other reaction parameters 
were also modified, however increased ee was not  observed.  During  the  screening,  we  
Scheme 3.11 Lewis-acid Mediated Asymmetric Rearrangement 
 
observed that the pyridine moiety is crucial for the high enantioselectivity, as well as the 
4-substitution on the oxazole ring. Employing ligands without these two attributes led to 
a substantial decrease in enantioselectivity. Accordingly, a transition state assembly 258 
was proposed for this asymmetric rearrangement. In model 258, the substrate coordinates 
with chiral scandium catalyst. The α face is blocked by the phenyl group of the R-Pybox 
ligand, in which case the allyl group would rearrange from the ß face. Accordingly, the 
stereochemical outcome of product 248 was predicted to be 2S 3R. 
            In order to synthesize highly enantioenriched sanggenons C (12) and O (13), we 
considered an alternative route. We envisioned that sanggenons C (12) and O (13) are 
both endo cycloadducts with the same absolute configurations for the chiral cyclohexene  
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Table 3.4 Model Asymmetric Diels-Alder Reaction 
 
entry catalyst condition  yield 260/261a ee 260/261b 
1 20 mol% TiCl2(OiPr)2 22 mol% TADDOL 262 DCE, 60ºC 21%/40% 40%/19% 
2 20 mol% TiCl2(OiPr)2 22 mol% BINOL 266 
DCE, 60ºC 32%/21% 61%/30% 
3 10 mol% 28  CH2Cl2, rt. no reaction -- 
4 10 mol% Fe (S,S)-PDP 264 CH2Cl2, rt. decomposed -- 
5 0.2 mol% AgNP, diene 265 CH2Cl2, rt. 44%/11% 2%/4% 
6 10 mol% B(OPh)3,  10 mol% BINOL 263 PhCF3,‒10 ºC 38%/20% 33%/10% 
7 10 mol% B(OPh)3,  10 mol% BINOL 266 PhCF3, 40 ºC 80%/13% 69%/31% 
8c 10 mol% B(OPh)3,  10 mol% BINOL 266 PhCF3, 40 ºC 75%/15% 96%/39% 
a Isolated yield determined using purified 260 and 261. bee determined for purified 260 
and 261  by chiral HPLC analysis on a ChiraPak AD-H column. c see text.  
 
 
moiety and epimers at both C-2 and C-3. Accordingly, we proposed that enantioselective 
[4+2] cycloaddition of chiral, racemic substrate 252 and dienophile 232 should efficiently 
		
164 
deliver two natural products simultaneously via a stereodivergent process. 
Before we proceeded to evaluate the proposed stereodivergent strategy, we 
investigated the asymmetric Diels-Alder cycloaddition of 2’-hydroxychalcone. A model 
reaction (Table 3.4) was conducted to facilitate our study. Our study commenced with 
literature reported chiral titanium TADDOL and BINOL complexes (entries 1, 2).142 
Moderate yields and enantioselectivities were observed, with the endo cycloadduct 
exhibiting up to 61% ee, whereas only 30% ee was observed for the exo cycloadduct. 
Chiral Lewis acid 28 (entry 3) was found to be inefficient in catalyzing this [4+2] 
cycloaddition. In our previous AgNP-mediated [4+2] cycloadditions of 2’-
hydroxychalcones, further studies provided strong evidence for an electron transfer 
mechanism. Accordingly, Fe(PDP) (PDP = [N, N-Bis(2-pyridylmethyl)]-2, 2’-
bipyrrolidine) catalyst was used as an electron shuttle type catalyst to mimic AgNPs. 
However, conditions with Fe(PDP) caused severe decomposition (entry 4). Inspired by 
Kobayashi and coworkers,143 we designed a chiral AgNP catalyst using chiral diene 265, 
which was prepared by first mixing AgBF4 with chiral diene 265 in dry CH2Cl2, followed 
by adding NBu4BH4. Compared to the achiral AgNPs previously prepared, chiral AgNPs 
produced cycloadducts in lower yield without any observable enantioselectivity (entry 5). 
We next screened conditions with B(OPh)3 and simple BINOL ligand 263, which 
produced moderate yields of cycloadducts and enantioselectivity (entry 6). Interestingly, 
conducting the same reaction at higher temperature produced cycloadducts in much 
higher yield and with higher diastereo- and enantioselectivities (entry 7). We speculated 
that under higher temperature a different chiral boron species may form in solution. 
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Wulff and coworkers reported that formation of boron complexes is sensitive to reaction 
parameters. The optimal condition to produce boron complex 269 was found to involve 
heating B(OPh)3, H2O and VAPOL under 80 ºC followed, by solvent removal under 
reduced pressure at the same temperature. Other conditions resulted in higher ratios of 
268 and 269. More interestingly, treatment of 268 and 269 mixture with DMAP led to the 
formation of the boroxinate complex 270. This complex was found to be a robust catalyst 
for asymmetric aziridination (Figure 3.4) to produce high enantioenriched aziridine 273; 
other boron complexes (eg. 271 and 272) were found to be much less reactive in terms of 
yield and selectivity.144 Accordingly, chalcone 60, B(OPh)3 and BINOL 266 were mixed 
and heated to 110 ºC. The resulting mixture was then cooled to 40 ºC and diene 259 was 
added. To our delight, cycloadducts 260 and 261 were isolated in 10 : 1 d.r. and 96% ee 
for endo-260 and 39% ee for exo-261 (entry 8).  
 
Figure 3.4  Condition-dependent boron complex formation. 
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 In an effort to improve this reactivity, a series of BINOL-type ligands were 
prepared and screened; results are depicted in Scheme 3.12. The 3 and 3’ substitutions 
were found to be crucial for enantioselectivity, as well as the diastereoselectivity. 3,3’-
Bis-Bromine substituted BINOL ligand 266 was found to be most efficient in catalyzing 
this reaction using B(OPh)3. Using PhCF3 as solvent provided optimal results in terms of 
yield and selectivity. 
Scheme 3.12 Ligand Screening for the Asymmetric Diels-Alder Cycloaddition 
 
In order to study the absolute configuration of the enantioenriched cycloadducts, 
brominated diene 274 was used to prepare corresponding cycloadducts endo-275 and 
exo-276. Using the optimized conditions, endo-275 and exo-276 were prepared in 91% 
yield, 10 : 1 d.r., 9.8% ee, and 41% ee respectively. A bright orange color change was 
observed when the borate catalyst and 2′-hydroxychalcone were combined, leading us to 
hypothesize that a borate-substrate complex 277 may be generated as an active species 
for [4+2] cycloaddition. By heating the mixture of 2′-hydroxychalcone 60, (S)-BINOL 
266, and B(OPh)3, we subsequently obtained borate complex 277, the structure of which 
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was confirmed by single X-ray crystal structure analysis. The predicted absolute 
stereochemistry of the corresponding endo cycloadduct 275 based on the expected face 
selectivity of complex 277 was also confirmed by X-ray crystallography analysis of 
cycloadduct 275. We found that 1 equivalent of phenol was also bound to the borate 
complex 277 through a hydrogen bond and edge to face interaction as shown in the X-ray 
crystal structure (Scheme 3.13).  The bound phenol  could  serve  to  further  activate  the 
Scheme 3.13 Proposed Active Complex for [4+2] Cycloaddition 
	
chalcone for cycloaddition and may also protonate the cycloadduct to turnover the 
boron/BINOL catalyst for additional catalytic cycles. Similarly, Wulff and coworkers 
have reported a hydrogen-bonded complex of a boroxinate catalyst and a protonated 
iminium substrate.145  We also found that treatment of crystalline 277 with diene 274 led 
to similar results to produce 275 in high enantioselectivity. The latter result reinforces the 
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likely involvement of borate complex 277 in the catalytic asymmetric Diels-Alder 
cycloaddition which is also supported by literature precedent.146 
With this advanced catalytic, asymmetric system in hand, we next applied it to the 
stereodivergent RRM strategy to synthesize enantioenriched sanggenons C (12) and O 
(13). Based on the model reaction, a catalytic amount of B(OPh)3  and  (R)-BINOL 266 
were used to mediate asymmetric [4+2] cycloaddition of diene precursor (±)-252 and 
dienophile 232. After sequential deprotection of both acetate and silyl protecting groups, 
promising enantioselectivities were observed. A number of BINOL ligands were 
evaluated; the best results were obtained when B(OPh)3 and  (R)-BINOL 266 were 
employed. A mixture of cycloadducts were observed which was followed by consecutive 
deprotections (NaHCO3; NEt3•3HF) to afford sanggenon C (12) and sanggenon O (13) in 
2: 1 ratio and 98%, 93% ee respectively and 54% combined yield. The high endo/exo 
selectivity (cf. Scheme 3.13) suggested that minimal amounts of exo diasteromers were 
generated which we were not able to isolate and characterize. In this transformation, we 
expected four different stereoisomers:  
Scheme 3.14 Proposed Active Complex for [4+2] Cycloadditions 
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sanggenon C (12) and ent-sanggenon O (13) from (2R, 3R)-254 ent-sanggenon C (12) 
and sanggenon O (13) from (2S, 3S)-254 (Scheme 3.14). As shown in the (R)-
BINOL/B(OPh)3/chalcone complex 278, the re face of the chalcone dienophile is blocked 
by the bulky bromo substituent. As a result, the derived dienes (2R, 3R)-254 and (2S, 3S)-
254 approach from the si face of the boron/chalcone complex 278 to afford sanggenon C 
(12) and sanggenon O (13). Using (S)-BINOL 266 as catalyst, ent-sanggenon C (12) and 
ent-sanggenon O (13) were isolated in a 2 : 1 ratio and in 99%, 93% ee, respectively. We 
also noticed that in the stereodivergent RRM, sanggenon C is produced in both high 
enantiomeric excess and diastereomeric ratio relative to sanggenon O. This result 
suggests that matched/mismatched cycloadditions may also be operative based on 
differential interactions of the chiral borate catalyst with both enantiomers of diene 254.  
 
Figure 3.5 DFT (B3LYP/6-31G*) computational study of the stereodivergent RRM. 
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In order to understand the greater preference for formation of sanggenon C vs. O 
(cf. Scheme 3.14), and the higher enantioselectivity observed for sanggenon C, we 
conducted computational studies of dienophile complex 278 using both enantiomers of a 
simplified variant of the diene (TMS instead of TBS groups) to analyze the interacting 
complex of reagents engaging in Diels-Alder cycloaddition.147 Simplified cycloaddition 
models A and B were shown previously in Scheme 3.14 with the lowest energy 
conformer of diene 254. It appears that cycloaddition through model A is favored in 
comparison to the corresponding model B using (R)-BINOL which results in greater 
amounts of sanggenon C derivatives and therefore favored production of (2R, 3R) 
stereoisomers in the product mixture. These preliminary reaction assembly calculations148 
(Figure 3.5) (conducted by Dr. Vincent Eschenbrenner-Lux of the Porco group) show 
that there are significant steric interactions between the prenyl and phenyl group on the 
chalcone dienophile which are likely responsible for the significantly increased energy 
(approx. 13.4 kcal/mol) in assemblies related to model B. Based on the X-ray structure of 
the chiral borate complex (cf. Scheme 3.13), we predicted that the use of (R)-BINOL as 
catalyst should yield (3’’S, 4’’R, 5’’S) for both sanggenons C and O. This prediction is in 
agreement with absolute stereochemistry determinations reported by Nomura and 
coworkers for the natural products.14  
3.5  Summary and Future Outlook 
In summary, we have achieved the first asymmetric syntheses of the flavonoid 
Diels-Alder natural products sanggenons C and O. The syntheses employ a Lewis acid-
promoted double Claisen rearrangement to construct the hydrobenzofuro[3,2-
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b]chromenone core scaffold of sanggenon A and sanggenol F. The first catalytic, 
enantioselective [4+2] cycloadditions of 2′-hydroxychalcones have been developed using 
BINOL-boron catalysis. The high enantioselectivity and diastereoselectivity of this 
catalytic system enabled a stereodivergent reaction of a chiral, racemic flavonoid diene 
precursor to afford enantioenriched sanggenons C and O.  Preliminary calculations of the 
interactions of diene-dienophile complexes support the stereochemical outcomes 
observed in stereodivergent cycloadditions. Future directions for this project include 
further studies on asymmetric double rearrangement of compound 222 to access more 
enantioenriched sanggenon natural products (eg. sanggenon A and saggenol F), as well 
post modification of sanggenon C to synthesize more complex compound such as  
cathayanin C (212). 
In addition, we would like to further study the obtained borate complex 277. It is 
possible that this complex could be used as an asymmetric catalyst (cf. Figure 3.4) for 
other asymmetric Diels-Alder cycloadditions (Scheme 3.15). If complex 277 (or other 
related compounds including 2’-hydroxyacetophenones) could be used as an efficient 
pre-dcatalyst, pre-heating of the chalcone substrate with Binol and borate could be 
avoided. Use of 277 would also further establish that this complex can achieve turnover 
with other chalcone dienophiles under catalytic conditions.  
Scheme 3.15  Proposed Further Study of Borate Complex 277 
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3.6  Experimental Section 
General Information 
1H NMR spectra were recorded at 400 or 500 MHz at ambient temperature with 
CDCl3 (Cambridge Isotope Laboratories, Inc.) as the solvent unless otherwise stated. 13C 
NMR spectra were recorded at 100 or 125 MHz at ambient temperature with CDCl3 as 
the solvent unless otherwise stated. Chemical shifts are reported in parts per million 
relative to CDCl3 (1H, δ 7.26; 13C, δ 77.16). Data for 1H NMR are reported as follows: 
chemical shift, integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet) and coupling constants. All 13C NMR 
spectra were recorded with complete proton decoupling. Infrared spectra were recorded 
on a Nicolet Nexus 670 FT-IR spectrophotometer. High-resolution mass spectra were 
obtained at the Boston University Chemical Instrumentation Center using a Waters Q-
TOF mass spectrometer. Melting points were recorded on a Mel-temp apparatus 
(Laboratory Devices).  Analytical LCMS was performed on a Waters Acquity UPLC 
(Ultra Performance Liquid Chromatography (Waters MassLynx Version 4.1) with a 
Binary solvent manager, SQ mass spectrometer, Water 2996 PDA (PhotoDiode Array) 
detector, and ELSD (Evaporative Light Scattering Detector). An Acquity UPLC BEH 
C18 1.7µm column was used for analytical UPLC-MS. Optical rotations were recorded 
on an AUTOPOL III digital polarimeter at 589 nm, and specific rotations are given [α]D20 
(concentration in grams/100 mL solvent). Chiral HPLC analysis of enantioenriched 
compounds was performed using a Waters 1525 Binary HPLC Pump with a Waters 2487 
diode array detector. Preparative HPLC was performed on a Gilson PLC2020 using a 
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Waters SunFire™ Prep C18 OBD™ 5µm 19X50 mm column. Analytical thin layer 
chromatography (TLC) was performed using 0.25 mm silica gel 60-F plates (Silicycle, 
Inc.). Flash chromatography was performed using 200-400 mesh silica gel (Sorbent 
Technologies, Inc.). Preparative TLC was conducted with glass backed 250 µm or 1000 
µm silica gel 60-F plates (Silicycle, Inc.). Preparative HPLC was conducted using a PLC 
2020 Personal Purification System (Gilson, Inc.). Yields refer to chromatographically and 
spectroscopically pure compounds, unless otherwise stated. Thermolyses were conducted 
in Teflon® capped, heavy wall sealed vials (Chemglass CG-1880, 15 mL or CG-4920-01 
Complete Package) to minimize solvent/reagent evaporation. All other reactions were 
carried out in oven-dried glassware under an argon/nitrogen atmosphere unless otherwise 
noted. The Scilligence ELN Reaction Planner (Scilligence Corp.) was used for 
experimental procedure planning.  
Chemical Reagents and Solvents 
HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, toluene, acetonitrile, and 
benzene were purchased from Fisher and VWR and were purified and dried by passing 
through a PURE SOLV® solvent purification system (Innovative Technology, Inc.). 
Anhydrous MeCN, PhCF3, and THF from Aldrich were degassed using freeze-pump-
thaw. The silica-supported AgNP catalyst was prepared by reduction of AgBF4 with 
Bu4NBH4.31 Reagents were purchased from Strem, Aldrich, Acros, TCI America, 
Indofine, and Alfa Aesar and were used as received.   
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Experimental Procedures and Compound Characterization 
A. Reaction Details and Additional Experiments 
General Experimental Procedure for Table 3.1: 
 
To a suspension of 4Å molecular sieves (100 mg, flame-dried under high vacuum) in a 
sealed tube was added M(OTf)3 (0.02 mmol, 0.15 mol%), bis-allyloxyflavone 222 (50 mg, 
0.13 mmol, 1.0 equiv) and a mixture of CH2Cl2 (1.0 mL) and HFIP (0.25 mL). The 
reaction mixture was allowed to stir at 50 °C for 12 to 24h. After removal of the 
molecular sieves by filtration of the crude mixture through a pad of Celite®, the solvent 
was evaporated in vacuo. The crude mixture was purified by silica gel chromatography 
(hexanes:EtOAc = 5:1 - 4:1) to afford the rearrangement products 221 and 248. Further 
separation was conducted using preparative TLC.   
B. Compound Synthesis and Characterization: 
 
 
 
5-Hydroxy-3, 7, 2’, 4’-tetra-MOM morin 244. To a solution of morin (5.0 g, 16.5 
mmol, 1.0 equiv) in dichloromethane (80 mL) was slowly added at 0 °C N,N-
diisopropylethylamine (14.4 mL, 82.5 mmol, 5.0 equiv), and chloromethyl methyl ether 
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(6.3 mL, 82.5 mmol, 5.0 equiv). The reaction was warmed to room temperature and 
stirred overnight. The mixture was neutralized with 1N aqueous HCl solution and 
extracted with ethyl acetate three times, the organic layer was combined, washed with 
brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture was purified by 
silica gel chromatography (hexanes: EtOAc =5:1 to 3:1) to afford compound 244 as a 
yellow oil (8.65 g, 9.1 mmol, 55%). 
Rf : 0.54 (hexanes: EtOAc = 3:2). 1H NMR (500 MHz, CDCl3) 12.56 (s, 1H), 7.42 (d, J = 
8.5 Hz, 1H), 6.94 (d, J = 2.3 Hz, 1 H), 6.81 (dd, J = 8.5, 2.3 Hz, 1H), 6.53 (d, J = 2.2 Hz, 
1H), 6.47 (d, J = 2.2 Hz, 1H), 5.22 (s, 2H), 5.21 (s, 2H), 5.19 (s, 2H), 5.01 (s, 2H), 3.50 
(s, 3H), 3.47 (s, 6H), 2.98 (s, 3H). 13C NMR (125 MHz, CDCl3) d 178.6, 162.9, 162.0, 
160.3, 157.6, 157.3, 156.6, 136.7, 132.0, 114.3, 108.7, 107.0, 103.6, 99.5, 97.5, 94.6, 
94.3, 94.24, 94.20, 56.6, 56.3, 56.23, 56.20. IR υmax (film): 2958, 2907, 2829, 1656, 1597, 
1496, 1451, 1409, 1344, 1308, 1245, 1220, 1150, 1074, 1012, 970, 922, 872, 813, 753, 
720 cm-1. HRMS-ESI (m/z) calculated [M+Na]+ C23H26O11Na 501.1373, found 501.1384. 
 
5-Allyloxy-3, 7, 2’, 4’-tetra-MOM morin 245. To a solution of 244 (8.65 g, 18.1 mmol, 
1.0 equiv) in DMF (80 mL) was slowly added allyl bromide (1.88 mL, 21.7 mmol, 1.2 
equiv) and Cs2CO3 (7.07 g, 21.7 mmol, 1.2 equiv). The reaction was heated at 60 °C 
overnight. The mixture was cooled to room temperature, neutralized with 1N aqueous 
HCl solution, and extracted with diethyl ether three times. The organic layer was 
combined and washed with brine, dried over Na2SO4, and concentrated in vacuo. The 
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crude mixture was recrystallized from methanol to afford compound 245 as a white solid 
(8.76 g, 16.8 mmol, 93%).  
Rf : 0.20 (hexanes: EtOAc = 3:2). m.p. = 72-74 °C (MeOH). 1H NMR (500 MHz, CDCl3) 
δ 7.43 (d, J = 8.6 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.78 (dd, J = 8.6, 2.4 Hz, 1H), 6.62 
(d, J = 2.1 Hz, 1H), 6.44 (d, J = 2.3 Hz, 1H), 6.15-6.07 (m, 1H), 5.68 (ddd, J = 17.2, 3.2, 
1.7Hz, 1H), 5.35 (ddd, J = 10.5, 3.1, 1.5 Hz, 1H), 5.20 (s, 2H), 5.19(s, 2H), 5.17 (s, 2H), 
5.03 (s, 2H), 4.69 (ddd, J = 4.9, 1.7, 1.7 Hz, 2H), 3.48 (s, 3H), 3.47 (s, 3H), 3.46 (s, 3H), 
2.93 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 173.5, 161.1, 160.0, 159.9, 159.1, 156.5, 
154.2, 138.8, 132.2, 132.0, 118.0, 114.9, 110.7, 108.6, 103.7, 97.9, 97.4, 95.7, 94.7, 94.4, 
94.3, 69.9, 56.4, 56.20, 56.19, 56.15. IR υmax (film): 3001, 2960, 2906, 2827, 1635, 1609, 
1575, 1504, 1486, 1433, 1409, 1344, 1312, 1266, 1219, 1150, 1076, 985, 937, 921, 867, 
827, 752, 709 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C26H31O11 519.1866, 
found 519.1859. 
 
 
3-Hydroxy-5-allyloxy-7, 2’, 4’-tri-MOM morin 246. To a solution of 245 (2.75 g, 5.3 
mmol, 1.0 equiv) in methanol (300 mL) was added NaI (600 mg, 4.0 mmol, 0.8 equiv), 
and 1N aqueous HCl (400 µL, 0.41 mmol, 0.077 equiv) under Ar. The reaction was 
heated to 40 °C and stirred for 12h. Water was added to the reaction mixture which was 
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then extracted with ethyl acetate three times. The organic layers were combined and 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude mixture was 
purified by silica gel chromatography (hexanes: EtOAc: MeOH=20:5:0.5 to 20:5:1) to 
afford 246 as a yellowish oil (1.83 g, 3.87 mmol, 73%). 
Rf : 0.20 (hexanes: EtOAc = 1:1) 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 8.6 Hz, 1H), 
6.89 (d, J = 2.3 Hz, 1H), 6.87 (s, 1H), 6.76 (dd, J =8.6, 2.3 Hz, 1H), 6.61 (d, J = 2.1 Hz, 
1H), 6.40 (d, J = 2.1 Hz, 1H), 6.09-6.02 (m, 1H), 5.66 (ddd, J = 17.2, 3.2, 1.7Hz, 1H), 
5.30 (ddd, J = 10.5, 3.2, 1.7 Hz, 1H), 5.16 (s, 2H), 5.15(s, 2H), 5.13 (s, 2H), 4.62 (ddd, J 
= 4.7, 1.7, 1.7 Hz, 2H), 3.422 (s, 3H), 3.415 (s, 3H), 3.40 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 171.7, 161.3, 159.8, 159.4, 159.0, 156.2, 142.2, 138.6, 132.0, 131.4, 117.6, 
114.2, 108.8, 107.4, 103.9, 97.2, 95.5, 94.7, 94.2, 94.1, 69.5, 56.2, 56.0, 55.9. IR υmax 
(film): 3010, 2953, 2910, 2823, 1676, 1601, 1545, 1433, 1401, 1333, 1312, 1245, 1218, 
1132, 1011, 950, 921, 827, 745, 703 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for 
C24H27O10  475.1604, found 475.1611. 
 
3, 5-Bis-allyloxy-7, 2’, 4’-tri-MOM morin 279. To a solution of 246 (1.26 g, 2.65 mmol, 
1.0 equiv) in DMF (12 mL) was slowly added allyl bromide (459 µL, 5.30 mmol, 2.0 
equiv), and Cs2CO3 (1.73 g, 5.30 mmol, 2.0 equiv). The reaction was heated to 60 °C and 
was stirred overnight. The mixture was cooled to room temperature, washed with water, 
and extracted with diethyl ether three times. The organic layers were combined and 
finally washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude 
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product was purified by silica gel chromatography (hexanes: EtOAc: MeOH=20:5:0.5) to 
afford compound 279 as a light yellow oil (1.31 g, 2.54 mmol, 96%)  
Rf : 0.20 (hexanes: EtOAc = 3:2). 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 8.6 Hz, 1H), 
6.91 (d, J = 2.3 Hz, 1H), 6.78 (dd, J = 8.5, 2.3 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 6.44 (d, 
J = 2.2 Hz, 1H), 6.16-6.08 (m, 1H), 5.81-5.73 (m, 1H), 5.68 (dd, J = 17.3, 1.5Hz, 1H), 
5.35 (dd, J = 10.6, 1.5 Hz, 1H), 5.21 (s, 2H), 5.19 (s, 2H), 5.15 (s, 2H), 5.10 (dd, J = 17.2, 
1.7 Hz, 1H), 5.02 (d, J = 10.3 Hz, 1H), 4.69 (ddd, J = 4.8, 1.7, 1.6 Hz, 2H), 4.49 (ddd, J = 
6.0, 1.4, 1.2 Hz, 2H), 3.50 (s, 3H), 3.48 (s, 3H), 3.44 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ 174.1, 161.1, 160.16, 160.1, 159.1, 156.5, 153.8, 141.0, 134.4, 132.4, 131.9, 
118.1, 117.6, 114.9, 110.9, 108.8, 103.9, 98.0, 95.8, 95.0, 94.5, 94.4, 73.5, 70.0, 56.5, 
56.4, 56.3. IR υmax (film): 3082, 2960, 2919, 2826, 1635, 1608, 1576, 1505, 1486, 1433, 
1396, 1338, 1299, 1242, 1217, 1194, 1150, 1119, 1096, 1079, 1028, 990, 922, 868, 827 
cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C27H31O10 515.1917, found 515.1906. 
 
3, 5-Bis-allyloxy-7, 2’, 4’-tri-hydroxy morin 222. To a solution of 279 (5.71 g, 11.1 
mmol, 1.0 equiv) in methanol (150 mL) was added concentrated HCl (7.5 mL) and the 
reaction was heated to 40 °C and stirred for 5h. The reaction mixture was cooled to room 
temperature, H2O was added, and the reaction mixture was extracted with ethyl acetate 
three times. The organic layer was combined and washed with brine, dried over Na2SO4 
and concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(hexanes: EtOAc: MeOH = 15:15:0 to 15:15:1) to afford compound 222 as pale yellow 
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crystals (3.94 g, 10.3mmol, 93%).  
Rf : 0.5 (hexanes: EtOAc: MeOH =10:10:1). m.p. = 130-132 °C (CHCl3). 1H NMR (500 
MHz, acetone-d6) δ 9.04 (bs, 3H), 7.43 (d, J = 8.4 Hz, 1H), 6.56 (dd, J = 8.4, 2.3 Hz, 
1H), 6.54 (d, J = 2.3 Hz, 1H), 6.52 (d, J = 2.2 Hz, 1H), 6.46 (d, J = 2.2 Hz, 1H), 6.15-
6.06 (m, 1H), 5..91-5.82 (m, 1H), 5.73 (d, J = 17.5 Hz, 1H), 5.27 (d, J = 10.7 1H), 5.21 
(d, J = 17.2, 1H), 5.08 (d, J = 10.3, 1H), 4.66-4.64 (m, 2H), 4.54 (d, J = 5.9 Hz, 2H). 13C 
NMR (100 MHz, acetone-d6) δ 173.3, 163.2, 161.8, 160.9, 160.0, 157.6, 154.5, 139.5, 
134.4, 133.5, 132.0, 118.4, 117.3, 110.9, 109.1, 108.6, 104.6, 97.9, 96.1, 74.4, 69.8. IR 
υmax (film): 3237, 1604, 1496, 1466, 1425, 1372, 1340, 1293, 1242, 1190, 1094, 980, 940, 
828 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C21H19O7 383.1131, found 
383.1141. 
 
Hydrobenzofuro[3,2-b]chromenone 221: To a 20 mL dram vial was added 4Å 
molecular sieves (600 mg) and the vial was kept in a vacuum oven at 130 °C for 12 h. 
After activation of the molecular sieves, the vial was transferred from the vacuum oven 
and was purged with argon. A solution of 222 (700 mg, 1.83 mmol, 1 equiv.) in a 4:1 
mixture of CH2Cl2 and 1,1,1,2,2,2-hexafluoroisopropanol (HFIP) (5 mL) was transferred 
to the vial via cannula and Yb(OTf)3 (170 mg, 0.27 mmol, 0.15 equiv.) was added in one 
portion. The reaction mixture was stirred at 50 °C for 24 h. The reaction was finally 
cooled to room temperature, filtered through Celite®, and concentrated in vacuo. The 
crude product mixture was purified by silica gel chromatography (hexanes : EtOAc = 5:1 
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- 4:1) to afford compound (±)-221 as a pale yellow oil (503 mg, 1.31 mmol, 72%). 
Rf : 0.58 (hexanes : EtOAc = 3 : 2, 2.5 mL total solvent with 3 drops of methanol). 1H 
NMR (500 MHz, acetone-d6) δ 11.93 (s, 1H), 7.36 (d, J = 8.2 Hz, 1H), 6.53 (dd, J = 8.2, 
2.1 Hz, 1H), 6.41 (d, J = 2.1 Hz, 1H), 5.97 (s, 1H), 5.96-5.85 (m, 2H), 5.22 (ddd, J = 18.0, 
1.7, 1.3 Hz, 1H), 5.03 (ddd, J = 10.1, 2.0, 1.5 Hz, 1H), 4.98 (ddd, J = 17.1, 2.0, 1.6 Hz, 
1H), 4.89 (ddd, J = 10.0, 1.7, 1.4 Hz, 1H), 3.28 (ddd, J = 6.2, 1.4, 1.4 Hz, 2H), 3.08 (ddd, 
J = 14.5, 8.0, 1.4 Hz, 1H), 2.94 (dddd, J = 14.5, 6.4, 2.5, 2.5 Hz, 1H). 13C NMR (100 
MHz, acetone-d6) δ 187.9, 166.6, 162.6, 161.5, 161.0, 160.9, 136.4, 132.5, 125.5, 120.8, 
119.8, 114.5, 109.6, 107.2, 102.2, 99.8, 99.2, 95.1, 90.6, 37.7, 26.3. IR υmax (film): 3450, 
3080, 3010, 2982, 2924, 1635, 1500, 1458, 1343, 1277, 1215, 1141, 1089, 962, 926, 834, 
762 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C21H19O7 383.1131, found 383.1133. 
 
Rearrangement product 248 was obtained from the condition listed in Table 3.1 (entry 5) 
as a white oil. Rf : 0.38 (hexanes : EtOAc = 3:2, drops of methanol). 1H NMR (400 MHz, 
acetone-d6) δ 7.40 (dd, J = 8.1, 0.7 Hz, 1H), 6.54 (dd, J = 10.5, 2.3 Hz, 1H), 6.53 (s, 1H), 
6.48 (s, 1H), 6.02 – 5.91 (m, 1H), 5.91 – 5.81 (m, 1H), 5.22 (ddd, J = 17.2, 1.6, 1.4 Hz, 
1H), 5.09 (ddd, J = 10.5, 2.0, 1.2 Hz, 1H), 5.03 (ddd, J = 17.1, 1.8, 1.2 Hz, 1H), 4.92 
(ddd, J = 10.0, 1.6, 1.2 Hz, 1H), 4.57 (dt, J = 5.9, 1.4 Hz, 2H), 3.41 (dt, J = 6.3, 1.6 Hz, 
2H). 13C NMR (125 MHz, acetone-d6) δ 181.2, 165.5, 164.1, 161.8, 160.4, 160.2, 132.6, 
132.2, 124.8, 120.3, 119.0, 116.3, 108.7, 102.9, 102.0, 98.2, 96.1, 94.2, 89.2, 68.7, 37.6. 
IR υmax (film): 2959, 2926, 2854, 1664, 1609, 1493, 1462, 1390, 1327, 1262, 1174, 1109, 
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959, 812, 756 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C21H19O7 383.1131, found 
383.1129. 
 
 
Tri-TBS sanggenol F (251): To a solution of compound (±)-221 (2.4 g, 6.42 mmol, 1.0 
equiv) in CH2Cl2 (80 mL, 0.08 M) at 0 °C were consecutively added TBSOTf (4.8 mL, 
20.72 mmol, 3.2 equiv) and triethylamine (2.72 mL, 19.44 mmol, 3.0 equiv.) The 
reaction mixture was warmed to room temperature and stirred for 6 h. After this time, the 
reaction mixture was concentrated in vacuo. The crude mixture was quickly purified by 
silica gel chromatography (hexanes : CH2Cl2 = 10 : 1) to afford a crude yellow oil (3.32 g) 
which was carried on to the next step. The crude product mixture (3.32 g) was added to a 
flame-dried seal tube containing degassed CH2Cl2 (6 mL) and the 2nd generation Grubbs 
catalyst (424 mg, 0.5 mmol, 0.1 equiv). Finally, isobutylene (20 mL) was condensed into 
the reaction flask at -78 °C. The vessel was sealed and heated at 40 °C for 24 h. After this 
time, the reaction was cooled to room temperature and was concentrated in vacuo. The 
crude product mixture was purified using silica gel chromatography (hexanes : CH2Cl2 = 
10 : 1) to afford compound 251 as a light yellow oil (3.30 g, 4.23 mmol, 92%).  
Rf : 0.88 (hexanes : EtOAc = 8:1). 1H NMR (500 MHz, CDCl3) δ 11.98 (s, 1H), 7.28 (d, J 
= 8.2 Hz, 1H), 6.49 (dd, J = 8.2, 2.1 Hz, 1H), 6.40 (d, J = 2.1 Hz, 1H), 5.78 (s, 1H), 5.24 
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(dd, J = 7.6 Hz, 1H), 5.09 (dd, J =6.6 Hz, 1H), 3.21 (d, J = 6.7 Hz, 2H), 3.02 (dd, J = 
14.9, 9.4 Hz, 1H), 2.72 (dd, J = 14.7, 5.5 Hz, 1H), 1.73 (s, 3H), 1.66 (s, 3H), 1.59 (s, 3H), 
1.57 (s, 3H), 0.98 (s, 9H), 0.97 (s, 9H), 0.73 (s, 9H), 0.30 (s, 3H), 0.27 (s, 3H), 0.24 (s, 
3H), 0.19 (s, 3H), 0.18 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 187.6, 163.3, 162.0, 
160.1, 159.7, 158.2, 135.9, 131.4, 124.4, 122.6, 122.3, 117.6, 113.9, 112.6, 103.8, 103.1, 
101.2, 97.9, 92.0, 31.3, 25.8, 25.7, 25.69, 25.65, 21.5, 18.6, 18.3, 18.2, 18.04, 18.0, −3.3, 
−3.5, −3.9, −4.0, −4.4 (2C). IR υmax (film): 2956, 2930, 2897, 2884, 2859, 1636, 1599, 
1571, 1496, 1472, 1439, 1338, 1289, 1255, 1226, 1209, 1178, 1155, 1096, 1050, 1006, 
970, 867, 839, 799, 783 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C43H69O7Si3 
781.4351, found 781.4358. 
 
(±)-Sanggenol F (206):  Tri-TBS sanggenol F (251) (120 mg, 0.15 mmol) was dissolved 
in dry CH3CN (4 mL) and NEt3•3HF (200 µL, 1.23 mmol, 8.0 equiv) was added 
dropwise at 0 °C. The reaction was stirred at 0 °C for 3 h and was quenched with pH 7 
buffer and extracted three times with ethyl acetate. The organic layer was combined and 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product 
mixture was purified by silica gel chromatography (hexanes : EtOAc = 6 : 1) to afford 
sanggenol F (206) a yellow oil (61 mg, 0.14 mmol, 91%). 
Rf : 0.50 (hexanes : EtOAc = 1:1) 1H NMR (500 MHz, acetone-d6) δ 11.92 (s, 1H), 9.94 
(br, 1H), 8.71 (br s, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.08 (br s, 1H), 6.51 (dd, J = 8.2, 2.1 
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Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 5.91 (s, 1H), 5.24 (t, J = 7.5 Hz, 1H), 5.18 (tm, J = 7.1 
Hz, 1H), 3.22 (d, J = 7.2 Hz, 2H), 3.12 (dd, J = 14.8, 8.6 Hz, 1H), 2.77 (dd, J = 15.9, 6.4 
Hz, 1H), 1.73 (s, 3H), 1.62 (s, 3H), 1.61(s, 3H), 1.51(s, 3H). 13C NMR (100 MHz, 
acetone-d6) δ 188.2, 166.5, 162.5, 161.4, 161.2, 161.0, 136.5, 131.4, 125.6, 123.2, 121.3, 
118.66, 118.63, 109.7, 109.0, 102.5, 100.1, 99.4, 95.2, 91.7, 32.0, 25.9, 21.5, 18.1, 17.8. 
IR υmax (film): 3379, 2964, 2928, 2854, 1636, 1611, 1501, 1455, 1343, 1281, 1206, 1152, 
1089, 1040, 993, 960, 835, 761 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for 
C25H27O7 439.1757, found 439.1747. 
 
 
1H NMR 
 
natural (+)-206 synthetic (±)-206 
(this work) 
Positions 
δ lit112 (acetone-d6) 
(JH-H in Hz) 
δ (500 MHz, acetone-d6) 
(JH-H in Hz) 
12, 13 1.50, 1.60 (each 3H, s) 1.51, 1.61 (each 3H, s) 
4’’, 5’’ 1.61, 1.72 (each 3H, s) 1.61, 1.73 (each 3H, s) 
9 2.76 (1H, br dd, 15, 6 ) 2.77 (1H, dd, 15.9, 6.4) 
9 3.11 (1H, br dd, 15, 9) 3.12 (1H, dd, 14.8, 8.6) 
1’’ 3.21 (2H, br d, 7) 3.22 (2H, d, 7.2) 
10 5.17 (1H, tm, 7) 5.18 (1H, tm, 7.1) 
2’’ 5.22 (1H, tm, 7) 5.24 (1H, tm, 7.5) 
8 5.91 (1H, s) 5.91 (1H, s) 
3’ 6.38 (1H, d, 2 ) 6.39 (1H, d, 2.1) 
5’ 6.50 (1H, dd, 8, 2) 6.51 (1H, d, 8.2, 2.1) 
3-OH  7.08 (1H, br s) 7.08 (1H, br) 
6’ 7.34 (1H, d, 8) 7.36 (1H, d, 8) 
4’-OH 8.56 (1H, br s) 8.71 (1H,br s) 
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7-OH 9.58 (1H, br s) 9.94 (1H,br s) 
5-OH               11.90 (1H, s) 11.92 (1H, s) 
13C NMR 
 
natural (+)-206 synthetic (±)-206 
 (this work) 
Positions δ lit.1 (CDCl3) δ (125 MHz, CDCl3) 
2 91.8 91.7 
3 102.6 102.5 
4 188.3 188.2 
4a 100.2 100.1 
5 162.6 162.5 
6 109.1 109.0 
7 166.7 166.5 
8 95.3 95.2 
8a 
9 
10 
11 
12 
13 
1’ 
161.5 161.5 
32.0 32.0 
118.7 118.6 
136.5 136.5 
18.1 18.1 
25.8 25.8 
121.4 121.3 
2’ 
3’ 
4’ 
5’ 
6’ 
1’’ 
161.3 161.2 
99.5 99.4 
161.2 161.0 
109.7 109.7 
125.6 125.6 
123.3 123.2 
3’’ 
4’’ 
131.4 131.4 
17.8 17.8 
5’’ 25.8 25.9 
 
 
(±)-Sanggenon A (207). To a solution of sanggenol F (206) (50 mg, 0.1 mmol, 1.0 equiv) 
in THF (10 mL) was added DDQ (31 mg, 0.01 mmol, 1.2 equiv) in one portion. The 
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reaction mixture was stirred at room temperature for 12 h and was quenched with water. 
The mixture was extracted with ethyl acetate, and the organic layer was combined and 
washed with brine three times, dried over Na2SO4 and concentrated in vacuo. The crude 
mixture was purified by silica gel chromatography (hexanes : EtOAc : MeOH = 40 : 10 : 
1) to afford sanggenon A (207) as a yellow oil (34 mg, 0.8 mmol, 78%). 
Rf : 0.64 (hexanes : EtOAc = 3:2). 1H NMR (500 MHz, CDCl3) δ 11.50 (s, 1H), 7.32 (d, J 
= 8.2 Hz, 1H), 6.59 (d, J = 10.1 Hz, 1H), 6.50 (d, J = 8.2 Hz, 1H), 6.44 (d, J = 2.1 Hz, 
1H), 5.78 (s, 1H), 5.50 (d, J = 10.1 Hz, 1H), 5.19 (t, J = 5.1 Hz, 1H), 5.06 (s, 1H), 4.92 (s, 
1H), 3.07 (dd, J = 14.6, 8.7 Hz, 1H), 2.77 (dd, J = 14.6, 6.4 Hz, 1H), 1.62 (s, 3H), 1.56 (s, 
3H), 1.43 (s, 3H), 1.40 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 186.3, 164.3, 162.4, 160.3, 
158.7, 158.5, 137.0, 126.5, 125.0, 121.3, 117.0, 115.1, 109.4, 102.8, 101.0, 99.5, 99.3, 
96.5, 90.9, 79.0, 31.3, 28.6, 28.5, 25.9, 18.2. IR υmax (film): 3366, 2961, 2918, 2850, 
1746, 1628, 1572, 1501, 1473, 1377, 1341, 1262, 1168, 1153, 1096, 1049, 961, 856, 805, 
762 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C25H25O7 437.1600, found 
437.1610. 
 
 1H NMR 
 
natural (+)-207 
synthetic (±)-207 
(this work) 
Positions 
δ lit113 (CDCl3) 
(JH-H in Hz) 
δ (500 MHz, CDCl3) 
(JH-H in Hz) 
8 5.77 (1H, d, 0.5) 5.78 (1H, s) 
3’ 6.44 (1H, d, 2) 6.44 (1H, d, 2.1) 
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5’ 6.50 (1H, dd, 8, 2) 6.50 (1H, d, 8.2) 
6’ 7.31 (1H, d, 8) 7.32 (1H, d, 8.2) 
9 2.77 (1H, dd, 15, 6) 2.77 (1H, dd, 14.6, 6.4) 
9 3.07 (1H, dd, 15, 8) 3.07 (1H, dd, 14.6, 8.7) 
10 5.18 (1H, m) 5.19 (1H, t, 5.1) 
12 1.62 (3H, s) 1.62 (3H, s) 
13 1.56 (3H, s) 1.56 (3H, s) 
14 6.59 (1H, dd, 10, 0.5) 6.59 (1H, d, 10.1) 
15 5.50 (1H, d, 10) 5.50 (1H, d, 10.1) 
17 1.40 (3H, s) 1.40 (3H, s) 
18 1.43 (3H, s) 1.43 (3H, s) 
3, 5, 4’OH Not observed 11.50, 5.06, 4.92 (each 1H, s) 
 
13C NMR 
 
natural (+)-207 synthetic (±)-207 
(this work) 
Positions δ lit.113 (CDCl3) δ (125 MHz, CDCl3) 
2 90.85 90.90 
3 102.75 102.83 
4 186.36 186.28 
4a 99.45 99.50 
5 158.65 158.54 
6 101.03 101.03 
7 164.25 164.29 
8 96.42 96.48 
8a 
1’ 
2’ 
3’ 
4’ 
5’ 
6’ 
162.39 162.40 
121.13 121.35 
160.23 160.33 
99.42 99.33 
158.65 158.68 
109.39 109.43 
124.94 125.02 
9 
10 
11 
12 
13 
14 
31.18 31.28 
116.98 117.01 
136.84 136.97 
25.78 25.94 
18.03 18.21 
115.06 115.13 
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15 
16 
126.38 126.47 
78.85 79.97 
17 28.41 28.58 
18 28.41 28.55 
 
(±)-Tri-TBS-chromene 61. To a solution of 251 (2.10 g, 2.69 mmol, 1.0 equiv) in THF 
(32.0 mL) in a flame-dried sealed tube was added DDQ (915.9 mg, 4.04 mmol, 1.5 
equiv) in one portion. The reaction mixture was stirred at 60 °C for 24h. The mixture was 
concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(hexanes: CH2Cl2=4:1 to 3:1) to afford compound 252 as a light yellow oil (1.52 g, 1.96 
mmol 73%).  
Rf : 0.64 (hexanes : EtOAc = 8:1). 1H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 8.2 Hz, 
1H), 6.45 (d, J = 9.9 Hz, 1H), 6.44 (dd, J = 8.2, 2.2 Hz, 1H), 6.36 (d, J = 2.2 Hz, 1H), 
5.80 (s, 1H), 5.45 (d, J = 9.9 Hz, 1H), 5.30 (ddd, J = 7.7, 5.6, 3.0 Hz, 1H), 2.97 (dd, J = 
15.1, 9.0 Hz, 1H), 2.72 (dd, J = 15.0, 5.0 Hz, 1H), 1.61 (s, 3H), 1.58 (s, 3H), 1.47 (s, 3H), 
1.46 (s, 3H), 0.97 (s, 9H), 0.96 (s, 9H), 0.73 (s, 9H), 0.31 (s, 3H), 0.23 (s, 3H), 0.22 (s, 
3H), 0.20 (s, 3H), 0.16 (d, J = 0.9 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ 181.9, 161.6, 
160.4, 158.2, 157.4, 156.4, 135.3, 126.8, 124.6, 122.7, 118.2, 116.8, 113.7, 108.3, 105.5, 
104.9, 103.8, 100.1, 91.6, 77.5, 31.8, 27.9, 27.8, 26.0, 25.9 (3C), 25.81 (3C), 25.80 (3C), 
18.7, 18.44, 18.35, 18.2, −3.22, −3.49, −4.10, −4.16, −4.32, −4.34. IR υmax (film): 2957, 
2919, 2850, 1737, 1589, 1473, 1377, 1256, 1159, 1099, 968, 842, 778 cm-1. HRMS-ESI 
(m/z): [M + H]+ calculated for C43H67O7Si3 779.4195, found 779.4199. 
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(±)-Sanggenons C (12) and O (13): To a solution of (±)-tri-TBS-chromene 252 (100 mg, 
0.13 mmol, 1 equiv) in DCE (0.5 mL) in a 10 mL dram vial were consecutively added 
acetylated 2′-hydroxychalcone 232 (50 mg, 0.13 mmol, 1 equiv), silver nanoparticles 
(AgNP’s) on silica gelS1 (100 mg, 0.20 mol% loading), and HOAc (10 µL, 0.2 mmol, 1.5 
equiv). The vial was sealed and the reaction was stirred at 65 °C for 3 days before being 
cooled to room temperature. The crude mixture was concentrated in vacuo and purified 
by chromatography (hexanes : EtOAc = 10 : 1 to 5 : 1) to afford a mixture of 
cycloadducts as a colorless oil (98 mg). 
The crude product was then dissolved in MeOH (2.0 mL), and saturated aqueous 
NaHCO3 solution (0.66 mL) was added. The reaction mixture was stirred at room 
temperature for 12 h and quenched with pH 7 buffer. The crude mixture was concentrated 
in vacuo and purified by chromatography (CH2Cl2: MeOH = 20 : 1) to afford a mixture 
of products as a colorless oil. The mixture was dissolved in CH3CN (4 mL) and 
NEt3·3HF (150 µL) was added at 0 °C. The reaction mixture was warmed to room 
temperature and stirred for 12h. The mixture was then concentrated in vacuo. The crude 
mixture was purified by chromatography (CH2Cl2 : MeOH = 40 : 1 to 20 : 1) to afford a 
4 : 1 mixture of sanggenons C and O as a colorless oil (33 mg, 0.047 mmol, 36% yield, 3 
steps). Further product separation was conducted using preparative TLC (hexanes : 
EtOAc : AcOH =30: 30:1). 
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(±)-Sanggenon C (12) Rf : 0.25 (CH2Cl2 : MeOH = 10:1). 1H NMR (500 MHz, acetone-
d6) δ 8.33 (d, J = 9.0 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.45 (dd, 
J = 8.2, 2.5 Hz, 1H), 6.42 (d, J = 2.5 Hz, 1H), 6.33 (dd, J = 9.0, 2.1 Hz, 1H), 6.29 (d, J = 
2.1 Hz, 1H), 6.24 (dd, J = 8.4, 2.5 Hz, 1H), 6.15 (d, J = 2.1 Hz, 1H), 5.71 (s, 1H), 5.51 (s, 
1H), 5.16 (t, J = 7.2 Hz, 1H), 4.53 (t, J = 6.0 Hz, 1H), 4.08 (s, 1H), 3.83 (ddd, J = 5.8 Hz, 
1H), 3.07 (dd, J = 14.7, 8.8 Hz, 1H), 2.70 (dd, J = 14.2, 7.0 Hz, 2H), 2.38 (d, J = 17.5 Hz, 
1H), 2.23 (t, J = 17.5 Hz, 1H), 1.84 (s, 3H), 1.57 (s, 3H), 1.49 (s, 3H). 13C NMR (125 
MHz, acetone-d6) δ 208.8, 188.4, 167.6, 166.9, 165.8, 163.9, 162.0, 161.2, 157.8, 156.5, 
136.8, 135.0, 134.8, 129.1, 125.7, 122.8, 122.2, 121.4, 118.6, 114.0, 109.7, 109.0, 108.7, 
107.6, 103.8, 103.6, 102.4, 100.0, 99.5, 96.5, 92.0, 48.2, 36.0, 33.8, 32.8, 32.0, 26.0, 23.8, 
18.1.  IR υmax (film): 3360, 2963, 2928, 2848, 1718, 1626, 1505, 1452, 1362, 1265, 1221, 
1165, 1096, 984, 959, 846, 797 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for 
C40H37O12 709.2285 found 709.2291. 
 
(±)-Sanggenon O (13) Rf : 0.25 (hexanes : EtOAc = 3:2). 1H NMR (500 MHz, acetone-
d6) δ 8.36 (d, J = 8.7 Hz, 1H), 7.33 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 8.4 Hz, 1H), 6.49 (dd, 
J = 8.2, 2.0 Hz, 1H), 6.45 (d, J = 2.0 Hz, 1H), 6.37 (dd, J = 8.7, 2.1 Hz, 1H), 6.36 (d, J = 
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1.6 Hz, 1H), 6.26 (dd, J = 8.4, 2.4 Hz, 1H), 6.20 (d, J = 2.4 Hz, 1H), 5.72 (s, 1H), 5.54 (s, 
1H), 5.05 (t, J = 7.4 Hz, 1H), 4.56 (t, J = 5.7 Hz, 1H), 4.07 (s, 1H), 3.82 (ddd, J = 5.8 Hz, 
1H), 3.08 (dd, J = 14.6, 9.2 Hz, 1H), 2.66 (dd, J = 14.5, 5.9 Hz, 1H), 2.43 (d, J = 18.2 Hz, 
1H), 2.25 (d, J = 18.2 Hz, 1H), 1.85 (s, 3H), 1.51 (s, 3H), 1.18 (s, 3H). 13C NMR (125 
MHz, acetone-d6) δ 208.6, 188.1, 167.5, 166.5, 165.7, 163.5, 161.8, 161.1, 161.0, 157.6, 
156.2, 136.8, 135.2, 134.6, 128.9, 125.5, 122.6, 121.9, 121.2, 118.3, 113.9, 109.6, 108.7, 
108.5, 107.4, 103.5, 103.3, 102.2, 99.9, 99.4, 96.5, 91.8, 47.9, 35.6, 33.5, 32.5, 31.8, 25.4, 
23.6, 17.9. IR υmax (film): 3360, 2954, 2923, 2852, 1713, 1628, 1463, 1379, 1362, 1262, 
1232, 1164, 1095, 1024, 840, 803 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for 
C40H37O12 709.2285 found 709.2298. 
 
1H NMR 
 
natural (+)-12 synthetic (–)-12 
(this work) 
Positions δ lit.14 (acetone-d6) 
δ (500 MHz, acetone-d6) 
(JH-H in Hz) 
8 5.73 (1H, s) 5.71 (1H, s) 
9 2.68 (1H, dd, 14, 6) 2.70 (1H, dd, 14.2, 7.0) 
9 3.08 (1H, dd, 14, 9) 3.07 (1H, dd, 14.7, 8.8) 
10 5.15 (1H, m) 5.16 (1H, t, 7.2) 
12 1.55 (3H, s) 1.57 (3H, s) 
13 1.47 (3H, s) 1.49 (3H, s) 
3’ 6.44 (1H, d, 2) 6.42 (1H, d, 2.5) 
5’ 6.45 (1H, dd, 8, 2) 6.45 (1H, dd, 2.5, 8.2) 
6’ 7.28 (1H, d, 8) 7.29 (1H, d, 8.2) 
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14 4.20-3.95 (1H) 4.08 (1H, brs) 
15 5.50 (1H) 5.51 (1H, s) 
17 1.82 (3H) 1.84 (3H, s) 
18 2.40-2.10 (2H) 2.23, 2.38 (each 1H, d, 15.7) 
19 3.95-3.80 (1H) 3.83 (1H, ddd, 5.8) 
20 4.53 (1H, dd, 5, 4) 4.53 (1H, t, 6.0) 
24 6.30 (1H, d, 2) 6.29 (1H, d, 2.1) 
26 6.33 (1H, dd, 8, 2) 6.33 (1H, dd, 9.0, 2.1) 
27 8.36 (1H, d, 8) 8.33 (1H, d, 9.0) 
30 6.17 (1H, d, 2) 6.15 (1H, d, 2.1) 
32 6.25 (1H, dd, 8, 2) 6.24 (1H, dd, 8.4, 2.5) 
33 6.90 (1H, d, 8) 6.90 (1H, d, 8.4) 
 
 
13C NMR 
 
natural (+)-12 synthetic (–)-12 
(this work) 
Positions δ lit.149 (acetone-d6) δ (125 MHz, acetone-d6) 
2 92.0 92.0 
3 102.4 102.4 
4 188.3 188.4 
4a 99.9 100.0 
5 163.9 163.9 
6 109.0 109.0 
7 167.6 167.6 
8 96.5 96.5 
8a 
1’ 
2’ 
3’ 
4’ 
5’ 
6’ 
161.9 162.0 
122.2 122.2 
161.2 161.2 
99.5 99.5 
161.2 161.2 
109.7 109.7 
125.6 125.7 
9 
10 
11 
12 
13 
32.0 32.0 
118.5 118.6 
136.7 136.8 
18.1 18.1 
25.9 26.0 
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14 35.9 36.0 
15 
16 
122.8 122.8 
135.0 135.0 
17 23.7 23.8 
18 33.8 33.8 
19 32.8 32.8 
20 
21 
22 
23 
48.3 48.2 
208.8 208.8 
114.0 114.0 
165.8 165.8 
24 
25 
103.8 103.8 
166.8 166.9 
26 107.6 107.6 
27 
28 
29 
129.0 129.1 
121.3 121.4 
156.5 156.5 
30 
31 
103.5 103.6 
157.8 157.8 
32 108.7 108.7 
33 134.7 134.8 
 
 
1H NMR 
 
natural (–)-13 synthetic (+)-13 
(this work) 
Positions 
δ lit.114 (400 MHz, acetone-d6) 
(JH-H in Hz) 
δ (500 MHz, acetone-d6) 
(JH-H in Hz) 
8 5.72 (1H, s) 5.72 (1H, s) 
9 2.68 (1H, dd, 14, 6) 2.66 (1H, dd, 14.5, 5.9) 
9 3.08 (1H, dd, 14, 9) 3.08 (1H, dd, 14.6, 9.2) 
10 5.08 (1H, dd, 9, 6) 5.05 (1H, t, 7.4) 
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12 1.53(3H, s) 1.51 (3H, s) 
13 1.22 (3H, s) 1.18 (3H, s) 
3’ 6.47 (1H, d, 2) 6.45 (1H d, 2.0) 
5’ 6.50 (1H, dd, 8, 2) 6.49 (1H, dd, 8.2, 2.0) 
6’ 7.36 (1H, d, 8) 7.33 (1H, d, 8.2) 
14 4.11 (1H, d, 6) 4.07 (1H, brs) 
15 5.54 (1H, s) 5.54 (1H, s) 
17 1.86 (3H, s) 1.85 (3H, s) 
18 2.28 2.43 (each 1H, d,16) 2.25, 2.43 (each 1H, d, 18.2) 
19 3.86 (1H, ddd, 5.5) 3.82 (1H, ddd, 5.8) 
20 4.54 (1H, dd, 6, 5.5) 4.56 (1H, t, 5.7) 
24 6.38 (1H, d, 2) 6.36 (1H, d, 1.6) 
26 6.36 (1H, dd, 8, 2) 6.37 (1H, dd, 8.7, 2.1) 
27 8.34 (1H, d, 8) 8.36 (1H, d, 8.7) 
30 6.19 (1H, d, 2) 6.20 (1H, d, 2.4) 
32 6.27 (1H, dd, 8, 2) 6.26 (1H, dd, 8.4, 2.4) 
33 6.93 (1H, d, 8) 6.92 (1H, d, 8.4) 
 
 
13C NMR 
 
natural (–)-13 synthetic (+)-13 
(this work) 
Positions δ lit. (acetone-d6) δ (125 MHz, acetone-d6) 
2 91.8 91.8 
3 102.2 102.2 
4 188.2 188.1 
4a 99.8 99.9 
5 163.4 163.5 
6 96.4 96.5 
7 167.5 167.5 
8 108.7 108.7 
8a 
1’ 
2’ 
3’ 
4’ 
5’ 
161.8 161.8 
121.9 121.9 
161.1 161.1 
99.3 99.4 
161.1 161.0 
109.5 109.6 
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6’ 125.5 125.5 
9 
10 
11 
12 
13 
14 
31.8 31.8 
118.4 118.3 
136.8 136.8 
18.0 17.9 
25.4 25.4 
35.6 35.6 
15 
16 
122.6 122.6 
135.1 135.2 
17 23.7 23.6 
18 33.6 33.5 
19 32.6 32.5 
20 
21 
22 
23 
47.9 47.9 
208.5 208.6 
113.8 113.9 
165.8 165.7 
24 
25 
103.5 103.5 
166.4 166.5 
26 107.3 107.4 
27 
28 
29 
128.9 128.9 
121.1 121.2 
156.4 156.2 
30 
31 
103.2 103.3 
157.6 157.6 
32 108.6 108.5 
33 134.6 134.6 
 
 
 
 
 
Enantioselective Model Cycloaddition: 
To a solution of 2′-hydroxychalcone 60 (50 mg, 0.22 mmol, 1.0 equiv) in PhCF3 (1 mL) 
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in a flame-dried round bottom flask were consecutively added B(OPh)3 (6.5 mg, 0.02 
mmol, 0.1 equiv) and (S)-3,3’-Br-BINOL-266 (9.9 mg, 0.02 mmol, 0.12 equiv.). The 
reaction mixture was stirred at 100 °C for 1h before being cooled down to 40 °C. Then 
diene 274 (58 mg, 0.26 mmol, 1.2 equiv) was added with aid of 1 mL of PhCF3. The 
mixture was stirred at 40 °C for 6h before being cooled to room temperature. The crude 
mixture was purified by silica gel chromatography (hexanes : EtOAc = 30 : 1) to afford a 
10 : 1 mixture of endo-275 and exo-276 as a colorless oil (91 mg, 0.20 mmol, 91% yield). 
Further separation was accomplished using preparative TLC (hexanes : EtOAc = 10 : 1).  
Asymmetric Cycloaddition using Boron Complex 277: 
To a solution of boron complex 277 (100 mg, 0.13 mmol, 1.0 equiv) in PhCF3 (1 mL) in 
a flame-dried round bottom flask were added diene 274 (35 mg, 0.16 mmol, 1.2 equiv). 
The mixture was stirred at 40 °C for 6h before being cooled to room temperature. The 
reaction mixture was quenched by addition of H2O, and extracted three times with ethyl 
acetate. The organic layer was combined and washed with brine, dried over Na2SO4, and 
concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(hexanes : EtOAc = 30 : 1) to afford a 10 : 1 mixture of endo-275 and exo-276 as a 
colorless oil (54 mg, 0.12 mmol, 93% yield). 
Further separation was accomplished using preparative TLC (hexanes : EtOAc = 10 : 1).  
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endo-275 Rf : 0.25 (hexanes : EtOAc = 10 : 1). m.p. = 120 °C, (MeOH). 1H NMR (500 
MHz, CDCl3) δ 11.83 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.49 (dd, J = 8.0, 7.3 Hz, 1H), 
7.35 (d, J = 8.3 Hz, 2H), 7.22-7.18 (m, 4H), 7.13-7.10 (m, 1H), 7.00 (dd, J = 8.4, 7.5 Hz, 
1H), 6.94 (d, J = 8.4 Hz 1H), 6.79 (d, J = 8.3 Hz, 2H), 5.56 (d, J = 3.8 Hz, 1H), 4.47 (dd, 
J = 11.6, 5.8 Hz, 1H), 3.99 (bs, 1H), 3.42 (ddd, J = 11.6, 11.6, 5.8 Hz, 1H), 2.52 (dd, J = 
18.3, 5.8 Hz, 1H), 2.30 (dd, J = 18.3, 11..6 Hz, 1H), 1.88 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ 206.2, 162.6, 144.8, 139.0, 136.4, 135.8, 131.2 (2C), 130.9 (2C), 129.2, 128.6 
(2C), 127.2 (2C), 126.4, 121.8, 121.3, 120.1, 119.2, 119.0, 50.5, 45.2, 40.0, 36.8, 23.3. IR 
υmax (film): 3027, 2934, 1638, 1485, 1447, 1158, 1012 cm-1. HRMS-ESI (m/z): [M + H]+ 
calculated for C26H24BrO2  447.0960, found 447.0945. Enantiopurity was determined 
using analytical chiral HPLC (>99% ee); [α]D 20 = ‒130.1º (c = 0.2, CHCl3) 
 
exo-276 Rf : 0.25 (hexanes : EtOAc = 10 : 1). 1H NMR (500 MHz, CDCl3) δ 12.17 (s, 
1H), 7.23 (d, J = 8.4 Hz, 2H), 7.17 (dd, J = 8.0, 7.3 Hz, 1H), 7.13-7.12 (m, 2H), 7.10-
7.07 (m, 2H), 7.02-6.99 (m, 4H), 6.64 (d, J = 8.4 Hz 1H), 6.47 (dd, J = 7.5, 7.5 Hz, 1H), 
5.48 (s, 1H), 3.91 (d, J = 10.8 Hz, 1H), 3.81 (dd, J = 10.8, 10.8 Hz, 1H), 3.42 (ddd, J = 
10.8, 10.8, 5.3 Hz, 1H), 2.50 (dd, J = 17.6, 10.8 Hz, 1H), 2.30 (dd, J = 17.6, 5.3 Hz, 1H), 
1.84 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 210.0, 161.9, 142.7, 142.5, 136.1, 135.1, 
131.6 (2C), 130.0, 129.6 (2C), 128.5 (2C), 127.6 (2C), 126.8, 124.0, 120.9, 120.6, 118.3, 
117.8, 54.2, 47.9, 45.1, 38.8, 23.4. IR υmax (film): 3014, 2930, 1620, 1495, 1433, 1150, 
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1014 cm-1. HRMS-ESI (m/z): [M + H]+ calculated for C26H24BrO2  447.0960 found 
447.0962 . 
 
Chiral HPLC analysis of cycloadduct exo-276.  
The following chiral HPLC conditions were used for the separation of enantiomers of 
exo-276: ChiralPak AD 150 × 4.6 mm column, 1% isopropanol in hexane. Flow rate: 1.0 
mL/min. UV detector: 214 nm. Retention times: 8.7 min and 10.4 min. 
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Chiral HPLC analysis of endo-cycloadducts 275.  
The following chiral HPLC conditions were used for the separation of enantiomers of 
endo-275: ChiralPak AD 150 × 4.6 mm column, 1% isopropanol in hexane. Flow rate: 
1.0 mL/min. UV detector: 214 nm. Retention times: 8.3 min and 13.1 min. 
 
 
 
Enantioselective Syntheses of (–)-Sanggenon C and (+)-Sanggenon O: 
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To a solution of acetylated 2′-hydroxychalcone 232 (595 mg, 1.49 mmol, 1.0 equiv) in 
PhCF3 (10 mL) in a flame-dried round bottom flask were consecutively added B(OPh)3 
(86mg, 0.30 mmol, 0.2 equiv), and (R)-3,3’-Br-BINOL 266 (199 mg, 0.35 mmol, 0.22 
equiv.). The reaction mixture was stirred at 80 °C for 2h before being cooled to 65 °C. 
Then tri-TBS-chromene 252 (1.02 g, 1.34 mmol, 0.9 equiv) was added in one portion. 
The mixture was stirred at 65 °C for 3 days before being cooled to room temperature. The 
crude mixture was concentrated in vacuo and purified by silica gel chromatography 
(hexanes : EtOAc = 10 : 1 to 5 : 1) to afford a mixture of cycloadducts as a colorless oil 
(1.1 g). 
The crude product mixture was then dissolved in MeOH (52 mL) and saturated aqueous 
NaHCO3 solution (5.85 mL) was added. The reaction mixture was stirred at room 
temperature for 12 h and quenched with pH 7 buffer. The crude mixture was concentrated 
in vacuo and purified by chromatography (CH2Cl2 : MeOH = 20 : 1) to afford a mixture 
as a colorless oil. The mixture was dissolved in CH3CN (50 mL) and NEt3·3HF (1.31 
mL) was added at 0 °C. The reaction mixture was warmed to room temperature and 
stirred for 12h. The mixture was then concentrated in vacuo. The crude mixture was 
purified by chromatography (CH2Cl2 : MeOH = 40 : 1 to 20 : 1) to afford a 2 : 1 mixture 
of (–)-sanggenon C and (+)-sanggenon O as a colorless oil (512 mg, 0.72 mmol, 54% 
yield, 3 steps). Further separation was conducted using preparative TLC (hexanes : 
EtOAc : AcOH =30: 30:1).  
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Enantioselective Syntheses of ent-Sanggenon C and ent-Sanggenon O: 
 
Ent-sanggenon C and ent-sanggenon O were synthesized via the same procedure as above 
by using (S)-3,3’-Br-BINOL as ligand. 
 
 
 
Optical rotations:  
Synthetic (+)-sanggenon C (98% ee): [α]D20= +370° (c=0.15 in methanol),   Synthetic 
ent-sanggenon C (99% ee): [α]D20= -280° (c=0.21 in methanol), 
Natural (+)-sanggenon C: [α]D16 = +304° (c=0.18 in methanol).3a 
Synthetic ent-sanggenon O (93% ee): [α]D20 = +48° (c=0.16 in methanol),    Synthetic (–
)-sanggenon O (93% ee): [α]D20= -63°(c=0.18 in methanol), 
Natural (–)-sanggenon O: [α]D16 -64°(c=0.13 in methanol). 4a 
 
Chiral HPLC analysis of sanggenon C.  
The following chiral HPLC conditions were used for the separation of enantiomers of 
sanggenon C: ChiralPak AD 150 × 4.6 mm column, 15% isopropanol in hexane. Flow 
rate: 1.0 mL/min. UV detector: 214 nm. Retention time: 6.7 min and 11.7 min. 
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Chiral HPLC analysis of sanggenon O.  
 
The following chiral HPLC conditions were used for the separation of enantiomers of 
sanggenon O: ChiralPak AD 150 × 4.6 mm column, 15% isopropanol in hexane. Flow 
rate: 1.0 mL/min. UV detector: 214 nm. Retention time: 6.1 min and 8.3 min. 
 
 
		
203 
 
 
C. X-Ray Crystallographic Data: 
 
X-ray crystallographic data for Compound 275 
 
 
 
 
 
 
 
 
Crystals of compound 275 suitable for X-ray analysis were obtained by slow evaporation 
from CH2Cl2. Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC # 1420399). Copies of the data can be obtained free 
of charge through application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK 
(fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
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Crystal data 
  C26H23BrO2 V = 2129.8 (3)  Å3 
Mr = 447.35 Z = 4 
Orthorhombic, P212121 Cu Ka radiation, l = 1.54178 Å 
a = 11.8799 (10) Å m = 2.77 mm-1 
b = 12.0496 (12) Å T = 100 K 
c = 14.8783 (13) Å 0.1 × 0.08 × 0.07 mm 
 
    
Data collection 
  Bruker D8 Venture MX  
diffractometer 
3738 independent reflections 
Absorption correction: multi-scan  
SADABS 2014/5 
3569 reflections with I > 2s(I) 
Tmin = 0.596, Tmax = 0.754 Rint = 0.025 
7795 measured reflections  
 
    
Refinement 
  R[F2 > 2s(F2)] = 0.025 H atoms treated by a mixture of 
independent and constrained refinement 
wR(F2) = 0.057 Dñmax = 0.19 e Å-3 
S = 1.08 Dñmin = -0.43 e Å-3 
3738 reflections Absolute structure:  Flack x determined 
using 1276 quotients [(I+)-(I-)]/[(I+)+(I-)]  
(Parsons, Flack and Wagner, Acta Cryst. 
B69 (2013) 249-259). 
267 parameters Flack parameter: 0.015 (9) 
0 restraints  
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq 
Br1 0.18550 (3) 0.91356 (3) 0.42704 (2) 0.02685 (9) 
O1 0.28270 (17) 0.39070 (18) 0.53924 (13) 0.0210 (5) 
H1 0.251 (3) 0.392 (4) 0.490 (3) 0.052 (13)* 
O2 0.25292 (15) 0.4130 (2) 0.36970 (11) 0.0172 (4) 
C24 0.3909 (3) 0.3681 (2) 0.51935 (17) 0.0160 (6) 
C8 0.4986 (2) 0.5530 (2) 0.16216 (17) 0.0165 (6) 
H8 0.5513 0.6112 0.1531 0.020* 
C19 0.4318 (2) 0.3691 (2) 0.42958 (18) 0.0145 (5) 
C7 0.4624 (2) 0.4994 (2) 0.09039 (17) 0.0161 (6) 
C18 0.3541 (2) 0.3973 (2) 0.35561 (16) 0.0129 (5) 
C9 0.4626 (2) 0.5288 (2) 0.25777 (16) 0.0140 (6) 
H9 0.5328 0.5216 0.2943 0.017* 
C3 0.2862 (3) 0.1977 (2) 0.20432 (18) 0.0196 (6) 
H3 0.3655 0.1909 0.2109 0.024* 
C23 0.4631 (3) 0.3431 (2) 0.59043 (17) 0.0209 (6) 
H23 0.4349 0.3421 0.6502 0.025* 
C12 0.3945 (2) 0.6235 (2) 0.29844 (17) 0.0132 (5) 
C4 0.2395 (2) 0.3022 (3) 0.19142 (17) 0.0158 (6) 
C16 0.3471 (2) 0.7380 (2) 0.42787 (19) 0.0189 (6) 
H16 0.3575 0.7565 0.4894 0.023* 
C15 0.2703 (2) 0.7955 (2) 0.37615 (19) 0.0175 (6) 
C20 0.5466 (2) 0.3463 (2) 0.41616 (17) 0.0172 (6) 
H20 0.5760 0.3474 0.3568 0.021* 
C6 0.3126 (2) 0.4054 (2) 0.18649 (14) 0.0143 (5) 
H6 0.2627 0.4721 0.1895 0.017* 
C21 0.6176 (3) 0.3223 (2) 0.48673 (19) 0.0199 (6) 
H21 0.6949 0.3075 0.4758 0.024* 
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C17 0.4088 (3) 0.6531 (2) 0.38904 (17) 0.0170 (6) 
H17 0.4621 0.6139 0.4245 0.020* 
C10 0.4013 (2) 0.4140 (2) 0.26170 (15) 0.0128 (5) 
H10 0.4589 0.3550 0.2510 0.015* 
C1 0.1045 (3) 0.1108 (3) 0.19546 (17) 0.0240 (7) 
H1A 0.0586 0.0462 0.1974 0.029* 
C26 0.1236 (3) 0.3092 (3) 0.17926 (18) 0.0191 (6) 
H26 0.0896 0.3797 0.1701 0.023* 
C13 0.3167 (3) 0.6838 (2) 0.24743 (15) 0.0156 (5) 
H13 0.3063 0.6659 0.1858 0.019* 
C25 0.3765 (2) 0.4073 (3) 0.09608 (15) 0.0165 (6) 
H25A 0.4150 0.3352 0.0876 0.020* 
H25B 0.3215 0.4161 0.0466 0.020* 
C11 0.5073 (3) 0.5244 (3) -0.00220 (18) 0.0225 (7) 
H11A 0.5583 0.5882 0.0008 0.034* 
H11B 0.4445 0.5416 -0.0426 0.034* 
H11C 0.5481 0.4597 -0.0251 0.034* 
C14 0.2545 (2) 0.7694 (2) 0.28540 (18) 0.0169 (6) 
H14 0.2018 0.8097 0.2502 0.020* 
C5 0.0568 (3) 0.2143 (3) 0.18029 (18) 0.0222 (7) 
H5 -0.0220 0.2205 0.1705 0.027* 
C22 0.5752 (2) 0.3197 (2) 0.57481 (19) 0.0211 (6) 
H22 0.6235 0.3020 0.6236 0.025* 
C2 0.2199 (2) 0.1029 (3) 0.20779 (18) 0.0214 (6) 
H2 0.2536 0.0327 0.2186 0.026* 
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X-ray crystallographic data for complex 277 
 
 
 
 
 
 
 
Crystals of compound 277 suitable for X-ray analysis were obtained by diffusion of 
cyclopentane into a CH2Cl2 solution of 277. Crystallographic data have been deposited 
with the Cambridge Crystallographic Data Centre (CCDC # 1420400). Copies of the data 
can be obtained free of charge through application to the CCDC, 12 Union Road, 
Cambridge CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk).  
 
Crystal data 
  C35H21BBr2O4·C6H6O Z = 2 
Mr = 770.25 F(000) = 776 
Monoclinic, P21 Dx = 1.236 Mg m-3 
Hall symbol:  P 2yb Cu Kα radiation, λ = 1.54178 Å 
a = 10.2781 (4) Å µ = 2.79 mm-1 
b = 12.6985 (4) Å T = 100 K 
c = 15.9497 (5) Å Prism, colorless 
β = 95.976 (2)° 0.15 × 0.12 × 0.05 mm 
V = 2070.39 (12)  Å3  
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Data collection 
  Bruker Proteum-R  
diffractometer 
7236 independent reflections 
Radiation source: rotating anode 7052 reflections with I > 2s(I) 
Montel Rint = 0.046 
ω and φ scans θmax = 66.6°, θmin = 2.8° 
Absorption correction: analytical  
SADABS (Bruker, 2006) 
h = -12→11 
Tmin = 0.690, Tmax = 0.898 k = -15→15 
41052 measured reflections l = -18→18 
 
 
Refinement 
  Refinement on F2 Secondary atom site location: difference 
Fourier map 
Least-squares matrix: full Hydrogen site location: difference Fourier 
map 
R[F2 > 2σ(F2)] = 0.033 H atoms treated by a mixture of 
independent and constrained refinement 
wR(F2) = 0.085  w = 1/[σ2(Fo2) + (0.046P)2 + 1.752P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.04 (Δ/σ)max = 0.001 
7236 reflections Δ〉max = 0.81 e Å-3 
445 parameters Δ〉min = -0.31 e Å-3 
1 restraint Absolute structure:  Flack x determined 
using 3243 quotients [(I+)-(I-)]/[(I+)+(I-)]  
(Parsons, Flack and Wagner, Acta Cryst. 
B69 (2013) 249-259). 
Primary atom site location: structure-
invariant direct methods 
Flack parameter: 0.042 (8) 
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq 
Br1 0.59811 (5) 0.17428 (3) 0.60898 (3) 0.02529 (13) 
Br2 0.85509 (5) 0.54296 (4) 0.27128 (3) 0.03074 (14) 
O4 0.7574 (3) 0.3541 (2) 0.36416 (19) 0.0180 (6) 
O3 0.6184 (3) 0.3489 (2) 0.47759 (18) 0.0178 (6) 
O2 0.8503 (3) 0.3131 (2) 0.50022 (19) 0.0206 (6) 
O1 0.7661 (3) 0.4886 (2) 0.46866 (19) 0.0194 (6) 
O1T 0.9617 (4) 0.2639 (3) 0.2899 (2) 0.0316 (8) 
H1T 0.910 (8) 0.293 (6) 0.308 (5) 0.047* 
C24 0.4642 (4) 0.1653 (4) 0.3187 (3) 0.0235 (9) 
C8 0.8395 (4) 0.6380 (3) 0.5432 (3) 0.0206 (9) 
H8 0.8868 0.6685 0.5915 0.025* 
C33 0.5837 (5) 0.5445 (4) 0.2202 (3) 0.0279 (10) 
H33 0.6035 0.6052 0.1892 0.033* 
C20 0.4150 (5) -0.0227 (4) 0.3306 (4) 0.0315 (12) 
H20 0.4095 -0.0837 0.3645 0.038* 
C7 0.7849 (4) 0.7005 (3) 0.4808 (3) 0.0206 (10) 
H7 0.7344 0.6667 0.4353 0.025* 
C23 0.4276 (5) 0.1558 (4) 0.2306 (3) 0.0259 (10) 
H23 0.4307 0.2160 0.1955 0.031* 
C26 0.5319 (4) 0.3585 (4) 0.3087 (3) 0.0173 (8) 
C10 0.8807 (4) 0.4525 (4) 0.6007 (3) 0.0199 (9) 
C18 0.4954 (4) 0.0783 (3) 0.4559 (3) 0.0229 (10) 
H18 0.4880 0.0179 0.4902 0.027* 
C16 0.5584 (4) 0.2608 (3) 0.4414 (3) 0.0171 (9) 
C35 0.6559 (4) 0.3998 (4) 0.3129 (3) 0.0195 (9) 
C25 0.5140 (4) 0.2606 (3) 0.3572 (3) 0.0180 (9) 
C1 0.8201 (5) 1.0326 (4) 0.4571 (4) 0.0310 (11) 
H1 0.8292 1.1064 0.4502 0.037* 
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C17 0.5436 (4) 0.1715 (4) 0.4909 (3) 0.0185 (8) 
C6 0.7631 (5) 0.9724 (4) 0.3919 (4) 0.0309 (11) 
H6 0.7328 1.0056 0.3402 0.037* 
C19 0.4576 (4) 0.0739 (4) 0.3692 (3) 0.0240 (10) 
C9 0.8268 (4) 0.5258 (3) 0.5370 (3) 0.0196 (9) 
C34 0.6801 (5) 0.4916 (4) 0.2662 (3) 0.0213 (9) 
C15 0.8896 (4) 0.3462 (4) 0.5787 (3) 0.0210 (9) 
C27 0.4241 (5) 0.4144 (4) 0.2625 (3) 0.0234 (9) 
C28 0.2935 (5) 0.3845 (4) 0.2652 (3) 0.0227 (10) 
H28 0.2743 0.3226 0.2949 0.027* 
C14 0.9462 (5) 0.2747 (3) 0.6386 (3) 0.0244 (10) 
H14 0.9560 0.2028 0.6239 0.029* 
C22 0.3876 (5) 0.0605 (5) 0.1953 (4) 0.0363 (12) 
H22 0.3638 0.0556 0.1362 0.044* 
C5 0.7485 (5) 0.8644 (4) 0.3995 (3) 0.0269 (10) 
H5 0.7075 0.8242 0.3540 0.032* 
C13 0.9873 (5) 0.3090 (4) 0.7186 (3) 0.0288 (11) 
H13 1.0224 0.2593 0.7593 0.035* 
C29 0.1928 (5) 0.4430 (5) 0.2258 (3) 0.0345 (12) 
H29 0.1048 0.4214 0.2283 0.041* 
C12 0.9790 (5) 0.4151 (4) 0.7422 (3) 0.0283 (10) 
H12 1.0095 0.4378 0.7975 0.034* 
C11 0.9255 (5) 0.4851 (4) 0.6825 (3) 0.0251 (10) 
H11 0.9187 0.5573 0.6970 0.030* 
C3 0.8524 (5) 0.8764 (4) 0.5421 (3) 0.0237 (10) 
H3 0.8835 0.8438 0.5940 0.028* 
C21 0.3821 (5) -0.0293 (4) 0.2464 (4) 0.0341 (12) 
H21 0.3551 -0.0948 0.2216 0.041* 
C4 0.7957 (4) 0.8153 (4) 0.4762 (3) 0.0211 (9) 
C30 0.2206 (5) 0.5362 (5) 0.1812 (4) 0.0394 (12) 
H30 0.1514 0.5783 0.1551 0.047* 
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C31 0.3458 (6) 0.5640 (5) 0.1763 (4) 0.0397 (13) 
H31 0.3633 0.6234 0.1431 0.048* 
C32 0.4518 (5) 0.5088 (4) 0.2185 (3) 0.0253 (10) 
C6T 0.7872 (5) 0.1736 (5) 0.2050 (3) 0.0316 (10) 
H6T 0.7252 0.1918 0.2428 0.038* 
C1T 0.9163 (5) 0.2078 (4) 0.2211 (3) 0.0280 (11) 
C2 0.8646 (5) 0.9851 (4) 0.5335 (3) 0.0282 (11) 
H2 0.9029 1.0263 0.5793 0.034* 
C2T 1.0069 (5) 0.1794 (5) 0.1643 (3) 0.0313 (10) 
H2T 1.0957 0.2008 0.1744 0.038* 
C3T 0.9657 (7) 0.1208 (5) 0.0950 (4) 0.0440 (14) 
H3T 1.0273 0.1020 0.0571 0.053* 
B1 0.7471 (5) 0.3724 (4) 0.4526 (3) 0.0190 (10) 
C5T 0.7489 (6) 0.1142 (5) 0.1351 (4) 0.0424 (14) 
H5T 0.6609 0.0906 0.1257 0.051* 
C4T 0.8363 (7) 0.0876 (6) 0.0776 (4) 0.0517 (17) 
H4T 0.8089 0.0483 0.0282 0.062* 
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D. Computational Studies.  
All structures were fully optimized by using Density Functional Theory (DFT) in 
Schrodinger 2015-3150 with the M06-2X151 functional. All calculations were carried out 
with the Los Alamos Effective Core Potentials Douvle Zeta (LACV3P) pseudospectral 
basis set152 for all atoms. Structures were evaluated by optimized energy values at the 
same level of theory.  
Transition states calculations were carried out as part of this study to explain the 
stereoselectivity of the Diels-Alder reaction reported in this publication. However, the 
size of the reagents involved in this intermolecular process made it difficult to carry out 
these calculations in a reasonable amount of time at the shared computing cluster at 
Boston University. Instead, calculations evaluating the approach of the diene to the 
dienophile before engaging the Diels-Alder calculations were carried out, in which the 
overall energy of the interacting complex of reagents were determined.  
Procedure 
Preparation of dienophile complex 277: 3D coordinates of reflected (another enantiomer) 
of the X-ray crystal structure 277 were used for the interaction calculations as the 
simplified dienophile.  
Preparation of diene 254: Optimized conformers of both enantiomers of dimer 254 were 
generated and ranked by energy. The two structures of lowest energies were used for the 
interaction calculations due to their low energy difference (Relative energy: +0.55 
kcal/mol for 254). The significant structural difference between the two diene conformers 
is represented by dihedral C25-C26-C5-C4 rotated by 174.1°. 
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Figure 3.5: Relevant Structures and Conformers for Diene 254 
 
Construction of Diels-Alder interacting complexes: Optimization calculations were 
performed using three-dimensional coordinates for both dienophile complex 277 and 
diene 254 as described before, and were set to converge to the interacting complex as if 
the C-C bonds to be formed were set for a length of 1.6Å, characteristic for pre-transition 
state Diels-Alder bond formation.153 
Analysis of the converged interacting complexes: DFT calculations of reaction assemblies 
with the diene conformer of lowest energy display a higher relative energy of the 
interacting complex [(S,S)-254a+277] leading to sanggenon O by 13.4 kcal/mol in 
(S,S)-254a 
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comparison to the [(R,R)-254a+277] complex leading to sanggenon C. For assembly 
(S,S)-254a+277, there appears to be significant steric interactions between the prenyl and 
phenyl group on the chalcone dienophile which are likely responsible for the significantly 
increased energy. Calculations employing the diene conformer with higher energy (254b: 
+0.55 kcal/mol), however, display a slight preference for the formation of sanggenon O 
(relative energy of complex [(R,R)-254b+277] leading to sanggenon C is 0.26 kcal/mol 
in comparison to complex [(S,S)-254b+277]) leading to sanggenon O). The overall 
results of these calculations are in agreement with the stereochemistry observed 
experimentally; a 13.4 kcal/mol difference in energy between the interacting complexes 
should lead to the formation of sanggenon C as a single diastereomer. However, the 
cycloaddition may proceed to a small extent through conformer 254b, thereby producing 
a small amount of sanggenon O. Furthermore, only endo-configured interacting 
complexes were obtained in the DFT optimizations, supporting the absence of the 
formation of exo-products experimentally. 
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1. Interacting complex with diene (R,R)-254'a leading to sanggenon C (Scheme 3.14 
model A):  
  
Relative energy of the complex [(R,R)-254'a+277]: 0.0 kcal/mol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Interacting complex with diene (S,S)-254'a leading to sanggenon O (Scheme 3.14, 
model B):  
 
Relative energy of the complex [(S,S)-254'a+277]: +13.4 kcal/mol. 
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3. Interacting complex with diene (R,R)-254'b leading to sanggenon C:  
Relative energy of the complex [(R,R)-254'b+277]: +0.26 kcal/mol. 
 
 
 
 
 
 
 
 
 
 
 
 
4. Interacting complex with diene (S,S)-254'b leading to sanggenon O:  
 Relative energy of the complex [(S,S)-254'b+277]: 0.0 kcal/mol. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DFT molecular model for substrate 222 
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E. Select Spectra: 
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Chapter 4 
Total Synthesis and Stereochemical Assignment of (±)-
Sorbiterrin A 
4.1  Introduction  
         Sorbicillinoids are a class of natural products derived from or related to the natural 
product sorbicillin (280).  These compounds belong to polyketide natural products,  and  
have  been from a variety of fungal sources, as well as marine and terrestrial sources. 
 
Figure 4.1  Representative sorbicillinoid natural products. 
In 1948 Cram and coworkers from Merck & Co., Inc. disclosed the isolation of sorbicillin 
(280) from Penicillium notatum.154 Sorbicillin was the first isolated hexaketide in which 
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cyclization had taken place on the carboxylate terminus.155 To date, over 50 members of 
this family have been isolated from fungal strains all over the world. In Figure 4.1, 
representative sorbicillinoid natural products are shown, most of which feature dimeric 
architectures derived from sorbicillinol (281).156 Specifically, bissorbicillinol (87),157 
isolated from Trichoderma sp., possesses a bicyclo[2.2.2]octanedione ring system 
derived from a [4+2] dimerization of sorbicillinol (281). Isolated from similar fungal 
strains, the dimeric natural product bisvertinol (283)158 was proposed to be derived from 
sorbicillinol (281) via a tandem Michael addition, ketalization and reduction. In addition, 
joining C7 and C3 of bisvertinol (283) would lead to the core structure of trichodimerol 
(284),159 which was also isolated from Trichoderma longibrachiatum by Ayer and 
coworkers. On another hand, only a handful of monomeric sorbicillionids such as 
epoxysorbicillinol (282)160 have been isolated.  
Sorbicillinol natural products feature a plethora of biological activities. For 
example, bisorbicillinol (87) was shown to have radical-scavenging activity with ED50 = 
31.4 µM. Sorbicillinoids also feature a broad spectrum of anticancer activities. Among 
them, trichodimerol (284) was shown to be a potent antiproliferative towards HL-60 
(leukemia) cancer cells with an IC50 value of 7.8 µM. The recently isolated sorbiterrin A 
(85),46 which possesses acetylcholinesterase inhibitory activity, is a novel sorbicillin 
derivative featuring an intriguing bridged [3.3.1] ring system, which captured our 
attention. Additionally, the relative stereochemistries at C-2 and C-3 were proposed 
based only on coupling constant analysis (3J2,3 = 2.8 Hz). Therefore, we aimed to develop 
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a concise approach to sorbiterrin A along with studies to confirm the relative 
stereochemistry. 
4.2  Related Sorbicillinol Synthesis 
         The synthesis of sorbicillinol natural products is exemplified by the work of Kuhn 
and Staab, who reported the first synthesis of sorbicillin in 1954.161 Their synthesis was 
quickly optimized by McOmie and Tute (Scheme 4.1a).  Using neat BF3·Et2O, a Friedel–
Crafts reaction between 286 and sorbic acid (287) was performed to afford boron 
complex 288.  Subsequently, boron complex 288 was hydrolyzed using aqueous MeOH 
to provide sorbicillin 280 in 15% overall yield. This method was further improved by 
Nicolaou and co-workers, who substituted methanol with THF which afforded up to 80% 
yield for the hydrolysis step.162 Alternatively, Sartori and coworkers installed the sorbyl 
side chain utilizing anionic conditions (Scheme 4.1b).163  
Scheme 4.1 Synthesis of Sorbicillin 
 
           In later studies, sorbicillin (280) was utilized in several syntheses of sorbicillinol-
derived dimers. Due to the unique biological activity and intriguing structural complexity, 
trichodimerol (284) was believed to be one of the most desired bisorbicillinoid targets. In 
		
237 
1999, Corey and coworkers reported the first synthesis of this dimeric natural product.164 
Shortly afterwards, the Nicolaou research group published their synthetic efforts towards 
this molecule.162 In both syntheses, Pb(OAc)4 was used to convert 280 to the desired 
acetoxy sorbicillinol 292 (Scheme 4.2). By manipulating the solvent, Nicolaou and 
coworkers improved the selectivity to 5 : 1 ratio favoring the desired product 292 over 
291. Enantiopure S-292 was subsequently isolated via chiral HPLC separation.  Corey 
and coworkers observed a 10% yield of trichodimerol (284) after treatment of S-292 with 
NaH2PO4·H2O. Nicolaou’s research group further studied this dimerization, and 
discovered that the reaction was very sensitive to the choice of base. Specifically, S-292 
can be converted to trichodimerol (284) in 16% yield by employing 10 equivalents of 
CsOH·H2O in methanol. Careful treatment of S-292 with KOH afforded the [4+2] 
dimerization  product  bisorbicillinol  (87)  in  40%  yield.    Compound  87  was  further 
Scheme 4.2 Synthesis of Bisorbicillinoids and Related Compounds 
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rearranged to yield bisorbibutenolide (293) under KHMDS-mediated conditions.                
The asymmetric syntheses of bisorbicillinoids were later achieved by Pettus and 
coworkers (Scheme 4.3a).165 A chiral auxiliary was introduced to sorbicillin 280 to form 
chiral compound 294, which was then treated with PIFA oxidation to afford sorbicillinol 
equivalent 295 in a diastereoselective manner. The chiral auxiliary was then removed and 
the resulting enantioenriched sorbicillinol yielded bisorbicillinol (87) in 51% ee via a 
[4+2] dimerization. In order to achieve the synthesis of an enantiopure sorbicillinol (281) 
intermediate, Deng and coworkers developed a novel reaction sequence (Scheme 
4.3b).166 A modified cinchona alkaloid catalyst was used to synthesize TMS-protected 
cyanohydrin 297 in quantitative yield and 92% ee, which was then treated with four 
sequential conditions (Grignard addition, alcohol protection, Wittig reaction, and acetal 
hydrolysis) to yield aldehyde 298. Knoevenagel condensation between 298 and 299 
generated an ynone intermediate, which readily underwent chemoselective ozonolysis to 
yield compound 300 in 92% yield over 2 steps. Treatment of 300 with the Trost–Lu 
procedure167 initiated alkyne isomerization into a sorbyl chain. Subsequent Dieckmann-
type condensation in the presence of in situ generated Ph3COK, deprotection of the 
quinol with TFA to generate the requisite S-sorbicillinol interemediate 281, and 
dimerization afforded (+)-bisorbicillinol 87 in 33% yield (3 steps). More interestingly, 
they observed that allowing 87 to stand in MeOH for 48 h furnished the rearranged 
product (+)-bisorbicillinolide 301 in 64% yield along with recovered 87 in 10% yield. 
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Scheme 4.3 Asymmetric Syntheses of Bisorbicillinoids and Related Compounds 
 
4.3  Biosynthesis and Our Designed Biomimetic Pathway 
           The biosynthesis of sorbicillinol natural products was studied by Abe and 
coworkers (Scheme 4.4). Feeding Trichoderma sp. cell cultures with [1-13C] sodium 
acetate 302 led to isolation of labelled sorbicillinol 281 and sorbicillin 280.168 Next, they 
conducted another feeding experiment with [1, 2-13C2] sodium acetate. Impressively, by 
analysis of the one-bond 13C–13C coupling constants, they were able to determine that 
hydroxylation of 303 occurs first to afford intermediate 304. Subsequently 304 cyclizes 
to yield sorbicillinol, which upon further reduction gives sorbicillin.169 
Scheme 4.4 Isotopic Labeling Study of Sorbicillinol 
 
           Sorbiterrin A (85) was proposed to originate from vinylogous acid 305 through 
an intramolecular aldol/dehydration sequence (Scheme 4.5). Precursor 305 may be 
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obtained from addition of 307 to arene oxide 306.  Inspired by previous syntheses of 
sorbicillinoids (cf. Scheme 4.2),170 we envisioned that key interemediate 305 may also be 
derived from sorbicillinol (281) instead of 306. Furthermore, the quaternary center of 305 
may be derived from consecutive Michael additions of 307 to the known sorbicillinol 281 
followed by elimination of water.  This synthetic strategy would allow very concise 
syntheses of sorbiterrin A and targeted analogues.   
Scheme 4.5 Biosynthetic vs Biomimetic Pathways 
 
 
4.4  Results 
          We initiated our study with preparation of the more stable acetoxy sorbicillinol 
292.171 Using the reported conditions with Pb(OAc)4 provided approximately a 20% yield 
of the desired product as well as 10% of regioisomer 291 (Scheme 4.6a). In order to 
access large quantities of 292, we designed another alternative sequence which is 
depicted in Scheme 4.6b. Selective acetylation of sorbicillin (280)164 (prepared by 
modified method of Corey’s) was achieved under basic conditions with acetyl chloride to  
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Scheme 4.6 Synthesis of Acetoxy Sorbicillinol 292 
 
afford 307 in 91% yield. Treatment of 307 with [bis(trifluoroacetoxy)iodo]benzene  
(PIFA)172  in acetonitrile/water (9:1) afforded acetoxy sorbicillinol 292 in 72% yield as a 
single product. One mechanism for this process may involve activation of 307 with PIFA 
to afford intermediate 308, ester trapping173 to generate acetoxonium ion intermediate 
309,174 and hydrolysis. Alternatively, nucleophilic addition of water to 309,175 followed 
by acyl migration, may also generate 292.  
 With acetoxy sorbicillinol 292 in hand, we next evaluated the proposed Michael 
addition. We prepared copper complex 310 and ketal protected 312 to overcome possible 
regioselectivity issues (Scheme 4.7). Treatment of 310 with a broad range of basic 
conditions (e.g. KHMDS, KOtBu, NaH), which was followed by addition of the resulting 
reaction mixture into a solution of 292 solution, resulted only in complex product 
mixtures after acidic work up. Analysis by UPLC revealed dimerization products of 292, 
which is in agreement with previous studies by Corey and Nicolaou (cf. Scheme 4.2). 
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Alternatively, treatment of the ketal-protected compound 312 with NaH resulted in a 14% 
yield of desired Michael addition product 313. However, further optimization failed to 
give higher yields for this reaction.   
Scheme 4.7 Attempts toward Michael Addition 
 
             Thereafter, we adjusted our retrosynthetic analysis (Scheme 4.8). We envisioned 
that 4-hydroxypyrone 315 could serve as a substitute for diketo acid 307. The resulting 
pyrone adduct 314 could then be hydrolyzed to give the requisite intermediate 305.  
 
Scheme 4.8 Revised Retrosynthesis of Sorbiterrin A 
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Scheme 4.9 Double Michael Additions 
 
               With this revised strategy, we examined a number of basic and Lewis acid-
mediated conditions to probe the feasibility of the Michael addition cascade between 
acetoxy sorbicillinol 292 and pyrone 315. 176 Acetoxy sorbicillinol 292 was highly 
unstable under basic conditions which resulted in significant degradation or dimerization 
(cf. Scheme 4.7). We also observed that several Lewis acid conditions (e.g. Yb(OTf)3, 
In(OTf)3, and Sc(OTf)3) afforded trace amounts of the pyrone adduct 316.  Reaction 
partners 292 and 315 were further treated with Lewis acid promoters under thermal 
conditions, in which case only decomposition was observed. To our delight, thermolysis 
of 292 and 315 in the presence of silica gel (130 ̊C) produced the spiro compounds 314 
and 317 in 80% yield (d.r. = 1.5 : 1). We were able to isolate compound 316 in 28% yield 
along with the spiro compounds 314 and 317 (50%) by lowering the reaction temperature 
to 90 ̊C. Treatment of 316 under higher temperature at 130 ̊C also afforded 314 and 317 
in 94% yield using silica gel as catalyst.  
       Structural assignment of the two spiro compounds 314 and 317 via NMR techniques 
was found to be extremely challenging, and furthermore 314 and 317 were found to be 
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non-crystalline. Accordingly, we considered further derivatization to help elucidate the 
structures. 3D models of compounds 314 and 317 were created at the DFT (B3LYP) level 
of theory (Scheme 4.10a). Examination of the π-orbital alignments for compounds 314 
and 317 suggested that they may have different reactivities under photocycloaddition 
conditions. The parallel arrangement of the two double bonds in 314 should allow for 
[2+2] photocycloaddition177 which may not occur with compound 317 as substrate. Upon 
photoirradiation, only 314 was converted to the [4.2.1.03.8] tricyclic structure178 318,  
Scheme 4.10  Formation of a Tricyclo [4.2.1.03.8] Derivative  
	
which was confirmed by X-ray crystallographic analysis (Scheme 4.10b).   
          In order to prepare intramolecular aldol substrate 305, the spiro compound 317 
was treated under various acidic (e.g. HCl, H2NTf, p-TsOH) and basic (e.g. NaOH, 
NaOMe, pyrrolidine) conditions. Unfortunately, all conditions led to degradation or 
decarboxylation products due to the instability of the quaternary carboxylic acid 
functionality. Accordingly, we targeted the synthesis of  the  corresponding  methyl  ester  
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Table 4.1 Spirocyclic Ring-opening via Transesterification 
 
entry Lewis acid additive  Temp. yield% (319, 320)a 
1 0.2 equiv Cu(OTf)2 3Å M.S. 40 ºC decomposed 
2 0.2 equiv Ti(OEt)4 3Å M.S. 60 ºC 7% 321 
3 0.2 equiv Mg(OTf)2 3Å M.S. 40 ºC trace 319+320 
4 0.2 equiv Er(OTF)3 3Å M.S. 60 ºC complex mixture 
5 0.2 equiv Zn(OTf)2 3Å M.S. 60 ºC 12%, 6% 
6 1.0 equiv Zn(OTf)2 3Å M.S. 60 ºC 22%, 10% 
7 3.0 equiv Zn(OTf)2 4Å M.S. 80 ºC 38%, 37% 
8 3.0 equiv Zn(OTf)2 5Å M.S. 80 ºC 30%, 31% 
 aIsolated yields determined using purified 319 and 320. 
 
45 through transesterification. A number of Lewis acids including Cu(OTf)2, Mg(OTf)2, 
Ti(OEt)4, and Zn(OTf)2179 were evaluated on substrate 317 using methanol as solvent 
(Table 4.1). Conditions with Cu(OTf)2, Mg(OTf)2, Ti(OEt)4 and lanthanide Lewis acids 
such as Er(OTf)3  failed to gave accetable yield of desired products (entries 1-4). Among 
these conditions, the strong Lewis acid Ti(OEt)4  catalyzed a reaction to afford small 
amounts of decarboxylated product 321 (entry 2), while Mg(OTf)2 mediated reactions 
only afforded trace amounts of the desired ring opening products 319 and 320 (entry 3). 
Further screening revealed that conditions with Zn(OTf)2 rendered very clean reactions 
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with the best mass balance. Using catalytic amounts of Zn(OTf)2  in the presence of 3 Å 
molecular sieves provided 12% of 319 as well as the epimerized product 320 in 6% yield 
(entry 5). Increasing the catalyst loading and temperature led to higher conversion and 
more epimerization (entries 6-7). Finally, the optimal reaction was found to be catalyzed 
by 3.0 equiv Zn(OTf)2 in the presence of 4Å molecular sieves at 80 ºC. Since 
epimerization seems to be inevitable under thermal conditions, a mixture of 314 and 317 
from previous reactions (cf. Scheme 4.9) were submitted to the Zn(OTf)2 conditions to 
prepare 319 and 320 in 74% yield and in a 1:1 ratio. The relative stereochemistries of 319 
and 320 were determined by correlation to sorbiterrin A (vide infra).  
            We next evaluated compounds 319 and 320 in the key intramolecular bridged 
aldol/dehydration step to construct the [3.3.1] ring system of sorbiterrin A. Considering 
the base-sensitive properties of compounds 319 and 320, we ruled out basic conditions 
which are commonly used in this type of transformation. Accordingly, we attempted the 
aldol reaction under acidic conditions (Table 4.2). We initiated our study by screening 
various Brønsted and Lewis acid catalysts including HCl in dioxane (entry 1),180 p-
toluenesulfonic acid (entry 2),181 trifluoroacetic acid (entry 3), and BF3·Et2O (entry 4)182 
for cyclization of 319. These conditions either degraded the starting materials or gave no 
reactivity. Based on our previous studies employing silica-supported silver nanoparticles 
(AgNP’s) as catalysts for activation of 2’-hydroxychalcones towards [4+2] 
cycloadditions,140 this catalyst system was also evaluated (entries 5-6). To our surprise, 
conditions employing silver nanoparticles afforded the desired product efficiently. After 
optimization, the best conditions involved treatment of  319 with 0.25 mol% AgNP’s  at 
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Table 4.2  Intramolecular Bridged Aldol/Dehydration 
 
entry condition solvent temp. resulta 
1 1 equiv HCl·dioxane CH2Cl2 rt, decomposed 
2 1 equiv PTSA benzene 60 ºC complex mixture 
3 0.2 equiv TfOH CH2Cl2 rt, complex mixture 
4 1 equiv BF3·Et2O CH2Cl2 40 ºC decomposed 
5 0.25 mol% AgNP toluene 100 ºC 55% of 323 
6 0.25 mol% AgNP PhCl 135 ºC 72% of 323 
7 1 equiv AgOTf toluene 135 ºC 0% of 323 
8 100 wt% silica gel  PhCl 135 ºC no reaction 
aIsolated yield of 323 after purification by sgc. 
 
135°C in chlorobenzene which afforded a 72% yield of the cyclized product 323 (entry 6). 
We next performed a series of mechanistic studies for the AgNP-mediated aldol 
condensation. Several silver salts as Lewis acids including AgBF4, Ag2O, and AgOTf 
(entry 7) did not afford the desired products. In addition, silica gel alone was also found 
to be not responsible for the observed reactivity.  
Scheme 4.11 Model Aldol Condensations 
	
		
248 
         To probe the generality of the AgNPs’ catalytic property in aldol reactions,  we 
examined the intermolecular aldol condensation between 2’,4’-dihydroxyacetophenone 
324 and benzaldehyde 325 (Scheme 4.11). This reaction was also found to be efficiently 
catalyzed by AgNP’s affording chalcone 326.171b In addition, no aldol condensation was 
observed when the corresponding 2’,4’-methoxyacetophenone (327) was used as 
substrate. Our previous studies showed that AgNPs initiated Diels-Alder cycloadditions 
of 2’-hydroxychalcones via a proposed radical cation intermediate. In line with our 
previous mechanistic studies, we hypothesized that the aldol condensation could also be 
catalyzed by the AgNP’s through an electron transfer mechanism. To probe involvement 
of possible radical intermediates, 5,5-dimethyl-1-pyrroline N-oxide (DMPO) was used as 
a spin trap183 to access long lifetime radicals (Figure 4.2). Electron paramagnetic 
resonance (EPR) measurements were conducted on a mixture of silica-supported AgNP 
catalyst, DMPO, and compound 319, in which case a strong radical signal was evident in 
the EPR spectrum (Figure 4.2a). Similar experiments were conducted using compound 
324 and vinylogous acid 328. A similar EPR signal was detected using 324 but not with 
328 which supports the unique property of the 2’-hydroxyacetophenone moiety to 
generate a radical species under AgNP-catalyzed conditions.  
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Figure 4.2  EPR spectra of spin trapping. 
a) Experimental EPR spectrum obtained from a mixture of silica-supported AgNP catalyst (150 mg), 
16 (19.4 mg, 0.05 mmol), and DMPO (20 μL, 0.18 mmol) in CH2Cl2 (0.5 mL) at 25 °C. aN = 14.4 G, 
aHβ = 21.7 G. b) Experimental EPR spectrum obtained from a mixture of silica-supported AgNP 
catalyst (150 mg), 23 (9.2 mg, 0.05 mmol), and DMPO (20 μL, 0.18 mmol) in CH2Cl2 (0.5 mL) at 
25 °C. aN = 14.1 G, aHβ = 22.4 G. c) Experimental EPR spectrum obtained from a mixture of silica-
supported AgNP catalyst (150 mg), 26 (11.0 mg, 0.05 mmol), and DMPO (20 μL, 0.18 mmol) in 
CH2Cl2 (0.5 mL) at 25 °C. 
            Based on our experimental results, we propose a mechanism for the AgNP-
mediated intramolecular aldol reaction of 319 as shown in Scheme 4.12. Absorption of 
319 to the AgNP surface may lead to proton removal and single electron transfer (SET)184 
from 319 to provide phenoxyl radical 330 (Scheme 4.12a) which is in resonance with the 
carbon-centered radical 329. We hypothesize that the electron deficient character of 
radical cation intermediate 329 may facilitate enolization of the ketone by increasing the 
kinetic acidity of the α-hydrogen atoms to afford enol tautomer 331. Further 
tautomerization of 331 generates 332 which is set to undergo intramolecular aldol 
reaction. The resulting intermediate may be followed by dehydration to intermediate 333 
followed by back electron transfer (BET) and protonation to product 323. Alternatively, 
enol tautomer 329 (Scheme 4.12b) may undergo a radical cyclization185 to afford 
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intermediate 335, which may be followed by back electron transfer, protonation, and 
dehydration to obtain product 323. 
Scheme 4.12 Model Aldol Condensation Reactions 
 
With advanced compound 323 in hand, we screened conditions for hydrolysis of 
methyl ester to prepare sorbiterrin A (85). The steric effect around the methyl ester 
functional groups prevent OH‒ ion from adding, which renders saponification difficult. 
Accordingly, MgI2 in toluene186 was used to achieve SN2 type-demethylation to afford a 
magnesium carboxylate intermediate (Scheme 4.13). Upon  acidic workup, sorbiterrin A 
was generated in 85% yield.  
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Scheme 4.13 Syntheses of Sorbiterrin A and 3-epi-Sorbiterrin A  
	
Treatment of the diastereomeric substrate 320 under similar conditions (0.25 mol% 
AgNP’s, 135°C, chlorobenzene) afforded a mixture of diastereomers 336 and 323 in a 2 : 
1 ratio and 50% combined yield. The inseparable mixture of 336 and 323 was 
demethylated using MgI2 to provide 3-epi-sorbiterrin A (337) and sorbiterrin A (85) and  
in a 2 : 1 ratio and 88% combined yield. 
Analysis of molecular models of the two proposed aldol transition states (Figure 
4.3 A and B, respectively, leading to 336 and 323) provides a plausible explanation for 
the C3 epimerization observed for substrate 320 (cf. Scheme 4.13). By comparing the  
		
Figure 4.3 Molecular models of two proposed aldol transition states. 
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two models, we hypothesize that the equatorially positioned propenyl substituent at C3 in 
A may interact with the methyl ketone (1,3-diaxial interaction) which should increase the 
energy barrier for the intramolecular aldol reaction. This steric repulsion is not observed 
in the corresponding transition state B. Due to the higher projected energy barrier of A, 
C3-epimerization may subsequentially occur by retro-Michael/Michael additions (cf. 
Scheme 4.13).   
Sorbiterrin A (85) and 3-epi-sorbiterrin A (337) were found to have very similar 1H 
NMR coupling constants between H-2 and H-3; Specifically 337 has a 3J2,3= 2.3 Hz in 
comparison to 3J2,3= 2.8 Hz  for 85. These similar coupling constant values called into 
question the assignment of the relative stereochemistry at H-2 and H-3 for 85. Numerous  
Scheme 4.14  Syntheses of Iodolactones 
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sorbiterrin A (85) with NIS and the Lewis base triphenylphosphine sulfide187 produced 
the 6-endo and 5-exo cyclization products 340 and 341 in 59% combined yield and 2 : 1 
ratio (Scheme 4.14a). In this trasformation, NIS oxidizes the alkene side chain into 
iodonium species which is stabilized by Ph3P=S. The resulting succinimide anion then 
deprotonates the carboxylic acid group to form carboxylate ion 339. Intermediate 339 
readily undergoes 6-endo or 5-exo cyclization to produce 340 or 341. By adding acidic 
additives such as TFA, the carboxylate ion is not likely to form. Instead, iodolactones 340 
and 341 are more likely to be generated through intermediate 342, which would explain 
the different products observed in Scheme 4.14b.  Both of these conditions were applied 
in the iodolactonization of 3-epi-sorbiterrin A (337). In both cases, only the 6-endo 
product 343 was observed in 63% yield. Additionally, compound 343 was found to be 
crystalline (Scheme 4.14c). X-ray crystallographic analysis revealed a cis configuration 
between H-2 and H-3 in 343 which indirectely confirmed the proposed trans 
configuration between H-2 and H-3 in sorbiterrin A (85).  
4.5  Conclusion and Future Outlook 
          In summary, we have developed a biomimetic synthesis of the bicyclo[3.3.1] 
natural product sorbiterrin A. The quaternary carbon center was established via 
consecutive Michael additions of a 4-hydroxypyrone to the substrate acetoxy sorbicillinol. 
The [3.3.1] ring system was constructed using a unique AgNP-catalyzed bridged aldol 
condensation. Mechanistic studies including EPR experiments support the involvement of 
radical intermediates in the aldol process.  
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Future studies for this project include the asymmetric synthesis of sorbiterrin A 
via an asymmetric double Michael addition (Scheme 4.15a). The requisite sorbicillinol 
281 may be obtained using a copper-sparteine complex for asymmetric hydroxylation.188 
Under Lewis acid conditions, 189  intermediate 281 may undergo diastereoselective 
Michael addition with pyrone 315, followed by proton transfer and tautomerization to 
afford intermediate 345. The possible chelation depicted in model 345 may lead to the 
production of the desired atropisomer 316190 after elimination of a water molecule and 
aromatization. Preliminary results have shown that chiral, racemic 316 can be 
successfully separated on chiral HPLC with more than 2 minutes retention time 
difference between two atropisomers. Alternatively, chiral, non-racemic compound 316 
could be prepared by developing an asymmetric dehydrogenative coupling between 
sorbicillin (280) and pyrone 315.191 Several chiral Pd catalysts have been developed for 
asymmetric Suzuki-Miyaura cross couplings (Scheme 4.15b).192 These catalysts may be 
used to form chiral complex 346, enantioenriched 316 could be formed after reductive 
elimination of 346.  Compound 316 could be further converted into sorbitterin A or ent- 
sorbiterrin A using the aforementioned synthetic sequence.  	  
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Scheme 4.15 Proposed Asymmetric Synthesis of Sorbiterrin A 
 
 
4.6  Experimental Section 
General Information 
A. Instrumentation and methods 
 
1H NMR spectra were recorded at 400 or 500 MHz at ambient temperature with CDCl3 
(Cambridge Isotope Laboratories, Inc.) as the solvent unless otherwise stated. 13C NMR 
spectra were recorded at 100 or 125 MHz at ambient temperature with CDCl3 as the 
solvent unless otherwise stated. Chemical shifts are reported in parts per million relative 
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to CDCl3 (1H, δ 7.26; 13C, δ 77.16). Data for 1H NMR are reported as follows: chemical 
shift, integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet) and coupling constants. All 13C NMR spectra were 
recorded with complete proton decoupling. Infrared spectra were recorded on a Nicolet 
Nexus 670 FT-IR spectrophotometer. High-resolution mass spectra were obtained at the 
Boston University Chemical Instrumentation Center using a Waters Q-TOF mass 
spectrometer. Melting points were recorded on a Mel-temp apparatus (Laboratory 
Devices). Analytical liquid chromatography was performed using a Waters ACQUITY 
UPLC® system equipped with PDA, ELS, and SQ detectors. Analytical thin layer 
chromatography (TLC) was performed using 0.25 mm silica gel 60-F plates (Silicycle, 
Inc.). Flash chromatography was performed using 200-400 mesh silica gel (Sorbent 
Technologies, Inc.). Preparative TLC was conducted with glass backed 250 µm or 1000 
µm silica gel 60-F plates (Silicycle, Inc.). Preparative HPLC was conducted using a PLC 
2020 Personal Purification System (Gilson, Inc.). Yields refer to chromatographically and 
spectroscopically pure compounds, unless otherwise stated. Thermolyses were conducted 
in Teflon® capped, heavy wall sealed vials (Chemglass CG-1880, 15 mL or CG-4920-01 
Complete Package) to minimize solvent/reagent evaporation. All other reactions were 
carried out in oven-dried glassware under an argon/nitrogen atmosphere unless otherwise 
noted. Photochemistry experiments were performed using a Rayonet RPR-100 
photochemical reactor equipped with RPR-3500 irradiation lamps (UVA 315-400 nm). 
Electron paramagnetic resonance (EPR) spectra were conducted in the Boston University 
Department of Chemistry using a Bruker EMX EPR spectrometer operating at 9.81 GHz 
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and at room temperature. The ArthurTM Suite Reaction Planner (Symyx Technologies, 
Inc.) was used for experimental procedure planning.  
B. Chemical reagents and solvents 
Sorbicillin (280)164 was prepared from commercially available starting materials 
according to literature procedures. HPLC grade tetrahydrofuran, methylene chloride, 
diethyl ether, toluene, acetonitrile, and benzene were purchased from Fisher and VWR 
and were purified and dried by passing through a PURE SOLV® solvent purification 
system (Innovative Technology, Inc.). Anhydrous 1,2-dichloroethane (DCE), 
chlorobenzene, and acetone from Aldrich were degassed using freeze-pump-thaw. The 
silica-supported AgNP catalyst was prepared by reduction of AgBF4 with Bu4NBH4.31 
Reagents were purchased from Strem, Aldrich, Acros, TCI America, Indofine, and Alfa 
Aesar and were used as received.   
Experimental Procedures and Compound Characterization 
Control experiment for the model aldol reaction: 
 
To a reaction vial equipped with stirbar were added mixture 327 (29.1 mg, 0.14 mmol, 
1.0 equiv), 325 (50.6 mg, 0.47 mmol, 3.0 equiv) silica-supported AgNP catalyst (100.0 
mg, containing 27.2 µg Ag, 0.2 mol% loading), and 1 mL of chlorobenzene at rt in the air. 
The vial was sealed with a Teflon® cap and heated at 100 oC for 12 h, then heated at 135 
oC for 12h. In this experiment, no aldol condensation product was detected by 1H NMR 
analysis.  
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To a reaction vial equipped with stirbar were added a mixture of 324 (25.2 mg, 0.14 
mmol, 1.0 equiv), 325 (50.6 mg, 0.47 mmol, 3.0 equiv) AgBF4 (4.2 mg, 0.02 mmol, 0.14 
equiv), and 1 mL of chlorobenzene at rt under argon. The vial was sealed with a Teflon® 
cap and heated at 80 oC for 36 h. In this experiment, no aldol condensation product 326 
was detected by 1H NMR analysis.  
Electron Paramagnetic Resonance (EPR) Spin Trapping Measurements 
Samples for EPR measurements were prepared in a nitrogen-filled, dry glove box using 
dry, deoxygenated methylene chloride (distilled over CaH2) at 25 ºC. The EPR 
spectrometer settings were as follows: modulation frequency, 100 kHz; modulation 
amplitude, 2.0 G; microwave power, 40 mW; receiver gain, 5.02e+4; time constant, 
10.240 ms; conversion time, 20.48 ms; magnetic field scan 150 G.  
Compound Synthesis and Characterization: 
 
Sorbicillin acetate 307: To a solution of sorbicillin (280) (1.2 g, 5.2 mmol) in CH2Cl2 
(50 mL, 0.7 M) were sequentially added acetyl chloride (0.44 mL, 6.2 mmol, 1.2 equiv) 
and anhydrous triethylamine (0.7 mL, 5.0 mmol, 1.0 equiv) at 0 oC. The reaction was 
stirred at 0 oC for 5 min. The mixture was concentrated under reduced pressure, then the 
crude product was purified by using silica gel chromatography (2-3% EtOAc in hexanes) 
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to afford compound 307 (1.27 g, 4.7 mmol, 91%).  
Orange/yellow solid, m.p.95-97oC (CH2Cl2), Rf: 0.27 (30% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.27 (1H, s), 7.48-7.43 (2H, m), 6.91 (1H, d, J = 14.9 
Hz), 6.35-6.23 (2H, m), 2.33 (3H, s), 2.10 (3H, s), 2.05 (3H, s), 1.88 (3H, d, J = 5.8 Hz); 
13C NMR (100.0 MHz, CDCl3) δ 193.1, 167.7, 161.3, 153.5, 145.3, 141.8, 130.3, 128.1, 
121.3, 120.3, 119.3, 117.1, 20.1, 18.7, 15.8, 8.7; IR νmax (film): 1763, 1644, 1570, 1363, 
1204, 1126, 1002 cm-1; HRMS (ESI+) m/z calculated for C16H19O4 (M + H+) 275.1283, 
found 275.1275. 
 
 
Sorbicillinol acetate 292: In an oven-dried flask, sorbicillin ester 307 (1.0 g, 4.0 mmol) 
was dissolved in 81 mL of CH3CN (HPLC grade) which was followed by addition of 9 
mL of deionized water. The resulting mixture was cooled to 0 oC and PIFA (1.9 g, 4.4 
mmol, 1.2 equiv) was added in one portion. The reaction mixture was warmed to rt, 
stirred for 30 min, and then diluted with 300 mL of EtOAc. The organic layer was 
sequentially washed with water, brine, dried over MgSO4, and concentrated in vacuo. The 
crude residue was purified by silica gel chromatography (14-33% EtOAc in hexanes) 
which afforded compound 292 (751 mg, 2.8 mmol, 72% yield) as a yellow solid.  
Characterization data for 292 were identical with those reported in the literature.164 
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3-Aryl-4-hydroxypyrone 316: To a reaction vial equipped with stirbar were added silica 
gel (50 mg), 4-hydroxy-6-methyl-2-pyrone 315 (32 mg, 0.26 mmol, 1.5 equiv), acetoxy 
sorbicillinol 292 (50 mg, 0.2 mmol, 1.0 equiv), and anhydrous, degassed PhCl (2.0 mL) 
at rt. under Ar. The vial was sealed with a Teflon® cap and was heated at 90 oC for 14 h. 
The reaction mixture was cooled to rt, filtered through a short Celite® pad with the aid of 
ethyl acetate, and concentrated in vacuo. Purification using silica gel chromatography 
(10-20% EtOAc in hexanes) afforded compound 316 (17 mg, 0.057 mmol, 28% yield) as 
a yellow oil along with compounds 314 and 317 (1.5:1 ratio, 31 mg, 0.084 mmol, 50% 
yield) 
3-Aryl-4-hydroxypyrone 316: yellow oil, Rf: 0.3 (20% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 17.56 (1H, s), 8.99 (1H, s), 7.36 (1H, dd, J = 14.7, 10.7 
Hz), 6.32-6.15 (3H, m), 6.06 (1H, s), 5.59 (1H, s), 2.32 (3H, s), 1.88 (3H, d, J = 6.3 Hz), 
1.78 (3H, s), 1.70 (3H, s); 13C NMR (100 MHz, CDCl3) δ 189.2, 177.0, 172.5, 167.3, 
166.8, 166.4, 141.9, 139.7, 130.9, 119.4, 107.8, 104.0, 97.3, 96.9, 90.9, 45.7, 23.3, 20.6, 
19.0, 7.1; IR νmax (film): 3489, 2924, 1676, 1617, 1573, 1454, 1386, 1247, 1025, 936 cm-
1; HRMS (ESI+) m/z calculated for C20H20O6Na (M + Na+) 379.1158, found 379.1150.  
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Spiro compounds 314 and 317: To a reaction vial equipped with stirbar were added 
silica gel (100 mg), 4-hydroxy-6-methyl-2-pyrone 315 (65 mg, 0.517 mmol, 1.5 equiv), 
acetoxy sorbicillinol 292 (100 mg, 0.34 mmol, 1.0 equiv), and anhydrous degassed PhCl 
(4.0 mL) at rt. under Ar. The vial was sealed with a Teflon® cap and heated at 130 oC for 
24 h. The resulting reaction mixture was cooled to rt, filtered through a short Celite® pad 
with the aid of ethyl acetate, and concentrated in vacuo. Purification using silica gel 
chromatography (20-33% EtOAc in hexanes) afforded compounds 314 and 317 (1.5:1 
ratio, 97 mg, 0.27 mmol, 80%) as tan oils. 
Alternative synthesis of 314 and 317 from 316: To a reaction vial equipped with stirbar 
were added silica gel (40 mg), 3-aryl-4-hydroxypyrone 316 (21 mg, 0.059 mmol, 1.0 
equiv), and anhydrous degassed PhCl (2.0 mL) at rt under Ar. The vial was sealed with a 
Teflon® cap and heated at 130 oC for 12 h. The resulting reaction mixture was cooled to 
rt, filtered through a short Celite® pad with the aid of ethyl acetate, and concentrated in 
vacuo. Purification using silica gel chromatography (33% EtOAc in hexanes) afforded 
compounds 314 and 317 (1.5:1 ratio, 19 mg, 0.055 mmol, 94%) as tan oils. 
Further separation of 314 and 317 was achieved by preparative TLC (20% EtOAc in 
hexanes) using four elutions.  
Spiro compound 314: tan oil, Rf: 0.20 (50% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 13.39 (1H, s), 5.95 (1H, bs), 5.89 (1H, s), 5.73 (1H, m), 
5.23 (1H, m), 3.28 (1H, ddd, J = 13.6, 9.7, 3.6 Hz), 2.92 (1H, dd, J = 17.0, 13.6 Hz), 2.47 
(1H, dd, J = 17.0, 3.6 Hz), 2.21 (3H, s), 2.01 (3H, s), 1.80 (3H, s), 1.69 (3H, dd, J = 6.5, 
1.5 Hz); 13C NMR (100 MHz, CDCl3) δ 200.8, 191.7, 171.0, 167.8, 162.0, 159.8, 137.7, 
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131.7, 125.4, 125.4, 113.7, 111.8, 108.0, 64.5, 49.7, 38.0 20.5, 17.9, 14.0, 7.4; IR νmax 
(film): 3444, 2918, 1780, 1655, 1621, 1384, 1259 995cm-1; HRMS (ESI+) m/z calculated 
for C20H21O6 (M + H+) 357.1338, found 357.1335.  
Spiro compound 317: tan oil, Rf: 0.20 (50% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.29 (1H, s), 5.89 (1H, t, J = 0.8 Hz), 5.68-5.61 (2H, m), 
5.38 (1H, m), 3.18 (1H, ddd, J = 12.7, 9.0, 3.5 Hz), 2.94 (1H, dd, J = 16.6, 12.7 Hz), 2.56 
(1H, dd, J = 16.6, 3.5 Hz), 2.23(3H, d, J = 0.8 Hz), 2.06 (3H, s), 1.81 (3H, s), 1.68 (3H, 
dd, J =6.5, 1.6 Hz); 13C NMR (125 MHz, CDCl3) δ 200.6, 194.5, 167.7, 167.3, 161.9, 
159.7, 137.4, 132.1, 125.2, 114.0, 112.2, 110.7, 108.0, 64.2, 47.7, 38.6, 20.5, 18.0, 14.5, 
7.5; IR νmax (film): 3444, 2918, 1777, 1655, 1622, 1383, 1260 992 cm-1; HRMS (ESI+) 
m/z calculated for C20H21O6 (M + H+) 357.1338, found 357.1348. 
 
 
[2+2] Cycloadduct 318: To a NMR tube were added 314 (30 mg, 0.084 mmol, 1.0 
equiv), anhydrous CH2Cl2 (2.0 mL) at rt under Ar. After three cycles of freeze-pump-
thaw degassing, the solution was irradiated in the Rayonet photoreactor for 36 h (cooling 
fan was turned on). The crude mixture was concentrated and purified by using silica gel 
chromatography (20-33% EtOAc in hexanes), to afford compound 318 (23 mg, 0.063 
mmol, 76%) as a white solid. 
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[2+2] Cycloadduct 318: White solid, m.p. >230 oC (decompose), Rf: 0.3 (40% EtOAc in 
hexanes); 
1H NMR (500 MHz, CDCl3) δ 12.88 (1H, s), 5.54 (1H, s), 3.37 (1H, dd, J = 5.9, 1.1 Hz), 
3.17 (1H, dd, J = 14.5, 4.7 Hz), 2.69 (1H, dd, J = 15.8, 4.7 Hz), 2.56 (1H, qdd, J = 7.4, 
1.2, 1.1 Hz), 2.32 (1H, dd, J = 15.8, 14.5 Hz), 2.16 (1H, dd, J = 5.9, 1.2 Hz), 2.13 (3H, s), 
1.85 (3H, s), 1.52 (3H, s), 1.30 (3H, d, J = 7.4 Hz); 13C NMR (100 MHz, CDCl3) δ 202.7, 
198.5, 171.4, 161.4, 160.3, 131.0, 117.2, 111.6, 110.8, 85.2, 64.8, 48.9, 47.4, 46.2, 41.5, 
40.5, 20.4, 16.6, 15.2, 7.6;  IR νmax (film): 3518, 2963, 1769, 1734, 1623, 1292. 1173 cm-
1; HRMS (ESI+) m/z calculated for C20H21O6 (M + H+) 357.1338, found 357.1340. 
 
 
Vinylogous acid 319: To a reaction vial equipped with stirbar were added a mixture of  
compounds 314 and 317 (1.5:1, 40 mg, 0.11 mmol, 1.0 equiv), 4Å M.S. (100 mg), 
Zn(OTf)2 (120 mg, 0.34 mmol, 3.0 equiv), and anhydrous methanol (4 mL) at rt under 
Ar. The vial was sealed with a Teflon® cap and was heated at 80 oC for 24 h. The 
resulting reaction mixture was cooled to rt, filtered through a short Celite® pad with the 
aid of ethyl acetate, and concentrated in vacuo. Purification using silica gel 
chromatography (10-25% EtOAc in hexanes with a few drops of methanol) afforded 
compounds 319 and 320 (1:1 ratio, 32 mg, 0.081 mmol, 74%) as tan oils. 
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Further separation of 319 and 320 was achieved by preparative TLC (27% EtOAc in 
hexanes with a few drops of AcOH).  
Vinylogous acid 319: tan oil, Rf: 0.4 (40% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 15.16 (1H, bs), 13.58 (1H, s), 5.89 (1H, s), 5.60-5.48 (3H, 
m), 3.65 (3H, s), 3.21 (1H, ddd, J = 8.9, 8.9, 4.5 Hz), 2.79 (1H, dd, J = 17.1, 8.9 Hz), 
2.69 (1H, dd, J = 17.1, 4.5 Hz), 2.15 (3H, s), 2.05 (3H, s), 1.94 (3H, s), 1.63 (3H, d, J = 
5.1 Hz); 13C NMR (100 MHz, CDCl3) δ 201.7, 196.3, 186.1, 169.9, 162.1, 159.6, 137.2, 
129.4, 128.5, 116.2, 111.2, 110.3, 99.6, 65.1, 52.6, 47.1, 40.8, 23.5, 18.1, 14.4, 7.7; IR 
νmax (film): 3474, 2918, 1734, 1617, 1434, 1229 cm-1; HRMS (ESI+) m/z calculated for 
C21H25O7 (M + H+) 389.1600, found 389.1590. 
Vinylogous acid 320: tan oil, Rf: 0.4 (40% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 15.65 (1H, bs), 13.58 (1H, s), 5.89 (1H, s), 5.60-5.45 (3H, 
m), 3.72 (3H, s), 3.37 (1H, ddd, J = 11.4, 9.0, 3.8 Hz), 2.75 (1H, dd, J = 17.3, 11.4 Hz), 
2.62 (1H, dd, J = 17.3, 3.8 Hz), 2.15 (3H, s), 2.06 (3H, s), 1.94 (3H, s), 1.66 (3H, d, J = 
6.1 Hz); 13C NMR (125 MHz, CDCl3) δ 202.0, 191.8, 189.0, 171.5, 162.2, 159.4, 138.6, 
129.5, 128.7, 115.4, 111.4, 110.2, 101.4, 64.4, 53.0, 47.3, 40.5, 24.4, 18.1, 13.7, 7.7; IR 
νmax (film): 3446, 2955, 1738, 1619, 1434, 1223, 973 cm-1; HRMS (ESI+) m/z calculated 
for C21H25O7 (M + H+) 389.1600, found 389.1600. 
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Sorbiterrin A methyl ester 323: To a reaction vial equipped with stirbar were added 319 
(40 mg, 0.1 mmol, 1.0 equiv), silica-supported AgNP catalyst (100 mg, containing 27.2 
µg Ag, 0.25 mol% loading), and 2 mL of anhydrous chlorobenzene at rt in the air. The 
vial was sealed with a Teflon® cap and heated at 135 oC for 27 h. The resulting reaction 
mixture was cooled to rt, filtered through a short Celite® pad with the aid of ethyl acetate, 
and concentrated in vacuo. Purification using silica gel chromatography (9-12% EtOAc 
in hexanes) afforded compound 323 (27 mg, 0.07 mmol, 72%) as a pale yellow oil. 
Sorbiterrin A methyl ester 323: Pale yellow oil, Rf: 0.4 (40% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 12.93 (1H, s), 5.72 (1H, q, J = 1.4 Hz), 5.70-5.64 (2H, m), 
5.46 (1H, m), 3.69 (3H, bs), 3.58 (1H, d, J = 9.3 Hz), 3.17 (1H, d, J = 2.8 Hz), 2.11 (3H, 
s), 2.09 (3H, s), 2.01 (3H, d, J = 1.4 Hz), 1.60 (3H, dd, J = 6.5, 1.5 Hz); 13C NMR (125 
MHz, CDCl3) δ 196.8, 190.3, 170.0, 162.6, 160.8, 157.9, 131.4 (2C), 126.9, 123.9, 118.1, 
111.6, 107.8, 61.8, 56.1, 52.3, 51.7, 22.9, 18.0, 13.9, 7.7; IR νmax (film): 3472, 2950, 
1743, 1677, 1621, 1433, 1255, 1050, 968 cm-1; HRMS (ESI+) m/z calculated for 
C21H23O6 (M + H+) 371.1495, found 371.1498. 
 
Methyl ester 323 and 336: To a reaction vial equipped with stirbar were added substrate 
320 (39 mg, 0.1 mmol, 1.0 equiv), silica-supported AgNP catalyst (100 mg, containing 
27.2 µg Ag, 0.25% loading), and 2 mL of anhydrous chlorobenzene at rt in the air. The 
vial was sealed with a Teflon® cap and heated at 135 oC for 27 h. The resulting reaction 
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mixture was cooled to rt, filtered through a short Celite® pad with the aid of ethyl acetate, 
and concentrated in vacuo. Purification using silica gel chromatography (9-12% EtOAc 
in hexanes) afforded an inseparable mixture of 323 and 336 (1 : 2, 20 mg, 0.05 mmol, 
50%) as light yellow oils. 
 
Sorbiterrin A (85): To a reaction vial equipped with stir bar were added 323 (15 mg, 
0.04 mmol, 1.0 equiv), MgI2 (20 mg, 0.07 mmol 1.8 equiv), and 2 mL of anhydrous and 
deoxygenated toluene at rt under Ar in the dark. The vial was sealed with a Teflon® cap 
and heated at 100 oC for 36 h. The resulting reaction mixture was cooled to rt, washed 
with 15% aqueous HCl solution, and extracted with EtOAc. The combined organic layers 
were washed with brine, dried with Na2SO4, and concentrated in vacuo. Purification on 
silica gel chromatography (25-50% EtOAc in hexanes with a few drops of methanol) 
afforded sorbiterrin A (85) (13 mg, 0.034 mmol, 85%) as a light yellow oil. 
IR νmax (film): 3300, 1718, 1674, 1617, 1422, 1356, 1382 cm-1; HRMS (ESI+) m/z 
calculated for C20H21O6 (M + H+) 357.1338, found 357.1332.  
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1H NMR: 
Positions Natural46 85 (600 MHz, DMSO-d6) Synthetic 85 (500 MHz, DMSO-d6)  
2 3.21 (1H, d, J=2.8 Hz) 3.21 (1H, d, J=2.8 Hz) 
3 3.57 (1H, dd, J=9.1, 2.8 Hz) 3.57 (1H, d, J=9.2 Hz) 
10 5.71(1H, d, J=0.9 Hz) 5.71 (1H, d, J=1.1 Hz) 
12 1.94 (3H, d, J=0.9 Hz) 1.95 (3H, d, J=1.1 Hz) 
13 5.37 (1H, dd, J=14.2, 9.1 Hz) 5.37 (1H, dd, J=14.4, 9.1 Hz) 
14 5.70 (1H, m) 5.70 (1H, m) 
15 1.55 (3H, d, J= 5.5 Hz) 1.55 (3H, dd, J= 6.4, 1.2 Hz) 
Me-5 1.99 (3H, s) 1.99 (3H, s) 
Me-7 2.01 (3H, s) 2.01 (3H, s) 
8-OH 13.00 (1H, s) 12.98 (1H, s) 
 
 
13C NMR: 
Positions Natural46 85 (125 MHz, DMSO-d6) Synthetic 85 (100 MHz, DMSO-d6) 
1 197.0 197.0 
2 55.5 55.4 
3 49.9 49.9 
4 60.7 60.6 
4a 131.9 131.8 
5 120.0 119.9 
6 162.6 162.4 
7 110.9 110.9 
8 161.6 161.5 
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8a 106.6 106.6 
9 190.5 190.3 
10 123.0 122.9 
11 158.4 158.4 
12 22.2 22.1 
13 127.7 127.5 
14 130.1 130.2 
15 17.8 17.8 
16 170.0 169.9 
Me-5 15.0 14.9 
Me-7 8.2 8.2 
 
 
 
3-Epi-sorbiterrin A 337: To a reaction vial equipped with stirbar were added a 2:1 
mixture of 336 and 323 (11 mg, 0.03 mmol, 1.0 equiv, 2:1), MgI2 (15 mg, 0.054 mmol, 
1.8 equiv), and 2 mL of anhydrous and deoxygenated toluene at rt under Ar in dark. The 
vial was sealed with a Teflon® cap and heated at 100 oC for 36 h. The resulting reaction 
mixture was cooled to rt, washed with 15% HCl solution, and finally extracted with 
EtOAc. The combined organic layers were washed with brine, dried with Na2SO4, and 
concentrated in vacuo. Purification using preparative TLC (50% EtOAc in hexanes with a 
few drops of AcOH) afforded compounds 337 and 85 (2:1 ratio, 9 mg, 0.034 mmol, 88%) 
as yellow oils.  
Further separation of 337 and 85 was achieved by preparative TLC (5% MeOH in DCM 
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with a few drops of AcOH).  
3-Epi-sorbiterrin A 337: light yellow oil, Rf: 0.4 (5% MeOH in CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 12.87 (1H, s), 11.82 (1H, bs), 5.90 (1H, q, J= 1.4 Hz), 
5.80 (1H, m), 5.63 (1H, bs), 5.39 (1H, m), 3.80 (1H, dd, J= 9.1, 2.3 Hz), 3.25 (1H, d, J= 
2.3 Hz), 2.10 (3H, s), 2.09 (3H, s), 2.06 (3H, d, J= 1.4 Hz), 1.70 (3H, dd, J= 6.6, 1.6 Hz); 
13C NMR (125 MHz, CDCl3) δ 197.9, 196.2, 172.0, 163.3, 160.0, 159.4, 135.3, 134.4, 
124.0, 123.5, 117.0, 111.9, 107.8, 59.1, 55.6, 52.6, 23.5, 18.3, 11.8, 7.7; IR νmax (film): 
3451, 2896, 1729, 1620, 1423, 1217 cm-1; HRMS (ESI+) m/z calculated for C20H21O6 (M 
+ H+) 357.1338, found 357.1547 and 339.1238 (-H2O). 
Key 1H NMR coupling constant comparison for sorbiterrin A (85) and 3-epi-sorbiterrin A 
(337). 
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Iodolactone 343: To a -40 oC suspension of N-iodosuccinimide (15 mg, 0.067 mmol, 1.2 
equiv) in 1.0 mL of dry CH2Cl2 under argon in dark was added a solution of 3-epi-
sorbiterrin A (20 mg, 0.056 mmol, 1.0 equiv) and TFA (0.5 µL, 0.006 mmol, 0.1 equiv) 
in 1.0 mL of dry CH2Cl2 by cannula which was followed by addition of 1.0 mL of CH2Cl2 
solution of Ph3P=S (1.6 mg, 0.006 mmol, 0.1 equiv). The solution was stirred for 3 h at -
40 oC. The resulting mixture was directly purified by silica gel chromatography (12-20% 
EtOAc in hexanes) to afford compound 343 (17 mg, 0.035 mmol, 63%) as a white solid. 
Iodolactone 343: White solid, m.p. >200 oC (CH2Cl2, decompose), Rf: 0.25 (20% EtOAc 
in hexanes) 
1H NMR (500 MHz, CDCl3) δ 12.71 (1H, s), 5.79 (1H, q, J = 1.4 Hz), 5.68 (1H, s), 4.78 
(1H, dq, J = 10.8, 6.1 Hz), 4.36 (1H, dd, J = 12.1, 10.8 Hz), 3.73 (1H, d, J = 2.2 Hz), 3.31 
(1H, dd, J = 12.1, 2.2 Hz), 2.13 (3H, s), 2.08 (3H, s), 2.03 (3H, d, J = 1.4 Hz), 1.67 (3H, d, 
J = 6.1 Hz); 13C NMR (125 MHz, CDCl3) δ 195.4, 188.1, 168.0, 163.2, 161.1, 154.1, 
131.6, 123.6, 119.6, 112.4, 107.9, 84.6, 61.9, 55.9, 51.6, 28.9, 23.3, 21.3, 14.3, 7.8; IR 
νmax (film): 3455, 2830, 1755, 1680, 1620, 1198, 1123 cm-1; HRMS (ESI+) m/z 
calculated for C20H20IO6 (M + H+) 483.0305, found 483.0316. 
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Chalcone 326: To a reaction vial equipped with stirbar were added 324 (25 mg, 0.14 
mmol, 1.0 equiv), 325 (51 mg, 0.47 mmol, 3.0 equiv) silica-supported AgNP catalyst 
(100.0 mg, containing 27.2 µg Ag, 0.2 mol% loading), and 1 mL of anhydrous 
chlorobenzene at rt in the air. The vial was sealed with a Teflon® cap and heated at 80 oC 
for 36 h. The resulting reaction mixture was cooled to rt, filtered through a short Celite® 
pad with the aid of ethyl acetate, and concentrated in vacuo. Purification using silica gel 
chromatography (5-10% EtOAc in hexanes) afforded chalcone 326 (34 mg, 0.12 mmol, 
92%) as a yellow solid. 
Chalcone 326: Yellow solid, m.p. 164-166 oC (CH2Cl2), Rf: 0.3 (10% EtOAc in 
hexanes); 
1H NMR (500 MHz, CDCl3) δ 13.56 (1H, s), 7.88 (1H, d, J = 15.5 Hz), 7.68-7.66 (2H, 
m), 7.61 (1H, d, J = 15.5 Hz), 7.57 (1H, s), 7.44-7.41 (3H, m), 5.31(1H, s), 2.26 (3H, s), 
2.18 (3H, s); 13C NMR (125 MHz, CDCl3) δ 192.2, 162.9, 159.1, 144.2, 135.1, 130.7, 
129.1, 129.0 (2C), 128.7 (2C), 120.8, 114.7, 113.8, 110.6, 15.8, 7.7; IR νmax (film): 3332, 
1632, 1562, 1081, 979, 687 cm-1; HRMS (ESI+) m/z calculated for C17H17O3 (M + H+) 
269.1178, found 269.1186. 
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X-ray crystallographic data for compound 318 
 
Crystals of compound 318 suitable for X-ray analysis were obtained by slow evaporation 
from CH2Cl2. Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC # 978301). Copies of the data can be obtained free 
of charge through application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK 
(fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Crystal data 
  C20H20O6 F(000) = 752 
Mr = 356.36 Dx = 1.479 Mg m-3 
Monoclinic, P21/n Cu Ka radiation, l = 1.54178 Å 
Hall symbol:  -P 2yn Cell parameters from 9754 reflections 
a = 10.0191 (3) Å q = 4.5–66.5° 
b = 10.3912 (3) Å m = 0.91 mm-1 
c = 15.5553 (5) Å T = 100 K 
b = 98.703 (1)° Bar, colorless 
V = 1600.82 (8)  Å3 0.14 × 0.06 × 0.05 mm 
Z = 4  
 
		
273 
Data collection 
  Bruker Proteum-R  
diffractometer 
2816 independent reflections 
Radiation source: rotating anode 2769 reflections with I > 2s(I) 
multilayer Rint = 0.046 
w & f scans qmax = 66.9°, qmin = 4.9° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -11®11 
Tmin = 0.694, Tmax = 0.753 k = -12®12 
56082 measured reflections l = -18®18 
 
    
Refinement 
  Refinement on F2 41 restraints 
Least-squares matrix: full Hydrogen site location: mixed 
R[F2 > 2s(F2)] = 0.040 H atoms treated by a mixture of 
independent and constrained refinement 
wR(F2) = 0.094  w = 1/[s2(Fo2) + (0.0213P)2 + 1.3872P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.18 (D/s)max < 0.001 
2816 reflections Dñmax = 0.24 e Å-3 
305 parameters Dñmin = -0.19 e Å-3 
      
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O1A 0.42044 
(14) 
0.57225 
(13) 
0.38556 (8) 0.0189 (3) 0.839 (2) 
O2A 0.3073 (3) 0.4176 (3) 0.3092 (2) 0.0207 (5) 0.839 (2) 
O3A 0.7124 (2) 0.5319 (2) 0.25872 
(17) 
0.0193 (5) 0.839 (2) 
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O4 0.30123 
(12) 
0.59702 
(12) 
-0.02467 (7) 0.0256 (3)  
O5 0.51784 
(12) 
0.08093 
(11) 
0.15688 (8) 0.0230 (3)  
O6 0.28312 
(12) 
0.35602 
(13) 
-0.05143 (7) 0.0272 (3)  
H6 0.2717 0.4348 -0.0622 0.041*  
C1A 0.4399 (3) 0.9351 (2) 0.38085 
(16) 
0.0215 (5) 0.839 (2) 
H1AA 0.3916 0.9994 0.3419 0.032* 0.839 (2) 
H1AB 0.5374 0.9496 0.3854 0.032* 0.839 (2) 
H1AC 0.4127 0.9425 0.4386 0.032* 0.839 (2) 
C2A 0.40589 
(19) 
0.80130 
(19) 
0.34475 
(12) 
0.0180 (4) 0.839 (2) 
H2A 0.3073 0.7810 0.3379 0.022* 0.839 (2) 
C3A 0.4690 (2) 0.7749 (2) 0.26170 
(15) 
0.0167 (5) 0.839 (2) 
H3A 0.4942 0.8536 0.2308 0.020* 0.839 (2) 
C9A 0.3977 (3) 0.6684 (2) 0.20179 
(13) 
0.0157 (5) 0.839 (2) 
H9A 0.2993 0.6671 0.2067 0.019* 0.839 (2) 
C10B 0.4989 (15) 0.5399 (19) 0.2321 (13) 0.0140 (5) 0.161 (2) 
C14 0.45672 
(16) 
0.42701 
(16) 
0.16992 
(10) 
0.0177 (3)  
C13 0.38886 
(16) 
0.44809 
(16) 
0.08426 
(10) 
0.0182 (3)  
C19 0.35437 
(16) 
0.34100 
(17) 
0.02959 
(10) 
0.0206 (4)  
C18 0.39250 
(16) 
0.21654 
(17) 
0.05529 
(11) 
0.0201 (4)  
C20 0.34904 
(18) 
0.10301 
(18) 
-0.00246 
(12) 
0.0266 (4)  
H20A 0.3471 0.0256 0.0333 0.040*  
H20B 0.4130 0.0906 -0.0435 0.040*  
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H20C 0.2587 0.1190 -0.0347 0.040*  
C6A 0.5549 (6) 0.7041 (5) 0.4850 (2) 0.0224 (9) 0.839 (2) 
H6AA 0.4816 0.7055 0.5202 0.034* 0.839 (2) 
H6AB 0.6074 0.7838 0.4944 0.034* 0.839 (2) 
H6AC 0.6138 0.6302 0.5019 0.034* 0.839 (2) 
C5A 0.4964 (2) 0.6929 (2) 0.39081 
(14) 
0.0172 (5) 0.839 (2) 
C7A 0.3907 (2) 0.5019 (2) 0.31328 
(13) 
0.0155 (4) 0.839 (2) 
C4A 0.59054 
(19) 
0.70471 
(19) 
0.31893 
(12) 
0.0173 (4) 0.839 (2) 
H4A 0.6741 0.7574 0.3350 0.021* 0.839 (2) 
C8A 0.6081 (2) 0.5818 (2) 0.27216 
(14) 
0.0155 (4) 0.839 (2) 
C11A 0.4150 (3) 0.6897 (2) 0.10738 
(15) 
0.0201 (5) 0.839 (2) 
H11A 0.3674 0.7695 0.0857 0.024* 0.839 (2) 
H11B 0.5121 0.7009 0.1036 0.024* 0.839 (2) 
C12 0.35964 
(16) 
0.57713 
(17) 
0.05054 
(11) 
0.0210 (4)  
C15 0.50235 
(16) 
0.30474 
(16) 
0.19570 
(10) 
0.0178 (3)  
C17 0.47371 
(16) 
0.20256 
(16) 
0.13574 
(11) 
0.0188 (3)  
C16 0.57567 
(17) 
0.27226 
(16) 
0.28521 
(10) 
0.0209 (4)  
H16A 0.5740 0.3469 0.3235 0.031*  
H16B 0.6695 0.2495 0.2813 0.031*  
H16C 0.5311 0.1993 0.3089 0.031*  
O1B 0.6484 (7) 0.6029 (6) 0.3577 (4) 0.0176 (17) 0.161 (2) 
C7B 0.6410 (15) 0.5439 (13) 0.2787 (9) 0.0155 (4) 0.161 (2) 
C4B 0.4003 (9) 0.6597 (9) 0.3363 (6) 0.016 (2) 0.161 (2) 
H4B 0.3246 0.6817 0.3689 0.020* 0.161 (2) 
		
276 
C2B 0.5442 (10) 0.8142 (9) 0.3307 (6) 0.0180 (4) 0.161 (2) 
H2B 0.6283 0.8300 0.3049 0.022* 0.161 (2) 
C5B 0.5486 (13) 0.6898 (12) 0.3827 (7) 0.0172 (5) 0.161 (2) 
O2B 0.7357 (19) 0.5085 (16) 0.2484 (12) 0.0193 (5) 0.161 (2) 
C9B 0.4659 (15) 0.6733 (11) 0.1897 (7) 0.025 (3) 0.161 (2) 
H9B 0.5481 0.7095 0.1692 0.030* 0.161 (2) 
C3B 0.4296 (14) 0.7548 (14) 0.2660 (8) 0.0167 (5) 0.161 (2) 
H3B 0.3536 0.8161 0.2479 0.020* 0.161 (2) 
C11B 0.3484 (17) 0.6751 (13) 0.1165 (8) 0.034 (3) 0.161 (2) 
H11C 0.2637 0.6609 0.1408 0.041* 0.161 (2) 
H11D 0.3428 0.7610 0.0887 0.041* 0.161 (2) 
C1B 0.4963 (13) 0.9324 (13) 0.3755 (9) 0.0215 (5) 0.161 (2) 
H1BA 0.5600 0.9512 0.4283 0.032* 0.161 (2) 
H1BB 0.4067 0.9156 0.3911 0.032* 0.161 (2) 
H1BC 0.4914 1.0063 0.3360 0.032* 0.161 (2) 
H5 0.5918 (18) 0.080 (2) 0.1927 (13) 0.032*  
C8B 0.3963 (14) 0.5281 (11) 0.2933 (8) 0.0155 (4) 0.161 (2) 
O3B 0.333 (2) 0.437 (2) 0.3172 (14) 0.0207 (5) 0.161 (2) 
C6B 0.571 (4) 0.683 (3) 0.4839 (13) 0.0224 (9) 0.161 (2) 
H6BA 0.5490 0.5966 0.5024 0.034* 0.161 (2) 
H6BB 0.5128 0.7462 0.5068 0.034* 0.161 (2) 
H6BC 0.6658 0.7023 0.5062 0.034* 0.161 (2) 
C10A 0.4640 (2) 0.5366 (3) 0.2353 (2) 0.0140 (5) 0.839 (2) 
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X-ray crystallographic data for Compound 343 
 
Crystals of compound 343 suitable for X-ray analysis were obtained by slow diffusion 
using hexanes and ethyl acetate. Crystallographic data have been deposited with the 
Cambridge Crystallographic Data Centre (CCDC # 978302). Copies of the data can be 
obtained free of charge through application to the CCDC, 12 Union Road, Cambridge 
CB21EZ, UK (fax: (+44)-1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Crystal data 
  C20H19IO6 Z = 2 
Mr = 482.25 F(000) = 480 
Triclinic, P¯1 Dx = 1.791 Mg m-3 
Hall symbol:  -P 1 Cu Ka radiation, l = 1.54178 Å 
a = 8.8558 (6) Å Cell parameters from 9863 reflections 
b = 10.4095 (7) Å q = 5.2–66.6° 
c = 11.3264 (7) Å m = 14.39 mm-1 
a = 89.959 (2)° T = 100 K 
b = 68.696 (2)° Prism, colorless 
g = 68.458 (2)° 0.33 × 0.28 × 0.24 mm 
V = 894.15 (10)  Å3  
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Data collection 
  Bruker Proteum-R  
diffractometer 
3152 independent reflections 
Radiation source: rotating anode 3143 reflections with I > 2s(I) 
multilayer Rint = 0.074 
w & f scans qmax = 66.7°, qmin = 4.2° 
Absorption correction: analytical  
SADABS (Sheldrick, 1997) 
h = -10®10 
Tmin = 0.551, Tmax = 0.753 k = -12®12 
30029 measured reflections l = -13®13 
 
    
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq  
I1 -0.51211 (3) 1.10866 (2) 0.84751 (2) 0.01480 
(14) 
 
O2 0.1992 (4) 1.0967 (3) 0.6054 (3) 0.0212 (6)  
O5 0.2526 (4) 0.5356 (3) 0.3725 (3) 0.0147 (6)  
H5 0.1485 0.5450 0.4159 0.022*  
O7 -0.0364 (4) 1.1789 (3) 0.7872 (3) 0.0179 (6)  
O9 -0.0582 (4) 0.6487 (3) 0.5489 (3) 0.0169 (6)  
O10 0.6901 (4) 0.6676 (3) 0.3929 (3) 0.0172 (6)  
H10 0.7055 0.7319 0.4253 0.026*  
O12 0.1632 (4) 0.9274 (3) 0.8873 (3) 0.0161 (6)  
C1 0.6028 (5) 0.5026 (4) 0.2637 (4) 0.0152 (8)  
H1A 0.6468 0.5514 0.1935 0.023*  
H1B 0.5480 0.4474 0.2376 0.023*  
H1C 0.7012 0.4404 0.2838 0.023*  
C2 0.4692 (5) 0.6072 (4) 0.3797 (4) 0.0106 (7)  
C3 0.5170 (5) 0.6907 (4) 0.4432 (4) 0.0128 (8)  
C4 0.3969 (5) 0.7910 (4) 0.5546 (3) 0.0106 (7)  
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C7 0.0902 (5) 1.0737 (4) 0.6923 (4) 0.0117 (7)  
C14 0.1669 (5) 0.7253 (4) 0.5379 (3) 0.0098 (7)  
C16 0.2948 (5) 0.6227 (4) 0.4309 (3) 0.0099 (7)  
C21 -0.3267 (6) 1.3163 (4) 0.9340 (4) 0.0183 (8)  
H21A -0.3118 1.2755 1.0091 0.028*  
H21B -0.4517 1.3534 0.9478 0.028*  
H21C -0.2845 1.3921 0.9212 0.028*  
C22 -0.2221 (5) 1.2054 (4) 0.8170 (4) 0.0130 (7)  
H22 -0.2532 1.2434 0.7441 0.016*  
C23 -0.2478 (5) 1.0685 (4) 0.8334 (4) 0.0102 (7)  
H23 -0.2349 1.0368 0.9138 0.012*  
C24 -0.1124 (5) 0.9557 (4) 0.7185 (3) 0.0099 (7)  
H24 -0.1262 0.9898 0.6389 0.012*  
C25 0.0766 (5) 0.9313 (4) 0.7071 (3) 0.0090 (7)  
C26 0.2191 (5) 0.8142 (4) 0.5963 (3) 0.0092 (7)  
C32 -0.1285 (5) 0.8149 (4) 0.7253 (3) 0.0112 (7)  
H32 -0.2529 0.8291 0.7420 0.013*  
C33 -0.0070 (5) 0.7236 (4) 0.5956 (4) 0.0111 (7)  
C36 0.4765 (5) 0.8558 (4) 0.6206 (4) 0.0164 (8)  
H36A 0.5702 0.7820 0.6373 0.025*  
H36B 0.3854 0.9126 0.7019 0.025*  
H36C 0.5261 0.9150 0.5657 0.025*  
C37 -0.0773 (5) 0.7417 (4) 0.8288 (4) 0.0125 (7)  
C38 0.0155 (5) 0.7808 (4) 0.8820 (4) 0.0121 (7)  
H38 0.0339 0.7394 0.9529 0.015*  
C39 0.0895 (5) 0.8848 (4) 0.8349 (3) 0.0108 (7)  
C40 -0.1291 (6) 0.6207 (4) 0.8636 (4) 0.0215 (9)  
H40A -0.2540 0.6484 0.8796 0.032*  
H40B -0.1096 0.5921 0.9411 0.032*  
H40C -0.0575 0.5424 0.7929 0.032*  
 
		
280 
Select Spectra: 
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Computational Models: 
3D models of spiro compounds 314 and 317. 
All structures were fully optimized by using Density Functional Theory (DFT) with the 
B3LYP/6-31G*.193 All calculations were carried out with the Dunning/Huzinaga valence 
double-zeta basis set for C, H and O atoms and a Hay-Wadt core potential.194 
 
Cartesian table:   
                    X                      Y                           Z 
C(1)         3.0840              -0.9190                 0.0030 
C(2)         1.4540              1.3910                 0.1320 
C(3)         1.6660              -1.0340                 -0.1120 
C(4)         3.6920              0.3270                 0.2060 
C(5)         2.8630              1.4470                 0.2610 
C(6)         0.8600              0.1370                 -0.0110 
C(7)         5.1910              0.4510                 0.3360 
C(8)         0.7040              2.7040                 0.1640 
C(9)         1.1060              -2.3510                 -0.3920 
C(10)         -0.6750           0.0220                            -0.0970 
C(11)         -0.3820           -2.4760                            -0.5920 
C(12)          -1.1570           -1.4560                             0.2460 
C(13)         -1.1480           0.3790                            -1.5270 
C(14)         -1.3340           0.8480                             1.0150 
C(15)         -2.6460           -1.6530                             0.1050 
C(16)         -3.4810           -1.8500                             1.1300 
C(17)         -4.9590           -2.0820                            1.0060 
C(18)         -2.3070           1.2520                            -1.6430 
C(19)         -2.8950           1.8090                            -0.5660 
C(20)         -4.0840            2.7120                            -0.5860 
H(21)         5.4900                0.8240                  1.3260 
O(22)         3.8840               -1.9910                  -0.0850 
H(23)         3.2860               -2.7760                   -0.2600 
O(24)         3.3950               2.6890                  0.4460 
H(25)         4.3590               2.6140                  0.5120 
H(26)         5.6610               -0.5230                  0.1980 
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H(27)         5.6150               1.1270       -0.4210 
H(28)         0.4340               3.0000      1.1860 
H(29)         -0.2090            2.6720                  -0.4350 
H(30)         1.3280               3.5010        -0.2470 
O(31)         1.8100               -3.3740       -0.4940 
H(32)         -0.6770           -3.4940                  -0.3220 
H(33)         -0.5950           -2.3410                  -1.6600 
O(34)         -0.9970            0.8120                   2.1660 
O(35)         -0.5820           -0.0970                  -2.5030 
H(36)         -0.8850           -1.5930                  1.2980 
H(37)         -3.0390           -1.6630                  -0.9130 
H(38)         -3.0780           -1.8480                  2.1450 
H(39)         -5.5260           -1.3210                  1.5580 
H(40)         -5.2430           -3.0540                  1.4330 
H(41)         -5.2840           -2.0610                   -0.0390 
O(42)         -2.4510           1.6190                  0.7130 
H(43)         -2.6830           1.4560                  -2.6390 
H(44)         -4.8930           2.2810                  0.0150 
H(45)         -4.4400           2.8690                 -1.6070 
H(46)         -3.8310           3.6810                 -0.1390 
 
 
 
Cartesian table: 
                  X                Y                  Z 
 
C(1)          3.0730         -0.9500            -0.0010 
C(2)          1.5020         1.3990                0.1390 
C(3)          1.6530         -1.0280            -0.1090 
C(4)          3.7140         0.2800                0.1970 
C(5)          2.9140         1.4200               0.2530 
C(6)          0.8740         0.1610                0.0030 
O(7)          3.8440         -2.0430            -0.0950 
H(8)          3.2260         -2.8110            -0.2690 
O(9)          3.4760         2.6500                0.4270 
H(10)          4.4390         2.5520                0.4900 
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C(11)          5.2160         0.3670                0.3190 
H(12)          5.6600         -0.6220             0.1980 
H(13)          5.5300         0.7510                1.3000 
H(14)          5.6550         1.0170                -0.4530 
C(15)          0.7930         2.7340                0.1820 
H(16)          0.6060         3.0640                1.2110 
H(17)          -0.1650         2.7170                -0.3410 
H(18)          1.4100         3.5000                -0.2950 
C(19)          1.0610         -2.3230            -0.4190 
O(20)          1.7340         -3.3660            -0.5250 
C(21)          -0.6670         0.0880                -0.0240 
C(22)          -0.4260         -2.3910            -0.6490 
H(23)          -0.7560         -3.4140            -0.4450 
H(24)          -0.6230         -2.1870            -1.7100 
C(25)          -1.1760         -1.3970            0.2420 
H(26)          -0.8950         -1.5830            1.2850 
C(27)          -2.6680         -1.5760            0.1070 
H(28)          -3.0830         -1.4610            -0.8960 
C(29)          -3.4780         -1.9220            1.1110 
H(30)          -3.0550         -2.0460            2.1090 
C(31)          -4.9550         -2.1590            0.9840 
H(32)          -5.5210         -1.4780            1.6320 
H(33)          -5.2200         -3.1790            1.2930 
H(34)          -5.2990         -2.0170            -0.0460 
C(35)          -1.1620         0.5050               -1.4100 
C(36)          -1.2960         0.8910                1.1440 
O(37)          -0.8510         0.7740                2.2750 
C(38)          -2.4720         1.6940                0.8370 
H(39)          -2.9710         2.1890                1.6620 
C(40)          -2.9400         1.8250                -0.4170 
O(41)          -2.3360         1.2450                -1.5050 
O(42)          -0.6410         0.1830                -2.4430 
C(43)          -4.1430         2.6040                -0.8330 
H(44)          -4.6230         3.0710                0.0290 
H(45)          -4.8640         1.9470                -1.3330 
H(46)          -3.8620         3.3810                -1.5540 
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Chapter 5 
Studies Toward the Total Synthesis of Diaporine 
 
5.1 Introduction  
 
Figure 5.1 Naphthopyranone Natural Products. 
         Naphthopyranone natural products are widely dispersed in nature, and typically 
possess a 1H-naphtho-[2,3-c]pyran-1-one core structure (Figure 5.1). These polyketide 
natural products have been isolated from a variety of sources including fungi, bacteria, 
lichens, and plants. For example, the atropisomeric compound pigmentosin A (349) is a 6, 
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6’-binaphthopyranone obtained from the lichen Hypotrachyna immaculate.195 The recent 
stereoselective synthesis of pigmentosin A (349) has established the absolute 
stereochemistry as shown in Figure 5.1.196 More commonly, these dimeric compounds 
feature an 8, 8’-binaphthopyranone core structure such as that found in xanthomegnin 
(348).197 Structurally, compound 348 is related to floccosin (347), which was isolated 
from Epidermophyton floccosum as an optically active compound.198  Several other 
molecules (e.g. xylindein (351)199  and viopurpurin (352)200) also feature novel dimeric 
structures, wherein the two monomeric units are additionally connected through aryl 
ether bonds. Interestingly, a trimeric molecule PF1158A (350) composed of three 
semivioxanthin moieties was isolated from Geosmithia argillacea. PF1158A shows 
striking antibiotic and antitumor biological properties (MIC = 0.39 µg/mL against 
Staphylococcus aureus; IC50 =46 ng/mL against P388 cells).201  
Comparing to other naphthopyranone nature products, diaporine (84) is unusual in 
that it possesses an isomeric naphthopyran-4-one (γ-pyrone) structure. It also contains a 
novel epoxyquinol dimer framework; the absolute configuration was determined by X-
ray crystallographic analysis (Figure 5.2). Initial biological studies show that this 
compound can alter the phenotype of tumor-associated macrophages (TAM's) from the 
M2 (anti-inflammatory) to the M1 (cell killing) phenotype. The compound also inhibits 
proliferation of non-small cell lung cancer (NSCLC) cells by upregulating microRNA 
(miR-99a) expression.202   
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Figure 5.2 Diaporine X-ray structure. 
5.2 Proposed Biosynthesis and Retrosynthetic Analysis of Diaporine  
         The biosynthesis of aurofusarin (353) and diaporine (84) was studied by Frandsen 
and coworkers.203 Gene replacement studies revealed that a 25 kb gene cluster containing 
PKS12, aurJ, aurF, gip1, and FG02329.1 was responsible for the synthesis of the 
pigment aurofusarin (353). As depicted in Scheme 5.1, one acetyl-CoA and six malonyl-
CoA units condense to form a linear heptaketide 354 via a PKS12-catalyzed reaction (cf. 
Figure 1.7). PKS12 is then activated as a Claisen cyclase to fold ketide 354 into nor-
rubrofusarin (355). AurJ-mediated methylation of 355 with a SAM cofactor afforded 
rubrofusarin (356). The flavin-dependent monooxygenase (AurF) catalyzed oxidation of 
356 to introduce a hydroxyl group at the 9 position may result in the production of 9-
hydroxyrubrofusarin (357). Previously, Kim and coworkers204 showed that a putative 
laccase type gene Gip1 is responsible for oxidative dimerization of 357 to form 
aurofusarin precursor 358. Finally, 358 may be oxidized to produce aurofusarin (353) via 
an AurO-mediated transformation. The biosynthesis of diaporine is not well understood; 
however the compound is likely derived from aurofusarin (353) via epoxidation and 
reduction catalyzed by a P450 or a laccase-type enzyme. 
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Scheme 5.1 Biosynthesis of Aurofusarin and Diaporine 
         Inspired by these biosynthetic studies, we envisioned that diaporine (84) could be 
accessed through selective reductions of 359 (Scheme 5.2). The cis bis-epoxide moieties 
may be installed by double epoxidation. At this time, it is not certain whether aurofusarin 
(353) is a chiral molecule at room temperature (cf. Scheme 5.18). It is interesting to note 
that the optical rotation of the natural sample was reported as [α]D26 = 0º. If 353 is an 
axially chiral natural product, we may be able to conduct axial-point chirality transfer205 
to synthesize the enantioenriched epoxide (359). The atropisomer 353 could be prepared 
from 358 (cf. Scheme 5.1), which in turn may be synthesized through dimerization of 9-
hydroxyrubrofusarin (357). 
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Scheme 5.2 Retrosynthetic Analysis of Diaporine 
 
5.3 Related Syntheses   
          The synthesis of hibarimicinone (368) was achieved around the same time by 
Shair (Scheme 5.3),206 and Tatsuta207 and coworkers. In Shair’s synthesis, they first 
performed regioselective ortholithiation of 360 and subsequent FeCl3-mediated oxidative 
dimerization to prepare biaryl compound 361. This compound was then brominated and 
lithium−halogen exchanged followed by acylation to afford the bis-ortho-toluate 362.  A 
single aryl methyl group was selectively lithiated and then brominated with (BrCF2)2 to 
give a derived benzyl bromide, which was latter oxidized by DMSO/NEt3 to the aldehyde. 
Following protecting group manipulation, aldehyde 363 was prepared in 53% yield over 
5 steps. Treatment of 363 with acetone cyanohydrin under basic conditions afforded a 
cyanophthalide, which was then converted to phenyl sulfide intermediate 364 in 69% 
yield over 2 steps using LiTMP and S-phenyl benzenethiosulfonate. Double 
Michael−Claisen reaction sequences were performed by treating 364 and enantiopure 365 
with LiHMDS to construct the core structure of hibarimicinone, followed by elimination 
of the C6-benzylic phenyl sulfide to afford (‒)-366 and its atropisomer in 50% combined 
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yield and about 1 : 1 d.r. The desired atropisomer 366 was then isolated and subsequently 
oxidized by DDQ, and treated with dry HCl to produce compound 367 in 77% yield over 
Scheme 5.3 Synthesis of Hibarimicinone 
 
2 steps. After global deprotection and oxidation under air, hibarimicinone (368) was 
prepared in 81% yield over 3 steps. Interestingly, it was found that the axial chirality of 
this molecular was dependent on both temperature and pH. The two atropisomers started 
to interconvert at 65 ºC or at pH values above 7.5. The proposed isomerization pathway is 
depicted in Scheme 5.4. The phenol moiety was proposed to be crucial for the 
isomerization. Even under slightly basic conditions, 370 and 371 can to be deprotonated 
to form intermediates 372 and 373, respectively, which can further tautomerize to either 
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374 or 375 and cause racemization. Interestingly, it was found that high temperatures (65 
ºC) could also initiate the interconversion of 368 and 369 (cf. Scheme 5.3) through the 
proposed deprotonation pathway (Scheme 5.4) rather than overcoming the necessary 
thermal energy to surpass the intrinsic activation barrier. This research finding solidifies 
our speculation about the possible chirality of aurofusarin (353) at room temperature (cf. 
Scheme 5.2). 
Scheme 5.4 Axial Chirality 
 
           Synthesis of natural products with 1H-naphtho-[2,3-c]pyran-1-one structure 
including semi-vioxanthin (385) have been achieved primarily through the Staunton–
Weinreb annulation.208 Müller and coworkers have been studying the biosynthesis of 
these natural products209 and they disclosed their total synthesis of semi-vioxanthin (385) 
in 2001. Starting from tert-butyl 3,5-dioxohexanoate (376), the investigators prepared 
optically pure R-377 using a regio- and stereoselective enzymatic reduction followed by 
acid-promoted lactonization. Compound 377 was methylated to afford R-378 in 53% 
yield. In a parallel synthesis, S-78 was prepared beginning with the Claisen condensation 
of tert-butyl acetate (379) followed by a similar cyclization sequence. Both R-378 and S-
378 were subjected to Staunton annulation conditions with 2,4-dihydroxy-6-
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methylbenzoate 379, and (R)- and (S)-semi-vioxanthin were prepared respectively after 
deprotection of the BOM group. However, this Staunton annulation strategy only 
provided a 27% yield of the desired 1H-naphtho-[2,3-c]pyran-1-one core structure.  
Scheme 5.5 Synthesis of a Monomeric 1H-naphtho-[2,3-c]pyran-1-one  
       
            White and coworkers disclosed their synthesis to achieve a scaffold similar to 
semi-vioxanthin using a regiocontrolled Diels-Alder reaction (Scheme 5.6a). Treatment 
of 2,5-dichlorobenzoquinone (386) with diene 387 under thermal conditions resulted in 
the Diels-Alder cycloaddition, which afforded compound 388 after elimination in 16% 
yield. Displacement of the chlorine substituent in 388 by methoxide afforded 389 in 64% 
yield. Finally, the methyl group was selectively removed using BCl3, which also 
promoted cleavage of the TBS group and subsequent lactonization to afford R-
semixanthomegnin (390) in 73% yield.  
        There is no reported total synthesis of xanthomegnin (348), the dimer of semi- 
xanthomegnin, to date. Holst and coworkers reported a formal synthesis of 348 as 
depicted in Scheme 5.6b.210 They first isolated semi-vioxanthin (385) from Trichophyton 
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megnini. Treatment of 385 with Fremy’s salt yielded semixanthomegnin (390), which 
was then demethylated using AlCl3. Monomer 391 was subjected to an oxidative 
dimerization with potassium persulfate  under  basic  conditions  to  produce  the  dimeric 
Scheme 5.6  Syntheses of Semixanthomegnin and Xanthomegnin 
 
compound 392. Methylation of 392 with CH2N2 gave a 1: 1 mixture of xanthomegnin 
(348) and its atropisomer. The 1H NMR spectra of both atropisomers highly overlapped; 
only the phenol protons appearing at 13.15 ppm and 13.13 ppm, respectively, were 
resolved. This result indicates that the two atropisomers of 2 are measurable on the NMR 
timescale under ambient conditions, which could indicate that bis-naphthoquinones such 
as aurofusarin (353) may possess axial chirality. 
            Beside oxidative dimerization to construct this type of dimeric compound,  Müller 
		
309 
and coworkers demonstrated that the biaryl bond can be made first,209b followed by a 
double Staunton annulation to prepare the natural product vioxanthin (397) (Scheme 5.7). 
They commenced their synthesis with the oxidative dimerization of compound 393 via an 
Fe(III)-mediated coupling reaction. The resulting racemic biaryl compound 394 was 
resolved using a camphanic derivative, followed by methylations to give optically pure 
compound 395. A double Stanton annulation of 395 was performed with lactone R-378 
under LDA-mediated conditions. After demethylation with BBr3, vioxanthin (397) was 
produced in only 2% yield over 2 steps. Regardless, this synthesis served to confirm the 
absolute configurations of the natural product vioxanthin (397).  
Scheme 5.7 Asymmetric Synthesis of Vioxanthin 
 
             Compared to the synthesis of naphthopyranones with the 1H-naphtho-[2,3-
c]pyran-1-one core structure, the synthesis of isomeric naphthopyran-4-one (γ-pyrone) 
natural products such as aurofusarin (353) and diaporine (84) are much more challenging 
due to their unstable properties. Staunton annulations have been found unsuccessful 
towards achieving the desired naphthopyran-4-one structure. As shown in Scheme 5.8, 
when γ-pyrone 399 was treated with 398 under LDA-mediated conditions, ring opening 
product 400 was observed after the first Michael addition. Compound 400 could be 
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converted to the naphthol compound 401 via a Claisen condensation and subsequent 
aromatization.  
Scheme 5.8 Attempted Synthesis of Naphthopyran-4-one via Staunton Annulation 
 
            The first synthesis of a naphthopyran-4-one compound, rubrofusarin dimethyl 
ether (409), was achieved by Arima and coworkers using an 8 step linear sequence.211 
Starting from the commercially available benzoic acid 402, a three step Arndt-Eistert 
synthesis was performed to prepare 3,5-dimethoxyphenyl acetic acid 403. Treatment of 
403 with PCl3 led to acyl chloride 404 which was then reacted with acetate 405 in 
presence of Mg to afford compound 406. On vacuum distillation of 406, 407 was 
produced in 16.5% yield (from 404). Naphthalene derivative 407 was then subjected to a 
Claisen condensation with ethyl acetate under NaH-mediated conditions; after acidic 
work up the core naphthopyran-4-one structure was obtained. Subsequent methylation 
with CH2N2 produced rubrofusarin dimethyl ether (409) in 19% yield (from 406). To 
date, there is limited information on efficient syntheses of other naphthopyran-4-ones 
reported. The synthetic challenge as well as intriguing biological activities of the 
complex dimer diaporine underscore this compound as an attractive target. 	  
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Scheme 5.9 Synthesis of Naphthopyran-4-one Compound 
 
5.3 Results   
             Since Staunton annulations have failed in the synthesis of naphthopyran-4-ones, 
we decided to employ a Hauser annulation strategy.212 Specifically, we synthesized 
amide 410 from the corresponding benzoic acid,207 which was then treated with s-BuLi; 
the resulting aryl lithium was quenched by DMF to result in benzaldehyde 411 (Scheme 
5.10).  
Scheme 5.10 Attempt to Access a Naphthopyran-4-one via Hauser Annulation 
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Benzaldehyde 411 was then reduced with NaBH4, followed by acidic work up to produce 
phthalide 412 in 37% yield. 2H-Pyran-4-one 416 was then prepared in 91% yield through 
a hetero Diels-Alder reaction between diene 415 and acetaldehyde.213 
            With both reaction partners in hand, we screened conditions for the [4+2] 
cycloaddition. Deprotonation of phthalide 412 with various lithium bases (e.g. LDA, 
LiHMDS) afforded lithium dienolate 417, which was then added to a solution of pyrone 
416. However, no new productd were observed in these reactions, and both starting 
materials were recovered. To increase the reactivity of phthalide 412, we next made the 
corresponding TMS isobenzofuran 418 in situ as indicated by 1H NMR, which was 
followed by the addition of pyrone 416. After acidic work up, only phthalide 412 and 
pyrone 416 were isolated.  
              We next proposed a synthesis of the monomer 9-hydroxyrubrofusarin (357) 
through a Michael-Dieckmann tandem reaction (Scheme 5.11). Instead of employing a 
benzyl anion-mediated Michael addition (cf. Scheme 5.3, Scheme 5.5, Scheme 5.7), we 
envisioned that substrate 419 for Dieckmann condensation could be prepared from a 
Michael addition between quinone 420 and dienolate 421. Compound 421 might be 
accessed from the symmetrical dimethyl pyrone 422. However, the synthesis of 421 
remained challenging considering the sensitive properties of such structures.  In addition, 
there were no reported examples of deprotonation of 422 to the best of our knowledge.  
Scheme 5.11 Retrosynthetic Analysis of 9-Hydroxyrubrofusarin (357) 
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               Initially, we tried LDA-mediated deprotonation of 422, followed by addition of 
TBSCl to the resulting solution to prepare dienolate 421. A number of other bases were 
also screened, however all these conditions lead to decomposition of 422. We next sought 
to activate pyrone 422 first, then deprotonate under milder conditions.  We envisioned 
that pyrone 422 has a resonance zwitterion intermediate 423. We proposed that 423 could 
be trapped by a strong Lewis acidic reagent such as TBSOTf to afford activated pyrone 
424, which could be deprotonated under mildly basic conditions with pyridine or the 
sterically bulky base 2,6-lutidine.214 Accordingly, treatment of 422 with TBSOTf at 60 ºC 
resulted in the precipitation of a white solid. Comparison of the 1H NMR spectra of 422 
and 424 (Scheme 5.12) shows downfield shifts for both vinylic C-H and methyl proton 
signals. We next treated 424 with 2,6-lutidine, followed by the addition of quinone 420. 
The resulting solution was stirred at -30 ºC for two hours, which  was  then  quenched  by  
Scheme 5.12 Activation of Pyrone 422 
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addition of tetra-N-butylammonium fluoride (TBAF). Surprisingly, the benzofuran 426 
was isolated instead of the desired Michael adduct 419 (Scheme 5.13). Apparently, the 
pyrone moiety was opened during the reaction. We proposed that after the first Michael 
addition, intermediate adduct 427 may be obtained. Under fluoride-mediated conditions, 
the TBS group was then removed to produce phenolate 428 after tautomerization. An 
oxa-Michael cyclization of 428 then leads to spiro compound 429, which may undergo 
elimination and deprotonation to yield side product 426.  
Scheme 5.13 Michael Addition between 420 and 422 
 
            To avoid unwanted phenolate intermediates such as 428, we decided to work up 
the reaction with acidic conditions. We observed that quenching the above reaction with 
1N HCl resulted in the production of the desired Michael adduct 419 in 38% yield as well 
as the double Michael addition product 431 in 33% yield. Previously, we noticed that 424 
and deprotonated intermediate 425 can equilibrate, and tautomer 424 dominated in CDCl3 
solution. Therefore, we optimized the reaction by slowly adding quinone 420 into a 
mixture of TBSOTf, 2,6-lutidine and pyrone 422 at -30 ºC. By doing so, the yield of the 
desired product 419 was improved to 75%.  
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With the Michael adduct in hand, we attempted protection of substrate 419. Ideally, 
we sought to prepare compound 434 for Dieckmann condensation (Scheme 5.15). Mono  
Scheme 5.14 Michael Addition between 420 and 422 
 
methylation of compound 419 to prepare 432 was attempted under numerous conditions, 
and among all the conditions screened, some double methylation to 433 seemed 
unavoidable. Optimal results were obtained using K2CO3 and MeI to afford 432 in 67% 
yield as well as 18% yield of the doubly methylated compound 433. Unfortunately, the 
separation of 432 and 433 was unsuccessful using various chromatography techniques. 
Using a mixture of 432 and 433 for the next step (MOM protection) also resulted in 
inseparable product mixtures. In order to prepare pure compound for the key Dieckmann 
condensation, Michael adduct 419 was fully converted to double methylation product 433 
in 88% yield. Consequently, 433 was then selectively demethylated using BCl3 to afford 
desired compound 422 in 85% yield. This compound was further converted to the MOM 
ether 434 using MOMCl and NaH in 89% yield.  	  
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Scheme 5.15 Protection of Michael Adduct 419 
 
               Next, we evaluated the proposed Dieckmann condensation on substrate 434 
using a number of bases (Table 5.1). No reaction was observed in conditions with 
LiHMDS (entry 1), which indicated that the desired deprotonation may require bases 
with higher pKa. However, metal alkoxide bases (entries 2, 3) with lower pKa caused 
severe degradation of the starting material. Presumably, a nucleophilic base such as 
NaOMe added to the pyrone moiety in 434 leading to decomposition. To our delight, 
conditions with LDA produced an approximate 30% yield of desired product 437 (entry 
4). We speculated that the very electron rich aromatic system of metal phenoxide 
intermediate 436 may react with trace amounts of O2 in the reaction solution, which may 
decrease the overall yield. Accordingly, use of carefully degassed solvent for this reaction 
led to an increase in yield for 437 to 77%. Conditions with bulkier bases such as LiTMP 
led to decreased yield (entry 5). In addition, ZnTMPCl·LiCl was also found to be 
inefficient in this Dieckmann condensation (entry 6).  
 
 
		
317 
Table 5.1 Dieckmann Condensation of 434 
 
entry base Temp. yield% a 
1 LiHMDS -78 ºC to -20 ºC No reaction 
2 KtBuO -78 to 0 ºC 30% 434 recovered 
3 NaOMe -78 to 0 ºC complex mixture 
4 LDA -78 ºC 77% 
5 LiTMP -78 ºC 56% 
6 ZnTMPCl·LiCl -20 ºC complex mixture 
a Isolated yield determined using purified 437. 
We next performed a methylation on compound 437 with Cs2CO3 and dimethyl 
sulfate (Me2SO4). Similar to our LDA-mediated Dieckmann condensation (cf. Table 5.1 
entry 4), higher yields were obtained after degassing the acetone solvent used in the 
methylation reaction. Treatment of 438 with TFA in dichloromethane led to the desired 
monomer 439 for dimerization reactions.  
Scheme 5.16 Synthesis of Compound 439 
                 
            Inspired by the biosynthesis study of aurofusarin (cf. Scheme 5.1) in which the 
dimerization reaction was shown to be catalyzed by Gip1, which is a copper-associated 
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enzyme, we proposed to mimic this process using metal-mediated conditions. 
Presumably, a metal catalyst could undergo ligand exchange with compound 439, 
followed by an intramolecular single electron transfer to afford complex 440. A 
sequential radical addition and further oxidization would result in the desired dimeric 
compound 441. Accordingly, we initiated our dimerization screening using copper salts 
with diamine ligands, which have been widely used in biaryl coupling reactions.215 
However, most of these conditions led to the production of the quinone monomer 442 
instead of the desired dimeric compound 441 (entry 1). Other single electron oxidation 
metal catalysts such as NH4VO3 (entry 2),216 FeCl3 (entry 3),217 SnCl4 (entry 4)218 and 
Ag(CO2CF3) (entry 5)207 were also evaluated. Unfortunately, no desired product was 
observed in those conditions.  
Table 5.2 Oxidative Dimerization of 439 
 
entry condition result  
1 20 mol% Cu(OH)Cl•TMEDA, O2, DCE, rt to 40 °C 43% yield of 442 
2 1.3 equiv NH4VO3, HClO4, water/aceteon, reflux decomposition 
3 1. 1 equiv FeCl3 on silica gel, MeNO2, rt complex mixture 
4 1.2 equiv SnCl4, or TiCl4, O2, DCE, 50 °C 22% yield of 442 
5 1.2 equiv Ag(CO2CF3), NEt3, DCE, 40 °C complex mixture 
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           We envisioned that the electron rich aromatic system in 439 would increase the 
pKa of the phenol proton, which may decrease the ligand exchange rate to form metal 
complex 440. Accordingly, we decided to synthesize the silyl ether-linked dimer 442. 
Treatment of monomer 439 with diisopropyl silyl dichloride and triethylamine in CH2Cl2 
led to the production of the desired compound 443 successfully (Scheme 5.17). 
Compound 443 was then subjected to oxidative coupling reaction conditions mediated by 
excess amounts of FeCl3.219 To our delight, aurofursarin methyl ether 444 was directly 
accessed, although in only 13% yield. In order to improve the yield, we decided to use 
milder dehydrogenative coupling conditions.220 Initially, we tried stoichiometric amounts 
of Pd(OAc)2 in DMSO at 70 ºC, and under these conditions a 44% yield of the desired 
dimeric compound 441 was obtained as a major product as well as other side products. 
More interestingly, monomer 439 was directly converted to dimer 441 directly in 54% 
yield under similar conditions. However, to achieve full conversion, stoichiometric 
amount of Pd(OAc)2 is necessary in this transformation.  
Scheme 5.17   Synthesis of Compound 441 
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             Encouraged by these promising results, we decided to develop a catalytic 
reaction. We screened a number of ligands to help turn over the Pd catalyst. Yu and 
coworkers have demonstrated that monoprotected amino acids can be utilized as chiral 
ligands in asymmetric C−H bond activation. 221  We evaluated different types of 
monoprotected amino acids with catalytic amounts of Pd catalyst. To our delight, the 
combination of simple N-acetyl-L-leucine and catalytic amount of Pd(OAc)2 led to good  
Table 5.3  Dehydrogenative Coupling of 439 to 441 
 
entry ligand solvent temp. time yielda (conv.b) 
1 Ac-L-Leu-OH DMSO 70 ºC 4 h 77% (100%) 
2 Ac-L-Leu-OH DCE 70 ºC 24 h 35% (47%) 
3 Ac-L-Leu-OH DMA 70 ºC 4 h decomposed 
4 Ac-L-Leu-OH DMSO 50 ºC 12 h 35% (60%) 
5 Boc-L-Pro-OH DMSO 70 ºC 14 h 28% (41%) 
6 Boc-L-Val-OH DMSO 70 ºC 12 h 48% (81%) 
7 box (95) DMSO 70 ºC 20 h 54% (70%) 
8 box (96) DMSO 70 ºC 20 h 41% (68%) 
9 none DMSO 70 ºC 20h  23% (30%) 
aIsolated yield determined using purified 441. bConversion determined by 1H NMR 
integration. 
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yields of dimer 441 after heating at 70 ºC for only 4 h (entry 1). We next evaluated 
solvent effects, which showed that dry DMSO provided optimal results. Conditions with 
halogenated solvents such as DCE (entry 2) provided much lower reactivity. Surprisingly, 
reaction with N,N-dimethylacetamide (entry 3) did not afford any desired product under 
similar conditions. Lower reaction temperatures (entry 4) led to substantially decreased 
reactivity. Other monoprotected amino acids as ligands were found to be less effective for 
this transformation (entries 5-6). Other types of bidentate ligands were also evaluated 
such as C2-symmetric bis(oxazoline) (box) ligands (entries 7-8). After reacting for much 
longer times (20 h), significant amounts of starting material were still observed in the 
reaction mixture. Control experiments (entry 9) showed that the ligand is crucial for the 
catalyst turnover. To our surprise, all these reactions with chiral ligands did not provide 
any enantioselectivity.  
           Before synthesizing aurofusarin or its derivatives, we studied the epoxidation on 
the model bis-quinone compound 450 (Scheme 5.18). The commercially available 
hydroxynaphthoquinone 448 was subjected to the ammonium persulfate-mediated 
oxidative coupling conditions222 which afforded the dimeric compound 449 as a brown 
solid in 52% yield. Subsequent methylation with TMSCHN2 then afforded model bis-
quinone 450.  Interestingly, the two atropisomers of 450 could be separated using chiral 
HPLC. This fact indicates that the bis-quinone structure (cf. aurofusarin 353) might be 
atropisomerically stable at room temperature. However, further experiments (dynamic 
NMR or HPLC) are needed to confirm this speculation. Several nucleophilic epoxidation 
conditions (Na2CO3/H2O2, NaBO3 etc.) were evaluated. Optimal results were observed 
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when NaOCl223 was used as an epoxidation reagent in MeCN as solvent, which afforded 
a 78% yield of the desired cis-epoxide 452 as a single diastereomer. As depicted in model 
assembly 451, the back and bottom faces of this compound are blocked by methoxy 
groups, leading to epoxidations from the front and top faces to afford product 452. The 
relative stereochemistry of 452 was also unambiguously confirmed by X-ray 
crystallographic analysis (Scheme 5.18).  
Scheme 5.18 Synthesis of Model Compound 452 
 
            Encouraged by these promising results, attentionnext turned to prepare the 
aurofusarin bis-epoxide 359. Treatment of biaryl 441 with CAN led to bis-
naphthoquinone 444 in 88% yield. Synthesis of the natural product aurofusarin was 
achieved on a gram scale by demethylation of 444 (78% yield). Direct epoxidation of 
aurofusarin (353) using various conditions all led to severe decomposition. Accordingly, 
aurofusarin acetate 453 was then considered as an ideal intermediate for the epoxidation. 
Acetylation of aurofusarin (353) with an excess amount of AcCl and pyridine allowed 
access to the relatively more stable intermediate 353, which was then subjected to phase 
transfer epoxidation conditions to afford bis-epoxide 454 in 77% yield. Deacetylation of 
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454 eventually delivered the requisite aurofusarin epoxide 359.  
Scheme 5.19 Synthesis of Compound 359 
 
            With the advanced bis-epoxide compound 359 in hand, we attempted several 
hydroxyl-directed reductions (Scheme 5.20). Representative reagents such as 
NaB(OAc)3H224 and B(OMe)Et2225 with NBu4BH4  gave complex product mixtures and 
no desired diaporine natural product was observed. (+)-B-
Chlorodiisopinocampheylborane226 and trichlorosilane227 were also examined, which did 
not afford any of the desired reduced product. In addition, Meerwein–Ponndorf–Verley 
type reductions led to severe decomposition of 359.  
Scheme 5.20 Attempted Reduction 
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5.5 Summary and Future Outlook      
             In summary, we have developed an efficient annulation involving pyrone 
addition to a quinone for rapid assembly of the γ-naphthopyrone core structure. 
Dimerization of a γ-naphthopyrone monomer was achieved through a novel Pd(II)-
mediated dehydrogenative coupling wherein a simple mono-protected amino acid was 
found to be a suitable ligand for development of catalytic reaction. In addition, 
diastereoselective epoxidation was conducted on a complex bis-naphthquinone structure 
to form the requisite bisepoxide molecule.  
Attempts at a proposed hydroxyl-directed reduction to produce diaporine (7) 
have currently been unsuccessful. Alternatively, we have considered a one-pot reaction to 
generate diaporine (84) from aurofusarin (353). It has been reported that enone double 
bonds can be hydrated using Mn(dpm)3, PhSiH3 and oxygen (Scheme 5.21).228 Under 
reductive condition, Mn(dpm)3 would be reduced to Mn(dpm)2 which will further react 
with O2 to form Mn peroxide species 457. Reactive 457 could add into the enone 455 
double bound to generate intermediate 458, followed by hydrogen abstraction to afford 
peroxide 459. Upon reduction of 459, the hydration product 456 could be formed. 
Inspired by this interesting radical mediated mechanism, we proposed that treatment of 
aurofusarin (353) with a transition metal (e.g. Co(dpm)3, Mn(dpm)3, Fe(dpm)3) and a 
silane (e.g. PhSiH3) under oxygen may result in diaporine in one pot. Initially, a Co(II) 
catalyst could complex with oxygen and react with aurofusarin (353) to form the radical 
intermediate 460 which is similar to the intermediate proposed in the Mukaiyama 
hydration mechanism.  
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Scheme 5.21 Mukaiyama Hydration and the Mechanism 
 
Scheme 5.21 Mukaiyama Hydration and Proposed One-pot Synthesis of Diaporine 
from Aurofusarin 
 
Hydrogen abstraction from silane would lead to the formation of enol 461, followed by 
epoxidation to afford protonated epoxide dimer 462. Intermediate 462 could be further 
reduced by excess silane to afford the desired natural product diaporine (84). Finally, the 
Co(III) species could be reduced by silane and reenter the catalytic cycle.229  
            The chirality of aurofusarin (353) or its methyl ether derivative (441) requires 
further evaluation.  Dynamic chiral HPLC studies would allow for determination of the 
half-life of bis-quinone atropisomers. Alternatively, we will derivatize the racemic 
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mixture of compound 441 with chiral reagents to afford derivatives such as camphanate 
diastereomers 463,207 which may be separated and treated with our previous oxidative 
conditions to form the enantioenriched bis-naphthquinone 444. The chirality of 444 may 
be investigated by measuring the optical rotation of 444 in solution. Finally, asymmetric 
dehydrogenative dimerization to access chiral, non-racemic biaryl 441 may be studied. 
Further exploration of chiral ligands (cf. Chapter 4, Scheme 4.15) will be conducted to 
enable asymmetric dimerization of monomer 439. 
Scheme 5.22 Proposed Resolution of Chiral, Racemic Biaryl 441 
 
5.6 Experimental Section     
General Information 
A. Instrumentation and methods 
 
1H NMR spectra were recorded at 400 or 500 MHz at ambient temperature with CDCl3 
(Cambridge Isotope Laboratories, Inc.) as the solvent unless otherwise stated. 13C NMR 
spectra were recorded at 100 or 125 MHz at ambient temperature with CDCl3 as the 
solvent unless otherwise stated. Chemical shifts are reported in parts per million relative 
to CDCl3 (1H, δ 7.26; 13C, δ 77.16). Data for 1H NMR are reported as follows: chemical 
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shift, integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet) and coupling constants. All 13C NMR spectra were 
recorded with complete proton decoupling. Infrared spectra were recorded on a Nicolet 
Nexus 670 FT-IR spectrophotometer. High-resolution mass spectra were obtained at the 
Boston University Chemical Instrumentation Center using a Waters Q-TOF mass 
spectrometer. Melting points were recorded on a Mel-temp apparatus (Laboratory 
Devices). Analytical liquid chromatography was performed using a Waters ACQUITY 
UPLC® system equipped with PDA, ELS, and SQ detectors. Analytical thin layer 
chromatography (TLC) was performed using 0.25 mm silica gel 60-F plates (Silicycle, 
Inc.). Flash chromatography was performed using 200-400 mesh silica gel (Sorbent 
Technologies, Inc.). Preparative TLC was conducted with glass backed 250 µm or 1000 
µm silica gel 60-F plates (Silicycle, Inc.). Preparative HPLC was conducted using a PLC 
2020 Personal Purification System (Gilson, Inc.). Yields refer to chromatographically and 
spectroscopically pure compounds, unless otherwise stated. Thermolyses were conducted 
in Teflon® capped, heavy wall sealed vials (Chemglass CG-1880, 15 mL or CG-4920-01 
Complete Package) to minimize solvent/reagent evaporation. All other reactions were 
carried out in oven-dried glassware under an argon/nitrogen atmosphere unless otherwise 
noted. The Scilligence Electronic Laboratory Notebook (Scilligence, Corp.) was used for 
experimental procedure planning.  
B. Chemical reagents and solvents 
HPLC grade tetrahydrofuran, methylene chloride, diethyl ether, toluene, acetonitrile, and 
benzene were purchased from Fisher and VWR and were purified and dried by passing 
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through a PURE SOLV® solvent purification system (Innovative Technology, Inc.). 
Anhydrous 1,2-dichloroethane (DCE), chlorobenzene, and acetone from Aldrich were 
degassed using freeze-pump-thaw cycles. Reagents were purchased from Strem, Aldrich, 
Acros, TCI America, Indofine, and Alfa Aesar and were used as received.   
Experimental Procedures and Compound Characterization 
 
Quinone methyl ester 420: To 100 g of silica gel in a 500 mL beaker was added 20 mL 
of a hot water solution of cerium ammonium nitrate (40 g, 74.3 mmol). The resulting 
mixture was then mixed until the silica gel became free-flowing. To this freshly prepared 
CAN on silica gel reagent was added 300 mL of CH2Cl2; the suspension was then 
vigorously stirred and cooled down to 0 ºC. 20 mL of a CH2Cl2 solution of benzoic 
methyl ester 464 (8.0 g, 34.4 mmol) was slowly added to the stirred CAN/silica gel and 
CH2Cl2 mixture. The resulting solution was allowed to warm to room temperature and 
further stirred for 40 min. The filtrate was then washed with water (3 × 200 mL) and 
brine (300 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated 
under reduced pressure. The product was further azeotropically dried with three portions 
of benzene. Finally 5.61 g of the pure quinone methyl ester 420 was produced (28.6 
mmol, 81% yield). Spectra of 420 are in agreement with those reported in the 
literature.230 
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Benzofuran 426: To a stirred solution of pyrone 422 (1.14 g, 9.18 mmol, 0.9 equiv) in 
CH2Cl2 (30 mL) at –78 ºC was added TBSOTf (3.71 mL, 20.39 mmol, 2.0 equiv) and 
2,6-lutidine (2.37 mL, 20.39 mmol, 2.0 equiv) slowly. After 30 min, a CH2Cl2 solution of 
quinone 420 (2.02 g, 10.20 mmol, 1.0 equiv) was added under Ar at –30 ºC over 3 h. 
After completion, the resulting purple solution was stirred for an additional 30 min. 
Finally the reaction mixture was quenched by adding NEt3·3HF (3.38 mL, 20.39 mmol, 
2.0 equiv) and stirred for 30 min. The reaction mixture was then diluted with water and 
subsequently washed with brine. The combined organic layers were then washed with 
brine (50 mL), dried over anhydrous sodium sulfate, filtered through a cotton plug, and 
concentrated under reduced pressure. The residue was then purified by flash column 
chromatography (silica gel, eluent: gradient, 50% → 100% EtOAc in hexanes) to afford 
benzofuran 426 (2.31 g, 7.24 mmol, 71%) as a pale yellow oil. 
Benzofuran 426: Rf: 0.3 (100% EtOAc in hexanes); 
1H NMR (500 MHz, CDCl3) δ 15.21 (1H, s), 11.30  (1H, s), 6.92 (1H, s), 6.36 (1H, s), 
5.51 (1H, s), 3.95 (6H, s), 3.76 (2H, s), 2.01 (3H, s); 13C NMR (100 MHz, CDCl3) δ 
190.0, 189.9, 171.0, 162.1, 153.4, 150.6, 138.4, 128.9, 107.6, 99.7, 96.6, 96.2, 56.2, 51.9, 
38.4, 24.3;  IR νmax (film): 1654, 1625, 1440, 1328, 1251, 1218, 1169, 1000 cm-1; HRMS 
(ESI+) m/z calculated for C16H17O7 (M + H+) 321.0974, found 321.0982. 
		
330 
 
Michael adduct 419: To a stirred solution of pyrone 422 (11.40 g, 91.76 mmol, 0.9 equiv) 
in CH2Cl2 (300 mL) at –78 ºC was added TBSOTf (37.11 mL, 203.92 mmol, 2.0 equiv) 
and 2,6-lutidine (23.75 mL, 203.9 mmol, 2.0 equiv) slowly. After 30 min, a CH2Cl2 
solution of quinone 420 (20.04 g, 101.96 mmol, 1.0 equiv) was added under Ar at –30 ºC 
over 3 hours. After completion, the resultaning purple solution was stirred for another 30 
min. Finally the reaction mixture was quenched by adding saturated aqueous sodium 
bicarbonate solution (300 mL) and stirred for 30 min. The reaction mixture was then 
diluted with water and subsequently washed with brine. The combined organic layers 
were then washed with brine (500 mL), and concentrated under reduced pressure. The 
residue was then dissolved in 300 mL of MeCN, and subsequently 200 mL of 1 M HCl 
solution was added. The resulting solution was stirred for 30 min and further extracted 
with EtOAc (3 × 200 mL). The combined organic layers were then washed with brine 
(500 mL), dried over anhydrous sodium sulfate, filtered through a cotton plug, and 
concentrated under reduced pressure. The residue was recrystallized from 300 mL of 
EtOAc and 300 mL of hexanes to afford the Michael adduct 419 (24.47 g, 76.46 mmol, 
75%) as a pale yellow solid. 
Michael adduct 419: White solid, m.p. = 132 ‒134 oC (EtOAc, hexanes), Rf: 0.4 (100% 
EtOAc in hexanes); 
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1H NMR (500 MHz, CDCl3) δ 11.29 (1H, s), 6.46  (1H, s), 6.03 (1H, s), 5.69 (1H, s), 
4.23 (2H, s), 3.87 (3H, s), 3.81 (3H, s), 2.26 (3H, s); 13C NMR (100 MHz, CDCl3) δ 
180.4, 171.0, 168.8, 165.3, 158.7, 152.3, 138.1, 119.4, 113.8, 112.0, 103.9, 99.3, 56.1, 
52.0, 31.4, 19.8;  IR νmax (film): 1660, 1601, 1438, 1228 cm-1; HRMS (ESI+) m/z 
calculated for C16H16O7Na+ (M + Na+) 343.0794, found 343.0800. 
 
O-methylated pyrone adduct 433: To a stirred solution of 419 (25.05 g, 78.05 mmol, 
1.0 equiv) in acetone (400 mL) was added K2CO3 (33.44 g, 241.97 mmol, 3.1 equiv) and 
methyl iodide (19.44 mL, 312.22 mmol, 4.0 equiv) dropwise. The resulting mixture was 
heated to 50 ºC under Ar. After stirring for 12 h, the reaction mixture was heated at 60 ºC 
for 12 h before Cs2CO3 (38.15 g, 117.07 mmoL, 1.5 equiv) was added. The resulting 
solution was allowed to react at same temperature for an additional 12 h. Finally, the 
reaction mixture was diluted with water and extracted with EtOAc (3 × 10 mL). The 
combined organic layers were then washed with brine (500 mL) and concentrated under 
reduced pressure. The residue was then dissolved in 300 mL of MeCN, and 200 mL of 1 
M HCl solution was added. The resulting solution was stirred for 30 min and extracted 
with EtOAc (3 × 200 mL). The combined organic layers were then washed with brine 
(500 mL), dried over anhydrous sodium sulfate, filtered through a cotton plug, and 
concentrated under reduced pressure. The residue was then purified by flash column 
chromatography (silica gel, eluent: gradient, 50% → 200% EtOAc in hexanes) to afford 
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compound 433 (23.92 g, 68.64 mmol, 88%) as a yellow oil. 
O-methylated pyrone adduct 433: Rf: 0.4 (100% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 6.43 (1H, s), 5.92  (1H, s), 5.86 (1H, s), 3.84 (2H, s), 3.82 
(3H, s), 3.75 (3H, s), 3.74 (3H, s), 3.66 (3H, s), 2.13 (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 180.0, 167.4, 167.0, 165.4, 154.1, 154.0, 141.2, 127.4, 115.8, 113.8, 113.4, 96.9, 
60.8, 56.5, 55.9, 52.1, 31.0, 19.6;  IR νmax (film): 1726, 1664, 1600, 1395, 1340, 1263, 
1206, 1038 cm-1; HRMS (ESI+) m/z calculated for C18H21O7 (M + H+) 349.1287, found 
349.1278. 
 
Pyrone adduct 432: A 1000-mL flame dried round-bottomed flask was charged with 
compound 433 (20.50 g, 58.85 mmol, 1.0 equiv) and azeotropically dried with three 
portions of benzene before dry CH2Cl2 (500 mL) was introduced. The solution was then 
cooled to -78 ºC before BCl3 (147.1 mL, 147.1 mmol) was added via a 250 mL addition 
funnel under Ar. The resulting reaction mixture was allowed to warm to room 
temperature. After 9 h, the reaction was cooled down to -78 ºC before 200 mL of MeOH 
was added at this temperature. The reaction was then warmed to room temperature and 
reacted for another 30 min.  Finally, the reaction mixture was quenched by water. The 
layers were separated, and the aqueous layer was further extracted with CH2Cl2 (3 × 200 
mL). The combined organic layers were then washed with water (25 mL) and brine (25 
mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 
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pressure. The residue was then purified by flash column chromatography (silica gel, 
eluent: gradient, 100% → 200% EtOAc in hexanes) to afford the pyrone adduct 432 
(16.72 g, 50.02 mmol, 85%) as a brown oil. 
Pyrone adduct 432: Rf: 0.4 (100% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 11.5 (1H, s), 6.49  (1H, s), 6.03 (1H, s), 5.70 (1H, s), 4.24 
(2H, s), 3.89 (3H, s), 3.79 (3H, s), 3.70 (3H, s), 2.26 (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 180.1, 170.7, 169.1, 165.1, 161.7, 158.5, 141.5, 128.7, 113.9, 112.2, 103.7, 
100.6, 61.2, 55.9, 52.0, 31.8, 19.7;  IR νmax (film): 1664, 1609, 1446, 1333, 1250, 1026 
cm-1; HRMS (ESI+) m/z calculated for C17H18O7Na (M + Na+) 357.0950, found 
357.0963. 
 
MOM ether pyrone adduct 434: A 500-mL flame dried round-bottomed flask was 
charged with compound 432 (12.80 g, 38.29 mmol, 1.0 equiv) and THF (250 mL) was 
introduced under Ar. The solution was then cooled to 0 ºC before 60% NaH (2.29 g, 
57.43 mmol, 1.5 equiv) was added in one portion. The resulting reaction mixture was 
allowed to stir for 40 min before MOMCl (2.90 mL, 38.29 mmoL, 1.1 equiv) was slowly 
added. The reaction was subsequently allowed to gradually warm to ambient temperature 
over 2 h. Water (100 mL) was then added to the reaction mixture which was stirred for 
another 1 h. The resulting solution was then extracted with EtOAc (3 × 200 mL).  The 
combined organic layers were then washed with brine (300 mL), dried over anhydrous 
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sodium sulfate, filtered, and concentrated under reduced pressure. The residue was then 
purified by flash column chromatography (silica gel, eluent: gradient, 100% → 200% 
EtOAc in hexanes) to afford MOM ether pyrone adduct 434 (12.90 g, 34.08, 89%) as a 
brown oil. 
MOM ether pyrone adduct 434: Rf: 0.4 (100% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 6.74 (1H, s), 6.00  (1H, s), 5.92 (1H, s), 5.13 (2H, s), 3.91 
(2H, s), 3.87 (3H, s), 3.80 (3H, s), 3.74 (3H, s), 3.48 (3H, s), 2.21 (3H, s); 13C NMR (100 
MHz, CDCl3) δ 180.1, 167.4, 167.1, 165.4, 154.5, 151.7, 142.4, 127.1, 117.1, 113.9, 
113.5, 100.6, 95.7, 60.9, 56.2, 55.9, 52.2, 31.0, 19.7;  IR νmax (film): 1725, 1664, 1599, 
1396, 1157, 1034 cm-1; HRMS (ESI+) m/z calculated for C19H22O8Na (M + Na+) 
401.1212, found 401.1215. 
 
Naphthopyrone 437: A 500-mL, 3-necked round bottom flask was charged with 
compound 434 (10.09 g, 26.43 mmol, 1.00 equiv) and was azeotropically dried with four 
portions of benzene before THF (100 mL) was introduced and was then equipped with a 
250 mL-addition funnel. The resulting solution was degassed and cooled to –78 °C. A 
solution of n-butyllithium in hexanes (2.5 M,  15.86 mL, 39.65 mmol, 1.5 equiv) was 
added via syringe to a stirred solution of diisopropylamine (5.55 mL, 39.65 mmol, 1.5 
equiv) in degassed THF (100 mL) at –78 °C in a 250-mL round-bottomed flask. The 
resulting solution was allowed to warm to 0 °C. After 30 min, the solution of LDA was 
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transferred to the 250 mL-addition funnel and was added dropwise to the stirred THF 
solution of 434 over 2 h. After completion, the reaction mixture was neutralized with 1 M 
HCl and then extracted with EtOAc (3 × 200 mL).  The combined organic layers were 
washed brine (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated 
under reduced pressure. The residue was then purified by flash column chromatography 
(silica gel, eluent: gradient,     25% →  50% EtOAc in hexanes) to afford naphthopyrone 
437 (8.45 g, 24.42 mmol, 77%) as a yellow solid.  
Naphthopyrone 437: Yellow solid, m.p. = 171 ‒ 173 oC (acetone), Rf: 0.3 (50% EtOAc 
in hexanes); 
1H NMR (400 MHz, CDCl3) δ 14.95 (1H, s), 7.36 (1H, s), 6.88 (1H, s), 5.98 (1H, s), 5.34 
(2H, s), 3.99 (3H, s), 3.88 (3H, s), 3.62 (3H, s), 2.36 (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 184.5, 167.8, 163.0, 153.9, 153.0, 151.6, 136.4, 134.3, 109.2, 107.1, 104.3, 
100.1, 96.6, 95.4, 60.8, 56.5, 56.4, 20.7;  IR νmax (film): 1670, 1660, 1430, 1345 cm-1; 
HRMS (ESI+) m/z calculated for C18H19O7 (M + H+) 347.1131, found 347.1123. 
 
Naphthopyrone 438: A 1000-mL 3-necked round bottom flask was charged with 
compound 437 (10.04 g, 28.87 mmol, 1.00 equiv) and Cs2CO3 (14.11 g, 43.31 mmol, 1.5 
equiv), which was followed by sequential introduction of 500 mL of degrassed acetone 
and dimethyl sulfate (4.11 mL, 43.31 mmol, 1.5 equiv). The resulant reaction mixture 
was stirred at 50 ºC under Ar.  After completion, the reaction mixture was cooled to 
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ambient temperature and diluted with water (500 mL), and then extracted with EtOAc (3 
× 300 mL). The combined organic layers were then washed with brine (500 mL) and 
concentrated under reduced pressure. The residue was finally purified by flash column 
chromatography (silica gel, eluent: gradient, 50% →  100% EtOAc in hexanes) to afford 
naphthopyrone 438 (8.94 g, 24.82 mmol, 86%) as a yellow solid.  
 
Naphthopyrone 438: Yellow solid, m.p. > 240 oC (decomposed), Rf: 0.2 (50% EtOAc in 
hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.79 (1H, s), 6.93 (1H, s), 5.96 (1H, s), 5.27 (2H, s), 3.98 
(3H, s), 3.96 (3H, s), 3.89 (3H, s), 3.58 (3H, s), 2.30 (3H, s); 13C NMR (100 MHz, 
CDCl3) δ 178.1, 164.3, 159.2, 154.2, 152.3, 150.1, 136.4, 133.2, 114.5, 114.1, 110.3, 
110.0, 103.3, 102.2, 97.0, 63.2, 60.8, 56.4, 20.0;  IR νmax (film): 1658, 1613, 1468, 1396, 
1152, 1035, 950  cm-1; HRMS (ESI+) m/z calculated for C18H21O7 (M + H+) 361.1287, 
found 361.1283. 
 
Naphthopyrone 439: A 500-mL round bottom flask was charged with compound 438 
(6.30 g, 17.48 mmol, 1.00 equiv) and dry CH2Cl2 (200 mL) was introduced. The resulting 
solution was cooled to –78 °C before TFA (13.39 mL, 174.83 mmol, 10.0 equiv) was 
added slowly. The reaction mixture was allowed to warm to ambient temperature and was 
stirred for 5 h. After completion, the reaction mixture was  neutralized by adding 
		
337 
saturated aqueous sodium bicarbonate (200 mL), and the layers were separated. The 
aqueous layer was then extracted with additional CH2Cl2 (3 × 200 mL).  The combined 
organic layers were washed with brine (300 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated under reduced pressure. The residue was then purified by flash 
column chromatography (silica gel, eluent: gradient, 30% → 50% EtOAc in hexanes) to 
afford naphthopyrone 439 (4.42 g, 13.98 mmol, 80%) as a yellow solid.  
Naphthopyrone 439: Yellow solid, m.p. = 128 ‒ 131 oC (acetone), Rf: 0.3 (50% EtOAc 
in hexanes); 
1H NMR (400 MHz, CDCl3) δ 9.90 (1H, s), 7.76 (1H, s), 6.69 (1H, s), 5.98 (1H, s), 4.13 
(3H, s), 3.97 (3H, s), 3.88 (3H, s), 2.33 (3H, s); 13C NMR (100 MHz, CDCl3) δ 177.7, 
165.1, 158.1, 154.0, 153.4, 152.0, 133.9, 132.2, 111.5, 110.04, 109.97, 103.9, 98.5, 64.8, 
61.0, 56.2, 20.3;  IR νmax (film): 1656, 1433, 1361, 1034 cm-1; HRMS (ESI+) m/z 
calculated for C17H17O6 (M + H+) 317.1025, found 317.1016. 
 
Dimeric naphthopyrone 441: A 250-mL flame dried round-bottomed flask was charged 
with compound 439 (2.40 g, 7.59 mmol, 1.0 equiv) and was azeotropically dried with 
three portions of benzene before dry DMSO (60 mL) was introduced. To another 100-mL 
flame dried round-bottomed flask was added Pd(OAc)2 (170.4 mg, 759 µmol, 0.1 equiv), 
N-acetyl-L-leucine (131.5 mg, 759 µmol, 0.1 equiv) and dry DMSO (30 mL). The 
resulting solution was stirred at ambient temperature for 2 h before being transferred to a 
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DMSO solution of 439. The combined reaction mixture was then heated to 70 oC for 4 h. 
After completion, the reaction was diluted by water and subsequently extracted with 
EtOAc (3 × 100 mL). The combined organic layers were then washed with brine (200 
mL), and concentrated under reduced pressure. The residue was then purified by flash 
column chromatography (silica gel, eluent: gradient, 25% →  50% EtOAc in hexanes) to 
afford dimeric compound 441 (8.94 g, 24.82 mmol, 86%) as a yellow solid.  
Dimeric naphthopyrone 441: Yellow solid, m.p. = 114 ‒ 116 oC (acetone), Rf: 0.4 (50% 
EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 10.17 (2H, s), 7.91 (2H, s), 6.05 (2H, s), 4.14 (6H, s), 3.96 
(6H, s), 3.92 (6H, s), 2.39 (6H, s); 13C NMR (100 MHz, CDCl3) δ177.7, 165.1, 157.9, 
153.9, 151.9, 149.9, 138.1, 132.7, 112.4, 112.1, 111.7,  110.2, 104.6, 64.9, 61.0, 60.8, 
20.3;  IR νmax (film): 1655, 1411, 1352, 1037 cm-1; HRMS (ESI+) m/z calculated for 
C34H31O12 (M + H+) 631.1816, found 631.1821. 
 
Bisnaphthoquinone 450: A warm solution of hydroxynaphthoquinone 448 (10.04 g, 
57.42 mmol, 1.0 equiv) in water (200 mL) containing NaOH (2.53 g, 63.16 mmol, 1.1 
equiv) was gradually added to (NH4)2S2O8 (26.21 g, 114.84 mmol, 2.0 equiv) dissolved 
in water (100 ml) for 40 min at 95 oC. After cooling to rt., water was added to the reaction 
mixture to separate brown solids, which were collected, washed with water and dried in 
vacuo. The brown product 449 (5.24 g) was then transferred to 100-mL round-bottomed 
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flask before MeCN (30 mL) and MeOH (3 mL) were introduced. The resulting solution 
was cooled to 0 oC. Trimethylsilyldiazomethane (45.13 mmol, 2M hexanes solution) and 
DIEA (5.26 mL, 30.09 mmol, 2.0 equiv) were sequentially added. The reaction mixture 
was allowed to warm to ambient temperature and was kept at this temperature for 2 h. 
After completion, the yellow solid in the reaction suspension was collected and 
recrystallized from EtOAc and hexanes to afford the bisnaphthoquinone 450 (3.45 g, 9.17 
mmol, 61%) as a brown solid.  
Bisnaphthoquinone 450: Brown solid, m.p. = 194 ‒ 197 oC (EtOAc), Rf: 0.3 (20% 
EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 8.12 (4H, m), 7.73 (4H, m), 4.12 (6H, s); 13C NMR (125 
MHz, CDCl3) δ 182.9, 181.2, 158.1, 134.1, 133.5, 131.9, 131.6, 126.6, 126.5, 123.8, 61.2;  
IR νmax (film): 1672, 1594, 1294, 1215, 1044, 919 cm-1; HRMS (ESI+) m/z calculated for 
C22H14O6Na (M + Na+) 397.0688, found 397.0691. 
 
Bisepoxide 452: A 250-mL flame dried round-bottomed flask was charged with 
compound 450 (501.1 mg, 1.33 mmol, 1.0 equiv) and MeCN (60 mL). The resulting 
solution was then added aqueous sodium hypochlorite solution (10%~15%, 7.0 mL) 
slowly. The reaction mixture was then stirred for 20 min and was quenched by diluting 
with water and subsequently extracted with EtOAc (3 × 100 mL). The combined organic 
layers were then washed with brine (200 mL) and were concentrated under reduced 
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pressure. The residue was then purified by flash column chromatography (silica gel, 
eluent: gradient, 10% →  15% EtOAc in hexanes) to afford compound 452 (422.8 mg, 
1.04  mmol, 78%) as a white solid.  
Bisepoxide 452: white solid, m.p. = 93 ‒ 95 oC (EtOAc), Rf: 0.2 (15% EtOAc in 
hexanes); 
1H NMR (400 MHz, CDCl3) δ 8.15 (2H, dd, J = 7.6, 1.7 Hz), 8.00 (2H, dd, J = 6.9, 1.9 
Hz), 7.79 (4H, m), 3.87 (6H, s); 13C NMR (125 MHz, CDCl3) δ 188.0, 187.7, 134.8 (4C), 
131.8, 131.7, 127.7, 127.6, 83.0, 64.9, 57.4;  IR νmax (film): 1710, 1563, 1264, 1205, 
1043, 917 cm-1; HRMS (ESI+) m/z calculated for C22H14O8Na (M + Na+) 429.0586, 
found 429.0583. 
 
Aurofusarin methyl ether 444: To 20 g of silica gel in a 500 mL round bottomed flask 
was added 2 mL of hot water solution of cerium ammonium nitrate (7.81 g, 14.25 mmol, 
5 equiv). The resulting mixture was then mixed until the silica gel became free-flowing. 
This fresh prepared CAN on silica gel was added 250 mL of CH2Cl2; the suspension was 
then vigorously stirred and cooled to 0 ºC. 10 mL of a CH2Cl2 solution of compound 441 
(1.80 g, 2.85 mmol) was slowly added to the stirred CAN/silica gel and CH2Cl2 mixture. 
The resulting solution was allowed to warm to room temperature and was further stirred 
for 40 min. The filtrate was washed with water (3 × 50 mL) and brine (100 mL), dried 
over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. 
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The residue was then purified by flash column chromatography (silica gel, eluent: 
gradient,     50% →  100% EtOAc in hexanes) to afford compound 444 (1.43 g, 2.50  
mmol, 88%) as a yellow solid. 
Aurofusarin methyl ether 444: Yellow solid, m.p. = 158 ‒ 160 oC (acetone), Rf: 0.2 
(100% EtOAc in hexanes); 
1H NMR (400 MHz, CDCl3) δ 7.94 (2H, s), 6.18 (2H, s), 4.10 (6H, s), 3.99 (6H, s), 2.40 
(6H, s); 13C NMR (125 MHz, CDCl3) δ 180.3, 179.7, 176.1, 164.8, 162.3, 160.2, 156.6, 
135.9, 127.3, 122.6, 120.7, 113.2, 113.1, 63.1, 61.0, 20.0;  IR νmax (film): 1668, 1593, 
1417, 1353, 1249, 1092 cm-1; HRMS (ESI+) m/z calculated for C32H22O12Na (M + Na+) 
621.1009, found 621.0998. 
 
 
Aurofusarin (353): A 250-mL flame dried round-bottomed flask was charged with 
compound 444 (1.40 g, 2.34 mmol, 1.0 equiv), which was azeotropically dried with three 
portions of benzene before dry CH2Cl2 (200 mL) was introduced. The solution was then 
cooled down to -78 ºC before BBr3 (7.02 mL, 7.02 mmol) was added dropwise under Ar. 
The resulting reaction mixture was allowed to stir at this temperature for 6 h before 50 
mL MeOH was added. After 30 min, the reaction mixture was quenched by water and the 
resulting mixture was warmed to rt.  The layers were then separated, and the aqueous 
layer was further extracted with CH2Cl2 (3 × 200 mL). The combined organic layers were 
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then washed with water (25 mL) and brine (25 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated under reduced pressure. The residue was then recrystallized 
from CH2Cl2 to afford aurofusarin (353) (1.04 g, 1.82 mmol, 78%) as a deep brown solid.  
Aurofusarin (353):  Deep brown solid, m.p. >200 oC (decomposed), Rf: not available. 
(Decomposed on silica gel, successful separation was only achieved by using oxalic acid 
impregnated silica gel-mediated column chromatography.)231 
1H NMR (500 MHz, CDCl3) δ14.14 (2H, bs), 7.63 (2H, s), 6.25 (2H, s), 4.11 (6H, s), 
2.46 (6H, s); 13C NMR δ183.4, 176.1, 172.6, 166.9, 163.9, 161.4, 159.3, 140.4, 129.3, 
118.5, 115.9, 115.1, 111.7, 64.9, 23.9;  IR νmax (film): 1681, 1663, 1651 cm-1; HRMS 
(ESI+) m/z calculated for C30H19O12 (M + H+) 571.0877, found 571.0886. 
 
1H NMR: 
Positions Natural 353 (500 MHz, CDCl3) Synthetic 353 (500 MHz, CDCl3) 
3, 3’ 6.26 (2H, s) 6.25 (2H, s) 
5, 5’ 14.14 (2H, s) 14.14 (2H, s) 
10, 10’ 7.63(2H, s) 7.63 (2H, s) 
11, 11’ 2.45 (2H, s) 2.46 (2H, s) 
12, 12’ 4.11 (2H, s) 4.11 (2H, s) 
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Acetyl aurofusarin 453: To a solution of aurofusarin (353) (100 mg, 175 µmol, 1 equiv) 
in dried CHCl3 (80 mL) and pyridine (2 mL), AcCl (2 mL) was added dropwise for 1 h 
under stirring in an ice-bath. After further addition of pyridine (1 mL) and AcCl (1 mL) 
for 1 h, the reaction mixture was allowed to stir for 1 h at room temperature and poured 
into ice-water. The separated CHCl3 layer separated was washed with a small amount of 
1% NaHCO3 and water and dried with anhydrous Na2SO4. The concentrated solution was 
chromatographed on silica gel using mixture of CHCl3 : acetone (20 : 1 to 10 : 1). Elution 
of the second yellow band from the bottom gave diacetate, which solidified with addition 
of a small amount of MeOH and recrystallized from CHCl3-benzene affording compound 
453 (62.3 mg, 96 µmol, 55%) as an orange yellow plates. The spectra of the synthetic 453 
were in agreement with those reported in the literature.222 
Acetyl aurofusarin 453: Orange yellow solid, m.p. = 184 ‒ 186oC (CH2Cl2), Rf: not 
stable on TLC. 
1H NMR (400 MHz, CDCl3) δ 8.04 (2H, s), 6.11 (2H, s), 4.06 (6H, bs), 2.42 (6H, s), 2.38 
(6H, s); 13C NMR  (125 MHz, CDCl3) δ 179.7, 179.1, 175.6, 169.1, 168.7, 165.6, 159.4, 
157.1, 135.3, 126.4, 120.9, 119.7, 115.4, 112.9, 61.1, 20.9, 20.1;  IR νmax (film): 1771, 
1682, 1664, 1652 cm-1; HRMS (ESI+) m/z calculated for C34H22O14Na (M + Na+) 
677.0907, found 677.0917. 
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Acetyl Aurofusarin bis-epoxide 454: Compound 453 was dissolved in CH2Cl2 (20 mL) 
with tetrabutylammonium bromide (10.8 mg, 38 µmol, 0.4 equiv) and was cooled to ‒10 
ºC. Aqueous sodium hypochlorite solution (2.8 mL, 379 µmol, 4.0 equiv) was then added 
slowly, and the resulting reaction mixture was allowed to warm to 0 ºC and stirred for 2 h. 
After completion, water was added to dilute the reaction, which was then extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layers were then washed with water (25 mL) 
and brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under 
reduced pressure. The residue was then purified by flash column chromatography (silica 
gel, eluent: gradient, 5% → 10% acetone in CH2Cl2) to afford compound 454 (50.5 mg, 
72  µmol, 77%) as a light yellow solid. 
Acetyl Aurofusarin bis-epoxide 454: Light yellow solid, m.p. = 134 ‒ 136oC (acetone), 
Rf: 0.2 (5% acetone in CH2Cl2); 
1H NMR (400 MHz, CDCl3) δ 8.03 (2H, s), 6.12 (2H, s), 3.82 (6H, s), 3.99 (6H, s), 2.40 
(6H, s); 13C NMR (125 MHz, CDCl3) δ 186.5, 183.5, 175.2, 168.6, 165.8, 159.7, 151.4, 
135.3, 121.3, 120.3, 115.8, 112.9, 83.5, 65.4, 57.3, 20.7, 20.1;  IR νmax (film): 1771, 
1660, 1354 cm-1; HRMS (ESI+) m/z calculated for C34H22O16Na (M + Na+) 709.0806, 
found 709.0807. 
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